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Abstract	
The	human	genome	encodes	a	number	of	inositol	phosphate	phosphatases	that	act	upon	
inositide	or	phosphoinositide	substrates.	Among	these,	the	5-phosphatases	have	become	
targets	for	therapeutic	intervention	in	human	pathologies	including	cancers	and	diabetes.	
Of	these,	SHIP1	and	SHIP2	(SH2-domain-containing	inositol	5-phosphatase	1	&	2),	which	
dephosphorylate	 phosphatidylinositol	 3,4,5-trisphophate	 have	 received	 particular	
attention.	 In	 this	 study,	 attempts	 have	 been	 made	 to	 solve	 X-ray	 crystallographic	
structures	 of	 these	 proteins	 in	 complex	 with	 physiologically	 relevant	 inositide	 and	
phosphoinositide	ligands	or	substrate	analogs.	The	substrate	analogs	that	have	proved	
most	 useful	 include	 a	 family	 of	 benzene	 polyphosphates	 (BzPs)	 and	 biphenyl	
polyphosphates	(BiPhs).	This	thesis	describes	the	cloning	and	expression	of	the	catalytic	
domains	of	SHIP1	and	SHIP2	in	E.	coli,	purification	of	these	proteins	and	structural	studies	
thereon.	A	structure	was	solved	to	2.75	Å	for	apo	SHIP2cd	and	from	this,	and	existing	
literature,	a	homology	model	was	made	for	SHIP1cd.	
While	BiPhs	have	been	reported	as	ligands	of	5-phosphatases,	this	thesis	extends	their	
use	to	the	study	of	a	inositol	phosphate	kinase;	Arabidopsis	thaliana	 inositol	1,3,4,5,6-
pentakisphosphate	(AtIPK1).	An	enzyme	catalysing	reversible	phosphotransfer	between	
ATP	and	IP5.	Structures	were	solved	to	2.1	Å	of	ternary	complexes	between	AtIPK1,	BiPh	
and	 ADP,	 the	 structures	 reveal	 the	 adoption	 by	 the	 protein	 of	 a	 ‘half-closed’	
conformation,	reported	previously	only	in	the	presence	of	nucleotide	alone.	
Close	scrutiny	of	the	structures	of	BiPh/protein	complexes	prompted	their	examination	
as	 potential	 inhibitors	 of	 SHIP1,	 SHIP2	 and	 AtIPK1.	 A	 fluorescence	 polarisation	 ligand	
displacement	assay	was	 constructed	with	a	 fluorescein-tagged	 inositol	phosphate	and	
comparisons	were	made	of	the	efficacy	of	different	biphenyl	phosphates	in	displacement	
of	this	ligand.	
The	same	polarisation	assay	was	used	to	screen	the	NCI	Diversity	Set	II	for	inhibitors	of	
SHIP2	and	AtIPK1.	A	number	of	compounds	were	identified,	and	characterised	for	dose	
response	with	 these	proteins.	 Similar	 screens,	which	 included	SHIP1,	were	performed	
with	 the	 NCI	 Approved	 Oncology	 Drug	 Set	 V.	 Potential	 lead	 compounds	 were	 taken	
forward	for	characterisation	of	their	ability	to	inhibit	AtIPK1.	 	
III	
	
Table	of	Contents	
Abstract	 II	
Table	of	Contents	 III	
Index	of	Tables	and	Figures	 IX	
Acknowledgements	 XVI	
	
Chapter	1	
1.1	Introduction	
1.1.1	Inositol	polyphosphates	and	phosphoinositides	 1	
1.1.1a	myo-inositol	structure	and	nomenclature	 1	
1.1.1b	General	synthesis	 3	
1.1.2	Physiological	roles	and	metabolism	of	Inositol	phosphates	 5	
and	phosphoinositides	
1.1.2a	Diverse	roles	of	phosphoinositides	–	regulation	of	Akt	and	human	disease	 5	
1.1.2b	Inositol	hexakisphosate	(IP)	 7	
1.1.3	Inositol	polyphosphate	surrogates	and	substrate	mimics	 8	
1.1.3a	Benzene	polyphosphates	 8	
1.1.3b	Biphenyl	polyphosphates	 11	
	 	
IV	
	
	
Chapter	2	
Structural	studies	of	Human	SHIP1	and	SHIP2	
2.1	Introduction	 15	
2.1.1	Inositol	polyphosphate	5-phosphatases	 15	
2.1.2	SHIP1	-	SH2	(Src	homology	2)-containing	inositol	5-phosphatase	 17	
2.1.3	SHIP2	-	SH2	(Src	homology	2)-containing	inositol	5-phosphatase	2	 17	
2.1.4	Structures	of	inositol	polyphosphate	5-phosphatases	 18	
2.1.5	Experimental	aims	 21	
2.2	Materials	and	methods	 22	
2.2.1	Primers	 22	
2.2.2	PCR	amplification	using	Phusion	High	Fidelity	DNA	polymerase	 22	
2.2.3	Agarose	gel	electrophoresis	 22	
2.2.4	PCR	clean	up	 23	
2.2.5	Treatment	with	T4	DNA	polymerase	 23	
2.2.6	Plasmid	DNA	extraction	 23	
2.2.7	Preparation	of	chemically	competent	E.	coli	cells	 23	
2.2.8	Transformation	of	E.	coli	standard	protocol	 24	
2.2.9	Restriction	digestion	 24	
2.2.10	Screening	of	transformants	by	colony	PCR	 24	
2.2.11	Plasmid	sequencing	 24	
2.2.12	Glycerol	stocks	 25	
2.2.13	Small	scale	expression	testing	of	SHIP1cd-His	 25	
2.2.14	Preparation	of	polyacrylamide	gels	 25	
2.2.15	Preparation	of	samples	for	SDS-PAGE	analysis	 26	
2.2.16	Large	scale	protein	expression	 26	
2.2.17	Standard	protein	purification	protocol	 27	
2.2.18	Removal	of	6xHistidine	tag	using	TEV	protease	 28	
2.2.19	SHIP2cd	crystal	screening	and	optimization	 28	
2.2.20	Crystal	cyroprotection	 28	
V	
	
2.2.21	Data	collection	 29	
2.2.22	Data	processing	and	refinement	 29	
2.3	Results	and	Discussion	 30	
2.3.1	Expression	and	purification	of	SHIP2cd	 30	
2.3.2	Crystallisation	of	SHIP2cd	 35	
2.3.3	Crystal	structure	of	SHIP2cd	 36	
2.3.4	Ligation	independent	cloning	of	INPP5Dcd	(SHIP1cd)	in	to	the	pNIC28-Bsa4	
vector	 43	
2.3.5	Expression	of	SHIP1cd-His	 48	
2.3.6	Purification	of	SHIP1cd-His	 50	
2.3.7	Structure	prediction	of	SHIP1cd	 58	
2.4	Conclusions	and	future	work	 64	
	
Chapter	3	
Structural	studies	of	Arabidopsis	thaliana	inositol	1,3,4,5,6-pentakisphosphate		
2-kinase	(AtIPK1)	in	complex	with	novel	inositol	phosphate	surrogates	
3.1	Introduction	 66	
3.1.1	IPK1	classification	 66	
3.1.2.	IPK1	characterisation	 67	
3.1.3	The	X-ray	crystal	structure	of	AtIPK1	 68	
3.1.4	Conformational	changes	of	AtIPK1	upon	ligand	and	nucleotide	binding	 70	
3.1.5	Experimental	aims	 72	
3.2	Materials	&	Methods	 73	
3.2.1	Small	scale	expression	testing	AtIPK1	 73	
3.2.2	Large-scale	expression	of	AtIPK1	for	purification	 73	
3.2.3	Using	3C	protease	to	remove	the	6xHistidine	tag	 73	
3.2.4	Crystal	screening	and	optimisation	 74	
3.2.5	Crystal	cryoprotection	 74	
3.2.6	Data	collection	 74	
3.2.7	Data	processing	and	refinement	 75	
	
VI	
	
3.3	Results	and	Discussion	 76	
3.3.1	Expression	and	Purification	of	AtIPK1-His	 76	
3.3.2	Cleaving	the	histidine	tag	and	purification	of	AtIPK1	 81	
3.3.3	Crystallisation	of	AtIPK1	with	biphenyl	2,3’,4,5’,6-pentakisphosphate,	
and	biphenyl	3,3’,4,4’,5,5’-hexakisphosphate.	 83	
3.3.4	Crystal	structures	of	AtIPK1	with	biphenyl	2,3’,4,5’,6-pentakisphosphate,	
and	biphenyl	3,3’,4,4’,5,5’-hexakisphosphate.	 85	
3.3.5	Conformational	changes	of	AtIPK1	upon	ligand	binding	 106	
3.4	Conclusions	and	Future	work	 111	
	
Chapter	4		
Novel	fluorescent	properties	of	the	benzene-	and	biphenyl-	polyphosphates,		
and	the	use	of	fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	
4.1	–	Introduction	 113	
4.1.1		Current	applications	of	the	benzene-	and	biphenyl-	polyphosphates	 113	
4.1.2		Current	applications	of	fluorescently	tagged	inositol	phosphates	 114	
4.1.3		Fluorescence	polarisation	 115	
4.1.4	Experimental	aims	 116	
4.2	Materials	&	methods	 117	
4.2.1	UV	absorbance	wave	scans	 117	
4.2.2	Fluorescence	intensity	 117	
4.2.3	Biphenyl	phosphate	anion	exchange	chromatography	assays;	SHIP1cd	and		
	 SHIP2cd	 117	
4.2.3a	Preliminary	assays	 117	
4.2.3b	Complete	assays	 118	
4.2.4	Kinetic	assays	with	the	biphenyl	polyphosphates	 118	
4.2.5	Fluorescence	polarisation;	dose-response	binding	and	inhibition	curves	 119	
4.3	Results	&	Discussion	 120	
4.3.1	UV	absorbance	and	fluorescence	properties	of	the	biphenyl	and	benzene	
polyphosphates	 120	
VII	
	
4.3.2	Biphenyl	polyphosphates	are	substrates	of	SHIP1	and	SHIP2	 128	
4.3.3	Using	fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	by	
fluorescence	polarisation	 141	
4.3.4	Known	inhibitors	of	SHIP1cd	&	SHIP2cd	–	validation	of	2-FAM-IP5-based										
assays	 152	
4.4	Conclusions	and	future	work	 156	
	
Chapter	5	
Application	of	fluorescently	tagged	inositol	polyphosphates	in	novel	inhibitor		
and	lead	compound	discovery	 156	
5.1	Introduction	 156	
5.1.1	Screening	for	lead	compounds	in	drug	discovery	 158	
5.1.2	The	Z-factor	 159	
5.1.4	Lipinski’s	rule	of	five	 159	
5.1.5	Experimental	aims	 160	
5.2	Materials	and	methods	 161	
5.2.1	High	throughput	screening	of	compound	libraries	 161	
5.2.2	Changes	in	AtIPK1	intrinsic	tryptophan	fluorescence	upon	ligand	binding	 161	
5.2.3	Coupled	enzyme	assay	 161	
5.3.	Results	and	discussion	 162	
5.3.1	Screening	compound	libraries	using	fluorescence	polarisation	 162	
5.3.2	Dose-response	curves	of	the	binding	of	screen	hits	–	Diversity	set	II	 168	
5.3.3	Further	investigation	of	screen	hits	with	AtIPK1,	SHIP2cd	&	SHIP1cd	–	
Approved	Oncology	Drugs	Set	V	 179	
5.3.4	Utilising	the	intrinsic	tryptophan	fluorescence	of	AtIPK1	to	investigate		
binding	of	potential	inhibitors,	validation	of	polarisation	screens	 188	
5.4.5	Inhibiting	the	kinase	activity	of	AtIPK1	-	coupled	assay	 195	
5.4	Conclusions	and	future	work	 198	
	 	
VIII	
	
Chapter	6	
Concluding	Remarks	 101	
	
Appendices	 207	
References	 210	
	
	 IX	
Index	of	Tables		
Table	1.1	 Structures,	 chemical	 names,	 abbreviations	 and	 the	 references	 given	 for	 the	
purpose	of	this	text	of	the	benzene	phosphates		 9	 	 	 	
Table	1.2		 Structures,	chemical	names,	abbreviations	and	the	references	for	the	purpose	of	
this	text	of	the	biphenyl	polyphosphates	 12		 	 	 	 	 	
Table	2.1																			X-ray	diffraction	data	processing	and	model	refinement	statistics	for	SHIP2cd		 37	
	
Table	2.2		 Primers,	 annealing	 temperatures,	 and	 elongation	 times	 used	 for	 the	 PCR	
amplification	of	 full	 length	 INPP5D	 and	 its	 catalytic	domain	 (INPP5Dcd)	 from	a	
cDNA	 clone	 template.	 Flanking	 sequences	 required	 for	 ligation	 independent	
cloning	are	shown	in	bold	italics.		 44	 	 	 	 	 	 	
Table	3.1		 X-ray	diffraction	data	processing	and	model	refinement	statistics	for	AtIPK1-His	
BiPh(2,3’,4,5’,6)P5	/	BiPh	1	and	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	/	BiPh3	 	 86	
	
Table	4.1		 UV	absorbance	lmax	of	100	μM	biphenyl	phosphate	 	 	 121	
Table	4.2		 Binding	of	fluorescently	tagged	inositol	phosphates	to	AtIPK1	and	SHIP2cd	 142	
Table	4.3		 Binding	of	the	biphenyl	phosphates	to	AtIPK1,	SHIP1cd	&	SHIP2cd		 	 		151	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 X	
	
Index	of	Figures	
Figure	1.1		 The	structure	of	myo-inositol	and	Agranoff’s	turtle.	Taken	from	Irvine	and	Schell,	
2001.	 (a)	Haworth	projection	 (b)	The	 thermodynamically	 stable	 chair	 structure	
(c)	Agranoff’s	turtle	analogy.	 2	
Figure	1.2		 myo-inositol	biosynthesis	 3 
Figure1.3	 Schematic	 of	 signaling	 pathways	 dependent	 on	 the	 regulation	 of	
phosphoinositides.	Taken	from	Ooms	et	al.,	2009.	 5	
Figure	1.4	 Conserved	 4-phosphate	 position	 of	 the	 5-phosphatases.	 (A)	 P4IM	 residues	
within	 SHIP2	 (green)	 in	 complex	 with	 BiPh1	 (magenta).	 (B)	 P4IM	 residues	
within	INPP5B	(magenta)	 in	complex	with	BiPh3	(green).	Protein	residues	and	
ligands	represented	as	sticks.	 14		
Figure	2.1																	Domain	structure	of	the	inositol	5-phosphatases.	Taken	from	Ooms	et	al,	2009.	 16	
Figure	2.2		 Crystal	 structure	 of	 two	 SHIP2cd	 molecules.	 One	 molecule	 (green)	 has	 the	
biphenyl	(3,3’,4,4’,5,5)P6	bound	in	the	shallow	inositide	binding	pocket,	and	has	
additional	 interactions	 with	 a	 symmetry	 related	 molecule	 (grey).	 The	 flexible	
loop	 which	 is	 stabilised	 by	 interactions	 with	 the	 symmetry	 mate	 is	 shown	 in	
blue.	Taken	from	Mills	et	al,	2012.		 	 19	
Figure	2.3	 LigPlot	 ligand	 interaction	 diagram	 of	 the	 coordination	 of	 biphenyl	
(3,3’,4,4’,5,5)P6	by	SHIP2cd.	 	 20	
Figure	2.4	 Immobilised	 metal	 affinity	 purification	 of	 SHIP2cd-His.	 SDS-PAGE	 analysis	 of	
eluate	fractions	recovered	during	NiNTA	chromatography.	(1)	Protein	molecular	
weight	marker.	 (2)	 Empty.	 (3)	 Sample	of	 supernatant	post	 column	 loading.	 (4)	
Empty.	(5-10)	Fraction	number;	14,	16,	18,	20,	22	&	24,	respectively.	 	 31	
Figure	2.5		 Coomassie	 blue	 (left)	 and	 InVision	 staining	 (right)	 of	 purified	 SHIP2cd-His.	 (1)	
Protein	molecular	weight	marker	(2)	1:4	(v/v)	dilution	of	purified	SHIP2cd-His.	 	 32	
Figure	2.6		 SDS-PAGE	analysis	on	a	12.5	%	acrylamide	gel	of	proteolytic	cleavage	of	the	N-
terminal	 6xHis	 tag	 from	 SHIP2cd-His	 using	 ProTEV	 plus	 protease.	 (1)	 Protein	
molecular	 weight	 marker.	 (2)	 Empty.	 (3)	 SHIP2cd-His.	 (4)	 Empty.	 (5)	 SHIP2cd	
post	incubation	with	TEV	protease.	 	 33	
Figure	2.7		 SDS-PAGE	analyisis	on	a	10	%	gel	of	final	purified	SHIP2cd.	(1)	Protein	molecular	
weight	marker.	(2)	Empty.	(3)	Purified	SHIP2cd.	 	 34	
Figure	2.8		 Crystal	of	SHIP2cd	exposed	to	the	beamline	for	data	collection	at	the	Diamond	
Light	Source.	 	 35	
Figure	2.9		 SHIP2cd	 crystal	 structure	 represented	as	a	 cartoon	and	 coloured	by	 secondary	
structure.	Symmetry-related	SHIP2cd	molecules	are	shown	in	green.	(A)	The	two	
molecules	 in	 the	 asymmetric	 unit.	 (B)	 Chain	 B	 interaction	 with	 a	 symmetry-
related	molecule.	(C)	Chain	A	interaction	with	a	symmetry	related	molecule.		 	 38	
Figure	2.10		 Interactions	 between	 the	 (P4IM)-containing	 loop	 of	 chain	 B,	 and	 a	 symmetry	
related	lattice	neighbour.	Chain	B	is	shown	as	a	cartoon	representation	coloured	
by	secondary	structure.	BiPh1(blue)	and	residues	that	facilitate	loop	interactions	
and	 conformation	 are	 shown	 as	 sticks.	 Residues	 in	 green	 arise	 from	 the	
symmetry	related	chain	A.	 	 39	
Figure	2.11	 Conformation	 of	 the	 P4IM-containing	 loop	 in	 the	 SHIP2cd	 crystal	 structure.	
Double	difference	Fourier	electron	density	is	shown	as	a	blue	mesh	with	a	map	
contour	of	1.2	σ.	(A)	Chain	B.	(B)	Chain	A.		 	 40	 	
	 XI	
Figure	2.12		 Alignments	of	apo	SHIP2cd	(magenta)	and	SHIP2cd	BiPh(2,3’,4,5’,6)P5	structures	
(cyan)	 (Mills	 et	 al.,	 2012).	 BiPh(2,3’,4,5’,6)P5	 is	 represented	 as	 sticks	 and	
coloured	by	element.	 (A)	Cartoon	representation	of	 the	binding	site	secondary	
structure	 elements.	 (B)	 Overlay	 of	 side	 chains	 that	 have	 direct	 protein-ligand	
interactions	with	BiPh(2,3’,4,5’,6)P5.	Adapted	from	PDB	file	4A9C.	 	 41	
Figure	2.13		 Gel	 purified	 PCR	 amplified	 products	 from	 the	 pCR4-TOPO-INPP5D	 template	
analysed	 on	 a	 1	 %	 agarose	 gel.	 (1)	 1	 kb	 plus	 DNA	 ladder.	 (2)	 Empty.	 (3)	 Full	
length	INPP5D.	(4)	Catalytic	domain	fragment	of	INPP5D	(INPP5Dcd).	 	 45	
Figure	2.14		 Linearised	and	gel	purified	pNIC28-Bsa4	vector	analysed	on	a	1	%	agarose	gel.	
(1)	1	kb	plus	DNA	ladder.	(2)	Empty.	(3)	pNIC28-Bsa4	digested	with	BsaI.		 	 46	
Figure	2.15	 Colony	 screening	 by	 PCR	 amplification	 of	 INPP5Dcd	 from	 two	 kanamycin	
resistant	E.	coli	colonies	analysed	on	a	1%	agarose	gel.	(1)	1	kb	plus	DNA	ladder.	
(2)	Colony	1.	(3)	Colony	2.	 	 47	
Figure	2.16	 Small	scale	expression	testing	of	SHIP1cd-His	by	E.	coli	Rosetta2	cells.	SDS–PAGE	
analysis	 on	 a	 10%	 acrylamide	 gel	 of	 whole	 cell	 pellets	 from	 IPTG	 induced	
cultures	originating	from	two	separate	transformation	colonies.	 	 	
A	–	non-ITPG	induced	cultures	(1)	Protein	molecular	weight	marker.	(2)	Culture	
A.	(3)	Culture	B.		
B	–	Expression	cultures	supplemented	with	 IPTG	(1)	Protein	molecular	marker.	
(2)	Culture	A	+0.2	mM	IPTG.	(3)	Culture	A	+0.5	mM	IPTG.	(4)	Culture	B	+0.2	mM	
IPTG.	(5)	Culture	B	+0.5	mM	IPTG.	 	 48	 	 	
Figure	2.17		 SDS-PAGE	 analysis	 of	 whole	 cell	 pellets	 from	 the	 large	 scale	 expression	 of	
SHIP1cd-His	analysed	on	a	1%	agarose	gel.	(1)	Protein	molecular	weight	marker.	
(2)	Empty.	(3)	1	L	expression	culture.	(4)	Empty.	(5)	1	L	expression	culture.	 	 49	
Figure	2.18	 Immobilised	metal	 affinity	purification	of	 SHIP1cd-His.	 SDS-PAGE	analysis	on	a	
10%	acrylamide	gel	of	eluate	fractions	recovered	during	NiNTA	chromatography.	
(1)	Protein	molecular	weight	marker.	(2-8)	Column	elute	fractions	corresponding	
to	the	UV	absorbance	peak	at	280	nm.	Fraction	number;	14,	16,	18,	20,	22,	24	&	
26,	respectively.	 	 50	
Figure	2.19	 Size	 exclusion	 chromatography	 of	 SHIP1cd-His.	 SDS-PAGE	 analysis	 on	 a	 10%	
acrylamide	 gel	 of	 elute	 fractions	 recovered	 from	 a	 sepharose	 gel	 filtration	
column.	 (1)	 Protein	 molecular	 weight	 marker.	 (2-8)	 Column	 elute	 fractions	
corresponding	to	the	UV	absorbance	peaks	at	280	nm.	Fraction	number;	7,	9,	11,	
13,	15,	17	&	19,	respectively.	 	 52	
Figure	2.20		 Coomassie	 blue	 (left)	 and	 InVision	 staining	 (right)	 of	 purified	 SHIP1cd-His.	 (1)	
Protein	molecular	weight	marker	(2)	1:2	(v/v)	dilution	of	purified	SHIP1cd-His.	 	 53	
Figure	2.21	 SDS-PAGE	analysis	on	a	12.5	%	acrylamide	gel	of	the	proteolytic	cleavage	of	the	
N-terminal	 6xHis	 tag	 from	SHIP1cd-His	using	ProTEV	plus	protease.	 (1)	Protein	
molecular	 weight	 marker.	 (2)	 Empty.	 (3)	 SHIP1cd-His.	 (4)	 SHIP1cd	 post	
incubation	with	TEV	protease.	 	 55	
Figure	2.22		 Immoblised	metal	affinity	purification	post	proteolytic	 cleavage	of	SHIP1cd-His	
with	 TEV	 protease.	 Samples	 of	 eluate	 fractions	 from	 the	 NiNTA	 column	 upon	
washing	 with	 NiNTA	 buffer	 A,	 Analysed	 on	 a	 12.5	 %	 acrylamide	 gel.	 (1)	
Molecular	 weight	 marker.	 (2)	 Initial	 10	 mL	 fraction.	 (3-6)	 Subsequent	 2	 mL	
fractions.	(7)	Final	10	mL	wash	with	NiNTA	buffer	B.	 	 56	
Figure	2.23		 SDS-PAGE	analyisis	on	a	12.5	%	gel	of	final	purified	SHIP1cd-His	and	SHIP1cd.	(1)	
Protein	 molecular	 weight	 marker.	 (2)	 Empty.	 (3)	 Purified	 SHIP1cd-His.	 (4)	
Purified	SHIP1cd.	 	 57	
Figure	2.24		 Alignment	of	 chain	B	of	 the	 SHIP2cd	 structure	 (cyan)	 to	 the	model	of	 SHIP1cd	
(magenta),	as	predicted	by	SWISS-MODEL	homology-modelling	server.	 	 59	
	 XII	
Figure	2.25	 The	 conserved	 ligand	 coordinating	 residues	 across	 all	 inositol	 5-phosphatase	
structures;	 alignment	 of	 these	 residues	 in	 SHIP2cd	 (cyan)	 and	 the	 SHIP1cd	
predicted	structure	(magenta).	 	 60	
Figure	2.26		 ENDscript	(Robert	and	Gouet,	2014)	representations	of	the	secondary	structure,	
solvent	accessibility	and	hydrophobicity	of	SHIP2cd,	and	the	homology	model	of	
SHIP1cd	 	 62	
	
Figure	3.1		 Overall	 structure	 of	 AtIPK1	 (taken	 from	 Gonzalez	 et	 al,	 2010).	 Cartoon	
representation	 indicting	 the	different	 lobes	and	 the	hinge	 that	connects	 them.	
The	 N-lobe	 is	 orange,	 and	 the	 C-lobe	 green	with	 the	 CIP	 region	 coloured	 dark	
pink.	 The	hinge	 connecting	hinge	 is	 blue.	 The	 IP5	 substrate	 and	AMPPNP	 (ATP	
analogue)	are	represented	as	black	sticks.	Magnesium	and	zinc	ions	are	red	and	
cyan	spheres.		 	 69	
Figure	3.2		 Conformational	changes	of	AtIPK1	upon	ligand	binding	(taken	from	Banos-Sanz	
et	 al,	 2012).	 Superposition	 of	 the	 open	 (red)	 and	 closed	 (blue)	 forms.	 The	
substrate	 and	 co-factor	 of	 the	 closed	 form	 are	 shown	 as	 purple	 surface	
representations.	 	 71	
Figure	3.3	 SDS-PAGE	 analysis	 on	 a	 10	%	 acrylamide	 gel	 of	 a	whole	 cell	 pellet	 originating	
from	 a	 1	 L	 expression	 culture	 of	 AtIPK1-His.	 (1)	 Protein	 molecular	 weight	
marker.	 (2)	Empty.	 (3)	1:1.5	 (v/v)	of	pelleted	culture	 to	SDS-loading	buffer.	 (4)	
1:10	(v/v)	dilution	of	lane	3	with	SDS-loading	buffer.	 	 77	
Figure	3.4		 Immobilised	metal	affinity	purification	of	AtIPK1-His.	SDS-PAGE	analysis,	on	a	10	
%	gel,	of	eluate	 fractions	 recovered	during	NiNTA	chromatography.	 (1)	Protein	
molecular	 weight	 marker.	 (2-6)	 Fraction	 number;	 15,	 17,	 19,	 21	 &	 23,	
respectively.	 	 78	
Figure	3.5		 Size	 exclusion	 chromatography	 of	 His-AtIPK1.	 SDS-PAGE	 analysis	 on	 a	 12.5	 %	
acrylamide	gel	of	the	fractions	from	sepharose	gel	filtration	column	eluate	that	
contain	 His-AtIPK1.	 (1)	 Protein	 molecular	 weight	 marker.	 (3,	 5	 ,7)	 Fraction	
number;	12,	14	&	16,	respectively.	(2,4,6)	Empty.	 	 79	
Figure	3.6		 SDS	PAGE	analysis	of	purified	AtIPK1-His	on	a	10	%	gel.	Coomassie	blue	staining	
(left)	and	 InVision	staining	 (right).	 (1)	Protein	molecular	weight	 ladder	 (2)	1:15	
dilution	of	purified	AtIPK1-His.	 	 80	
Figure	3.7		 Immoblised	 metal	 affinity	 purification	 post-proteolytic	 cleavage	 of	 His-AtIPK1	
with	 3C	 protease.	 Samples	 of	 eluate	 fractions	 from	 the	 NiNTA	 column	 upon	
washing	 with	 NiNTA	 buffer	 A,	 Analysed	 on	 a	 12.5	 %	 acrylamide	 gel.	 (1)	
Molecular	 weight	 marker.	 (2)	 Initial	 10	 mL	 fraction.	 (3-7)	 Subsequent	 2	 mL	
fractions.	(8)	Final	10	mL	wash	with	NiNTA	buffer	B.	 	 82	
Figure	3.8		 Example	 of	 an	 AtIPK1-His	 crystal	 exposed	 for	 data	 collection	 at	 the	 Diamond	
Light	 Source.	 Image	 is	 of	 an	 AtIPK1-His	 BiPh(3,3’,4,4’,5,5’)P6	 crystal	 before	
exposure	to	the	beamline.	 	 83	
Figure	3.9		 AtIPK1-His	BiPh(2,3’,4,5’,6)P5	and	ADP	crystal	structure	represented	as	a	cartoon	
and	 coloured	 by	 secondary	 structure	 elements.	 (A)	 The	 two	molecules	 in	 the	
asymmetric	 unit.	 (B)	 A	 single	molecule	 of	 the	 asymmetric	 unit	 -	 Chain	 F.	 The	
active	 site	 is	 indicated	 by	 the	 presence	 of	 BiPh(2,3’,4,5’,6)P5	 and	 ADP,	 and	 is	
represented	as	blue	sticks.	The	two	magnesium	ions	in	the	active	site	are	shown	
as	green	spheres,	and	zinc	as	a	grey	sphere.	A	tris	molecule	that	associates	with	
the	protein	upon	crystallisation	is	shown	as	orange	sticks.	 	 88	
Figure	3.10		 The	 firemans	grip	 interaction	 formed	by	the	6xHis	 tags	 from	two	neighbouring	
asymmetric	units	between	molecule	F	(magenta)	and	molecule	A	(blue).	 	 89	
	 	
	 XIII	
Figure	3.11	 Active	sites	of	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	and	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	
showing	 binding	 positions	 and	 simulated	 annealing	 omit	maps.	 (A)	 AtIPK1-His	
BiPh(2,3’,4,5’,6)P5	 (B)	 AtIPK1-His	 BiPh(3,3’,4,4’,5,5’)P6.	 Ligands	 are	 shown	 as	
green	sticks,	ADP	as	red	sticks	and	magnesium	atoms	as	magenta	spheres.	The	
density	maps	are	represented	as	a	blue	mesh	and	are	at	a	contour	level	of	1.2	σ.	 	 91	
Figure	3.12		 Ligplot	 diagrams	 of	 the	 contacts	 formed	 by	 the	 BiPh(2,3’,4,5’,6)P5	 and	
BiPh(3,3’,4,4’,5,5’)P6	ligand	in	the	active	site	of	AtIPK1-His.	(A)	BiPh(2,3’,4,5’,6)P5	
(B)	BiPh(3,3’,4,4’,5,5’)P6.	 	 93	
Figure	3.13		 Global	 alignment	 of	 AtIPK1-His	 BiPh(2,3’,4,5’,6)P5	 (magenta)	 and	 AtIPK1-His	
BiPh(3,3’,4,4’,5,5’)P6	 (blue)	 complexes.	 (A)	 The	overlaid	 active	 sites	 of	 the	 two	
complexes.	 (B)	 Active	 site	 residues	 that	 co-ordinate	 the	 ligands.	
BiPh(2,3’,4,5’,6)P5	 and	BiPh(3,3’,4,4’,5,5’)P6	 can	 been	 seen	 in	 the	 active	 site	 of	
the	 structures	 in	 both	 images,	 and	 are	 represented	 as	 sticks.	 The	magnesium	
ions	are	shown	as	spheres	and	ADP	as	sticks,	coloured	according	to	the	complex	
to	which	they	belong.	Phosphate	positions	are	labeled	according	to	BiPh1.	 	 96	
Figure	3.14		 Global	 alignment	 of	 the	 AtIPK1-His	 myo-IP6	 (green)	 with	 (1)	 AtIPK1-His	
BiPh(2,3’,4,5’,6)P5	 (magenta)	and	 (2)	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	 (blue);	 (A)	
The	overlaid	active	sites	of	the	two	complexes.	(B)	Active	site	residues	that	co-
ordinate	 the	 ligands.	 Ligands	 are	 represented	 as	 sticks,	 magnesium	 ions	 as	
spheres	 and	 ADP	 as	 sticks,	 coloured	 according	 to	 the	 complex	 to	 which	 they	
belong.	 	 98	
Figure	3.15			 Global	 alignment	 of	 AtIPK1-His	 Bz(1,2,4,5)P4	 (cyan)	 with	 (1)	 AtIPK1-His	
BiPh(2,3’,4,5’,6)P5	(magenta),	and	(2)	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	(blue);	(A)	
The	overlaid	active	sites	of	the	two	complexes.	(B)	Active	site	residues	that	co-
ordinate	 the	 ligands.	 Ligands	and	ADP	are	 represented	as	 sticks	&	magnesium	
ions	 as	 spheres,	 coloured	 according	 to	 the	 complex	 to	 which	 they	 belong.	
Phosphates	are	numbered	according	to	Bz3.	 	 101	
Figure	3.16		 Overlay	of	the	binding	positions	of	ligands	in	complex	with	AtIPK1-His.	(A,B	&	C)	
Views	of	 ligand	binding	from	different	perspectives;	myo-IP6	(green),	Bz3	(red),	
BiPh(2,3’,4,5’,6)P5	 (magenta)	 &	 BiPh(3,3’,4,4’,5,5’)P6	 (blue).	 The	 phosphates	
(positions)	labeled	are	those	of	myo-IP6.	 	 104	
Figure	3.17	 The	 structure	of	 the	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	 active	 site	 superimposed	on	
to	 the	 three	 distinct	 binding	 conformations	 of	 AtIPK1.	 The	 N-	 and	 C-lobes	 of	
AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(red	&	black)	and	the	AtIPK1	conformations	(pink	
&	grey)	are	represented	as	a	cartoon,	and	BiPh(2,3’,4,5’,6)P5	(blue)	as	sticks.	(A)	
The	 apo-form	 of	 a	 W129A	 AtIPK1	 mutant,	 which	 denotes	 the	 “open”	
conformation	 of	 the	 enzyme	 (PDB	 4AXC).	 (B)	 The	AtIPK1	AMPPNP	 complex	 in	
the	“half-closed”	conformation.	AMPPNP	(orange)	and	ADP	(blue)	are	shown	as	
sticks	 (PDB	 4XAD).(C)	 The	 AtIPK1	 myo-IP6	 ADP	 complex	 that	 describes	 the	
“closed”	 conformation	 of	 the	 protein	 (PDB	 2XAM).	 The	 myo-IP6	 and	 ADP	
molecule	associated	with	the	complex	are	shown	as	orange	sticks.	 	 107	
Figure	3.18		 The	structure	of	the	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	active	site	superimposed	on	
to	 the	 three	 distinct	 binding	 conformations	 of	 AtIPK1.	 The	 N-	 and	 C-lobes	 of	
AtIPK1-His	 BiPh(3,3’,4,4’,5,5’)P6	 (red	 &	 black)	 and	 the	 AtIPK1	 conformations	
(pink	&	 grey)	 are	 represented	 as	 a	 cartoon,	 and	BiPh(3,3’,4,4’,5,5’)P6	 (blue)	 as	
sticks.	(A)	The	apo-form	of	a	W129A	AtIPK1	mutant,	which	denotes	the	“open”	
conformation	 of	 the	 enzyme	 (PDB	 4AXC).	 (B)	 The	AtIPK1	AMPPNP	 complex	 in	
the	“half-closed”	conformation.	AMPPNP	(orange)	and	ADP	(blue)	are	shown	as	
sticks	 (PDB	 4XAD).	 (C)	 The	 AtIPK1	 myo-IP6	 ADP	 complex	 that	 describes	 the	
“closed”	 conformation	 of	 the	 protein	 (PDB	 2XAM).	 The	 myo-IP6	 and	 ADP	
molecule	associated	with	the	complex	are	shown	as	orange	sticks.	 	 109	
Figure	4.1		 UV	 absorbance	 wave	 scans	 of	 100	 μM	 biphenyl	 phosphate	 and	 benzene	
phosphate	in	a	96-well	quartz		plate.	 	 121	
	 XIV	
Figure	4.2		 Fluorescence	 properties	 of	 100	μM	biphenyl	 phosphates.	 Intensity	 readings	 at	
emission	 wavelength	 340	 nm.	 Values	 are	 corrected	 against	 the	 background	
signal	from	the	buffer.	 	 123	
Figure	4.3		 Fluorescence	 wave	 scans	 of	 100	 μM	 benzene	 polyphosphate	 (A)	 Excitation	
spectra	at	a	fixed	an	emission	wavelength	of	310	nm.	(B)	Emission	spectra	fixed	
at	an	excitation	wavelength	of	275	nm.	Spectra	are	corrected	for	against	buffer	
background	signal.	 	 125	
Figure	4.4		 Fluorescence	properties	of	100	μM	benzene	polyphosphates.	Intensity	readings	
at	 a	 fixed	 emission	 wavelength	 of	 340	 nm.	 Values	 are	 corrected	 against	 the	
background	 signal	 from	 the	 buffer.	 Only	 benzene	 1,2,4,5-tetrakisphosphate	
(Bz3)	&	 benzene	 1,2,4-trisphosphate	 (Bz5)	 are	 shown,	 since	 only	 they	 possess	
fluorescent	properties	at	these	wavelengths.	 	 127	
Figure	4.5		 SHIP2cd	 vs.	 biphenyl	 2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2).	 Detection	 of	
reaction	products	by;	(A)	Absorbance	at	270	nm	(B)	Fluorescence	at	ex	270	nm,	
em	 330	 nm	 (C)	 Suppressed	 ion	 conductivity,	 left	 to	 right	 the	 arrows	 indicate	
peaks	 of	 inorganic	 phosphate	 and	 biphenyl(2,2’,4,4’,5,5’)P6,	 respectively.	 The	
structure	of	BiPh2	is	shown	in	the	top	right.	 	 130	
Figure	4.6		 SHIP2cd	 vs.	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	 (BiPh3).	 Detection	 of	
reaction	products	by;	(A)	Absorbance	at	270	nm	(B)	Fluorescence	at	ex	270	nm,	
em	 330	 nm	 (C)	 Suppressed	 ion	 conductivity,	 left	 to	 right	 the	 arrows	 indicate	
peaks	of	inorganic	phosphate	and	biphenyl(3,3’,4,4’,5,5’)P6,	respectively.	 	 132	
Figure	4.7		 Turnover	 of	 biphenyl	 2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2)	 by	 SHIP2cd	
analysed	by	anion	exchange	chromatography.	Elution	of	BiPh2	from	the	column	
was	detected	by	fluorescence	at	λex	=	285	nm	λem	=	330	nm.	Inset	in	the	top	right	
is	a	progress	of	reaction	curve	for	the	assay	and	the	structure	of	BiPh2	below.	 	 135	
Figure	4.8		 Turnover	 of	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	 (BiPh3)	 by	 SHIP1cd	
analysed	by	anion	exchange	chromatography.	Elution	of	BiPh3	from	the	column	
was	detected	by	fluorescence	at	λex	=	285	nm	λem	=	330	nm.	Inset	in	the	top	right	
is	a	progress	of	reaction	curve	for	the	assay	and	the	structure	of	BiPh3	below.	 	 137	
Figure	4.9		 Progress	 of	 reaction	 for	 the	 turnover	 biphenyl	 phosphates	 by;	 (A)	 SHIP1cd	 (B)	
SHIP2cd.	Fractional	change	in	peak	area	(%).	 	 138	
Figure	4.10		 SHIP2	 vs.	 BiPh(3,3’,4,4’,5,5’)P6	 preliminary	 kinetics	 data.	 Loss	 in	 fluorescence	
from	BiPh3	followed	at	λex	=	265	nm	λem	=	330	nm.	SHIP2cd	fixed	at	1.5	μM.	 	 140	
Figure	4.11		 Dose-response	 binding	 curves	 of;	 (A)	 AtIPK1,	 (B)	 SHIP1cd	 &	 (C)	 SHIP2cd	 to	 2-
FAM-IP5.	Binding	is	monitored	by	the	change	in	polarisation	of	2-FAM-IP5	upon	
increased	concentration	of	protein,	λex	=	485,	λem	=	520.		 	 144	
Figure	4.12		 Inhibition	 curves;	 Displacement	 of	 2-FAM-IP5	 by	 inositol	 1,3,4,5-
tetrakisphosphate	and	inositol	1,3,4,5,6-pentakisphosphate	from	(A)	SHIP1cd	&	
(B)	SHIP2cd.	 IC50	values	are	shown	in	black	for	displacement	with	IP4	and	grey	
for	IP5.	 	 146	
Figure	4.13		 Inhibition	 curves;	 displacement	 of	 2-FAM-IP5	 by	 biphenyl	 (3,3’,4,4’,5,5’)P6	
(BiPh3)	 from	 (A)	 AtIPK1,	 (B)	 SHIP1cd	 &	 (C)	 SHIP2cd.	 Protein	 concentration	 is	
fixed	at	200	nM,	probe	at	2	nM.	 	 148	
Figure	4.14		 Displacement	of	2-FAM-IP5	by	AS	1949490,	a	SHIP2	inhibitor	with	a	reported	30-
fold	decreased	affinity	for	SHIP1.	(A)	SHIP1cd.	(B)	SHIP2cd.	 	 153	
Figure	4.15															Binding	of	3-α-aminocholestane	to	SHIP1cd	 	 155	
	 	
	 XV	
Figure	5.1		 Results	 of	 the	 Diversity	 Set	 II	 screen	 for	 AtIPK1,	 polarisation	 results	 for	 each	
compound	 are	 randomised	 for	 visual	 purposes	 and	 raw	 polarisation	 values	
plotted	against	the	y-axis.	Points	shown	in	red	 indicate	 ‘hits’	that	were	chosen	
for	 further	 investigation.	The	arrow	 indicates	a	hit	 that	appeared	 in	results	 for	
both	AtIPK1	and	SHIP2cd.	 	 164	
Figure	5.2		 Results	of	the	Approved	Oncology	Drugs	Set	V	screen	for	(A)	AtIPK1,	(B)	SHIP2cd	
&	(C)	SHIP1cd.	Polarisation	results	for	each	compound	are	randomised	for	visual	
purposes	and	raw	polarisation	values	plotted	against	the	y-axis.	Points	shown	in	
red	 indicate	 ‘hits’	 that	 were	 chosen	 for	 further	 investigation.	 The	 arrow	
indicates	a	hit	that	appeared	in	results	for	all	proteins.	 	 166	
	
Figure	5.3			 Purpurogallin	 as	 a	 2-FAM-IP5	 displacing	 ligand	 (A)	 AtIPK1,	 (B)	 SHIP2cd.	 Errors	
bars	(SE)	are	shown	or	are	smaller	than	the	symbol	used.	 	 171	
Figure	5.4		 5,6,7,8,4’-pentahydroxyflavone	as	 a	 2-FAM-IP5	displacing	 ligand	 (A)	AtIPK1,	 (B)	
SHIP2cd.	Errors	bars	(SE)	are	shown	or	are	smaller	than	the	symbol	used.	 	 173	
Figure	5.5		 Galloflavin	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd.	Errors	bars	
(SE)	are	shown	or	are	smaller	than	the	symbol	used.	 	 175	
Figure	5.6		 Taken	 from	 Ichihara	 et	 al.,	 2013.	 Example	 of	 the	 incorporation	 of	 groups	 to	
increase	bioavailability	and	improved	affinity	for	the	target	protein.	 	 177	
Figure	5.7																	Structures	of;	(A)	Cynarin,	(B)	Chaetochromin	 178	
Figure	5.8		 Estramustine	sodium	phosphate	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	
SHIP2cd,	(C)	SHIP1cd.	Errors	bars	(SE)	are	shown	or	are	smaller	than	the	symbol	
used.	 	 181	
Figure	5.9		 Valrubicin	as	a	2-FAM-IP5	displacing	 ligand	 (A)	AtIPK1,	 (B)	SHIP2cd.	Errors	bars	
(SE)	are	shown	or	are	smaller	than	the	symbol	used.	 	 183	
Figure	5.10															Pomalidomide	displacing	2-FAM-IP5	from	AtIPK1.	 185	
Figure	5.11		 SHIP1cd	 exhibiting	 increased	 affinity	 for	 2-FAM-IP5	 upon	 titration	 with	 two	
AODV	screen	compounds;	(A)	Bosutinib	&	(B)	Crizotinib.			 	 187	
Figure	5.12		 Fractional	 change	 in	 fluorescence	 intensity	 of	 AtIPK1	 upon	 binding	 inositol	
1,3,4,5,6	 pentakisphosphate	 (IP5).	 Error	 bars	 show	 the	 standard	 errors	 in	 that	
data.	 	 189	
Figure	5.13	 Fractional	change	in	the	intrinsic	fluorescence	intensity	of	AtIPK1	upon	binding	
compounds	 were	 positive	 hits	 as	 potential	 inhibitors	 from	 the	 diversity	 set	 II	
library.	 (A-C);	Purpurogallin,	5,6,7,8,4’-pentahydroxyflavone	&	galloflavin.	Error	
bars	show	the	standard	errors	in	that	data.	 	 192	
Figure	5.14		 Fractional	change	in	the	intrinsic	fluorescence	intensity	of	AtIPK1	upon	binding	
compounds	that	were	positive	hits	as	potential	 inhibitors	 for	AtIPK1	only	 from	
the	diversity	 set	 II	 library.	 (A)	Cynarin	 (B)	Chaetochromin.	Error	bars	 show	 the	
standard	errors	in	that	data.	 	 194	
Figure	5.15		 Coupled	enzyme	assay;	phosphorylation	of	inositol	1,3,4,5,6	pentakisphosphate	
by	AtIPK1	and	inhibition	of	phosphorylation	by	100	µM	IP6.		 	 196	
Figure	5.16		 Fractional	 change	 in	 velocity	 of	 the	 phosphorylation	 of	 inositol	 1,3,4,5,6	
pentakisphosphate	by	AtIPK1	upon	increasing	concentrations	of	purpurogallin.	 	 197	
	 	
	 XVI	
Acknowledgements	
	
Firstly,	 I	would	 like	 to	 thank	my	 supervisor	Dr	 Charles	 Brearley	 for	 providing	me	with	
such	a	great	opportunity	to	work	and	study	with	him	and	the	rest	of	lab	1.44.	An	even	
bigger	thank	you	for	sourcing	funding	for	the	project,	and	the	ongoing	support	and	kind	
patience	I	have	received	and	am	most	grateful	for	at	a	particularly	trying	time	in	my	life.	
My	 secondary	 supervisor	 Dr	 Andrew	 Hemmings,	 who	 provided	 unequivocal	 protein	
crystallography	 and	 structure	 guidance	 as	well	 as	 offering	wise	words	 and	 a	 place	 to	
vent	(cry).	
	
Hayley,	 you	 guided	me	 in	 every	 way	 possible	 for	 the	 past	 four	 years,	 five	 if	 you	 can	
include	when	 I	was	 a	mere	 21	 year	 old	 undergraduate	 project	 student	 in	 the	 lab.	 It’s	
hard	 to	 find	 a	 suitable	 way	 to	 ever	 express	 my	 gratitude.	 You	 offered	 me	 so	 much	
understanding,	 kindness	 and	 advice,	 as	 well	 as	 your	 brilliant	 scientific	 knowledge.	 It	
wouldn’t	have	happened	without	you,	and	I’m	not	sure	I	would	have	stuck	it	out.	Most	
of	 all,	 you	 are	 a	 brilliant	 friend	 who	 always	 provided	 entertainment	 during	 long	 lab	
hours	and	it	was	a	pleasure	working	with	you	(plus	you	make	good	cake!).	Megan	and	I	
are	both	very	lucky	to	have	had	you	guide	us	through	our	Ph.D.	projects.	
	
An	ongoing	and	never-ending	thank	you	is	owed	to	my	parents	who	have	always	made	
me	 feel	 so	 proud	 of	 myself,	 and	 have	 provided	 generous	 and	 unwavering	 support	
throughout	my	academic	studies.	They	have	always	encouraged	me	to	do	what	makes	
me	happy	without	judgement,	pressure	or	expectation.	
	
I’d	also	like	to	thank	Megan	Gilmartin,	Arthur	Li,	Marcus	Edwards	for	their	help,	support,	
advice,	and	last	minute	pre-viva	preparations.	Alexandra	Howat,	who	as	an	already	long	
standing	friend	provided	invaluable	moral	support	when	experiencing	post-graduate	life	
together.	 And	 finally,	 Eileen	 Gallagher	 who	 left	 the	 lab	 for	 pastures	 new	 part	 way	
through	 the	project	 but	whose	PCR	 skills,	 cat	 stories	 and	hilarity	were	missed	 for	 the	
remainder.	
	
Chapter	1	-	Introduction	
1		
	
Chapter	1	
	
1.1 Introduction	
	
1.1.1 Inositol	polyphosphates	and	phosphoinositides	
All	 eukaryotic	 organisms	 and	 most	 archaea	 contain	 inositol	 phosphates	 (inositides)	
and/or	 inositol-containing	phospholipids	(phosphoinositides)	that	have	diverse	roles	 in	
biochemical,	physiological	and	developmental	processes,	and	particularly	in	animal	cells	
in	cell	proliferation	and	differentiation	(Michell,	2009,	Michell,	2011).	Though,	in	the	case	
of	inositides	(phytate,	inositol	hexakisphosphate),	first	identified	as	a	phosphate	storage	
compound	in	seeds,	the	remit	of	these	molecules	has	been	extended	to	 include	many	
aspects	 of	 cell	 biology.	 In	 recent	 years,	 these	molecules	 have	 been	 implicated	 in	 the	
control	 of	many	 nuclear	 processes	 including	 the	 regulation	 of	 chromatin	 remodeling,	
gene	expression,	mRNA	export	and	DNA	repair	(Irvine,	2003,	York,	2006).		
	
1.1.1a	myo-inositol	structure	and	nomenclature	
Myo-inositol	is	the	simple	framework	upon	which	inositol	polyphosphates	(IPs)	are	built.	
IPs	exclusively	contain	just	inositol	and	phosphate,	and	are	water	soluble.	Myo-inositol	
consists	of	a	six-carbon	ring	(cyclohexane),	each	with	hydroxyl	moieties	and	a	hydrogen	
atom.	It	is	the	most	common	of	the	inositol	stereoisomers	found	in	nature,	with	a	further	
eight	 stereoisomers	 found	 in	 nature	 in	 which	 the	 axial/equatorial	 orientation	 of	 the	
hydroxyl	groups	vary,	but	 they	will	not	be	discussed	 further	 in	 this	 text	 (Turner	et	al.,	
2012).	Myo-inositol	(Ins)	has	an	axial	hydroxyl	group	at	the	2-position	of	the	ring	with	the	
remainder	 of	 the	 hydroxyl	 groups	 positioned	 equatorially.	 It	 assumes	 a	
thermodynamically	 stable	 chair	 conformation.	 To	 help	 with	 its	 visualisation	 and	
nomenclature	 it	 is	 often	 likened	 to	 a	 turtle	 in	 an	 analogy	 called	 Agranoff’s	 turtle	
(Agranoff,	1978)	(Figure	1.1).		
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The	 carbon	 positions	 are	 analogous	 to	 the	 turtle’s	 extremities	 and	 are	 labeled	
anticlockwise	using	 the	D-numbering	 system	beginning	with	 its	 front	 right	 flipper,	 the	
turtle’s	head	is	the	axial	hydroxyl	whilst	the	flippers	and	tail	are	the	hydroxyl	groups	that	
lie	in	the	plane	of	the	ring	(equatorial).	Ins	is	achiral	due	to	a	plane	of	reflection	within	
the	molecule	that	lies	along	the	C2	-	C5	axis,	but	substitution	of	certain	hydroxyl	groups	
can	make	 it	 optically	 active.	 Inositol	 polyphosphates	 (IPs),	 as	 the	 name	 suggests,	 are	
phosphorylated	inositols.	There	are	63	possible	IPs	(excluding	those	with	pyrophosphate	
moieties,	more	correctly	called	diphosphoinositol	phosphates)	and	most	of	these	inositol	
phosphates	exist	biologically,	though	only	a	few	have	been	extensively	studied	and	their	
metabolisms	defined	(Irvine	and	Schell,	2001).	
	
Inositol	 lipids	 (phosphoinositides),	 in	 addition	 to	 inositol	 and	 phosphate	 contain	 a	
hydrophobic	component	usually	consisting	of	two	fatty	acids	esterified	to	a	diacylglycerol	
moiety,	with	the	1-hydroxyl	of	the	inositol	ring	attached	through	a	diester	phosphate.	For	
many	years,	inositol	lipid	research	dominated	over	inositol	phosphates	due	to	their	roles	
in	important	cellular	processes.	They	can	be	phosphorylated	at	the	3,	4,	&	5	positions	to	
create	an	array	of	7	molecules	that	have	discrete	functions	in	signalling	pathways	(Astle	
et	al.,	2011).	 	
Figure	1.1	–	The	structure	of	myo-inositol	and	Agranoff’s	turtle.	Taken	from	Irvine	and	Schell,	2001.	(a)	Haworth	
projection	(b)	The	thermodynamically	stable	chair	structure	(c)	Agranoff’s	turtle	analogy.	
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1.1.1b	General	synthesis	
Before	considering	the	biosynthesis	of	the	physiologically	relevant	inositol	phosphates	it	
is	necessary	to	start	with	the	unit	upon	which	they	are	built.	The	route	in	which	Ins	 is	
synthesised	has	been	referred	to	as	the	Loewus	pathway	(Eisenberg	et	al.,	1964,	Chen	
and	Charalampous,	1966,	Sherman	et	al.,	1969b,	Loewus	and	Loewus,	1980,	Loewus	et	
al.,	1980).	The	synthesis	of	Ins	begins	with	the	conversion	of	D-glucose-6-phosphate	to	
1D-myo-inositol	 3-phosphate	 (Ins3P),	 catalysed	 by	myo-inositol-3-phosphate	 synthase	
(MIPS)	(Eisenberg,	1967,	Barnett	et	al.,	1973,	Sherman	et	al.,	1969a).	This	is	followed	by	
dephosphorylation	by	myo-inositol	monophosphatase	(IMP)	(Eisenberg,	1967,	Gee	et	al.,	
1988,	 Yoshikawa	 et	 al.,	 1997)	 (Figure	 1.2).	Although	 IMP	 is	 acting	 upon	 Ins3P	 in	 this	
scheme	 it	 can	 also	 dephosphorylate	 other	 isomers	 of	 inositol	 phosphates,	 excluding	
inositol	2-phosphate,	and	cannot	dephosphorylate	 inositol	phosphates	with	additional	
phosphate	moieties	(Eisenberg,	1967,	Gee	et	al.,	1988,	Yoshikawa	et	al.,	1997).	
	
	
Figure	1.2	–	myo-inositol	biosynthesis 
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Inositol	is	incorporated	into	lipids	by	the	chemical	combination	of	activated	phosphatidic	
acid	(CMP-PtdOH)	to	form	phosphatidylinositol	(PtdIns).	The	liberation	of	Ins(1,4,5)P3	by	
the	receptor-activated	and	PtdIns(4,5)P2-directed	phospholipase	C	(PLC)	 isoforms,	 is	 in	
eukaryotes,	an	additional	route	of	production	of	this	specific	IP3	that	lends	itself	to	the	
production	of	the	higher	 inositol	phosphates.	Animals	and	yeast	depend	on	this	 ‘lipid-
dependent’	pathway	to	produce	the	inositol	phosphates	through	IP3	to	IP6,	but	plants	and	
slime	 moulds,	 and	 perhaps	 also	 animal	 cells,	 have	 an	 added	 ability	 to	 sequentially	
phosphorylate	from	Ins3P	through	to	 IP6,	omitting	the	 lipid	 intermediate	(Brearley	and	
Hanke,	1996,	Odom	et	al.,	2000,	Ongusaha	et	al.,	1998,	Saiardi	et	al.,	1999,	Stephens	and	
Irvine,	1990,	York	et	al.,	1999).	Polyphosphoinositides	have	not	been	shown	to	exist	in	
prokaryotes.	 Although	 PtdIns	 has	 been	 identified	 in	 some	 prokaryotes,	 no	 inositol	
phosphates	derived	from	membrane	lipids	have	been	found	so	far,	nor	has	the	route	by	
which	prokaryotes	break	down	inositol	lipids	been	characterised	(Irvine,	2005,	Lee	and	
Ballou,	1964).	
As	mentioned	previously,	Ins3P	is	generated	by	MIPS	during	Ins	synthesis,	in	addition	to	
this	 it	 is	known	that	 in	plants	and	slime	moulds	 Ins3P	can	be	synthesised	 from	 Ins	by	
phosphorylation	 via	 an	 inositol	 3-kinase	 (English	 et	 al.,	 1966,	 Loewus	 et	 al.,	 1982,	
Stephens	and	Irvine,	1990).	Furthermore,	in	animals	Ins3P	can	be	produced	as	a	product	
of	dephosphorylation	of	Ins(3,4)P2	by	inositol-3,4-bisphosphate	4-phosphatase	(Howell	
et	 al.,	 1989,	 Norris	 et	 al.,	 1995,	 Norris	 et	 al.,	 1997).	 This	 enzyme	 can	 also	 hydrolyse	
Ins(1,3,4)P3	to	Ins(1,3)P2.	
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1.1.2 Physiological	 roles	 and	 metabolism	 of	 Inositol	 phosphates	 and	
phosphoinositides	
	
1.1.2a	Diverse	signaling	roles	of	phosphoinositides	–	regulation	of	Akt	activation	and	
human	disease	
Following	 receptor	 activation	 (eg.	 receptor	 tyrosine	 kinase)	 by	 an	 agonist,	 PI3K	
(phosphoinositide	 3-kinase)	 is	 recruited	 to	 the	 membrane	 where	 phosphorylation	 of	
phosphatidylinositol	4,5-bisphosphate	(PtdIns(4,5)P2)	occurs	to	generate	PtdIns(3,4,5)P3.	
This	then	recruits	proteins	with	lipid-binding	domains	to	the	membrane,	for	example	the	
serine/threonine	kinase	Akt	(protein	kinase	B)	(Figure	1.3).		
	
	
	 	
Figure	1.3	–	Schematic	of	signaling	pathways	dependent	on	the	regulation	of	phosphoinositides.	Taken	from	Ooms	
et	al.,	2009.	
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The	 activating	 protein	 of	 Akt,	 phosphoinositide–dependent	 kinase	 (PDK1)	 is	 also	
recruited.	The	Pleckstrin	Homology	(PH)	domain	of	Akt	can	bind	to	both	PtdIns(3,4,5)P3	
and	PtdIns(3,4)P2	and	on	doing	so	becomes	phosphorylated	and	activated	by	PDK1	and	
mTORC2	(mammalian	target	of	rapamycin	complex	2)	(Alessi	et	al.,	1997,	Sarbassov	et	
al.,	2005).	Akt	then	disassociates	from	the	membrane	to	elicit	a	variety	of	responses	via	
the	phosphorylation	of	downstream	effectors,	eg.	GSK3β	(glycogen	synthase	kinase	3β),	
which	 goes	on	 to	 promote	 glucose	uptake.	Others	 include	proteins	 that	 promote	 cell	
growth	and	cell	survival	(Ooms	et	al.,	2009,	Manning	and	Cantley,	2007).	More	widely	
known,	PtdIns(3,4,5)P3	also	promotes	the	recruitment	of	phospholipase	C	(PLC)	resulting	
in	 IP3	 mediated	 Ca2+	 signalling.	 PtdIns(3,4,5)P3	 levels	 are	 not	 only	 governed	 by	 its	
synthesis	by	PI3K,	but	 its	degradation	by	phosphatases.	For	example,	SHIP1	and	SHIP2	
(chapter	 2)	 and	 other	 5-phosphatases,	 as	 well	 as	 the	 3-phosphatase,	 PTEN.	 It	 is	
unsurprising	given	the	diversity	of	second	messengers	and	effector	proteins	associated	
with	 phosphoinositides	 that	 their	 regulation	 has	 implications	 in	 disease.	 The	 relative	
levels	 of	 the	 different	 signalling	 phosphoinositides	 are	 dependent	 on	 the	 receptor	
activated	 as	 well	 as	 cell	 type	 and	 tissue	 specific	 expression	 of	 phosphoinositide	
phosphatases	(Ooms	et	al.,	2009).	
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1.1.2b	Inositol	hexakisphosate	(IP6)	
	
As	well	as	playing	many	important	roles	in	cell	biology,	such	as	mRNA	export,	DNA	repair,	
maintenance	 of	 basal	 resistance	 to	 plant	 pathogens,	 apoptosis,	 and	 regulation	 of	
chromatin	structure	(Ives	et	al.,	2000),	inositol	hexakisphosphate	is	the	most	abundant	
inositol	phosphate	derivative	in	plants	and	provides	the	main	form	of	phosphorus	storage	
in	 seeds	 as	 the	 salt,	 phytate.	 It	 allows	 for	 the	 retrieval	 of	 phosphorus,	 inositol	 and	
minerals	during	development	and	germination.	It	also	accumulates	in	other	plant	tissues	
and	organs	 such	as	pollen,	 roots,	 and	 tubers	 (Raboy,	2003).	Human	grain	based	diets	
provide	excess	of	 IP6	which	can	bring	about	detrimental	effects	on	health.	This	 is	such	
because	 it	 is	 a	 potent	 chelator	 of	 essential	 ions	 such	 as	 Zn2+	 and	 Fe2+,	 which	 causes	
deficiencies	that	can	contribute	to	malnutrition	(Raboy,	2001),	an	 issue	affecting	third	
world	countries	in	particular.	In	contrast	to	this	detrimental	effect,	phytate	can	act	as	a	
powerful	antioxidant,	which	can	be	advantageous	in	cancer	prevention	by	preventing	the	
formation	of	hydroxyl	radicals	and	suppression	of	lipid	peroxidation	(Graf	et	al.,	1987).	
There	are	also	environmental	concerns	as	monogastric	animals	are	unable	to	digest	IP6,	
which	is	excreted	as	salts	that	contribute	to	eutrophication	of	waterways.	It	is	in	the	latter	
steps	of	inositol	synthesis	where	IP6	is	formed	from	inositol	1,3,4,5,6-pentakisphosphate	
(IP5)	by	2-phosphorylation	of	the	 inositol	ring	and	 is	catalysed	by	a	family	of	enzymes	
called	inositol	1,3,4,5,6-pentakisphosphate	2-kinases	(IPK1)	(see	chapter	3).	
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1.1.3	Inositol	polyphosphate	surrogates	and	substrate	mimics	
	
1.1.3a	Benzene	polyphosphates	
The	long	standing	interest	in	Ins(1,4,5)P3	3-kinases	and	Ins(1,4,5)P3	5-phosphatases	in	the	
study	 of	 disease	 and	 cell	 regulatory	 processes	 has	 led	 to	 the	 synthesis	 of	 inositol	
polyphosphate	 surrogates	 as	 simple	 alternatives	 to	 chemically	 synthesising	 complex	
inositol	 polyphosphates,	 which	 is	 a	 time	 consuming	 process	 involving	 long	 multistep	
routes	and	protecting	group	chemistry	(Ward	et	al.,	1995,	Mills	et	al.,	2006,	Mills	et	al.,	
2007,	 Mills	 et	 al.,	 2008).	 Benzene	 polyphosphates	 represent	 achiral	 polyanionic	
analogues	 of	 inositol	 phosphates	 in	 which	 the	 inositol	 ring	 is	 replaced	 by	 a	 planar	
aromatic	core.	This	ceases	any	conformational	flexibility	arising	from	within	the	ring,	with	
the	 only	 flexibility	 occurring	 from	 the	 phosphate	 groups,	 which	 provides	 new	 and	
intriguing	ligands	for	inositol	phosphate	metabolising	enzymes.	Additionally,	the	nature	
of	the	benzene	ring	may	encourage	the	formation	of	new	intermolecular	ligand-protein	
interactions	 such	 as	 π–cation	 interactions	 that	 are	 not	 observed	 in	 inositol	
polyphosphates	 (Vandeput	 et	 al.,	 2007).	 The	 structures	 of	 each	 of	 the	 benzene	
phosphates	that	have	been	provided	by	collaborators	(Potter,	B.V.L.,	Bath,	UK)	for	this	
study	can	be	seen	in	Table	1.1.		
	
Studies	have	shown	that	such	compounds	can	inhibit	PI	3-kinase	(PI3K),	type	I	Ins(1,4,5)P3	
5-phosphatase	(INPP5A)	and	the	SH2-domain-containing	inositol	5-phosphatase,	SHIP2.	
Bz(1,2,4)P3	(Bz5)	 in	particular	was	found	to	 inhibit	PI3K	activity	with	an	IC50	of	25	μM	
(Ward	et	al,	1995).	In	another	study	it	was	found	to	inhibit	both	PI3K	(IC50	6.1	μM)	and	
INPP5A	 (IC50	32	μM),	as	well	as	 interacting	with	 the	 Ins(1,4,5)P3	 receptor	and	weakly	
inhibiting	Ca2+	release	(Poitras	et	al,	1993).	Furthermore,	both	INPP5A	and	SHIP2	activity	
is	inhibited	by	Bz(1,2,3,4)P4	(Bz1),	Bz(1,2,3,5)P4	(Bz2),	and	Bz(1,2,4,5)P4	(Bz3)	(Vandeput	
et	al,	2007).		
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Table	1.1	–	Structures,	chemical	names,	abbreviations	and	the	references	given	for	the	purpose	of	this	text	for	the	
benzene	phosphates	(Mills	et	al.,	2006,	Mills	et	al.,	2007,	Mills	et	al.,	2008).	
	
	 	
Name Abbreviation Reference Structure
benzene%1,2,3,4+tetrakisphosphate Bz(1,2,3,4)P4 Bz1
benzene%1,2,3,5+tetrakisphosphate Bz(1,2,3,5)P4 Bz2
benzene%1,2,4,5+tetrakisphosphate Bz(1,2,4,5)P4 Bz3
benzene%1,2,3+trisphosphate Bz(1,2,3)P3 Bz4
benzene%1,2,4+trisphosphate Bz(1,2,4)P3 Bz5
benzene%1,3,5+trisphosphate Bz(1,3,5)P3 Bz6
3+hydroxybenzene%1,2,4+trisphosphate 3+OH+Bz(1,2,4)P3 Bz7
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The	first	crystal	structure	of	a	benzene	phosphate	in	complex	with	a	protein	was	with	the	
PH-domain	of	protein	kinase	Bα	(Mills	et	al.,	2007).	Bz(1,2,3,4)P4	(Bz1)	co-crystallised	with	
the	PH-domain	and	bound	with	a	IC50	of	6.35	μM	when	compared	with	6.22	μM	for	the	
natural	head	group	 Ins(1,3,4,5)P4,	and	therefore	was	 identified	as	an	effective	 inositol	
phosphate	surrogate	even	though	it	is	structurally	removed	from	the	natural	lipid	head	
group.		
	
Since	these	studies,	all	of	the	benzene	phosphate	compounds	1-7	in	Table	1.1	have	been	
shown	 to	 inhibit	 the	activity	of	 INPP5A	with	only	Bz	1-6	exhibiting	effects	on	 the	PH-
domain	of	PKBα	(Mills	et	al,	2008).		
	
Interestingly,	3-hydroxybenzene	1,2,4-trisphosphate	(Bz7)	has	also	been	characterised	as	
a	 substrate	 for	 INPP5A,	which	 removes	 the	2-phosphate	 to	yield	 the	symmetrical	2,3-
digydroxybenzene	1,4-bisphosphate,	and	was	the	first	non-inositol	based	compound	to	
be	a	substrate	for	a	5-phosphatase	(Mills	et	al,	2006).	
	
Recently,	the	crystal	structure	of	type	II	inositol	polyphosphate	5-phosphatase	(INPP5B),	
has	 been	 solved	 to	 2.9	 Å	 in	 complex	with	 Bz(1,2,4,5)P4	 (Bz3),	which	 has	 offered	 new	
insights	in	to	the	mechanism	of	INPP5B-catalysed	phosphate	group	cleavage	(Mills	et	al,	
2016).	 Unlike	 INPP5A,	 it	 is	 able	 is	 hydrolyse	 both	 inositol	 phosphates	 and	 inositol	
phospholipids.	
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1.1.3b	Biphenyl	polyphosphates	
	
The	benzene	polyphosphates	were	identified	as	novel	inositol	5-phosphatase	inhibitors	
for	use	as	molecular	tools	for	studies	within	intact	cells.	This	prompted	a	further	pursuit	
for	 phosphatase	 inhibitors	 of	 this	 family	 of	 enzymes	 to	 facilitate	 comparison	 of	 their	
catalytic	domains.	Consequently,	a	better	understanding	of	their	individual	functions	and	
control	of	intracellular	levels	of	inositol	phosphates	and	phosphoinositides	would	follow	
(Vandeput	et	al.,	2007).		
	
The	discovery	of	the	inhibition	of	Ca2+	release	via	the	Ins(1,4,5)P3	receptor	by	Bz(1,2,4)P3	
(Bz5),	 and	 the	 studies	 that	 followed	 between	 the	 benzene	 phosphates	 and	 type	 I	
Ins(1,4,5)P3	5-phosphatase	 (INPP5A)	 (Poitras	et	al,	1993,	Mills	et	al,	2006),	 incited	 the	
synthesis	of	a	highly	novel	and	related	derivative.	The	compound	biphenyl(2,3’,4,5’,6)P5	
(BiPh1)	consists	of	five	phosphates	across	two	phenyl	rings	(Table	1.2),	and	was	found	to	
be	the	most	potent	inhibitor	of	INPP5A	and	SHIP2	across	the	series	of	inhibitors	at	that	
point.	Furthermore,	it	was	found,	like	the	BzPs,	to	bind	to	the	Ins(1,4,5)P3	receptor	and	
inhibit	 Ins(1,4,5)P3	 induced	Ca2+	release	 in	permeabilised	cells	 (Vandeput	et	al.,	2007).	
Just	 like	 the	 benzene	 phosphates	 they	 have	 been	 shown	 to	 substitute	 for	 inositol	
phosphates	 and	 phosphoinositides	 in	 many	 incidences	 since.	 Four	 biphenyl	
polyphosphate	compounds	exist	in	this	current	series	of	related	inositol	5-phosphatase	
inhibitors	(Table	1.2).	
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Table	1.2	–	Structures,	chemical	names,	abbreviations	and	the	references	for	the	purpose	of	this	text	of	the	biphenyl	
polyphosphates	 (Vandeput	et	al.,	2007,	Mills	et	al.,	2012,	Mills	et	al.,	2016).	Substituents	on	the	 ‘lower	ring’	are	
represented	with	a	comma.		
	
In	a	subsequent	study	that	focused	on	the	PH	domain	of	PKBα	as	well	as	INPP5A,	BiPh1	
was	also	identified	as	an	inhibitor	alongside	the	Bz	compounds,	not	including	Bz7,	that	
did	not	bind	to	the	PH	domain	of	PKBα	(Mills	et	al,	2008).	This	led	to	molecular	modeling	
of	BiPh1	docked	in	to	the	active	site	of	the	PH-domain	of	PKBα	based	on	the	previous	
crystal	 structure	 in	 complex	 with	 Bz1	 (Mills	 et	 al,	 2007).	 Where	 the	 aryl	 2,4,6-
trisphosphate	 motif	 docks	 to	 the	 same	 amino	 acid	 residues	 as	 Bz1,	 and	 the	 3’,5’-
bisphosphate	motif	 is	potentially	 implicated	 in	a	 cation-π	 interaction	with	an	arginine	
residue	(Mills	et	al,	2008).	These	structures,	along	with	PKBα	PH	domain	in	complex	with	
Ins(1,3,4,5)P4,	 led	 to	 the	 development	 of	 a	 docking	 protocol	 to	 identify	 drug-like	
inhibitors	by	virtual	screening	(Du-Cuny	et	al,	2009).	
Name Abbreviation Reference Structure
biphenyl)2,3',4,5',61tetrakisphosphate BiPh(2,3',4,5',6)P5 BiPh)1
biphenyl)2,2',4,4',5,5'1hexakisphosphate BiPh(2,2',4,4',5,5')P6 BiPh)2
biphenyl)3,3',4,4',5,5'1hexakisphosphate BiPh(3,3',4,4',5,5')P6 BiPh)3
6,6'1difluorobiphenyl)3,3',4,4'1tetrakisphosphate 6,6'1F21BiPh(3,3',4,4')P4 BiPh)4
biphenyl	2,3’,4,5’,6-p nt i t 	
2	 4	 5	
3’	5’	
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Later	came	a	2.1	Å	resolution	crystal	structure	of	BiPh1	coordinated	in	a	shallow	pocket,	
containing	the	inositol	phosphate-binding	site,	of	the	5-phosphatase,	SHIP2	(Mills	et	al,	
2012).	In	this	structure	the	majority	of	direct	protein-ligand	interactions	are	focused	on	
the	 6-phosphate	 of	 BiPh1	 by	 a	 region	 assigned	 as	 the	 4-phosphate	 interacting	motif	
(P4IM),	named	as	 so	because	 these	 residues	 coordinate	 the	4-phosphate	of	 a	natural	
substrate	or	product	 in	the	active	site	of	type	II	 inositol	polyphosphate	5-phosphatase	
(INPP5B)	and	SPSynaptoganin	(Mills	et	al,	2012)	(Figure	1.4	–	A).	As	discussed	in	chapter	
2.	
	
Recently,	alongside	the	complex	with	Bz3	noted	previously,	the	crystal	structure	of	BiPh3	
bound	to	the	active	site	of	INPP5B	has	been	solved	to	a	resolution	of	2.89	Å	(Mills	et	al,	
2016).	Again,	the	BiPh	is	bound	in	a	shallow	pocket	with	most	of	the	interactions	focused	
on	the	3-,	4-	and	5-phosphates	of	one	ring	of	the	compound	(Figure	1.4	–	B).	
	
Given	 the	 current	 wealth	 of	 inhibitory	 and	 structural	 information	 on	 the	 synthetic	
benzene	and	biphenyl	phosphates,	they	could	find	utility	 in	early	stage	drug	discovery	
and	structure-based	inhibitor	design	of	phosphoinositide	and	inositol	phosphate	related	
pathways.	This	study	begins	to	explore	this	further	by	exploiting	their	novel	properties	
with	three	inositol	phosphate	metabolising	enzymes.	
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Figure	1.4	–	Conserved	4-phosphate	position	of	the	5-phosphatases.	(A)	P4IM	residues	within	SHIP2	(green)	in	
complex	with	BiPh1	(magenta).	(B)	P4IM	residues	within	INPP5B	(magenta)	in	complex	with	BiPh3	(green).	Protein	
residues	and	ligands	represented	as	sticks.	
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2.1	Introduction	
	
2.1.1	Inositol	polyphosphate	5-phosphatases	
The	human	inositol	polyphosphate	5-phosphatases	consist	of	ten	isozymes,	all	of	which	
can	cleave	the	5-phosphate	from	membrane-bound	inositol	phospholipids.	Asides	from	
type	 I	 inositol	5-phosphatase	 (INPP5A),	named	as	 such	because	 it	was	 the	 first	 family	
member	 to	 be	 purified	 and	 cloned,	 which	 specifically	 only	 acts	 on	 soluble	 inositol	
phosphates	and	regulates	 intracellular	calcium	signalling.	The	rest	are	either	only	able	
to	hydrolyse	the	former	or	both	(Ooms	et	al.,	2009).	The	family	also	contains	four	yeast	
enzymes.	 Many	 of	 the	 5-phosphatases	 are	 able	 to	 remove	 the	 5-phosphate	 from	
PtdIns(3,4,5)P3	to	 yield	 PtdIns(3,4)P2,	 which	 in	 turn	 gets	 degraded	 by	 4-phosphatases	
and	terminates	PI3K/Akt	signalling.	The	pathway	 is	also	deactivated	by	3-phosphatase	
PTEN	to	yield	PtdIns(4,5)P2.	Some	5-phosphatases	are	also	active	against	PtdIns(4,5)P2,	
and/or	PtdIns(3,5)P2.	For	 these	reasons	they	are	 implicated	 in	many	disorders	such	as	
cancer,	 diabetes,	 obesity	 and	 neurodegenerative	 diseases	 (Majerus	 and	 York,	 2009).	
Additionally,	the	presence	of	phosphoinositides	and	inositol	phosphates	in	the	nucleus	
are	 implicated	 in	 the	 regulation	 of	 many	 cellular	 processes,	 including	 chromatin	
remodeling,	gene	expression,	mRNA	export	and	DNA	repair	 (Irvine,	2003,	York,	2006).	
Each	contains	a	conserved	300	amino	acid	catalytic	domain	which	is	flanked	by	various	
functional	 domains,	which	 via	 subcellular	 localisation	 and	protein-protein	 interactions	
targets	 them	 for	 diverse,	 unique	 and	 tissue	 specific	 roles	 (Figure	 2.1)	 (Eramo	 and	
Mitchell,	2016).	
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The	 catalytic	 activity	 and	 their	 substrate	 specificities	 for	 a	 range	of	phosphoinositides	
and	 inositol	 phosphates	has	 recently	 been	 summerised	by	 Eramo	and	Mitchell,	 2016.	
The	 SH2	 (Src	 homology	 2)-containing	 inositol	 5-phosphatase	 (SHIP1)	 and	 SHIP2,	
amongst	 others,	 preferentially	 degrade	 PtdIns(3,4,5)P3	 (in	 vivo).	 Whereas	 others	
preferentially	 degrade	 PtdIns(4,5)P2,	 such	 as	 type	 II	 inositol	 5-phosphatase	 and	
Synaptojanin	1.	
	 	
Figure	2.1	–	Domain	structure	of	the	inositol	5-phosphatases.	Taken	from	Ooms	et	al,	2009.	
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2.1.2	SHIP1	-	SH2	(Src	homology	2)-containing	inositol	5-phosphatase	
The	SHIP	family	encompasses	SHIP1	and	SHIP2.	Both	contain	a	SH2	domain	N-terminal	
to	their	5-phosphatase	domain,	NPXY	motifs	that	can	be	tyrosine	phosphorylated,	and	
divergent	proline	 rich	domains	C-terminal	 to	 the	 catalytic	domain	 (Ooms	et	 al.,	 2009,	
Mondal	 et	 al.,	 2012).	 SHIP1	 was	 first	 identified	 as	 a	 5-phosphatase	 that	
dephosphorylates	 PtdIns(3,4,5)P3	 to	 PtdIns(3,4)P2,	 and	 Ins(1,3,4,5)P4	 to	 Ins(1,3,4)P3	
(Damen	 et	 al.,	 1996,	 Lioubin	 et	 al.,	 1996).	 The	 145	 kDa	 protein	 is	 expressed	 in	
haematopoietic	 cells	 and	 is	 an	 established	 key	 regulator	 of	 the	 immune	 system,	with	
known	 implications	 in	 the	 negative	 regulation	 of	 various	 cellular	 processes	 via	 the	
inhibition	of	PI3K/Akt-dependent	processes;	 including	phagocytosis,	cell	migration,	cell	
survival,	proliferation	and	differentiation	(Leung	et	al.,	2009,	Parry	et	al.,	2010).	SHIP1	-/-	
B-cells	have	shown	resistance	to	cell	death	and	possess	enhanced	proliferative	activity	
due	 to	 increased	 Akt	 activity	 following	 receptor	 stimulation,	 attributed	 by	 greater	
PtdIns(3,4,5)P3	and	reduced	PtdIns(3,4)P2	signals	(Brauweiler	et	al.,	2000).	
	
2.1.3	SHIP2	-	SH2	(Src	homology	2)-containing	inositol	5-phosphatase	2	
SHIP2	is	a	142	kDa	protein	that,	 in	terms	of	domain	structure,	 is	very	similar	to	SHIP1,	
main	 differences	 lie	 in	 the	 fact	 that	 SHIP2	 contains	 a	 SAM	 (sterile	 α	 motif)	 at	 its	 C-
terminus	 and	 the	 sequence	 divergence	 in	 their	 proline	 rich	 regions	 (Backers	 et	 al.,	
2003).	SAM	domains	span	70	residues	and	form	five-helix	bundles	with	two	interaction	
interfaces.	 They	 can	 self-associate	 forming	 dimers	 and	 possibly	 more	 extended	
structures,	 with	 suggested	 additional	 abilities	 in	 RNA	 binding.	 Originally	 SHIP2	 was	
recognised	 to	 dephosphorylate	 PtdIns(3,4,5)P3	and	 Ins(1,3,4,5)P4,	 but	 recently	 in	 vitro	
studies	 suggest	 a	 wider	 and	 preferred	 substrate	 specificity	 of	 Ins(1,2,3,4,5)P5	 >	
Ins(1,3,4,5)P4	>	PtdIns(3,4,5)P3	≈	PtdIns(3,5)P2	≈	Ins(1,4,5,6)P4	(Pesesse	et	al.,	1998,	Chi	
et	al.,	2004).	It	is	more	ubiquitous	than	SHIP1	and	is	expressed	in	both	haematopoietic	
and	non-haematopoietic	 tissues,	 including	brain,	 skeletal	muscle,	 heart,	 and	 liver	 and	
kidney	 tissues,	 the	 latter	 to	 a	 lesser	 extent.	 SHIP2	 plays	 a	 negative	 role	 in	 insulin	
signalling	 as	 has	 been	 demonstrated	 in	 many	 in	 vitro	 cellular	 models,	 where	
overexpression	 decreases	 insulin	 stimulated	 PI3K	 signalling	 and	 Akt	 activation	 which	
leads	to	reduced	GLUT4	translocation	to	the	plasma	membrane,	subsequently	reducing	
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glucose	 uptake	 and	 glycogen	 synthesis	 (Blero	 et	 al.,	 2001,	Wada	 et	 al.,	 2001).	 SHIP2	
overexpression	 in	mice	 reduces	 glucose	 tolerance	 and	 increases	 body	 weight	 due	 to	
decreased	 insulin-stimulated	 Akt	 phosphorylation	 (Kagawa	 et	 al.,	 2008).	 On	 the	
contrary,	 SHIP2	 knockout	 mice	 are	 protected	 from	 high	 fat	 diet-induced	 obesity	
(Sleeman	et	al.,	2005).		
	
Inhibition	of	SHIP1	and	SHIP2	activity,	using	pan-SHIP1/2	inhibitors	and	SHIP1	specific	3-
α-aminocholestane	 (3AC),	 in	 cancer	 cell	 lines	 decreases	 Akt	 phosphorylation.	
Observations	 included	 reduced	multiple	myeloma	 (MM)	cell	 growth	and	viability,	 and	
decreased	IGF-1-induced	phosphorylation	of	Akt	 in	the	presence	of	3AC	(Brooks	et	al.,	
2010).	Additionally,	pan-SHIP1/2	inhibitors	in	breast	cancer	cell	 lines	prohibited	SHIP2-
mediated	 PtdIns(3,4,5)P3	 degradation,	 decreased	 IGF-1-stimulated	 phosphorylation	 of	
Akt	and	induced	cell	cycle	arrest	and	apoptosis	in	a	similar	manner	(Fuhler	et	al.,	2012).	
	
2.1.4	Structures	of	inositol	polyphosphate	5-phosphatases	
Crystal	 structures	 of	 five	 of	 the	 inositol	 5-phosphatases	 are	 currently	 available.	 Four	
structures	are	available	of	type	II	inositol	5-phosphatase	(INPP5B)	alone,	all	in	complex	
with	 ligands;	 diC8PtdIns(4)P1	 (PDB	 3MTC),	 diC8PtdIns(3,4)P2	 (PDB	 4CML),	 and	 most	
recently	 with	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	 and	 benzene	 1,2,4,5-
tetrakisphosphate	(BiPh3/Bz3-	see	section	1.1.3)	(PDB	5A7I	&	5A7J)	(Trésaugues	et	al.,	
2014,	 Mills	 et	 al.,	 2016a).	 The	 5-phosphatase	 domain	 of	 yeast	 Schizosaccharomyces	
pombe	 SPsynaptojanin	 in	 complex	 with	 Ins(1,4)P2	 and	 SHIP2	 bound	 with	 biphenyl	
2,3’,4,5’,6-pentakisphosphate	 are	 also	 available	 (PDB,	 1I9Z	 &	 4A9C,	 respectively)	
(Tsujishita	 et	 al.,	 2001,	 Mills	 et	 al.,	 2012).	 The	 structure	 of	 Lowe	 oculocerebrorenal	
syndrome	protein	(OCRL)	has	been	resolved	with	an	inorganic	phosphate	ion	and	is	the	
closet	structural	family	member	to	INPP5B	(PDB	4CMN)	(Trésaugues	et	al.,	2014),	Lastly,	
the	apo-form	of	phospholipid-specific	INPP5E	is	available	(PDB	2XSW)	.	
	
No	structure	is	available	for	SHIP1,	but	there	are	two	structures	available	of	the	catalytic	
domain	of	the	isozyme	SHIP2	(SHIP2cd).	One	in	the	apo-form	(PDB	3NR8),	the	other	in	
complex	with	BiPh1,	as	mentioned	above	(Trésaugues	et	al.,	2014,	Mills	et	al.,	2016a).	
The	overall	structure	of	this	complex	can	be	seen	in	Figure	2.2.	
Chapter	2	–	Structural	studies	of	Human	SHIP1	and	SHIP2	
19		
	
	
The	 two	 published	 crystal	 structures	 of	 SHIP2cd	 are	 in	 the	 same	 conformation	 and	
crystallise	under	similar	conditions	in	the	same	space	group,	regardless	of	the	presence	
of	a	 ligand	or	not.	The	protein	crystallises	with	two	molecules	 in	the	asymmetric	unit,	
with	 one	molecule	 contacting	 a	 symmetry	 related	molecule	 via	 a	 flexible	 loop	 that	 is	
consequently	 stabilised,	 it	 is	 disordered	 in	 the	 other	 molecule	 as	 it	 lacks	 the	 same	
contacts	with	 a	 symmetry	mate.	A	molecule	of	BiPh1	was	only	 found	 in	 the	 inositide	
binding	 site	 of	 the	 molecule	 with	 the	 stabilised	 loop.	 The	 inositide	 binding	 site	 was	
originally	 identified	 from	 the	 complex	 between	 the	 related	 INNP5B	 and	 PtdIns(4)P.	
BiPh1	binds	 in	 to	 the	 shallow	pocket	via	multiple	 interactions	between	 the	3’-	 ,4-	 ,5’-	
and	6-phosphates	 (Figure	2.3).	Nine	water	molecules	are	also	found	 in	the	active	site,	
eight	of	which	mediate	hydrogen	bonds	between	phosphates	of	BiPh1	and	SHIP2cd.	The	
role	of	ligand	coordinating	residues	are	discussed	in	more	detail	in	due	course,	as	well	
as	the	role	of	the	flexible	loop	above	the	active	site	that	is	stabilised	and	constrained	by	
a	symmetry	related	molecule	in	the	crystal	structure.	
	 	
Figure	2.2	–	Crystal	structure	of	two	SHIP2cd	molecules.	One	molecule	(green)	has	the	biphenyl	(2,3’,4,5’,6)P5	
bound	 in	 the	 shallow	 inositide	 binding	 pocket,	 and	 has	 additional	 interactions	 with	 a	 symmetry	 related	
molecule	(grey).	The	flexible	loop	which	is	stabilised	by	interactions	with	the	symmetry	mate	is	shown	in	blue.	
Taken	from	Mills	et	al,	2012.	(PDB	4A9C).		
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Figure	2.3	–	LigPlot	ligand	interaction	diagram	of	the	coordination	of	biphenyl	(3,3’,4,4’,5,5)P6	by	SHIP2cd.	
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Much	 is	 still	 left	 undiscovered	when	 considering	 the	mechanism	of	 SHIP1	 and	 SHIP2,	
and	indeed	the	rest	of	the	5-phosphatases,	although	the	first	evidence	and	speculations	
on	 the	mechanism	have	 recently	 been	 revealed.	 These	 are	based	on	 the	 structure	of	
INPP5B	in	complex	with	BiPh3	containing	an	inorganic	phosphate	(Pi)	 in	the	active	site	
that	is	likely	to	be	in	the	position	of	a	liberated	5-phosphate,	and	acts	directly	with	the	
expected	catalytic	base	Asp-447.	Arg-451	was	for	the	first	time	considered	as	a	catalytic	
residue	 due	 to	 its	 proximity	 to	 the	 Pi	 and	 its	 conservation	 across	 the	 5-phosphatases	
(Mills	et	al.,	2016a).	
	
2.1.5	Experimental	aims	
No	crystal	structure	of	SHIP1	or	 its	catalytic	domain	 is	currently	available.	Additionally	
there	 is	 an	 added	 lack	 of	 in	 vitro	 studies,	 as	most	 characterisation	 has	 been	 done	 in	
terms	of	 its	 regulation	and	 its	 regulatory	 influence	of	 the	pathways	 it	 is	 implicated	 in	
within	live	cells.	Therefore	a	key	objective	in	this	work	was	to	clone	Ship1	(INPPL1)	and	
its	catalytic	domain	 in	 to	a	suitably	selected	expression	vector	 for	overexpression	and	
subsequent	 protein	 purification	 for	 use	 in	 in	 vitro	 binding	 and	 enzymatic	 assays.	
Secondly,	attempts	to	crystallise	the	catalytic	domain	of	SHIP1	(SHIP1cd)	were	made	as	
it	 shares	 high	 homology	 with	 the	 catalytic	 domain	 of	 SHIP2,	 of	 which	 there	 is	 a	
structure.	Comparison	of	crystal	structures	would	confirm	the	presence	of	the	extended	
loop	above	the	active	site	that	is	said	to	be	specific	only	to	SHIP1	and	SHIP2;	in	which	in	
the	latter	it	has	already	been	identified	(as	introduced	above).	Secondly	it	may	elucidate	
the	mechanisms	and	residues	responsible	for	their	differing	substrate	specificities.		
	
Furthermore,	in	light	of	the	current	structure	of	SHIP2cd	in	complex	with	BiPh1	and	the	
concerns	 that	 come	 along	 with	 it;	 such	 as	 the	 BiPh1	 interactions	 with	 a	 symmetry	
related	molecule,	it	would	be	beneficial	to	gain	more	structures	of	SHIP2cd	in	complex	
with	ligands	and	inhibitors.	A	good	place	to	start	was	with	the	additional	biphenyl-	and	
benzene-	phosphate	compounds	in	Tables	1.1	&	1.2.		
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2.2	Materials	and	methods	
	
2.2.1	Primers	
Primers	were	designed	manually	and	the	necessary	flanking	sequences	for	the	ligation	
independent	cloning	were	added	(Gileadi	et	al.,	2008,	Savitsky	et	al.,	2010)	 (see	Table	
2.2).	 Synthesis	 was	 carried	 out	 by	 MWG	 Eurofins	 and	 the	 lyophilized	 primers	 were	
stored	 as	 100	 μM	 stocks	 in	 nuclease	 free	 water	 (Qiagen)	 at	 -20	 °C.	 Diluted	 working	
stocks	at	20	μM	were	made	 for	use	 in	PCR	 to	prevent	degradation	of	 the	main	 stock	
through	repeated	freeze-thaw.	
	
2.2.2	PCR	amplification	using	Phusion	High	Fidelity	DNA	polymerase	
All	 PCR	was	 carried	 out	 in	 a	MJ	 Research	 Dyad	 Thermal	 Cycler.	 PCR	 amplification	 of	
INPP5Dcd	 and	 INPP5D	 was	 performed	 using	 Phusion	 High	 Fidelity	 Polymerase	 (New	
England	 Biolabs)	 as	 per	manufacturer’s	 instructions	 and	 using	 the	 primer	 sequences,	
annealing	 temperatures,	 and	elongation	 times	provided	 in	 Table	2.	 .	Deoxynucleotide	
triphosphates;	 dATP,	 dTTP,	 dGTP	 &	 dCTP	 (Roche),	 were	 combined	 at	 equal	
concentration	to	give	a	working	stock	of	10	μM.	
	
2.2.3	Agarose	gel	electrophoresis	
A	1	%	 agaraose	 gel	was	 used	 throughout	 and	made	by	 adding	 1	 g	 of	 electrophoresis	
grade	agarose	(Melford)	to	100	mL	1	x	TAE	buffer	(see	Appendix	2).	This	was	heated	in	a	
600	W	microwave	for	approximately	3	min	and	allowed	to	cool	to	50	°C	before	addition	
of	5	μM	10	mg/mL	ethidium	bromide	 (Sigma-Aldrich).	The	gel	was	cast,	adding	a	well	
comb,	and	allowed	to	set	before	placing	in	a	Bio-Rad	electrophoresis	tank	containing	1	x	
TAE	buffer.	Loading	dye	was	added	to	the	samples,	and	where	appropriate	either	10	%	
of	 the	 reaction	 or	 the	 full	 volume	 was	 loaded.	 Gels	 were	 run	 at	 90-100	 V	 until	 the	
loading	dye	had	migrated	a	suitable	distance.	The	resulting	gel	was	imaged	using	a	Bio-
Rad	Chemidoc	Gel	Imaging	System.	
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2.2.4	PCR	clean	up	
The	appropriately	sized	band	was	excised	 from	the	gel	under	UV	 illumination	and	the	
Wizard®	SV	Gel	and	PCR	Clean-Up	System	(Promega)	used	as	per	the	supplied	protocol.	
	
2.2.5	Treatment	with	T4	DNA	polymerase	
Purified	PCR	product	and/or	plasmid	were	treated	T4	DNA	polymerase	(Clontech)	in	the	
presence	of	the	appropriate	dNTP	for	30	min	at	11	°C	followed	by	20	min	at	75	°C.	
	
2.2.6	Plasmid	DNA	extraction	
Plasmid	 purification	 from	 E.	 coli	 cells	 was	 performed	 using	 the	 Wizard®	Plus	SV	
Miniprep	 DNA	 Purification	 System	 (Promega)	 following	 suppliers	 standard	 protocol.	
Additionally,	 the	 sample	 was	 incubated	 at	 room	 temperature	 for	 2	 min	 after	 the	
addition	of	the	Cell	Lysis	Solution,	and	again	for	5	min	before	addition	of	50	μL	nuclease	
free	water	in	the	final	steps	of	the	protocol.	
	
2.2.7	Preparation	of	chemically	competent	E.	coli	cells	
Rosetta	 expression	 host	 E.	 coli	 cells	 (Novagen)	 were	 streaked	 on	 to	 a	 LB	 agar	 plate	
containing	 34	 μg/mL	 chloramphenicol	 (to	 maintain	 the	 chloramphenicol-resistant	
pRARE	plasmid)	from	a	-80	°C	stored	glycerol	stock	and	 incubated	O/N	at	37	°C.	From	
the	 resulting	 growth,	 a	 single	 colony	 was	 selected	 to	 inoculate	 5	 mL	 of	 LB	 medium	
supplemented	with	 chloramphenicol,	 and	 grown	 in	 a	 37	 °C	 shaking	 incubator	O/N	 at	
220	rpm.	The	resulting	culture	was	used	to	inoculate	SOB	medium	in	a	ratio	of	3:500	mL	
(v/v)	and	incubated	at	30	°C	with	shaking	at	220	rpm	until	an	OD595	of	~0.5	was	reached.	
All	 further	 steps	were	 carried	out	 on	 ice	or	 4	 °C,	 and	with	 ice-cold	buffers.	 A	 10	min	
centrifugation	at	 5000	 rpm	of	 the	 ice-cold	 culture	was	used	 to	obtain	 a	pellet,	which	
after	 decanting	 off	 the	 supernatant,	 was	 gently	 re-suspended	 in	 100	 mL	 TB	 buffer	
before	 incubation	on	 ice	 for	10	min.	After	an	 identical	 second	centrifugation	step	 the	
pellet	was	re-suspend	 in	18.6	mL	of	TB	buffer,	plus	an	addition	of	1.4	mL	1	M	DMSO.	
The	cells	were	then	left	to	rest	on	ice	for	at	least	10	min	before	being	frozen	in	100	μL	
aliquots	in	liquid	nitrogen	and	stored	at	-80	°C	in	0.5	mL	micro-centrifuge	tubes.	
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2.2.8	Transformation	of	E.	coli	standard	protocol	
Chemically	competent	E.	coli	cells	were	thawed	on	ice	for	30	min	and	50	μL	transferred	
to	a	pre-chilled	sterile	1.5	mL	micro-centrifuge	tube.	Between	1	to	5	μL	of	plasmid	DNA	
was	added	to	the	cells	to	obtain	successful	levels	of	transformants,	and	mixed	by	gentle	
pipetting	before	 incubation	on	 ice	 for	30	min.	The	cells	were	heat	 shocked	 in	a	42	 °C	
water	bath	for	45	sec	and	immediately	returned	to	the	ice	for	2	min.	Cell	recovery	and	
growth	was	achieved	by	an	addition	of	250	μL	LB	and	shaking	incubation	of	the	cells	at	
37	°C	for	1	h.	The	cells	were	gently	centrifuged	at	5000	rpm	and	the	pellet	re-suspended	
in	50	μL	LB	before	the	entire	volume	was	spread	on	to	a	plate	containing	LB	agar	media	
and	 the	 appropriate	 selective	 antibiotics.	 The	 plate	was	 then	 inverted	 and	 incubated	
O/N	at	 37	 °C.	 The	next	day,	 a	 single	 colony	was	picked	 from	 the	plate	using	 a	 sterile	
pipette	 tip	 and	 used	 to	 inoculate	 10	mL	 LB	 containing	 selective	 antibiotics.	 This	 was	
repeated	for	at	least	5	single	colonies.	The	cultures	were	then	grown	O/N	in	a	shaking	
incubator	at	37	°C.	
	
2.2.9	Restriction	digestion	
Plasmid	 was	 digested	 with	 BsaI-HF	 restriction	 enzyme	 (New	 England	 Biolabs)	 as	 per	
manufacturer’s	guidelines	with	the	appropriate	buffer.	
	
2.2.10	Screening	of	transformants	by	colony	PCR	
PCR	was	performed	on	1	μL	of	O/N	culture	(section	2.2.8)	using	GoTaq®	G2	Flexi	DNA	
Polymerase	 (Promega)	 as	 per	 manufacturer’s	 protocol,	 using	 the	 primers	 and	
parameters	in	Table	2.	.	The	reaction	mix	was	first	incubated	at	98	°C	for	5	min	to	lyse	
the	cells	before	adding	the	polymerase.	
	
2.2.11	Plasmid	sequencing	
Aliquots	of	extracted	plasmid	were	sent	to	Source	BioScience	for	sequencing	using	the	
pLIC-for	and	pLIC-rev	primers	(Gileadi	et	al.,	2008).	
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2.2.12	Glycerol	stocks	
Under	 sterile	 conditions,	 cultures	 were	 spread	 on	 to	 three	 plates	 containing	 LB	 agar	
media	plus	the	appropriate	selective	antibiotics	and	incubated	O/N	at	37	°C.	Liquid	LB	(1	
mL)	was	added	to	each	plate	and	scraped	using	a	glass	spreader	to	release	the	bacteria	
from	 the	plate.	The	 resuspended	bacteria	was	aliquoted	 in	 to	1.5	mL	microcentrifuge	
tubes	and	330	μL	60	%	glycerol	 (v/v)	added	before	 snap	 freezing	 in	 liquid	nitrogen	 in	
preparation	for	storage	at	-80	°C.	Bacteria	were	recovered	by	scraping	the	surface	of	the	
frozen	culture	using	a	sterile	loop	and	streaking	on	to	a	selective	LB	agar	plate.	
	
2.2.13	Small	scale	expression	testing	of	SHIP1cd-His	
In	sterile	30	mL	tubes,	5	mL	of	LB	was	inoculated	using	20	μL	starter	culture	and	grown	
to	OD600	0.5	at	37	°C.		The	cultures	were	incubated	at	20	°C	for	1	hr	before	addition	of	
0.2	mM	or	0.5	mM	IPTG	(no	addition	to	control	samples)	and	incubated	for	a	further	16	
hrs	at	200	rpm.	
	
2.2.14	Preparation	of	polyacrylamide	gels	
The	resolving	gel	(see	appendix	2)	was	pipetted	between	1	mm	glass	spacer	plates	held	
in	casting	 frames	on	a	casting	stand	(Bio-Rad),	until	 the	gel	 level	was	approximately	2	
cm	from	the	top	of	the	front	plate.	Drops	of	 isopropanol	were	immediately	applied	to	
the	top	of	the	gel	until	it	was	even	and	free	of	bubbles,	before	being	left	to	polymerise	
for	 1	 h.	 The	 isopropanol	 was	 washed	 off	 with	 dH2O	 and	 dried	 thoroughly	 with	 filter	
paper.	The	5	%	stacking	gel	was	pipetted	on	top	of	the	resolving	gel	up	to	the	very	top	
of	the	front	plate	and	a	1	mm	10-well	comb	inserted,	and	again	left	to	polymerise	for	1	
h.	Gels	not	for	immediate	use	were	stored	at	4	°C	wrapped	in	cling	film.	
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2.2.15	Preparation	of	samples	for	SDS-PAGE	analysis		
The	relevant	protein	expression	culture	was	removed	from	the	shaking	incubator	at	the	
required	time-point	and	a	200	μL	sample	was	transferred	to	a	1.5	mL	microcentrifuge	
tube.	The	culture	was	then	returned	if	necessary.	The	sample	was	centrifuged	for	1	min	
at	13000	rpm,	and	the	supernatant	discarded.	A	300	μL	(or	1:1.5	(v/v))	aliquot	of	1	x	SDS	
loading	 buffer	 (see	 appendix	 2)	 was	 used	 to	 re-suspend	 the	 resulting	 pellet	 before	
boiling	 for	 7	min.	Once	 cooled	 slightly	 the	 sample	was	 pulse	 centrifuged.	 	 If	working	
with	purified	or	 partially	 purified	protein,	 centrifugation	was	 skipped	 and	1:3	 (v/v)	 of	
sample	to	3	x	SDS	loading	buffer	was	used.	
	
The	 comb	was	 removed	 from	a	pre-prepared	polyacrylamide	gel	 and	 the	wells	 gently	
rinsed	with	dH2O	before	being	placed	 in	 the	electrophoresis	 tank	 (Bio-Rad)	 filled	with	
SDS	running	buffer	(see	appendix	2)	to	cover	the	gel.	Typically	10	μL	of	the	sample	was	
loaded	 in	 to	 a	 well,	 with	 a	 protein	 molecular	 weight	 marker	 loaded	 as	 per	
manufacturer’s	instructions	in	an	adjacent	well.	The	gel	ran	at	150	–	180	V	until	the	dye	
front	 was	 approximately	 1	 cm	 from	 the	 bottom	 of	 the	 gel.	 Once	 extracted	 from	
between	 the	 glass	 plates	 and	 rinsed	 with	 dH2O,	 the	 gel	 was	 stained	 using	 either	
InstantBlue	 (Expedeon)	 or	 PageBlue	 (ThermoFischer	 scientific),	 according	 to	 the	
manufacturer’s	guidelines.	
	
2.2.16	Large	scale	protein	expression	
Large-scale	expression	cultures	were	1	L	in	volume	and	at	least	2	L	of	expression	culture	
was	used	per	purification.	Each	1	L	LB	plus	antibiotic	was	inoculated	using	10	mL	of	O/N	
culture	 and	 treated	 as	 per	 the	 small	 scale	 expression	 tests,	 adding	 the	 appropriate	
amount	of	IPTG	for	optimum	expression.	The	1	L	expression	cultures	were	centrifuged	
at	5000	rpm	for	20	min	at	4	°C,	with	each	resulting	pellet	being	resuspended	in	10	mL	
cell	lysis	buffer	(see	appendix	2)	before	being	snap	frozen	in	liquid	nitrogen	and	stored	
at	-80	°C.	
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2.2.17	Standard	protein	purification	protocol	
The	 bacterial	 suspensions	 of	 the	 expression	 culture	 pellets	 were	 recovered	 from	 the	
freezer	 and	 thoroughly	 thawed	 on	 ice.	 Mechanical	 cell	 disruption	 was	 achieved	 by	
French	 press	 at	 a	 working	 pressure	 of	 17000	 PSI,	 with	 a	 maximum	 of	 30	 mL	 of	
suspension	being	loaded	in	to	the	cell	at	any	one	time.	The	suspension	and	lysate	were	
kept	on	ice	during	all	steps	and	each	suspension	was	subjected	to	3	passes	through	the	
French	 pressure	 cell	 to	 ensure	 complete	 homogenisation.	 Ultracentrifugation	 of	 the	
lysate	 at	 40000	 rpm	 and	 4	 °C	 for	 1	 h	 was	 used	 to	 remove	 the	 cell	 debris,	 and	 the	
supernatant	 carefully	 decanted	 in	 to	 a	 pre-chilled	 tube	 and	 stored	 on	 ice	 ready	 for	
loading	on	to	a	5	mL	Ni-NTA	Superflow	Cartridge	(Qiagen).	
	
Purification	was	carried	out	using	an	ÄKTAprime	purification	system	(GE	Lifesciences)	at	
4	°C.	The	5	mL	NiNTA	superflow	cartridge	(Qiagen)	was	equilibrated	with	buffer	A	(see	
Appendix	2)	and	the	supernatant	loaded	at	0.5	mL/min	followed	by	an	80	mL	wash	with	
buffer	A.	A	gradient	of	 imidazole	was	applied	 to	 the	column	over	50	mL	 from	20	mM	
(buffer	 A)	 to	 500	 mM	 (buffer	 B)	 (see	 Appendix	 2),	 followed	 by	 washing	 with	 50	 mL	
buffer	B.	Fractions	were	collected	throughout;	10	mL	during	the	wash	phases	and	2	mL	
during	the	imidazole	gradient.	The	absorbance	of	the	eluate	was	monitored	at	280	nm,	
and	 from	 the	 resulting	 UV	 absorbance	 trace	 fractions	 containing	 protein	 could	 be	
identified.	A	 sample	was	 taken	of	 each	UV	absorbing	 fraction	 to	be	 analysed	by	 SDS-
PAGE.	Fractions	confirmed	to	contain	protein	were	pooled	and	concentrated	using	an	
Amicon®	 stirred	 ultrafiltration	 cell	 with	 a	 10	 kDa	 cut	 off	 membrane	 to	 a	 volume	 of	
approximately	 2.2	 mL	 in	 preparation	 for	 loading	 on	 to	 a	 HiLoad	 16/60	 Superdex	 75	
column	(GE	Lifesciences)	for	size	exclusion	chromatography.	
	
Again,	 the	 column	 was	 use	 in	 tandem	 with	 an	 ÄKTA	 prime	 purification	 system	 and	
equilibrated	with	240	mL	(two	volumes)	of	sepharose	buffer	(see	Appendix	2).	After	the	
concentrated	 protein	was	 injected,	 the	 column	was	 run	 at	 1	mL/min	with	 sepharose	
buffer	for	120	mL.	Throughout,	2	mL	fractions	of	eluent	were	collected	and	monitored	
with	the	UV	absorbance	detector	setting	at	280	nm.	From	the	resulting	UV	absorbance	
trace,	fractions	assumed	to	contain	purified	protein	were	first	analysed	by	SDS-PAGE		
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before	 being	 pooled	 and	 concentrated.	 Protein	 concentration	 was	 estimated	 using	 a	
NanoDrop	 (Thermo	 Scientific)	 to	 measure	 absorbance	 at	 280	 nm	 together	 with	 the	
extinction	coefficient	to	calculate	protein	concentration.	The	purified	and	concentrated	
protein	was	centrifuged	at	13000	rpm	for	5	minutes	at	4	°C	before	being	snap	frozen	in	
liquid	nitrogen	for	storage	at	-80	°C.	
	
2.2.18	Removal	of	6xHistidine	tag	using	TEV	protease	
Pro	TEV	plus	protease	(Promega)	was	used	to	remove	the	His-tag	from	SHIP1cd-His	and	
SHIP2cd-His,	 following	 the	manufacturers	 guidelines.	 In	 general,	 the	 protein	was	 first	
concentrated	to	typically	1	–	2.5	mL	to	reduce	the	reaction	volume,	and	the	suggested	
volume	 of	 the	 supplied	 reaction	 buffer	 added.	 The	 reaction	 was	 found	 to	 be	 most	
effective	at	an	ambient	temperature	of	approximately	18	°C	for	16	hr.	
	
2.2.19	SHIP2cd	crystal	screening	and	optimisation		
Although	 the	 conditions	 for	 the	 crystallisation	 of	 SHIP2cd	 were	 already	 established	
(Mills	 et	 al.,	 2012,	 Trésaugues	 et	 al.,	 2014),	 and	 therefore	 high	 throughput	 screening	
was	 not	 required,	 some	 optimisation	 was	 necessary.	 Crystals	 were	 grown	 in	 96-well	
plates	using	a	sitting	drop	method	at	16	°C	and	equilibrated	against	a	25	µL	reservoir	of	
buffer	that	was	used	as	a	precipitant.	For	the	structure	presented	in	this	study,	optimal	
conditions	were	identified	as	20	%	PEG	6000,	0.1	M	citric	acid	pH	5.	Protein	at	9	mg/mL,	
plus	 10	 mM	MgSO4,	 was	 incubated	 at	 16	 °C	 prior	 to	 setting	 drops	 in	 a	 1:2	 ratio	 of	
protein	to	precipitant.	Crystals	formed	as	needle	clusters	within	48	hr	and	were	allowed	
to	 continue	 to	 grow	 for	 a	 further	 48-72	 hr.	 The	 crystals	 were	 separated	 as	 narrow	
individual	plates	and	were	harvested	depending	on	crystal	size	and	quality.		
	
2.2.20	Crystal	cyroprotection	
Single	crystals	were	harvested	 in	to	20	%	PEG	6000,	30	%	ethylene	glycol,	0.1	M	citric	
acid	pH	5,	and	flash	frozen	in	liquid	nitrogen.	
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2.2.21	Data	collection		
X-ray	diffraction	data	was	remotely	collected	at	Diamond	Light	Source	(Oxford)	on	beam	
line	i24.	
	
2.2.22	Data	processing	and	refinement	
X-ray	 diffraction	 data	 was	 indexed	 and	 auto	 processed	 using	 Xia2.	 Molecular	
replacement	 was	 performed	 using	 Phaser-MR	within	 the	 Phenix	 suite	 (McCoy,	 2007)	
and	 structures	 refined	 using	 Phenix	 refine	 (Afonine	 et	 al.,	 2005).	 Coot	 (Emsley	 et	 al.,	
2010)	 was	 used	 for	 manual	 adjustment	 to	 models	 between	 rounds	 of	 automatic	
refinement.	
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2.3	Results	and	Discussion	
	
2.3.1	Expression	and	purification	of	SHIP2cd	
	
An	expression	clone	of	 INPPL1cd	 (SHIP2cd)	 in	the	vector	pNIC-MBP	was	purchased	via	
the	 Structural	 Genomics	 Consortium	 (SGC)	 from	 Source	 BioScience	 (Clone	 accession	
TC124029).	 The	 clone	 was	 supplied	 as	 an	 E.	 coli	 stock	 on	 an	 agar	 slope	 which	 was	
treated	as	per	the	supplier’s	recommendations	before	purifying	the	plasmid	using	the		
Wizard®	Plus	SV	Miniprep	DNA	Purification	System	(Promega).	To	prepare	the	vector	it	
was	 transformed	 into	 stellar	 competent	 E.	 coli	 cells	 (Clontech)	 and	 single	 kanamycin	
resistant	 colonies	 selected,	 from	which	 overnight	 cultures	 were	 grown	 for	 high	 yield	
plasmid	extraction.	The	plasmid	was	transformed	into	expression	host,	E.	coli	Rosetta2	
cells,	 single	 kanamycin	 resistant	 colonies	 selected,	 and	 the	 expression	 of	 SHIP2cd-His	
tested	 via	 small	 scale	 expression	 tests	 (see	 section	 2.2.13).	 Parameters	 investigated	
were;	 temperature,	 IPTG	 concentration	 and	 length	 of	 incubation	 post	 IPTG	 addition	
(results	not	shown).	
	
Subsequently,	 large	 scale	expression	 cultures	were	 set	up	 for	purification	of	 SHIP2cd-
His.	 Two	1	 L	 cultures	were	 set	 up	 and	 expression	 carried	 out	 as	 outlined	 in	methods	
(section	2.2.16)	using	0.2	mM	IPTG	to	induce	protein	expression	(results	not	shown).	It	
was	 later	 found	 that	 4	 L	 of	 culture	 was	 necessary	 to	 produce	 enough	 protein	 for	
crystallography	studies.	
	
SHIP2cd-His	 protein	was	 purified	 as	 per	 the	method	 described	 in	 section	 2.2.17.	 The	
lysate	 of	 the	 2	 L	 culture	 was	 centrifuged	 to	 remove	 cell	 debris	 before	 loading	 the	
supernatant	on	 to	 a	 5	mL	Ni-NTA	 superflow	 cartridge	 (Qiagen)	 for	 immobilised	metal	
affinity	chromatography.	Figure	2.4	shows	the	SDS-PAGE	analysis	of	fractions	that	were	
identified	as	containing	SHIP2cd-His	from	the	UV	absorbance	trace	during	nickel	affinity	
purification.	The	overexpressed	SHIP2cd-His	(38.6	kDa)	can	be	seen	most	prominently	in	
fractions	16-24	(lanes	6-10),	with	the	most	heavy	contamination	occurring	in	fractions		
Chapter	2	–	Structural	studies	of	Human	SHIP1	and	SHIP2	
31		
	
16-20	 (lanes	6-8).	As	 these	contaminated	 fractions	also	contained	 the	highest	yield	of	
SHIP2cd	 they	 were	 pooled,	 along	 with	 fractions	 22-24,	 for	 concentrating	 before	 size	
exclusion	chromatography	on	a	HiLoad	16/600	Superdex	75	pg	column	(GE	Healthcare	
Life	 Sciences),	 performed	 according	 to	 section	 2.2.17.	 Lane	 3	 shows	 the	 lysate	 after	
loading	on	to	the	NiNTA	column	and	reveals	that	some	of	the	SHIP2cd-His	protein	did	
not	 bind	 to	 the	 column,	 a	 higher	 capacity	 column	 may	 be	 considered	 for	 future	
purifications.	
	
	 	
Figure	2.4-	Immobilised	metal	affinity	purification	of	SHIP2cd-His.	SDS-PAGE	analysis	of	eluate	fractions	recovered	
during	 NiNTA	 chromatography.	 (1)	 Protein	molecular	weight	marker.	 (2)	 Empty.	 (3)	 Sample	of	 supernatant	 post	
column	loading.	(4)	Empty.	(5-10)	Fraction	number;	14,	16,	18,	20,	22	&	24,	respectively.	
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A	sample	of	the	final	purified	and	concentrated	protein	was	analysed	by	SDS-PAGE	and	
stained	with	 InVision™	 His-tag	 In-gel	 Stain	 (Novex	 by	 Life	 Technologies),	 used	 as	 per	
manufacturer’s	 guidelines.	 Subsequently,	 the	 same	 gel	was	 stained	with	 a	 Coomassie	
blue	stain	as	per	section	2.2.15	 (Figure	2.5).	As	 the	sample	was	highly	concentrated	a	
1:4	dilution	of	the	protein	was	used.	
	
The	final	purified	protein	appears	to	have	very	little	contaminants,	bearing	in	mind	the	
protein	 is	 at	 high	 concentration	 on	 the	 gel,	 and	 does	 not	 appear	 to	 have	 truncated	
protein	with	His	tag	which	would	be	made	visible	by	the	InVision	stain.	
	
Cleavage	of	the	6xHistidine	tag	was	set	up	post	size	exclusion	chromatography	using	Pro	
TEV	 plus	 protease	 (Promega)	 after	 concentrating	 the	 protein	 to	 2.5	mL	 volume.	 The	
manufacturer’s	 guidelines	 were	 followed	 and	 the	 reaction	 was	 incubated	 for	
approximately	16	hr	at	room	temperature	(18	°C)	(section	2.2.18).	
	
Figure	2.5	-	Coomassie	blue	(left)	and	InVision	staining	(right)	of	purified	SHIP2cd-His.	(1)	Protein	molecular	weight	
marker	(2)	1:4	(v/v)	dilution	of	purified	SHIP2cd-His.	
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A	sample	was	taken	prior	to	cleavage	to	compare	to	a	post	incubation	sample,	both	of	
which	 were	 analysed	 by	 SDS-PAGE	 using	 a	 12.5%	 acrylamide	 gel,	 with	 the	 aim	 to	
achieve	 a	 clear	 separation	 of	 the	 two	 samples	 in	 order	 to	 visualise	 the	 change	 in	
molecular	weight	that	occurs	when	the	6xHistide	tag	is	removed	(Figure	2.6).	The	post	
TEV	protease	incubation	sample	is	of	lower	molecular	weight	indicating	the	removal	of	
the	tag	was	successful,	although	some	tagged	protein	still	remained.	Longer	incubation	
or	 the	 use	 of	 more	 TEV	 protease	 should	 be	 considered	 to	 recover	 a	 higher	 yield	 of	
SHIP2cd.	
	
	 	
Figure	2.6	-	SDS-PAGE	analysis	on	a	12.5	%	acrylamide	gel	of	proteolytic	cleavage	of	the	N-terminal	6xHis	tag	from	
SHIP2cd-His	using	ProTEV	plus	protease.	(1)	Protein	molecular	weight	marker.	(2)	Empty.	(3)	SHIP2cd-His.	(4)	Empty.	
(5)	SHIP2cd	post	incubation	with	TEV	protease.	
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The	 products	 of	 the	 His-tag	 cleavage	 reaction	 were	 loaded	 on	 to	 a	 5	 mL	 NiNTA	
superflow	cartridge	(Qiagen),	equilibrated	with	buffer	A	(see	appendix	2),	at	a	flow	rate	
of	0.5	mL/min	in	a	continuous	loop	for	30	min.	Elution	of	the	column	with	buffer	A	at	
1ml/min	 yielded	 SHIP2cd,	 collected	 in	 a	 10	 mL	 fraction	 and	 five	 subsequent	 2	 mL	
fractions.	 Subsequently,	 a	 single	 10	mL	 fraction	was	 collected	 in	 buffer	 B	 (results	 not	
shown).	
	
The	fractions	containing	SHIP2cd	were	pooled,	concentrated	to	2.2	mL	and	subjected	to	
a	 final	 round	 of	 size	 exclusion	 chromatography	 (results	 not	 shown).	 Final	 purified	
SHIP2cd	was	concentrated	to	9	mg/mL	and	snap	frozen	before	storage	at	-80	°C.	Figure	
2.7	 shows	 a	 sample	 of	 this	 preparation.	 The	 gel	 is	 overloaded	 to	 visualise	 the	
occurrence	of	contaminants,	which	are	negligible	when	compared	to	the	concentration	
of	 SHIP2cd.	 Final	 protein	 yield	 approximated	 to	 9	 mg/mL	 obtained	 from	 4	 L	 of	
expression	culture.	 	
Figure	2.7	 -	 SDS-PAGE	analyisis	 on	a	10	%	gel	 of	 final	 purified	 SHIP2cd.	 (1)	 Protein	molecular	weight	marker.	 (2)	
Empty.	(3)	Purified	SHIP2cd.	
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2.3.2	Crystallisation	of	SHIP2cd	
	
SHIP2cd	 was	 crystallised	 as	 per	 section	 2.2.19,	 which	 was	 adapted	 from	 a	 previous	
method	 published	 by	 Mills	 et	 al,	 2012.	 Crystals	 grew	 as	 individual	 plates	 or	 rods,	
appearing	 after	 2	 days	 and	 continued	 to	 grow	 for	 3-5	 days.	 Crystallisation	 was	
attempted	 several	 times	 and	was	 not	 consistent,	 resulting	 in	 a	 lower	 than	 hoped	 for	
yields	of	 crystals.	Nevertheless,	 individual	 crystals	were	harvested	 into	cryoprotectant	
and	stored	 in	 liquid	nitrogen	 (section	2.2.20).	An	example	of	a	SHIP2cd	crystal	 can	be	
seen	in	Figure	2.8.	
	
	
	
	 	
Figure	2.8	–	Crystal	of	SHIP2cd	exposed	to	the	beamline	for	data	collection	at	the	Diamond	Light	Source.	
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2.3.3	Crystal	structure	of	SHIP2cd	
	
Attempts	were	made	to	crystallise	SHIP2cd	with	biphenyl	phosphate	ligands.	The	work	
here	was	guided	by	the	report	of	a	crystal	structure	for	a	catalytic	domain	of	SHIP2	with	
bound	biphenyl	2,3’,4,5’-pentakisphosphate	ligand	resolved	to	2.1Å	(Mills	et	al.,	2012).	
Both	 co-crystallisation	and	 soaking	methods	were	 implemented	 in	attempts	 to	obtain	
crystals	 of	 	 protein/ligand	 complexes.	 As	 well	 as	 optimisatisation	 of	 the	 previously	
published	 conditions,	 exploration	 of	 alternative	 conditions	 via	 high-throughput	
screening	was	also	attempted.	Prior	to	the	work	of	Mills	and	coworkers	(2012),	the	only	
structure	 of	 a	 5-phosphatase	 catalytic	 domain	 that	 had	 been	 reported	 is	 that	 of	
Schizosaccharomyces	 pombe	 synaptojanin	 (SPsynaptojanin).	 The	 structure	 was	
determined	 in	 complex	 with	 a	 soluble	 inositol	 1,4-bisphosphate	 product	 of	 5-
phosphatase	 action	 on	 inositol	 1,4,5-trisphosphate	 (Tsujishita	 et	 al.,	 2001).	 As	 such,	
neither	structure	inform	how	5-phosphatases	as	a	class	co-ordinate	the	lipid	moieties	of	
their	phosphoinositide,	particularly	PtdIns(3,4,5)P3,	substrates.	Since	then,	the	work	of	
Trésaugues	 et	 al.,	 2014,	 provided	 a	 number	 of	 structures	 of	 the	 catalytic	 domains	 of	
other	 5-phosphatase	 family	 members:	 INPP5B	 in	 apo,	 PtdIns4P-bound	 and	
PtdIns(3,4)P2-bound	 structures	 (PDB	 3N9V,	 3MTC	 and	 4CML	 at	 2.65Å,	 2.4Å	 and	 2.3Å	
respectively),	SHIP2	in	apo	form	(3NR8	at	2.8Å),	and	OCRL	in	apo	form	(4CMN	at	3.13Å).	
It	is	noteworthy	that	the	position	of	scissile	5-phosphate	of	substrate	is	lacking	from	all	
these	structures.		
	
Although	no	dataset	could	be	gained	here	for	SHIP2cd	with	this	or	any	of	a	number	of	
other	biphenyl	phosphate	compounds,	as	initially	described	in	the	experimental	aims,	a	
successful	data	set	for	apo	SHIP2cd	was	collected	and	refined	to	a	resolution	of	2.8	Å.	
Data	processing	and	refinement	in	the	P21	space	group	was	achieved	using	the	Phenix	
suite	 (Adams	et	al.,	2010).	Table	2.1	contains	data	collection	and	refinement	statistics	
for	the	apo-protein.	
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Table	2.1	-	X-ray	diffraction	data	processing	and	model	refinement	statistics	for	SHIP2cd.	 	
Space	Group P	21	Unit	Cella,	b,	c		(Å)α,	β,	γ	(°) 44.7,	61.1,	114.292.19Resolution	(Å) 57.08-2.75	(2.88-2.75)Rmerge		(%) 10.7	(39.2)<I/σ(I)> 7.4	(2.1)CC	1/2 0.949	(0.630)Completeness	(%) 97.8	(97.8)Multiplicity 2.8	(2.7)Wilson	B-factor 6.326
Number	of	Non-hydrogen	atomsWaters 482076Resolution	(Å) 57.08-2.75	(2.92-2.75)Rwork		(%) 22.8	(27.8)Rfree	(%) 30.4	(39.2)Mean	B-value	(Å2) 25.37RMSD	Bonds	(Å) 0.009RMSD	Angles	(°) 1.223RMSD	Planes	(Å) 0.005
Refinement
Data	Processing
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During	 the	 course	 of	 this	 study	 a	 second	 structure	 of	 SHIP2cd	 was	 solved	 to	 2.8	 Å,	
Protein	Data	 Bank	Acession	 3NR8	 (Trésaugues	 et	 al.,	 2014),	 again	 in	 P21	 space	 group	
and	the	same	unit	cell	as	the	apo	structure	presented	here.		
	
Just	 like	 the	 previously	 published	 structures,	 SHIP2cd	 crystallised	with	 two	molecules	
(chains	A	and	B)	in	the	asymmetric	unit	(AU).	These	align	to	each	other	with	a	RMSD	of	
0.319	(Figure	2.9	–	A).	Crystallisation	in	this	space	group	and	unit	cell	may	be	expected	
as	 the	 same	 recombinant	protein	 and	 very	 similar	 crystallisation	methods	were	used.	
Here,	 both	molecules	 interact	with	 symmetry	 related	molecules	 in	 neighbouring	AUs,	
and	 these	 interactions	 are	 likely	 to	 be	 required	 for	 the	 stabilisation	 of	 the	 lattice	
structure	(Figure	2.9	B	&	C).		
	 	
Figure	2.9	–	SHIP2cd	crystal	structure	represented	as	a	cartoon	and	coloured	by	secondary	structure.	Symmetry-
related	 SHIP2cd	 molecules	 are	 shown	 in	 green.	 (A)	 The	 two	 molecules	 in	 the	 asymmetric	 unit.	 (B)	 Chain	 B	
interaction	with	a	symmetry-related	molecule.	(C)	Chain	A	interaction	with	a	symmetry	related	molecule.		
Disordered	
loop	
P4IM-containing	
loop	
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Contacts	 occur	 via	 the	 4-phosphate	 interacting	 motif	 (P4IM)-containing	 loop	 (Figure	
2.9),	which	 is	thought	to	be	uniquely	extended	in	SHIP1	and	SHIP2,	and	shorter	 in	the	
other	inositol	polyphosphate	5-phosphatases	(Trésaugues	et	al.,	2014,	Mills	et	al,	2012).	
The	same	interactions	can	be	seen	in	the	published	structures	of	SHIP2cd,	where	chain	
B	 interacts	with	a	chain	A	 lattice	neighbour,	with	 the	converse	being	 true	 for	 chain	A	
(Figure	2.2).	 In	 chain	B,	 interactions	occur	 at	 the	apex	of	 the	extended	 loop	between	
P678,	H-bonded	with	M502	and	with	hydrophobic	 interaction	with	V525,	both	of	 the	
symmetry	 related	 molecule.	 These	 interactions,	 and	 that	 of	 R479	 of	 the	 neighbour	
which	 co-ordinates	 the	 6-phosphate	 of	 biphenyl	 2,3’,4,5’,6-pentakisphosphate	 ligand,	
likely	constrain	the	loop	to	this	conformation	(Figure	2.10).	
	
	
	 	
P678	
V525	
M502	
Figure	 2.10	 –	 Interactions	 between	 the	 (P4IM)-containing	 loop	 of	 chain	 B,	 and	 a	 symmetry	 related	 lattice	
neighbour.	 Chain	 B	 is	 shown	 as	 a	 cartoon	 representation	 coloured	 by	 secondary	 structure.	 BiPh1(blue)	 and	
residues	that	facilitate	loop	interactions	and	conformation	are	shown	as	sticks.	Residues	 in	green	arise	 from	the	
symmetry	related	chain	A.	
R479	
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The	 P4IM-containing	 loop	 of	 chain	 A	 is	 directed	 towards	 a	 disordered	 region	 in	 the	
symmetry	 related	 molecule,	 causing	 consecutive	 disorder	 in	 the	 loop	 itself.	 This	
disordered	region	in	chain	B	is	indicated	in	Figure	2.9,	and	consists	of	a	loop	formed	by	
residues	456-460.	
	
As	can	be	seen	 in	Figure	2.11	 -B,	 the	electron	density	 for	 the	P4IM-containing	 loop	 in	
chain	A	is	lacking,	suggesting	flexibility	and/or	multiple	conformations.	
	
	 	
Figure	2.11	–	Conformation	of	the	P4IM-containing	loop	in	the	SHIP2cd	crystal	structure.	Double	difference	Fourier	
electron	density	is	shown	as	a	blue	mesh	with	a	map	contour	of	1.2	σ.	(A)	Chain	B.	(B)	Chain	A.		
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This	 loop	 is	 thought	 to	 be	 flexible	 and	 disordered	 in	 the	 apo-form,	 but	 regains	 order	
when	a	substrate	or	inhibitor	is	bound	resulting	in	it	folding	over	the	active	site	pocket,	
as	has	been	postulated	by	molecular	dynamics	 simulations	 (Mills	et	al.,	2012).	Having	
said	this,	the	structure	of	apo	SHIP2cd	presented	here	is	near	identical	to	the	SHIP2cd	
structure	 in	 complex	with	 biphenyl	 2,3’,4,5’,6	 pentakisphosphate	 (BiPh1)	 (Mills	 et	 al.,	
2012).	
	
	 	
Figure	2.12	–Alignments	 of	 apo	 SHIP2cd	 (magenta)	 and	SHIP2cd	BiPh(2,3’,4,5’,6)P5	 structures	 (cyan)	 (Mills	 et	 al.,	
2012).	 BiPh(2,3’,4,5’,6)P5	 is	 represented	 as	 sticks	 and	 coloured	 by	 element.	 (A)	 Cartoon	 representation	 of	 the	
binding	 site	 secondary	 structure	elements.	 (B)	Overlay	of	 side	 chains	 that	have	direct	protein-ligand	 interactions	
with	BiPh(2,3’,4,5’,6)P5.	Adapted	from	PDB	file	4A9C.	
K541	
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The	 two	 structures	 align	 with	 an	 RMSD	 of	 0.239,	 with	 the	 PI4M-containing	 loop	 in	
seemingly	near	identical	positions	regardless	of	a	ligand	being	present,	and	appears	to	
be	structured.	This	 is	reinforced	by	the	double	difference	electron	density	around	this	
loop	(Figure	2.11	&	Figure	2.12	-A),	inferring	that	the	P4IM-containing	loop	must	not	be	
essential	in	coordinating	BiPh1	in	the	active	site	pocket,	but	instead	is	only	stabilised	by	
the	 interactions	with	 the	symmetry	 related	molecule	 in	 the	 lattice	 (chain	B	only).	The	
structural	 organisation	 of	 this	 region	 is	 also	 only	 defined	 in	 chain	 B	 of	 a	 previously	
published	 apo-structure	 of	 the	 same	 space	 group	 as	 well,	 therefore	 supporting	 this	
notion	(Trésaugues	et	al.,	2014).	
	
The	interactions	that	coordinate	BiPh1	in	the	Mills	et	al.	2012	structure	occur	with	P3’,	
P4,	P5’	and	P6.	Regardless	of	BiPh1	being	bound	in	the	active	site,	the	position	of	the	
residues	that	are	reported	to	interact	with	these	phosphates	are	not	altered	relative	to	
those	 in	 the	 apo-structure,	 indicating	 that	 no	 conformational	 changes	 in	 the	 binding	
pocket	take	place	upon	ligand	binding	(Figure	2.12	–	B).	This	is	supported	by	the	double	
difference	electron	density	around	these	residues.		
	
As	stated	previously,	in	the	crystal	environment	BiPh1	is	coordinated	by	the	symmetry	
related	molecule	at	its	3’,	5’-	and	6-phosphates.		The	true	binding	orientation	of	BiPh1	
in	 the	 active	 site	 of	 SHIP2	 remains	 a	 concern,	 even	 despite	 the	 molecular	 dynamics	
simulations	 on	 the	 SHIP2cd	 BiPh1	 structure	 which	 suggest	 that	 the	 P4IM-containing	
loop	folds	over	and	eliminates	interactions	with	the	lattice	neighbour	(Mills	et	al.,	2012).		
In	consideration	of	the	assumed	mobility	of	the	P4IM-containing	loop.	
	
In	the	absence	of	the	identification	of	novel	 ligands	of	SHIP2cd	complexes	in	the	work	
presented	 in	 this	 thesis,	 the	 structure	 reported	 here	 does	 not	 offer	 insight	 to	 the	
unanswered	 question	 of	 the	 co-ordination	 of	 the	 scissile	 5-phosphate	 of	 inositide	 or	
phosphoinositide	 substrates.	 To	 obtain	 further	 information,	 an	 attempt	was	made	 to	
solve	 structures	 of	 the	 related,	 but	 exclusively	 hematopoietically-expressed	 SHIP1	
protein.		
	 	
Chapter	2	–	Structural	studies	of	Human	SHIP1	and	SHIP2	
43		
	
2.3.4	 Ligation	 independent	 cloning	 of	 INPP5Dcd	 (SHIP1cd)	 in	 to	 the	 pNIC28-Bsa4	
vector	
	
Unlike	the	5-phosphatase	domain	of	SHIP2	(SHIP2cd/INPPL1cd)	(see	section	2.3.3)	there	
was	no	expression	clone	available	for	the	SHIP1	protein	from	the	Structural	Genomics	
Consortium	(SGC,	materials	available	from	Source	BioScience).	Although	the	SGC	have	a	
selection	 of	 plasmids	 available	 for	 purchase,	 pNIC-MBP,	which	 INPPL1cd	 is	 in,	 is	 not.	
Therefore,	 it	 was	 necessary	 to	 seek	 out	 appropriate	 alternatives	 that	 would	 provide	
equally	 successful	 yields	 of	 active	 protein.	 As	 SHIP2	 and	 SHIP1	 are	 close	 homologues	
and	their	5-phosphatase	domains	share	63.9	%	identity,	sensible	options	would	include	
vectors	similar	to	pNIC-MBP.	This	plasmid	adds	a	MBP-TVMV-His6-TEV	fusion	to	the	N-
terminal	 of	 the	 protein,	 and	 the	MBP	 tag	 is	 cleaved	 in	 vivo	 via	 the	 TVMV	 sequence.	
There	is	very	little	information	about	the	plasmid	freely	available,	but	it	is	presumed	the	
MBP	tag	is	necessary	to	enhance	solubility	of	the	target	expression	protein	and/or	assist	
with	correct	folding	and	stability.	
	
Firstly,	the	expression	vector	pMCSG19	was	selected	due	to	its	similarity	to	pNIC-MBP;	
it	also	adds	a	MBP-TVMV-His6-TEV	N-terminal	fusion	to	cloned	proteins	(Donnelly	et	al.,	
2006,	 Eschenfeldt	 et	 al.,	 2009)	 (DNASU-plasmid	 repository).	 The	 pNIC28-Bsa4	
expression	vector	was	also	selected	due	to	its	extensive	use	by	SGC	to	successfully	clone	
and	 express	 many	 mammalian	 proteins;	 adding	 a	 His-TEV	 N-terminal	 fusion	 to	 the	
cloned	expression	target	(Gileadi	et	al.,	2008,	Savitsky	et	al.,	2010)	(GenBank	EF198106).	
Cloning	 in	 to	 pMCSG19	 was	 undertaken	 in	 tandem	 with	 pNIC28-Bsa4	 by	 a	 similar	
ligation	independent	method	(Eschenfeldt	et	al.,	2009)	but	at	first	pass	did	not	produce	
successful	clones	in	the	latter	stages	of	cloning	and	was	not	pursued	further.	This	may	
have	increased	solubility	and	purity	of	the	protein	if	pursued	and	optimised.	
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Table	2.2	–	Primers,	 annealing	 temperatures,	 and	elongation	 times	used	 for	 the	PCR	amplification	of	 full	 length	
INPP5D	and	its	catalytic	domain	(INPP5Dcd)	from	a	cDNA	clone	template.	Flanking	sequences	required	for	ligation	
independent	cloning	are	shown	in	bold	italics.		
	
The	template	used	for	PCR	amplification	of	INPP5Dcd	was	purchased	as	a	fully	sequence	
cDNA	clone	(Source	BioScience)	in	the	vector	pCR4-TOPO	and	contained	the	full	INPP5D	
sequence	(I.M.A.G.E.	ID	–	8322634)	(Accession	BC113582).	As	SHIP1	and	SHIP2	share	a	
high	 percentage	 identity	 in	 their	 catalytic	 domains,	 the	 sequence	 for	 the	 catalytic	
domain	 of	 SHIP1	 (SHIP1cd)	 was	 identified	 via	 alignment	 of	 the	 full	 length	 SHIP1	
sequence	with	the	SHIP2cd	sequence	supplied	by	the	SGC,	which	is	also	available	in	the	
NCBI	database	(Accession	3NR8_A).	
PCR	amplification	of	 INPP5Dcd	was	carried	out	using	Phusion	high	 fidelity	polymerase	
(New	England	Biolabs)	(section	2.2.2)	as	per	manufacturer’s	 instructions	and	using	the	
primer	 sequences,	 annealing	 temperature	 and	 elongation	 time	provided	 in	 Table	 2.2.	
The	additional	sequences	required	 for	 ligation	 independent	cloning	are	shown	 in	bold	
italics	(Gileadi	et	al.,	2008).	Also	shown	is	a	primer	set	for	the	amplification	of	full	length	
SHIP1,	but	this	did	not	produce	successful	clones	in	the	final	phases	of	cloning.	
	
To	 remove	 primers	 and	 other	 contaminants,	 the	 PCR	 products	 were	 purified	 by	 gel	
extraction	using	the	Wizard®	SV	Gel	and	PCR	Clean-Up	System	(Promega)	after	agarose	
gel	electrophoresis	(see	section	2.2).	The	PCR	products	shown	in	Figure	2.13	were	the	
expected	 fragment	 sizes	 for	 full	 length	 SHIP1	 and	 SHIP1cd;	 3567	 bp	 and	 957	 bp,	
respectively.	
	 	
Gene	name	 Template	IMAGE	ID Forward	primer	(5'	to	3') Reverse	primer	(5'	to	3') Fragment	size	(bp) Annealing	temperature	(°C) Elongation	time	(sec)
INPP5D 8322634 TACTTCCAATCCATGGTCCCCTGCTGGAACCAT TATCCACCTTTACTGTCACTGCATGGCAGTCCTGCC 3567 57 70
INPP5D-cd 8322634 TACTTCCAATCCATGGAGCAGCCGGAGCCCGAC TATCCACCTTTACTGTCACTGGGAAGTGACTCCTGCCTC 957 64 30
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The	 purified	 PCR	 product	 was	 treated	 with	 T4	 DNA	 polymerase	 (Clontech)	 in	 the	
presence	of	dCTP	 for	 30	min	at	 11	 °C	 followed	by	20	min	at	 75	 °C.	 The	exo-nuclease	
activity	of	the	polymerase	hydrolyses	nucleotides	from	the	3’	ends	until	 it	reaches	a	C	
residue,	creating	a	single	stranded	5’	overhang.	
	
The	 pNIC-Bsa4	 vector	 was	 purchased	 from	 the	 SGC	 (Source	 BioScience)	 and	 was	
supplied	 as	 an	E.	 coli	 stock	 on	 an	 agar	 slope	which	was	 treated	 as	 per	 the	 supplier’s	
recommendations	 before	 purifying	 the	 plasmid	 using	 the	 Wizard®	 Plus	 SV	 Miniprep	
DNA	Purification	System	(Promega).	To	prepare	vector,	 it	was	transformed	into	Stellar	
competent	 E.	 coli	 cells	 (Clontech),	 single	 kanamycin	 resistant	 colonies	 selected,	 from	
which	O/N	cultures	were	grown	for	later	plasmid	extraction.	The	plasmid	was	digested	
with	 BsaI-HF	 restriction	 enzyme	 (New	 England	 Biolabs)	 as	 per	 the	 manufacturer’s	
protocol,	 which	 subsequently	 released	 a	 2	 kb	 fragment	 if	 digested	 correctly	 at	 both	
restriction	sites.	The	digested	plasmid	was	analysed	by	agarose	gel	electrophoresis	and		
	
Figure	2.13	–	Gel	purified	PCR	amplified	products	from	the	pCR4-TOPO-INPP5D	template	analysed	on	a	1	%	agarose	
gel.	 (1)	 1	 kb	 plus	 DNA	 ladder.	 (2)	 Empty.	 (3)	 Full	 length	 INPP5D.	 (4)	 Catalytic	 domain	 fragment	 of	 INPP5D	
(INPP5Dcd).	
1.0$
kb$
4.0$3.0$2.0$1.6$
0.85$
1$ 2$ 3$ 4$
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the	linearised	~5.5	kb	plasmid	extracted.	The	recovered	plasmid	was	then	analysed	by	
agarose	gel	electrophoresis	(Figure	2.14).	
	
To	 generate	 the	 cohesive	 ends	 required	 for	 ligation	 independent	 cloning,	 the	 BsaI	
digested	plasmid	was	treated	with	T4	DNA	polymerase	in	the	presence	of	dGTP	for	30	
min	 at	 11	 °C	 followed	 by	 20	 min	 at	 75	 °C;	 creating	 single	 stranded	 5’	 overhangs	
complementary	to	the	PCR	products.	
	
Annealing	of	 the	 treated	plasmid	and	 insert	was	achieved	by	 incubating	a	 ratio	of	2:1	
(v/v)	plasmid	 to	 insert	at	 room	temperature	 followed	by	 incubation	on	 ice	 for	10	min	
before	transforming	in	to	stellar	competent	E.	coli	cells.	Only	a	few	transformants	were	
generated	 for	 SHIP1cd	 and	 none	 for	 full	 length	 SHIP1.	 Therefore,	 only	 SHIP1cd	 was	
pursued	 due	 to	 the	 time	 constraints	 of	 this	 project.	 Changing	 the	 ratios	 of	 each	
fragment	or	higher	yields	of	plasmid	and	insert	may	have	remedied	this.	The	PCR	yield	
of	full	length	SHIP1	was	not	as	high	as	SHIP1cd.	
	 	
1.0$
kb$
4.0$3.0$2.0$1.6$
0.85$
1$ 2$ 3$
Figure	 2.14	 –	 Linearised	 and	 gel	 purified	 pNIC28-Bsa4	 vector	 analysed	 on	 a	 1%	 agarose	 gel.	 (1)	 1	 kb	 plus	 DNA	
ladder.	(2)	Empty.	(3)	pNIC28-Bsa4		digested	with	BsaI.		
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Two	 kanamycin	 resistant	 colonies	 were	 selected	 and	 grown	 overnight	 in	 LB.	 Colony	
screening	was	carried	out	on	the	overnight	cultures	via	PCR	amplification	using	GoTaq®	
G2	Flexi	DNA	Polymerase	(Promega)	as	per	manufacturer’s	instructions	and	detailed	in	
materials	 and	 methods	 (section	 2.2.10).	 The	 primers,	 annealing	 temperatures,	 and	
elongation	times	were	as	Table	2.2.	
	
Both	colonies	contained	the	plasmid	with	the	 INPP5Dcd	 insert	(Figure	2.15),	and	were	
extracted	using	the	Wizard®	Plus	SV	Miniprep	DNA	Purification	System	(Promega).	The	
insert	of	the	final	construct	(Figure	2.	–B	(4))	was	sequenced	using	the	pLIC-for	and	pLIC-
rev	 primers	 (Gileadi	 et	 al.,	 2008),	 which	 verified	 the	 correct	 sequence	 before	
transformation	of	 the	plasmid	 in	 to	E.	 coli	 Rosetta2	 competent	 cells	 and	E.	 coli	 BL21-
pRARE2	competent	cells	for	protein	expression	testing.	
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Figure	2.15	 –	Colony	 screening	by	PCR	 amplification	 of	 INPP5Dcd	 from	 two	kanamycin	 resistant	E.	 coli	 colonies	
analysed	on	a	1%	agarose	gel.	(1)	1	kb	plus	DNA	ladder.	(2)	Colony	1.	(3)	Colony	2.	
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2.3.5	Expression	of	SHIP1cd-His	
	
Two	 single	 colonies	 were	 selected	 from	 the	 transformation	 plate	 to	 cultivate	 starter	
cultures	for	subsequent	expression	testing.	Expression	tests	were	carried	as	outlined	in	
methods,	 and	 consequently	 analysed	 by	 SDS-PAGE.	 The	 estimated	 protein	 size	 for	
SHIP1cd-His	 is	39320.5	Da,	as	computed	by	ProtParam	(Wilkins	et	al.,	1999),	 from	the	
sequence	available	on	the	NCBI	database	together	with	the	N-terminal	fusion	sequence.	
	
	 	
Figure	2.16	–	 Small	scale	expression	testing	of	 SHIP1cd-His	by	E.	coli	Rosetta2	 cells.	SDS–PAGE	analysis	on	a	10%	
acrylamide	 gel	 of	 whole	 cell	 pellets	 from	 IPTG	 induced	 cultures	 originating	 from	 two	 separate	 transformation	
colonies.	
	A	–	non-ITPG	induced	cultures	(1)	Protein	molecular	weight	marker.	(2)	Culture	A.	(3)	Culture	B.		
B	 –	 Expression	 cultures	 supplemented	with	 IPTG	 (1)	 Protein	 molecular	 marker.	 (2)	 Culture	 A	 +0.2	mM	 IPTG.	 (3)	
Culture	A	+0.5	mM	IPTG.	(4)	Culture	B	+0.2	mM	IPTG.	(5)	Culture	B	+0.5	mM	IPTG.	
Chapter	2	–	Structural	studies	of	Human	SHIP1	and	SHIP2	
49		
	
All	cultures,	including	the	non-IPTG	induced,	were	left	to	grow	overnight	at	20	°C.	All	the	
IPTG-induced	expression	cultures	successfully	expressed	SHIP1cd-His	in	E.	coli	Rosetta2	
cells	(Figure	2.16	-	B).	The	only	notable	difference	was	seen	in	culture	A	supplemented	
with	0.5	mM	 IPTG,	which	appeared	 to	 give	a	 lower	expression	 yield.	 In	 light	of	 these	
results,	culture	B	was	chosen	to	carry	forward	for	large	scale	expression	and	purification	
because	of	the	apparent	strong	and	consistent	expression	levels.	There	appeared	to	be	
no	basal	“leaky”	protein	expression	(Figure	2.16	–	A)	 therefore	there	was	no	need	for	
glucose	 supplementation	 to	 suppress	 expression	 during	 the	 growth	 phase.	 This	 is	 as	
expected	 due	 to	 Rosetta2	 containing	 the	 pLysS	 plasmid	 (discussed	 in	 chapter	 3).	 No	
expression	was	observed	in	BL21-pRARE2	E.	coli	cells	(data	not	shown).	
	
Subsequently,	 large	scale	expression	cultures	were	set	up	that,	 if	successful,	would	be	
carried	 forward	 to	 purify	 SHIP1cd-His.	 Two	 1	 L	 cultures	 were	 set	 up	 and	 expression	
carried	 out	 as	 outlined	 in	 methods	 using	 0.4	mM	 IPTG	 to	 induce	 protein	 expression	
(Figure	2.17).		
	
Figure	2.17	–	SDS-PAGE	analysis	of	whole	cell	pellets	from	the	large	scale	expression	of	SHIP1cd-His	analysed	on	a	1%	
agarose	gel.	(1)	Protein	molecular	weight	marker.	(2)	Empty.	(3)	1	L	expression	culture.	(4)	Empty.	(5)	1	L	expression	
culture.	
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Both	cultures	showed	high	 levels	of	expression	under	 these	conditions.	Consequently,	
they	were	subjected	to	mechanical	cell	disruption	to	be	taken	forward	for	purification	
of	SHIP1cd-His.	
	
2.3.6	Purification	of	SHIP1cd-His	
	
SHIP1cd-His	 protein	was	 purified	 as	 per	 the	method	 described	 in	 section	 2.2.17.	 The	
lysate	of	the	2	L	culture	from	section	2.3.2	was	centrifuged	to	remove	cell	debris	before	
loading	 the	 supernatant	 on	 to	 a	 5	 mL	 Ni-NTA	 superflow	 cartridge	 (Qiagen)	 for	
immobilised	metal	affinity	chromatography.	
	
	
	 	
Figure	2.18	-	Immobilised	metal	affinity	purification	of	SHIP1cd-His.	SDS-PAGE	analysis	on	a	10%	acrylamide	gel	
of	eluate	fractions	recovered	during	NiNTA	chromatography.	(1)	Protein	molecular	weight	marker.	(2-8)	Column	
eluate	fractions	corresponding	to	the	UV	absorbance	peak	at	280	nm.	Fraction	number;	14,	16,	18,	20,	22,	24	&	
26,	respectively.	
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Figure	2.18	shows	the	SDS-PAGE	analysis	of	fractions	that	were	identified	as	containing	
SHIP1cd-His	 from	 the	 UV	 absorbance	 trace	 during	 nickel	 affinity	 purification.	 The	
overexpressed	SHIP1cd-His	(39.5	kDa)	can	be	seen	most	prominently	in	fractions	16-24	
(lanes	3-7),	with	the	most	heavy	contamination	occurring	in	fractions	16-20	(lanes	3-5).	
As	 these	 contaminated	 fractions	 also	 contained	 the	 highest	 yield	 of	 SHIP1cd-His	 they	
were	 pooled,	 along	 with	 fractions	 21-24,	 for	 concentrating	 before	 subjection	 to	 size	
exclusion	chromatography	on	a	HiLoad	16/600	Superdex	75	pg	column	(GE	Healthcare	
Life	Sciences),	performed	according	to	section	2.2.17.		
	
Two	 peaks	 were	 observed	 on	 the	 resulting	 UV	 trace	 from	 the	 size	 exclusion	
chromatography,	albeit	not	overly	distinctive	with	some	observed	overlap.	As	the	first	
peak	 is	 expected	 to	 be	 the	 larger	 contaminant	 proteins	 eluting	 in	 the	 void	 volume,	
samples	of	the	fractions	from	the	wide	second	peak	were	analysed	by	SDS-PAGE	(Figure	
2.19).	 SHIP1cd-His	 appeared	 to	 be	 present	 in	 fractions	 7-17	 (lanes	 2-7)	 in	 varying	
magnitudes	and	co-eluted	with	contaminants.	 It	 is	 likely	there	 is	some	protein-protein	
interactions	occurring	between	SHIP1cd	and	the	contaminants,	accounting	for	the	wide	
overlapping	 peaks	 on	 the	UV	 trace.	 Nevertheless,	 fractions	 10-18,	 therefore	 avoiding	
some	of	the	large	and	more	prominent	contaminants	observed	in	lane	3,	were	pooled	
and	concentrated	to	approximately	3.5	mg/mL	and	a	volume	of	2	mL.		
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Other	attempts	at	purifying	SHIP1cd-His	used	different	buffers,	salt	concentrations	and	
DTT	 or	 TCEP,	 see	 section	 2.2.9	 and	 appendix	 2	 for	 more	 details.	 A	 HiLoad	 16/600	
Superdex	 200	 pg	 (GE	 Healthcare	 Life	 Sciences)	 was	 also	 utilised	 in	 an	 attempt	 to	
improve	 separation	 between	 SHIP1cd-His	 and	 the	 contaminating	 proteins	 during	 size	
exclusion	 chromatography,	 much	 to	 the	 same	 avail.	 Upon	 reflection,	 the	 pH	 of	 the	
buffers	should	be	adjusted	as	the	next	effort	to	reduce	protein-protein	interactions	by	
altering	 the	net	charge	of	SHIP1cd-His.	ExPASy’s	ProtParam	tool	 (Wilkins	et	al.,	1999),	
calculates	the	pI	of	SHIP1cd-His	to	be	6.81	and	the	buffers	were	the	same	as	those	used	
for	 AtIPK1	 (Chapter	 3),	 which	 were	 pH	 7.5.	 This	 may	 have	 been	 too	 close	 to	 the	
isoelectric	point	of	SHIP1cd-His	and	could	have	rendered	some	of	the	protein	insoluble,	
resulting	in	aggregation	and	interactions	with	contaminating	proteins.	Nevertheless,	as	
will	 be	 seen	 later	 on	 in	 this	 text,	 soluble	 and	 catalytically	 active	 SHIP1cd	protein	was	
obtained.	
	 	
Figure	2.19	 -	 Size	 exclusion	 chromatography	of	 SHIP1cd-His.	 SDS-PAGE	 analysis	 on	a	 10%	acrylamide	 gel	 of	 elute	
fractions	recovered	from	a	sepharose	gel	filtration	column.	(1)	Protein	molecular	weight	marker.	(2-8)	Column	elute	
fractions	 corresponding	 to	 the	 UV	 absorbance	 peaks	 at	 280	 nm.	 Fraction	 number;	 7,	 9,	 11,	 13,	 15,	 17	 &	 19,	
respectively.	
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A	sample	of	the	final	purified	and	concentrated	protein	was	analysed	by	SDS-PAGE	and	
stained	with	 InVision™	 His-tag	 In-gel	 Stain	 (Novex	 by	 Life	 Technologies),	 used	 as	 per	
manufacturer’s	 guidelines.	 Subsequently,	 the	 same	 gel	was	 stained	with	 a	 Coomassie	
blue	stain	as	per	section	2.2.15	(Figure	2.20).	As	the	sample	was	highly	concentrated	a	
1:2	 dilution	 of	 the	 protein	 was	 used.	 The	 InVision	 stain	 binds	 specifically	 to	 the	
6xHistidine	tag	and	can	be	used	to	accurately	detect	the	presence	of	His-tagged	fusion	
proteins	due	to	its	fluorescent	properties.	Its	excitation	maximum	is	at	a	wavelength	of	
560	 nm,	 and	 its	 emission	 maxima	 at	 590	 nm,	 the	 parameters	 pre-set	 for	 visualising	
ethidium	bromide	sufficed.	It	can	provide	a	quicker	and	simpler	alternative	to	a	western	
blot	to	confirm	the	presence	of	His-tagged	fusion	proteins.	
	
	 	
Figure	2.20	-	Coomassie	blue	(left)	and	InVision	staining	(right)	of	purified	SHIP1cd-His.	(1)	Protein	molecular	weight	
marker	(2)	1:2	(v/v)	dilution	of	purified	SHIP1cd-His.	
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The	 final	 purified	 protein	 contains	 contaminants	 and	 it	 appears	 there	 are	 truncated	
versions	of	SHIP1cd-His,	as	can	be	seen	by	the	right	hand	side	of	the	gel	in	Figure	2.20	
where	 only	 proteins	 with	 a	 histidine-tag	 are	 stained.	 This	 could	 be	 due	 to	 the	
production	 of	 truncates	 during	 expression,	 degradation	 of	 SHIP1cd-His	 and/or	
hydrolysis	by	proteases.	Having	these	presumably	non-folded	and	truncated	versions	of	
SHIP1cd-His	 present	may	 also	 reduce	 the	 solubility	 and	 activity	 of	 the	 protein	 due	 to	
aggregation.	Protease	inhibitors	should	be	considered	during	purification.	
	
It	 is	preferential	to	remove	the	6xHistidine	tag	for	the	purpose	of	enzymatic	assays	to	
avoid	 any	 interference,	 which	 could	 perhaps	 occur	 by	 additional	 non-canonical	
interactions.	 Cleavage	 of	 the	 6xHistidine	 tag	 was	 set	 up	 post	 size	 exclusion	
chromatography	using	Pro	TEV	plus	protease	(Promega)	after	concentrating	the	protein	
to	 a	 1	 mL	 volume.	 Manufacturers	 guidelines	 were	 followed	 and	 the	 reaction	 was	
incubated	for	approximately	16	hr	at	room	temperature	(18	°C).	
	
A	sample	was	taken	prior	to	cleavage	to	compare	to	a	post	incubation	sample,	both	of	
which	 were	 analysed	 by	 SDS-PAGE	 using	 a	 12.5%	 acrylamide	 gel,	 with	 the	 aim	 to	
achieve	 a	 clear	 separation	 of	 the	 two	 samples	 in	 order	 to	 visualise	 the	 change	 in	
molecular	weight	that	occurs	when	the	6xHistide	tag	is	removed	(Figure	2.21).	The	post	
TEV	protease	incubation	sample	is	of	lower	molecular	weight	indicating	the	removal	of	
the	tag	was	successful,	although	some	tagged	protein	still	remained.	
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The	 products	 of	 the	 His-tag	 cleavage	 reaction	 were	 loaded	 on	 to	 a	 5	 mL	 NiNTA	
superflow	cartridge	(Qiagen),	equilibrated	with	buffer	A	(see	appendix	2),	at	a	flow	rate	
of	 0.5	 mL/min	 in	 a	 continuous	 loop	 for	 30	 min.	 The	 eluate	 containing	 SHIP1cd	 was	
collected	in	a	10	mL	fraction	and	five	subsequent	2	mL	fractions	whilst	the	column	was	
subjected	to	buffer	A	at	a	1	mL/min	flow	rate.	Subsequently,	a	final	10	mL	fraction	was	
collected	when	washing	the	column	with	buffer	B.	All	 fractions	were	analysed	by	SDS-
PAGE	(Figure	2.22).	The	majority	of	SHIP1cd	was	eluted	in	the	initial	10	mL	fraction	(lane	
2)	whilst	the	6xHistidine	tag	and	TEV	protease	remained	on	the	column.	The	final	10	mL	
fraction	contained	some	SHIP1cd,	confirming	the	removal	of	the	6xHisidine	tag	was	not	
100	 %	 effective	 (lane	 7).	 The	 cleaved	 protein	 in	 lanes	 2-6	 appear	 to	 still	 contain	 a	
contaminant	 larger	than	SHIP1cd,	but	some	smaller	contaminants	have	been	removed	
as	seen	in	lane	7	which	are	likely	to	be	those	seen	in	figure	2.		Other	bands	seen	in	lane	
7	are	likely	to	be	the	6xHistidine	tag	and	TEV	protease,	as	well	as	some	un-cleaved		
Figure	2.21	-	SDS-PAGE	analysis	on	a	12.5	%	acrylamide	gel	of	the	proteolytic	cleavage	of	the	N-terminal	6xHis	tag	
from	SHIP1cd-His	using	ProTEV	plus	protease.	(1)	Protein	molecular	weight	marker.	(2)	Empty.	(3)	SHIP1cd-His.	(4)	
SHIP1cd	post	incubation	with	TEV	protease.	
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SHIP1cd-His.	 The	 comparatively	 small	 concentration	 of	 TEV	 protease	 used	 was	
reasonably	efficient	under	the	conditions	tested	but	perhaps	a	higher	concentration	of	
TEV	protease	or	longer	incubation	would	have	remedied	this.	
	
	 	
Figure	2.22	 -	 Immoblised	metal	 affinity	purification	post	proteolytic	 cleavage	of	 SHIP1cd-His	with	 TEV	protease.	
Samples	of	 eluate	 fractions	 from	 the	NiNTA	 column	upon	washing	with	 NiNTA	buffer	 A,	Analysed	on	a	 12.5	%	
acrylamide	gel.	(1)	Molecular	weight	marker.	(2)	Initial	10	mL	fraction.	(3-6)	Subsequent	2	mL	fractions.	(7)	Final	10	
mL	wash	with	NiNTA	buffer	B.	
	
Chapter	2	–	Structural	studies	of	Human	SHIP1	and	SHIP2	
57		
		
The	fractions	were	pooled,	concentrated	to	2.2	mL	and	subjected	to	a	final	round	of	size	
exclusion	chromatography	(results	not	shown).	Final	purified	SHIP1cd	was	concentrated	
to	3.2	mg	/	mL	(from	2	L	of	expression	culture)	and	snap	frozen	before	storage	at	-80	°C.	
As	 can	 be	 seen	 in	 Figure	 2.23,	 removing	 the	 6xHistidine	 tag	 from	 SHIP1cd-His	 also	
removes	many	of	the	contaminants	when	compared	to	the	non-cleaved	protein.		
	 	
Figure	2.23	–	SDS-PAGE	analyisis	on	a	12.5	%	gel	 of	 final	purified	SHIP1cd-His	 and	SHIP1cd.	 (1)	Protein	molecular	
weight	marker.	(2)	Empty.	(3)	Purified	SHIP1cd-His.	(4)	Purified	SHIP1cd.	
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2.3.7	Structure	prediction	of	SHIP1cd		
	
Due	 to	 time	 constraints,	 suitably	 pure	 protein	 was	 not	 obtained	 in	 order	 to	 submit	
SHIP1cd	in	to	crystallisation	trials	as	anticipated.	As	well	as	the	time	and	effort	involved	
in	the	execution	of	crystallisation	trials,	the	purification	process	would	first	need	to	be	
optimised.		
	
The	 SWISS-MODEL	automated	protein	 structure	homology-modelling	 server	 is	 able	 to	
generate	 3D	models	 for	 proteins	 where	 experimental	 data	 is	 not	 available.	 It	 allows	
users	 to;	 conveniently	 search	 for	 suitable	 templates	 using	 sensitive	 Hidden	 Markov	
Model	 searches	 against	 the	 SWISS-MODEL	 Template	 Library,	 analyse	 alternative	
templates	 and	 alignments,	 perform	 structural	 superposition	 and	 comparison,	 explore	
ligands	and	cofactors	in	templates	and	compare	the	resulting	models	using	mean	force	
potential	based	model	quality	estimation	tools	(Biasini	et	al,	2014).	
	
As	there	are	no	structures	of	SHIP1cd	available	in	the	PDB,	it	was	submitted	for	protein	
structure	homology-modelling	using	the	SWISS-MODEL	server,	which	is	available	via	the	
ExPASy	web	server.	A	search	for	appropriate	templates	was	first	carried	out	against	the	
SHIP1cd	sequence	used	 in	 this	study,	 this	 resulted	 in	a	suggestion	that	a	structure	 for	
SHIP2cd	 (PDB	 3NR8)	 was	 the	 top	 scoring	 template,	 closely	 followed	 by	 the	 SHIP2cd	
BiPh(2,3’,4,5’,6)P5	structure	(PDB	4A9C).		
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The	SHIP2cd	structure	 from	this	 study	was	used	as	a	 template	 for	 the	SHIP1cd	model	
generated	 by	 SWISS-MODEL.	 The	 resulting	 model	 superimposes	 to	 the	 SHIP2cd	
structure	with	an	RMSD	of	0.141,	indicating	that	the	model	has	very	minimal	changes	in	
structure	when	compared	to	its	template	(Figure	2.24).	This	is	unsurprising	considering	
they	share	64	%	sequence	identity	and	are	isozymes.		
	 	
Figure	2.24	–	Alignment	of	chain	B	of	the	SHIP2cd	structure	(cyan)	to	the	model	of	SHIP1cd	(magenta),	as	predicted	
by	SWISS-MODEL	homology-modelling	server.	
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As	mentioned	in	previously,	there	are	six	available	structures	of	inositol	5-phosphatases	
in	 complex	with	 ligands	 (Mills	 et	 al.,	 2012,	Mills	 et	 al.,	 2016b,	 Tsujishita	 et	 al.,	 2001).	
These	 proteins	 display	mutually	 conserved	 residues	within	 their	 binding	 pockets	 that	
coordinate	 the	 various	 ligands.	 Five	 of	 those	 residues	 are	 involved	 in	 coordination	 of	
BiPh1	 in	 to	 the	active	site	of	SHIP2cd;	K541,	Y661,	R682	&	N684	 (Figure	2.25).	Where	
K541	coordinates	the	P1	site;	defined	according	to	structures	of	 INPP5B	with	PtdIns4P	
and	PtdIns(3,4)P2,	and	the	5-	and	6-	hydroxyl	site.	These	positions	are	occupied	by	P3’	
and	 P5’	 of	 BiPh1,	 respectively.	 The	 remaining	 conserved	 residues	 contact	 the	 P4	
position,	 P2	 of	 BiPh1.	 When	 overlaying	 these	 residues	 from	 SHIP2cd	 with	 the	
corresponding	residues	of	the	SHIP1cd	model,	they	align	quite	accurately	but	with	one	
key	difference;	R682	becomes	K682	 in	SHIP1cd	 (Figure	2.25).	 It	 is	one	of	 the	 residues	
that	contacts	the	P4	position	that	is	thought	to	be	the	position	that	confers	specificity	
since	 the	 5-phosphatases	 selectively	 hydrolyse	 PI(4,5)P2	or	 PI(3,4,5)P3.	 Therefore	 this	
change	of	 amino	acid	 can	be	 considered	 to	 remain	viable	 for	 ligand	binding	due	 to	 it	
conferring	selectivity	towards	the	substrate,	and	since	arginine	and	lysine	both	possess	
positively	charged	side	chains.	
	 	
Figure	2.25	–	The	conserved	ligand	coordinating	residues	across	all	inositol	5-phosphatase	structures;	alignment	of	
these	residues	in	apo-SHIP2cd	(cyan)	and	the	SHIP1cd	predicted	structure	(green).	
K682	
R682	
N684	
Y661	
K541	
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Out	 of	 the	 ten	 enzymes	 in	 the	 inositol	 polyphosphate	 5-phosphatase	 family,	 only	
SHIP1cd	and	SHIP2cd	are	described	to	have	the	extended	P4IM-containing	loop	(Mills	et	
al.,	2012).	Small	changes	in	this	active	site	loop	can	be	seen	between	the	SHIP1cd	model	
and	 the	 SHIP2cd	 structure.	 This	 is	 also	 observed	 in	 the	 pre-existing	 structures	 of	
SHIP2cd	 in	 the	PDB.	The	homology	modelling	of	SHIP1cd	places	 this	 loop	 in	 the	same	
length	 of	 polypeptide	 as	 in	 the	 SHIP2cd	 structure,	 as	 can	 be	 seen	 by	 observing	 the	
secondary	 structure	 (Figure	 2.26).	 The	 two	 antiparallel	 β-sheet,	 β10	 &	 β11,	 are	
connected	 by	 a	 β-turn	 and	 are	 composed	 of	 the	 same	 number	 of	 residues	 in	 both	
structures.	However,	there	is	only	50%	identity	in	these	secondary	structure	elements,	
again	 supporting	 the	hypothesis	 that	 the	P4IM-containing	 loop	 is	not	 critical	 in	 ligand	
binding	and	can	likely	adjust	to	a	variety	of	ligands	interacting	with	the	binding	pocket.	
Conversely,	 the	 electron	 density	 map	 for	 this	 region	 in	 SHIP2cd	 would	 ideally	 be	 of	
higher	resolution	and	more	whole	(section	2.3.6),	which	may	have	led	to	a	partial	model	
being	built	 for	 this	 region	during	structure	determination.	This	 is	also	observed	 in	 the	
pre-existing	structures	of	SHIP2cd	in	the		
PDB.	Additionally,	the	loop	is	constrained	at	the	apex	of	the	β-turn	due	to	interactions	
with	the	symmetry	related	molecule,	this	would	in	turn	force	the	P4IM-containing	loop	
of	SHIP1cd	to	this	constrained	orientation	during	structure	prediction.	
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It	 is	 noteworthy	 to	 mention	 the	 variability	 of	 structure	 prediction	 and	 homology	
modelling	methods.	When	the	same	SHIP1cd	sequence	is	 input	 in	to	Phyre2	(Kelley	et	
al.,	 2015),	 a	 different	 template	 is	 suggested	 as	 the	 top	 scoring	 suggestion.	 The	 result	
was	 a	 model	 that	 did	 not	 contain	 the	 SHIP-specific	 extension	 known	 as	 the	 P4IM-
conating	 loop,	 because	 the	 model	 had	 skewed	 towards	 the	 arrangement	 of	 the	
template,	 the	 5-phosphatase	 OCRL-1	 (results	 not	 shown).	 This	 method	 produced	 a	
SHIP1cd	model	that	did	not	contain	the	extended	P4IM-containg	 loop	that	 is	allegedly	
unique	to	SHIP1	and	SHIP2.	
	
According	to	critical	assessment	of	protein	structure	prediction	methods	(CASP)	(Moult	
et	al.,	2014)	,	it	is	observed	that	there	are	no	major	differences	in	accuracy	of	all	widely	
used	web	servers	for	protein	modelling.	It	is	therefore	surprising	that,	when	processing	
the	 same	 SHIP1cd	 sequence,	 SWISS-MODEL	 and	 Phyre2	 choose	 different	 top	 scoring	
templates	to	base	the	model	on.	Both	methods	appear	to	use	very	similar	algorithms,	
but	employ	separate	self-assembled	databases	to	search	for	templates.	Although	they	
both	 use	 the	 same	 sources	 of	 information	 to	 build	 the	 libraries,	 the	 subsequent	
methodology	and	arrangement	within	each	database	must	result	in	altered	outcomes.	
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2.4	Conclusions	and	future	work	
	
No	 structures	 of	 SHIP1cd	 are	 yet	 available,	 and	 now	 that	 this	 work	 has	 produced	 a	
suitable	 clone	 that	 provides	 soluble	 SHIP1cd	 protein,	 further	 studies	 will	 seek	 to	
crystallise	this	based	on	what	has	been	learnt	from	SHIP2cd.	This	would	hopefully	clarify	
the	 true	 structure	 of	 SHIP1cd	 and	 the	 presence	 of	 the	 P4IM-conating	 loop	 that	 is	
apparently	only	present	in	SHIP1	and	SHIP2.	Furthermore,	the	residues	responsible	for	
the	 differing	 substrate	 specificities	 between	 the	 isozymes	 may	 be	 revealed.	 Their	
specificities	 towards	 the	 biphenyl	 phosphates	 is	 also	 different	 (chapter	 4).	
Crystallographic	studies	should	also	continue	with	SHIP2cd	to	attempt	to	gain	additional	
structures	in	complex	with	the	benzene-	and	biphenyl	phosphates.	These	might	include	
additional	mutagenesis	studies	on	the	P4IM-containing	loop	in	order	to	gain	structures	
in	 which	 the	 loop	 is	 closed	 over	 the	 inositide	 binding	 pocket,	 as	 suggested,	 and	 not	
stabilised	by	interaction	with	a	symmetry	related	molecule.	This	would	give	insight	into	
the	 true	 role	 of	 this	 SHIP	 specific	 loop.	 Furthermore,	 as	 SHIP1	 and	 SHIP2	 are	 clinical	
targets	for	many	diseases,	structures	with	additional	ligands	are	likely	to	provide	more	
information	 for	 a	 framework	 for	 rational	 inhibitor/drug	 design	 based	 on	 key	 ligand	
coordinating	and	catalytic	residues.	
	
Since	 the	 experiments	 performed	 in	 this	 thesis	 were	 conducted,	 the	 Potter	 group	
reported	the	structure	of	the	related	5-phosphatase	INPP5B	in	complex	with	a	second	
biphenyl	 compound,	 biphenyl	 3,3',4,4',5,5'-hexakisphosphate	 (BiPh3),	 and	 a	 complex	
with	the	simpler	compound	benzene	1,2,4,5-tetrakisphosphate	(Bz3)	(Mills	et	al.,	2016).	
INPP5B	 hydrolyses	 the	 5-phosphate	 group	 from	 water-	 and	 lipid-soluble	 signalling	
messengers.	Crystal	structures	were	resolved	to	2.89Å	with	BiPh3	and	to	2.9Å	with	Bz3;	
comparisons	 of	 the	 potency	 of	 these	 ligands	 assayed	 by	 phosphate	 release	 from	
Ins(1,4,5)P3	yielded	IC50s	of	5.5	and	6.3	µM.		
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For	BiPh3	one	of	the	substituted	phenyl	rings	occupied	the	binding	site	occupied	by	the	
lipid	 head	 group	 of	 PtdIns4P	 in	 published	 INPP5B-C8-PtdIns4P	 complex	 (PDB	 3MTC)	
(Trésaugues	et	al.,	2014).	The	second	phenyl	ring	was	solvent-exposed	in	the	structure	
and	was	bound	to	the	6xhistidine	tag	of	another	INPP5B	molecule,	with	a	molecule	of	
inorganic	 phosphate	 (Pi)	 also	 present	 in	 the	 active	 site.	 The	 position	 of	 this	 Pi	 is	
interpreted	 to	 mimic	 the	 cleaved	 5-phosphate	 of	 inositol	 phosphate	 substrates	 and	
allowed	 the	 authors	 to	 identify,	 for	 the	 first	 time,	 the	 likely	 importance	 to	 catalytic	
mechanism	of	R451	which	coordinates	this	phosphate	and	an	active	site	water	molecule	
interpreted	 to	 initiate	 hydrolysis	 of	 the	 ‘unobserved’	 5-phosphate	 of	 5-phosphate-
containing	inositol	phosphate	substrates.		
	
Aided	by	these	structures,	and	the	information	provided	in	chapter	4,	that	benzene		and	
biphenyl	 polyphosphates	 are	 substrates	 for	 SHIP1	 and	 SHIP2,	 it	would	 be	 possible	 to	
construct	 mutagenesis	 experiments,	 modifying	 individual	 active	 site	 residues,	 to	 test	
the	contribution	of	R451	equivalent	in	SHIP2	(R611)	and	the	other	implicated	residues.	
This	 endeavor	 would	 be	 greatly	 assisted	 by	 hydroxyl-containing	 benzene	 and/or	
biphenyl	 polyphosphate	 standards.	 3-Hydroxy	 benzene	 1,2,4-trisphosphate	 (Bz7)	 is	
available,	 but	 a	 lack	 compounds	 are	 available	 that	 might	 represent	 the	
dephosphorylation	products	of	e.g.	Bz3,	solved	in	the	structure	of	 INPP5B	(Mills	et	al.,	
2016).	 Of	 particular	 interest	 would	 be	 2-hydroxy	 benzene	 1,4,5-trisphosphate	 (2-OH	
Bz(1,4,5)P3)	 since	Mills	 and	 coworkers	 have	 shown	 that	 in	 INPP5B	 complexes,	 the	 2-
phosphate	 of	 Bz3	 interacts	 with	 E303,	 K380	 and	 H400	 sidechains	 of	 chain	 A	 (of	 the	
asymmetric	unit)	and	shows	longer	range	interactions	with	both	N449	(3.3	Å)	and	R451	
(3.5	Å).		Due	to	the	electron	withdrawing	effect	of	the	delocalised	electrons,	a	singularly	
substituted	 phenol	 has	 a	 pKa	 of	 approximately	 9.9	 when	 compared	 to	 the	 hydroxyl	
group	moiety	of	cyclohexanol	which	is	approximately	16	(phosphate	substituents	would	
also	 influence	the	pKa	of	a	hydroxyl).	Such	postulation	assumed	that	the	 lower	pKa	of	
the	generated	phenolic	hydroxyl,	as	compared	to	an	inositol	hydroxyl,	allows	hydrolysis	
of	 phosphates	 from	 benzene	 phosphate	 substrates.	 Crucially,	 the	 data	 in	 chapter	 4	
shows	 that	 benzene	 and	 biphenyl	 polyphosphates	 are	 substrates	 for	 at	 least	 two	
members	of	the	5-phosphatase	family.	
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Chapter	 3	 –	 Structural	 studies	 of	 Arabidopsis	 thaliana	 inositol	 1,3,4,5,6-
pentakisphosphate	 2-kinase	 (AtIPK1)	 in	 complex	 with	 novel	 inositol	
phosphate	surrogates	
3.1	Introduction	
3.1.1	IPK1	classification	
Kinase	activity	leading	to	the	biosynthesis	of	IP6	from	each	of	the	four	separable	IP5’s	was	
first	detected	by	ion	exchange	chromatography	from	mung	bean	extracts	(Biswas,	1978).	
Subsequently,	a	description	of	 IP5	phosphorylation	 in	mammalian	cells	was	described,	
along	with	an	account	of	the	complete	pathway	for	the	synthesis	of	IP6	from	Ins(3)P	in	
slime	 mould	 in	 which	 multiple	 inositol	 pentakisphosphate	 kinases	 were	 detected	
(Stephens	et	al,	1991).	Inositol	1,3,4,5,6-pentakisphosphate	(Ins(1,3,4,5,6)P5)	was	found	
to	be	 a	 prevalent	 intermediate	 above	 the	other	 IP5	 isomers	 in	 both	 animal	 and	plant	
systems.	This	observation	later	led	to	the	isolation	and	purification	of	a	inositol	1,3,4,5,6-
pentakisphosphate	 2-kinase	 (IP52K)	 (Phillipy	 et	 al,	 1994).	 An	 inositol	 polyphosphate	
kinase	found	to	be	linked	to	nuclear	mRNA	export	 in	yeast,	designated	with	the	name	
Ipk1p,	was	also	identified	and	characterised	as	an	IP52K	(York	et	al,	1999).	Classification	
of	all	kinases	occurs	in	to	25	families	and	10-folds,	where	IP52Ks	belong	to	a	structural	
family	within	the	lipid	kinase-like	family	(Cheek	et	al,	2005).	Also	in	the	lipid	kinase-like	
family	is	inositol	1,4,5-trisphosphate	kinase	(I3P3K),	of	which	the	human	and	rat	crystal	
structures	have	been	solved	(Gonzalez	et	al.,	2004,	Miller	et	al	2004).	ATP	grasp-like	fold	
proteins	also	belong	in	the	lipid	kinase-like	family,	with	the	structure	of	inositol	(1,3,4)-
trisphosphate	5/6-kinase	adopting	such	a	fold	(Miller	et	al,	2005).	Although	I3P3K,	and	
other	inositol	polyphosphate	kinases	(IPKs),	share	conserved	residues	with	IP52K	at	their	
substrate	 and	 cofactor	 binding	 sites,	 IP52K	 is	 unique	 in	 that	 it	 is	 the	 only	 IPK	 to	
phosphorylate	the	axial	2-OH	position	of	myo-ins(1,3,4,5,6)P5	(Phillipy	et	al,	1994).	
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3.1.2.	IPK1	characterisation	
As	noted	above,	 the	 IPK1	gene	was	 identified	when	 investigating	 factors	 that	mediate	
messenger	RNA	export	in	a	yeast	mutant	deficient	in	Gle1P,	a	protein	that	associates	with	
the	nuclear	pore	complex	(NPC)	(York	et	al,	1999).	The	gene	was	found	to	encode	an	IP5	
kinase	and	enzymatic	analysis	revealed	that	it	was	converted	Ins(1,3,4,5,6)P5	to	IP6,	thus	
classifying	it	as	a	IP5	2-kinase.	Mutations	in	IPK1	led	to	IP6	and	mRNA	export	deficiencies,	
shedding	light	on	essential	NPC-factors	that	contribute	to	successful	nuclear	export	and	
demonstrating	a	requirement	for	IP6	 in	this	process.	The	genetic	screen	that	identified	
IPK1	also	recognised	phospholipase	C	and	an	IP3	kinase	as	essential	for	efficient	mRNA	
nuclear	export,	also	due	to	their	involvement	in	the	pathway	to	IP6	synthesis.		
	
Not	 long	 after,	 a	 comprehensive	biochemical	 and	 functional	 characterisation	of	 IP5	 2-
kinases	in	fission	and	budding	yeast	provided	additional	evidence	that	IPK1	encoded	an	
IP5	2-kinase	(Ives	et	al,	2000).	Many	IPK1	orthologs	across	organisms	have	been	identified	
since	 including	 human	 (Verbsky	 et	 al	 2002),	Drosophila	 (Seeds	 et	 al,	 2004),	 and	most	
pertinent	to	this	study,	plants	(Stvenson-Paulick	et	al,	2005,	Sweetman	et	al,	2006).	
	
As	introduced	in	section	1.3,	phytate	(IP6)	is	the	main	store	of	phosphate	in	plant	seeds.	
In	 Arabidopsis	 thaliana,	 disruption	 of	 IPK1	 (AtIPK1)	 coincided	 with	 a	 loss	 in	 phytate	
without	an	accumulation	of	precursors,	therefore	reporting	a	requirement	for	AtIPK1	in	
the	later	steps	of	seed	phytate	synthesis	(Stevenson-Paulik	et	al.,	2005).	When	measured	
in	 wild	 type	 seeds,	 the	 major	 inositol	 phosphate	 was	 IP6,	 with	 levels	 of	 IP4	 and	 IP5	
undetectable	(Stevenson-Paulik,	Nagy	et	al,	2009).	Conversely,	in	the	mutant	AtIPK1	T-
DNA	insertion	line,	atipk1-1,	IP6	levels	were	reduced,	levels	of	Pi	were	higher	and	lower	
inositol	phosphates	such	as	IP4	and	IP5	remained	low	and	did	not	accumulate	(Stevenson-
Paulik	 et	 al.,	 2005).	 A	 desirable	 trait	 in	 cereal	 crops	 due	 to	 the	 deleterious	 effects	 of	
phytate	in	human	and	animal	nutrition	(see	section	1.3),	but	has	negative	influences	in	
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terms	of	plant	growth.	If	this	can	be	overcome	in	crop	species,	the	high	Pi-low	phytate	
phenotype	could	be	utilised	in	cereal	crop	agriculture.	
Further	 characterisation	 of	 AtIPK1	 and	 its	 substrate	 specificities	 was	 provided	 by	
Sweetman	 et	 al,	 (2006).	 Using	 radiolabelled	 ATP	with	 thin	 layer	 chromatography	 and	
HPLC	methods,	 it	was	confirmed	that	 Ins(1,3,4,5,6)P5	was	a	substrate	for	AtIPK1	along	
with	ATP	as	a	co-substrate,	with	subsequent	kinetic	analysis	providing	a	KM	of	22	µM	and	
Vmax	of	35	nmol.min-1	(Sweetman	et	al.,	2006).	Interestingly,	Ins(1,4,5,6)P4	was	also	found	
to	be	a	substrate	and	yielded	an	IP5	product	albeit	with	weak	activity,	Stevenson-Paulik	
et	al.	(2005)	had	previously	reported	that	it	was	an	equally	good	substrate	of	AtIPK1.	
	
3.1.3	The	X-ray	crystal	structure	of	AtIPK1	
As	 previously	 eluded	 to,	 AtIPK1	 is	 novel	 in	 its	 structural	 class	 due	 to	 being	 the	 only	
phosphatase	 with	 the	 unique	 ability	 to	 phosphorylate	 at	 the	 2-OH	 position,	 which	 is	
directionally	axial	compared	the	equatorial	phosphates	at	all	other	positons	of	the	myo-
inositol	ring	(Gonzalez	et	al,	2010).	This	 leads	to	striking	differences	 in	structure	when	
compared	to	the	remaining	family	of	IPK	proteins	and	renders	it	a	distant	family	member.		
	
Overall	the	fold	consists	of	two	lobes,	designated	the	N-terminal	(N-lobe)	and	C-terminal	
(C-lobe)	lobes,	connected	by	a	hinge	(Figure	3.1).	The	group	of	features	that	provide	the	
majority	of	the	interactions	that	bind	the	inositide	substrate	are	within	the	large	C-lobe	
and	are	referred	to	as	the	CIP-lobe	(Gonzalez	et	al,	2010).	
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The	inositide	binding	pocket	has	been	identified	along	with	the	residues	responsible	for	
the	recognition	of	the	axial	2-OH	that	make	this	enzyme	so	distinctive	amongst	the	family	
(Gonzalez	 et	 al.,	 2010).	 An	 IP	 substrate	 is	 tightly	 bound	 in	 the	 binding	 site	 through	
interactions	 with	 all	 phosphate	 groups,	 which	 mostly	 occur	 from	 within	 the	 region	
designated	as	the	CIP-lobe	with	the	exception	of	the	phosphate	at	the	1	position	(P1)	that	
is	 coordinated	 via	 two	hydrogen	bonds	with	 an	 arginine	 from	 the	N-lobe	only	 (R130)	
(Figure	3.1).	All	interactions	are	deemed	essential	in	positionally	orienting	the	IP	so	the	
axial	2-OH	is	bought	close	to	the	nucleotide	cofactor	and	magnesium	ions	for	catalysis.	
The	two	residues	that	lend	to	this	enzymes	uniqueness	are	D368	and	K168	which	contact	
the	P2(2-OH)	position	and	are	likely	to	confer	the	specificity	for	this	IP5	conformer.	
	 	
Figure	3.1	 –	Overall	 structure	of	 AtIPK1	 (taken	 from	Gonzalez	 et	 al,	 2010).	 Cartoon	 representation	 indicting	 the	
different	lobes	and	the	hinge	that	connects	them.	The	N-lobe	is	orange,	and	the	C-lobe	green	with	the	CIP	region	
coloured	 dark	 pink.	 The	 hinge	 connecting	 hinge	 is	 blue.	 The	 IP5	 substrate	 and	 AMPPNP	 (ATP	 analogue)	 are	
represented	as	black	sticks.	Magnesium	and	zinc	ions	are	red	and	cyan	spheres.		
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In	light	of	this	structural	information	providing	details	on	inositol	phosphate	coordination	
in	 to	 the	 active	 site,	 site	 directed	mutagenesis	 studies	 of	 some	 of	 the	 observed	 key	
residues	 were	 carried	 out	 (Gonzalez	 et	 al,	 2010).	 Mutants	 that	 replaced	 K168,	 the	
catalytic	 residue	 that	 interacts	 with	 the	 axial	 2-OH,	 were	 unsurprisingly	 catalytically	
inactive.	Additionally	a	D407A	mutant,	a	catalytic	residue	that	recognises	the	Pγ	of	the	
cofactor	and	the	magnesium	ion,	maintained	only	3	%	catalytic	activity.	A	mutation	in	the	
second	residue	that	contacts	the	2-OH,	D368,	also	renders	an	inactive	enzyme.	As	noted	
above,	R130	is	one	of	only	two	contacts	between	the	N-lobe	and	the	IP	substrate,	and	
the	inactivity	of	a	mutant	highlights	the	importance	of	P1	binding	in	catalysis	and	the	role	
of	the	N-lobe.	These	mutagenesis	studies	supported	all	the	observable	conclusions	for	
ligand	binding	from	the	structure.	
	
3.1.4	Conformational	changes	of	AtIPK1	upon	ligand	and	nucleotide	binding	
As	noted	above,	 residues	 in	both	 the	N-	and	C-lobes	coordinate	an	 inositide	 in	 to	 the	
active	 site,	 this	 consequently	brings	 the	 two	 lobes	 together	and	has	been	 termed	 the	
“closed	form”	of	the	protein.	The	closed	form	also	features	local	changes	where	a	clasp	
is	formed	between	residues	of	α6	and	L3,	effectively	closing	the	active	site	(Figure	3.2).		
W129	and	R130	are	the	α6	residues	that	interact	with	E255	and	G254	of	L3,	respectively.	
Mutation	 in	 R130	 results	 in	 a	 6-fold	 decrease	 in	 activity	 towards	 IP5,	 but	 as	 it	 also	
coordinates	P1	 it	 is	 not	 clear	 if	 this	 is	 a	 result	 of	 compromised	 substrate	binding	 and	
therefore	 catalytic	 function,	 or	 a	 hindrance	 from	 destruction	 of	 the	 clasp.	 It	 was	
concluded	that	mutation	in	W129	does	not	compromise	enzyme	function	and	its	role	in	
clasp	 formation	 is	 not	 critical.	 Interestingly,	 shortening	 L3	 increased	 enzyme	 activity	
which	is	thought	to	be	a	result	of	improved	product	release,	therefore	the	clasp	maybe	
relevant	for	modulating	kinetics	rather	than	being	essential	for	catalysis.	 	
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The	open	form	of	the	protein	 is	 represented	by	the	apo-protein	 (W129A	mutant),	 the	
clasp	is	unconnected	and	L3	can	be	considered	mobile.	Additionally,	α6	shows	disorder	
in	this	form	therefore	the	conformation	and	stability	of	α6	and	L3	is	dependent	on	the	
clasp	formation.	Furthermore,	the	N-	and	C-lobes	show	a	general	rigid-body	movement	
and	are	further	apart.	Movement	occurs	via	the	three	hinges	that	are	highly	mobile	and	
therefore	disordered	in	the	crystal	structure.	A	comparison	of	the	open	and	closed	forms	
revealed	little	difference	in	the	inositide	binding	site.	It	is	mostly	pre-formed	in	the	apo-
protein	apart	from	the	residues	that	recognise	the	inositide	from	within	the	distant	N-
lobe;	the	CIP	is	the	same	in	both	arrangements.	
	 	
Figure	 3.2	 –	 Conformational	 changes	 of	 AtIPK1	 upon	 ligand	 binding	 (taken	 from	 Banos-Sanz	 et	 al,	 2012).	
Superposition	of	the	open	(red)	and	closed	(blue)	forms.	The	substrate	and	co-factor	of	the	closed	form	are	shown	
as	purple	surface	representations.	
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A	 third	conformation	 is	 represented	by	 the	nucleotide-bound	structure	of	 the	protein	
(W129A	mutant)	and	is	termed	the	half-closed	form,	as	it	denotes	an	intermediate	state	
between	the	apo-form	and	the	closed-form	of	the	protein.	In	this	conformation	the	N-	
and	C-lobes	are	closer	than	in	the	apo-form	(open)	but	are	still	too	distant	to	fully	form	
the	clasp	between	α6	and	L3.	These	elements	are	only	fully	formed	in	the	closed-form	
where	L3	is	also	forming	a	“lid”	that	closes	over	the	active	site	pocket.	However,	it	appears	
to	be	partly	formed	through	interaction	of	R130	and	G252.	The	essential	elements	in	the	
ATP	binding	site	for	nucleotide	recognition	are	the	same	when	compared	to	that	of	the	
ternary	complex	(closed),	but	Mg2+	is	missing.		
	
3.1.5	Experimental	aims	
As	crystal	structures	of	other	 IP5-binding	enzymes	have	been	solved	with	the	biphenyl	
polyphosphates	as	novel	ligand	surrogates	(Mills	et	al.,	2016a,	Mills	et	al.,	2012),	it	was	
intriguing	to	submit	AtIPK1	in	to	crystallisation	trials	to	see	if	it	could	also	accommodate	
these	IP	analogues.	Furthermore,	crystal	structures	of	AtIPK1	in	complex	with	three	of	
the	benzene	polyphosphate	compounds	had	already	been	solved	to	good	resolution	by	a	
colleague	(H.	Whitfield,	unpublished)	(section	1.3.1),	which	had	revealed	new	precedence	
of	essential	 ligand	binding	elements	when	compared	 to	 the	 canonical	 substrates.	Any	
resulting	structures	would	further	reveal	the	ligand	flexibility	of	AtIPK1,	and	could	provide	
new	 notions	 on	 substrate	 coordinating	 residues	 as	 well	 as	 provide	 a	 well-informed	
framework	for	the	design	of	other	novel	ligands	and	inhibitors.	
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3.2	Materials	&	Methods	
Appendix	1	contains	supplier	addresses.	Guidelines	for	all	self-prepared	buffers,	media,	
and	other	additives	can	be	found	in	appendix	2.	
	
3.2.1	Small	scale	expression	testing	AtIPK1	
A	1.5	mL	aliquot	of	overnight	 culture	grown	 in	LB	containing	0.5	%	 (w/v)	glucose	and	
ampicillin	was	centrifuged	at	5000	rpm	and	the	supernatant	discarded.	The	cells	were	re-
suspended	in	5	mL	LB	with	ampicillin	plus	either;	0,	0.2,	0.5,	or	1	mM	IPTG.	The	resulting	
cultures	were	 incubated	at	either	18	or	25	°C	for	up	to	16	h	with	shaking	at	200	rpm.	
Protein	expression	levels	of	each	culture	were	analysed	by	SDS	PAGE.		
	
3.2.2	Large-scale	expression	of	AtIPK1	for	purification	
Large-scale	expression	cultures	were	1	L	in	volume	and	at	least	2	L	of	expression	culture	
was	used	per	purification.	Per	1	L	culture,	300	mL	of	O/N	culture	grown	in	LB	containing	
0.5	%	(w/v)	glucose	was	used	to	inoculate.	The	300	mL	culture	was	centrifuged	at	5000	
rpm	 and	 the	 supernatant	 discarded	 to	 harvest	 the	 cells.	 The	 resulting	 pellet	 was	
resuspended	in	to	1	L	LB	containing	ampicillin.	Optimum	expression	levels	were	achieved	
when	the	culture	was	supplemented	with	0.2	mM	IPTG	and	expressed	O/N	(approx.	16	
h)	at	18	°C	with	shaking	at	200	rpm.	The	1	L	expression	cultures	were	centrifuged	at	5000	
rpm	for	20	min	at	4	°C,	with	each	resulting	pellet	being	resuspended	in	10	mL	cell	lysis	
buffer	(see	appendix	2)	before	being	snap	frozen	in	liquid	nitrogen	and	stored	at	-80	°C.	
	
3.2.3	Using	3C	protease	to	remove	the	6xHistidine	tag	
The	protein	was	concentrated	to	3	mL	and	the	manufacturers	guidelines	for	the	use	of	
HRV3C	Protease	(Sigma-Aldrich)	followed.	The	reaction	was	incubated	for	approximately	
16	hr	at	room	temperature	(18	°C).	
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3.2.4	Crystal	screening	and	optimisation	
The	 optimised	 conditions	 for	 the	 crystallisation	 of	 AtIPK1-His	 had	 already	 been	
established	 by	 a	 colleague	 and	 were	 based	 upon	 previously	 published	 conditions	
(Gonzalez	et	al.,	2010).	As	AtIPK1-His	possesses	a	6xHistidine	tag	and	was	expressed	from	
the	pOPINF	vector	some	optimisation	upon	literature	conditions	was	required.	Crystals	
were	grown	in	48-well	plates	using	a	sitting	drop	method	at	16	°C	and	equilibrated	against	
a	50	µL	reservoir	of	buffer	that	was	used	as	precipitant.	Initially,	crystals	were	grown	in	
the	presence	of	myo-IP6	and	ADP.	Optimal	conditions	were	identified	as	20	%	PEG	3350,	
0.1M	bis-tris	propane	pH6	with	2	mM	MgCl2.	Protein	at	10	mg/mL	was	incubated	at	16	°C	
with	2	mM	myo-IP6	and	ADP	prior	to	setting	drops	in	a	1:1	ratio	of	protein	to	precipitant.	
Crystals	 formed	 as	 rod	 clusters	 within	 24	 hr	 and	 were	 harvested	 in	 to	 a	 seed	 bead	
(Hampton	Research)	with	50	µL	precipitant	 to	 generate	a	 seed	 stock	 for	downstream	
microseeding.	 Using	 6	 mg/mL	 protein,	 drops	 under	 the	 same	 conditions	 were	 set	
replacing	 myo-IP6	 with	 the	 same	 concentration	 of	 the	 novel	 ligand.	 Immediately,	
approximately	0.1	µL	of	microseeding	 solution	was	added	 to	each	drop	and	 the	plate	
sealed.	Crystals	grew	as	plate	clusters	within	2-3	days	and	were	harvested	to	produce	a	
new	seed	stock.	Fresh	and	final	drops	were	set	in	the	presence	of	novel	ligand	and	again	
microseeded,	 this	 step	 being	 necessary	 to	 avoid	 the	 growth	 of	 mixed	 active	 site	
occupancy	 crystals	 and	 to	 improve	 crystal	 quality.	 The	 crystals	 grew	 as	 individual	 or	
clustered	plates	and	were	harvested	between	2-3	days	of	growth	depending	on	crystal	
size	and	quality.		
	
3.2.5	Crystal	cryoprotection	
Single	crystals	were	harvested	in	to	20	%	PEG	3350,	25	%	EG,	0.1	M	bis-tris	propane	pH	6,	
2	mM	MgCl2,	1	mM	novel	ligand	and	1	mM	ADP,	and	flash	frozen	in	liquid	nitrogen.	
	
3.2.6	Data	collection	
X-ray	diffraction	data	was	remotely	collected	at	Diamond	Light	Source	(Oxford,	UK).	
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3.2.7	Data	processing	and	refinement	
Diffraction	data	was	 indexed	and	auto	processed	by	Xia2.	Molecular	 replacement	was	
performed	using	Phaser-MR	within	the	Phenix	suite	(McCoy	et	al.,	2007)	and	structures	
refined	using	Phenix	refine	(Afonine	et	al.,	2005).	Coot	(Emsley	et	al.,	2010)	was	used	for	
manual	adjustment	to	models	between	rounds	of	automatic	refinement.	Ligands	were	
built	based	upon	biphenyl	2,3',4,5',6-	pentakisphosphate	(PDB	4A9C)	and	edited	in	REEL	
before	refinement	in	eLBOW	(Moriarty	et	al.,	2009).	
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3.3	Results	and	Discussion	
	
3.3.1	Expression	and	Purification	of	AtIPK1-His	
	
Cloning	of	AtIPK1-His	in	to	the	pOPINF	vector	was	previously	accomplished	by	a	colleague	
and	the	construct	stored	as	a	glycerol	stock	in	E.	coli	Stellar	cells.	The	plasmid	was	purified	
using	 the	Wizard®	Plus	 SV	Miniprep	DNA	Purification	 System	 (Promega)	 from	an	O/N	
culture	 which	 had	 been	 inoculated	 using	 the	 Stellar	 glycerol	 stock,	 and	 grown	 in	 LB	
medium	supplemented	with	ampicillin	 (Section	2.2.6).	Once	purified,	 the	plasmid	was	
transformed	 in	 to	chemically	competent	E.	coli	Rosetta	cells	 (sections	2.2.7	&	8).	Two	
single	colonies	were	selected	to	inoculate	100	mL	cultures	in	LB	containing	0.5	%	(w/v)	
glucose	and	ampicillin	for	use	as	starter	cultures	for	the	small	scale	protein	expression	
testing	 of	 AtIPK1-His,	 as	 described	 in	 section	 3.2.1.	 Parameters	 investigated	 were;	
temperature,	IPTG	concentration	and	length	of	incubation	post	IPTG	addition	(results	not	
shown).	It	is	necessary	to	grow	the	starter	cultures	in	the	presence	of	0.5	%	glucose	to	
minimise	basal	or	“leaky”	expression	of	AtIPK1-His	which	can	be	toxic	to	the	cells	when	
trying	to	reach	the	exponential	growth	phase.	This	can	lead	to	plasmid	instability	and/or	
loss	of	the	plasmid,	causing	the	culture	not	to	grow.	Additionally,	protein	aggregation	or	
expression	 in	 to	 inclusion	 bodies	 can	 occur,	 affecting	 the	 solubility.	 Cells	 must	 be	
harvested	by	gentle	centrifugation	and	re-suspended	in	media	without	glucose	to	allow	
IPTG	 inducible	 expression	 of	 AtIPK1-His.	 This	 step	 could	 be	 avoided	 by	 the	 use	 of	 an	
expression	 host	 strain	 containing	 the	 pLysS	 plasmid,	 which	 provides	 constitutive	
expression	of	phage	T7	lysozyme	to	inhibit	the	T7	RNA	polymerase	that	is	expressed	from	
a	chromosomal	gene	and	is	under	the	control	of	the	lacUV5	promoter	for	IPTG	induced	
expression.	Intrinsic	inhibition	of	T7	RNA	polymerase	like	this	would	eliminate	the	need	
for	the	addition	of	glucose	to	repress	induction	of	the	lac	promoter	by	lactose	found	in	
the	media.	The	most	efficient	expression	of	AtIPK1-His	by	the	Rosetta	expression	host	
cells	was	achieved	using	0.2	mM	IPTG	to	induce	protein	expression,	with	incubation	at	18	
°C	plus	shaking	at	200	rpm	for	approx.	16	h	post	IPTG	addition.		
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This	was	then	applied	to	large	scale	expression	tests	with	1	L	cultures	(Figure	3.3)	(Section	
3.2.2).	 A	 high	 expression	 yield	 in	 the	 larger	 cultures	 was	 also	 observed	 under	 these	
conditions	 and	 a	 strong	 band	 the	 approximate	 size	 of	 AtIPK1-His	 (51.5	 kDa)	 can	 be	
visualised	 on	 the	 SDS-PAGE	 gel,	 therefore	 these	were	 pursued	 for	 the	 purification	 of	
AtIPK1-His.	A	glycerol	stock	of	the	original	starter	culture	was	made	and	snap	frozen	then	
stored	at	-80	°C	for	later	use.	
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Figure	3.3–	 SDS-PAGE	analysis	on	a	10	%	acrylamide	gel	of	 a	whole	cell	pellet	originating	 from	a	1	L	expression	
culture	of	AtIPK1-His.	 (1)	Protein	molecular	weight	marker.	 (2)	 Empty.	 (3)	1:1.5	 (v/v)	of	pelleted	culture	to	 SDS-
loading	buffer.	(4)	1:10	(v/v)	dilution	of	lane	3	with	SDS-loading	buffer.	
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AtIPK1-His	 protein	was	 purified	 in	 a	 simple	 two	 step	 purification,	 as	 per	 the	method	
described	in	section	2.2.17.	To	obtain	a	high	yield	of	protein	suitable	for	crystallographic	
studies	at	least	2	L	of	expression	culture	was	required.		
	
Figure	3.4	shows	the	SDS-PAGE	analysis	of	 fractions	that	were	 identified	as	containing	
AtIPK1-His	 from	 the	 UV	 absorbance	 trace	 during	 nickel	 affinity	 purification.	 The	
overexpressed	AtIPK1-His	can	be	seen	in	fractions	15	to	21	(lanes	2-5)	but	is	negligible	in	
fraction	 23	 (lane	 6).	 Overall,	 very	 few	 contaminants	 can	 be	 seen	 therefore	 fraction	
numbers	14	to	22	were	combined	and	carried	forward	for	subjection	to	size	exclusion	
chromatography.	
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Figure	 3.4	 –	 Immobilised	metal	 affinity	 purification	 of	 AtIPK1-His.	 SDS-PAGE	 analysis,	 on	 a	 10	%	 gel,	 of	 eluate	
fractions	recovered	during	NiNTA	chromatography.	(1)	Protein	molecular	weight	marker.	(2-6)	Fraction	number;	15,	
17,	19,	21	&	23,	respectively.	
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Size	exclusion	chromatography	was	performed	as	described	in	section	2.2.17	on	a	HiLoad	
16/600	Superdex	75	pg	column	(GE	Healthcare	Life	Sciences)	and	resulted	in	a	peak	on	
the	UV	absorbance	 trace	 corresponding	 to	 fraction	numbers	 12-16,	 samples	of	which	
were	 analysed	 by	 SDS-PAGE	 (Figure	 3.5).	 An	 earlier	 peak	 was	 also	 detected	 but	 was	
assumed	to	be	larger	contaminant	proteins	eluting	in	the	void	volume.	It	was	confidently	
concluded	that	fractions	12	to	14	contain	purified	AtIPK1-His	(lanes	3	&5).	Fraction	16	
also	had	small	amount	of	purified	protein	so	it	can	be	assumed	fraction	15	also	contains	
AtIPK1-His.	It	 is	also	likely	that	fraction	11	had	a	high	quantity	of	AtIPK1-His,	therefore	
fractions	 11-16	 were	 subsequently	 pooled	 for	 concentration	 to	 10	 mg/mL.	 A	 typical	
protein	yield	obtained	from	a	2	L	preparation	was	20	mg.	
	
	 	
1" 2" 3" 4" 5"" 6"" 7""
30"
kDa"
175"
80"58"46"
25"
Figure	3.5	–	 Size	exclusion	 chromatography	of	His-AtIPK1.	 SDS-PAGE	analysis	on	a	12.5	%	acrylamide	gel	of	 the	
fractions	from	sepharose	gel	filtration	column	eluate	that	contain	His-AtIPK1.	(1)	Protein	molecular	weight	marker.	
(3,	5	,7)	Fraction	number;	12,	14	&	16,	respectively.	(2,4,6)	Empty.	
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A	sample	of	the	final	purified	and	concentrated	protein	was	analysed	by	SDS-PAGE	and	
stained	 with	 InVision™	 His-tag	 In-gel	 Stain	 (Novex	 by	 Life	 Technologies),	 then	
subsequently	with	a	Coomassie	blue	stain	as	per	section	3.2.6	(Figure	3.6).	As	the	sample	
was	highly	concentrated,	a	1:15	dilution	of	the	protein	was	used.	
	
	
The	InVision	stain	binds	specifically	to	the	6xHistidine	tag	and	can	be	used	to	accurately	
detect	the	presence	of	His-tagged	fusion	proteins	due	to	its	fluorescence	properties	at	an	
excitation	wavelength	 of	 560	 nm,	 and	 emission	maxima	 at	 590	 nm.	 It	 can	 provide	 a	
quicker	and	simple	alternative	to	a	western	blot	to	confirm	the	presence	of	His-tagged	
fusion	proteins.	As	can	be	seen	in	figure	3,	AtIPK1-His	can	be	identified	with	both	staining	
methods	 with	 low	 levels	 of	 contaminant	 proteins	 present.	 The	 InVision	 staining	 also	
confirms	the	absence	of	any	6xHistidine	tagged	truncates	of	AtIPK1-His	that	may	have	
occurred	during	overexpression,	or	due	to	protein	degradation	or	hydrolysis	by	proteases	
during	purification.	
	 	
Figure	3.6	 –	 SDS	PAGE	analysis	of	purified	AtIPK1-His	on	a	10	%	gel.	Coomassie	blue	staining	 (left)	and	 InVision	
staining	(right).	(1)	Protein	molecular	weight	ladder	(2)	1:15	dilution	of	purified	AtIPK1-His.	
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3.3.2	Cleaving	the	histidine	tag	and	purification	of	AtIPK1		
	
The	 original	 cloning	 strategy	 placed	 a	 3C	 protease	 recognition	 site	 between	 the	 N-
terminal	6xHistidine	tag	and	the	protein	coding	sequence.	Although,	as	explained	later	in	
this	study,	the	6xHistidine	tag	is	advantageous	to	successful	crystallisation	of	AtIPK1,	it	is	
preferential	to	remove	this	tag	for	the	purpose	of	enzymatic	assays	and	other	studies.	
The	protein	was	purified	as	previously	detailed	in	3.3.1,	and	cleavage	of	the	6xHistidine	
tag	 set	 up	 post	 size	 exclusion	 chromatography	 using	 HRV3C	 Protease	 (Sigma-Aldrich)	
(Section	3.2.3).	The	protein	was	concentrated	to	3	mL	and	the	manufacturers	guidelines	
followed.	The	reaction	was	incubated	for	approximately	16	hr	at	room	temperature	(18	
°C)	(results	not	shown).	
	
The	products	of	the	His-tag	cleavage	reaction	were	loaded	on	to	a	5	mL	NiNTA	superflow	
cartridge	(Qiagen),	equilibrated	with	buffer	A,	at	a	flow	rate	of	0.5	mL/min	in	a	continuous	
loop	for	30	min.	The	eluate	containing	AtIPK1	was	collected	in	a	10	mL	fraction	and	five	
subsequent	2	mL	fractions	whilst	the	column	was	subjected	to	buffer	A	at	a	1	mL/min	
flow	rate.	Subsequently,	a	final	10	mL	fraction	was	collected	when	washing	the	column	
with	buffer	B.	All	fractions	were	analysed	by	SDS-PAGE	(Figure	3.7).	The	majority	of	AtIPK1	
was	 eluted	 in	 the	 initial	 10	 mL	 fraction	 whilst	 the	 6xHistidine	 tag	 and	 3C	 protease	
remained	on	the	column.	The	final	10	mL	fraction	contained	some	AtIPK1-His	meaning	
the	removal	of	the	6xHistidine	tag	was	not	100	%	effective	(lane	8).	However,	this	 is	a	
trivial	 quantity	when	 compared	 to	 the	 successfully	 cleaved	 protein	 (lanes	 2-5).	 Other	
bands	 seen	 in	 lane	 8	 are	 likely	 to	 be	 the	 6xHistidine	 tag	 and	 3C	 protease.	 The	
comparatively	 small	 concentration	 of	 3C	 protease	 used	 was	 very	 efficient	 under	 the	
conditions	tested	and	produced	a	high	yield	of	protein	recovery.	
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A	 final	 size	 exclusion	 chromatography	 step	 was	 added,	 and	 performed	 as	 described	
previously,	 returning	 the	 protein	 to	 an	 imidazole	 free	 buffer.	 The	 protein	 was	
concentrated	prior	to	snap	freezing	in	liquid	nitrogen	and	subsequently	stored	at	-80	°C.		
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Figure	 3.7	 –	 Immoblised	 metal	 affinity	 purification	 post-proteolytic	 cleavage	 of	 His-AtIPK1	 with	 3C	 protease.	
Samples	of	 eluate	 fractions	 from	 the	 NiNTA	 column	upon	washing	with	 NiNTA	buffer	 A,	Analysed	on	a	 12.5	%	
acrylamide	gel.	(1)	Molecular	weight	marker.	(2)	Initial	10	mL	fraction.	(3-7)	Subsequent	2	mL	fractions.	(8)	Final	10	
mL	wash	with	NiNTA	buffer	B.	
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3.3.3	 Crystallisation	 of	 AtIPK1	 with	 biphenyl	 2,3’,4,5’,6-pentakisphosphate,	 and	
biphenyl	3,3’,4,4’,5,5’-hexakisphosphate.	
	
Biphenyl	phosphates	have	been	described	as	synthetic	ligands	and	inhibitors	of	inositol	
polyphosphate-converting	enzymes,	examples	of	which	were	discussed	in	chapters	1	&	2	
(Vandeput	 et	 al.,	 2007,	 Mills	 et	 al.,	 2012,	 Mills	 et	 al.,	 2016b).	 AtIPK1	 has	 also	 been	
investigated	by	the	Brearley	lab	for	binding	of	single	ring	benzene	polyphosphates,	which	
are	 also	 reported	 as	 synthetic	 substrates	 and	 inhibitors	 of	 inositol	 polyphosphate-
metabolising	enzymes	(Ward	et	al.,	1995,	Mills	et	al.,	2006,	Mills	et	al.,	2008).	Structures	
of	AtIPK1-His	in	complex	with	three	of	these	inositol	polyphosphate	mimics	have	been	
solved	(unpublished).	To	follow	on	from	this	work,	AtIPK1	has	been	investigated	for	its	
ability	 to	 coordinate	 the	 double	 ringed	 biphenyl	 polyphosphate	 compounds.	 Four	
biphenyl	 phosphate	 compounds	 were	 available	 from	 collaborators	 (Potter,	 B.V.L.;	
University	 of	 Bath),	 and	 are	 described	 in	 section	 1.1.3.	 All	 of	 which	 were	 utilised	 in	
crystallisation	trials	with	AtIPK1.		
	
Crystals	were	obtained	using	6xHistidine	tagged	AtIPK1	(AtIPK1-His)	protein	as	previous	
experience	 in	 the	 lab	 indicated	 that	 the	 tagged	 version	 of	 the	 recombinant	 protein	
resulted	in	crystals	that	diffracted	to	a	higher	resolution	when	compared	to	those	grown	
with	 AtIPK1	 protein	 that	 had	 been	 cleaved	 of	 the	 6xHistidine	 tag.	 Crystallisation	was	
achieved	 as	 described	 in	 the	 section	 3.2.4,	 using	 buffers	 and	 precipitant	 that	 had	
previously	proved	successful	in	generating	high	quality	AtIPK1-His	crystals.	This	method	
differs	 from	 the	 published	 conditions	 from	 the	 González	 group,	which	 used	 a	 bis-tris	
methane	buffer	as	opposed	to	bis-tris	propane.	Additionally,	the	González	structures	of	
AtIPK1	contain	no	6xHistidine	tag.		
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Crystals	 grew	 as	 plate	 or	 rod	 clusters,	 and	 after	 two	 to	 three	 days	 of	 growth	 were	
separated	and	individually	harvested	in	to	cryoprotectant	for	storage	in	liquid	nitrogen.	
The	 morphology	 of	 crystals	 of	 AtIPK1	 with	 biphenyl-2,3’,4,5’,6-pentakisphosphate	
[BiPh(2,3’,4,5’,6)P5]	 and	 ADP,	 and	 with	 biphenyl-3,3’,4,4’,5,5’-hexakisphosphate	
[BiPh(3,3’,4,4’,5,5’)P6]	and	ADP	can	be	seen	in	Figure	3.8.	
	
	
Successful	and	high	quality	crystals	of	AtIPK1-His	in	complex	with	BiPh(2,3’,4,5’,6)P5	or	
BiPh(3,3’,4,4’,5,5’)P6	were	only	achieved	by	using	the	co-crystallisation	and	micro-seeding	
method	described	in	the	materials	and	methods.		
	 	
Figure	3.8	–	Example	of	an	AtIPK1-His	crystal	exposed	for	data	collection	at	the	Diamond	Light	Source.	Image	is	of	
an	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	crystal	before	exposure	to	the	beamline.	
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3.3.4	 Crystal	 structures	 of	 AtIPK1	 with	 biphenyl	 2,3’,4,5’,6-pentakisphosphate,	 and	
biphenyl	3,3’,4,4’,5,5’-hexakisphosphate.	
	
The	 highest	 resolution	 data	 sets	 collected	 for	 AtIPK1-His	 in	 ternary	 complexes	 with	
BiPh(2,3’,4,5’,6)P5	and	BiPh(3,3’,4,4’,5,5’)P6	(and	ADP)	were	from	crystals	that	diffracted	
to	resolutions	of	2.18	Å	and	2.07	Å,	respectively.	Data	processing	and	model	refinement	
in	the	P1	space	group	was	achieved	using	the	Phenix	suite	(Adams	et	al.,	2010).	Table3.1		
contains	the	data	collection	and	refinement	statistics	for	both	ternary	complexes,	from	
herein	 referred	 to	 as	 AtIPK1-His	 BiPh(2,3’,4,5’,6)P5	 /	 BiPh1	 and	 AtIPK1-His	
BiPh(3,3’,4,4’,5,5’)P6	/	BiPh3.	
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Table	3.1		–	X-ray	diffraction	data	processing	and	model	refinement	statistics	for	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	/	BiPh	
1	and	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	/	BiPh3.	
	
	 	
BiPh(2,3’,4,5’,6)P5 BiPh(3,3’,4,4’,5,5')P6Space	Group P1 P1Unit	Cella,	b,	c		(Å)α,	β,	γ	(°) 59.9,	59.8,	85.487.7,	87.7,	63.6 59.6,	59.8,	85.387.8,	88.1,	64.0Resolution	(Å) 53.6-2.18	(2.24-2.18) 53.6-2.07	(2.12-2.07)Rmerge		(%) 0.062	(0.588) 0.050	(0.495)<I/σ(I)> 8.7	(1.7) 9.3	(1.9)CC	1/2 0.991	(0.616) 0.996	(0.721)Completeness	(%) 95.31	(96.0) 96.67	(97.0)Multiplicity 2.8	(2.9) 2.9	(3.0)Wilson	B-factor 48.22 49.77
BiPh(2,3’,4,5’,6)P5 BiPh(3,3’,4,4’,5,5')P6Number	of	Non-hydrogen	atomsWaters 7055193 7214268Resolution	(Å) 53.6-2.18	(2.22-2.18) 53.6-2.07	(2.10-2.07)Rwork		(%) 18.4	(29.7) 17.9	(27.9)Rfree	(%) 23.0	(34.5) 22.0	(29.7)Mean	B-value	(Å2) 57.5 60RMSD	Bonds	(Å) 0.008 0.008RMSD	Angles	(°) 1.182 1.117RMSD	Planes	(Å) 0.005 0.005Ligand	Occupancy	(%)Chain	AChain	B 79	77 8485
Refinement
Data	Processing
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Previously	published	structures	of	AtIPK1	were	obtained	in	a	different	space	group	and	
unit	cell	dimension	to	those	in	this	study,	although	it	should	be	noted	some	of	these	were	
structures	of	a	W129A	mutant	of	IPK1	(Baños-Sanz	et	al.,	2012;	González	et	al.,	2010).	
The	observed	space	groups	for	the	mutant	and	native	IPK1	in	the	literature	were	P21212	
and	 P212121,	 respectively.	 However,	 similarities	 can	 be	 drawn	 upon;	 the	 refined	 P1	
AtIPK1-His	 BiPh1	 and	 AtIPK1-His	 BiPh3	 structures	 presented	 here	 also	 have	 two	
molecules	 (A	 and	 F)	 present	 in	 the	 asymmetric	 unit	 (AU),	 comparable	 to	 the	 native	
protein	in	both	binary	and	tertiary	complexes	from	the	previous	studies	(Figure	3.9	A).	
The	 observed	 P1	 space	 group	 is	 in	 agreement	 with	 all	 other	 AtIPK1-His	 structures	
generated	from	the	Brearley	lab	(unpublished	data).	
	
The	 two	AtIPK1-His	 complexes	presented	have	a	bis-tris	propane	molecule	 associated	
with	molecule	A	and	a	tris	molecule	associated	with	molecule	F.	As	this	appears	in	both	
AtIPK1-His	 structures,	 bis-tris	 propane	 is	 likely	 to	 be	 critical	 to	 crystal	 packing	 and	
stabilisation	of	the	molecules	within	the	unit	cell.	Additionally,	attempts	of	crystallisation	
without	 bis-tris	 propane,	 under	 the	 conditions	 that	 the	 González	 group	 used,	 were	
unsuccessful.	 The	 density	 for	 the	 tris	 molecule	 associated	 with	 molecule	 F	 in	 both	
structures	 is	 likely	 to	 be	 another	 bis-tris	 molecule,	 but	 it	 could	 not	 be	 confidently	
modelled	to	the	double	difference	Fourier	electron	density,	so	was	left	simply	as	a	tris	
molecule.	 Although,	 an	 argument	 can	be	made	 that	 as	 this	 occurs	 in	 both	AtIPK1-His	
structures	presented	here,	it	could	be	a	real	artifact	of	crystal	packing.	Additionally,	the	
tris	molecule	associated	with	molecule	 F	 is	 also	present	 in	previous	AtIPK1	 structures	
produced	by	the	lab	(unpublished	data),	but	there	is	also	speculation	in	this	case	that	it	
could	also	be	a	bis-tris	propane,	again	because	it	could	not	be	satisfactorily	modelled	to	
the	electron	density	maps.		
	
Both	refined	structures	contain	the	novel	ligand	(BiPh1/BiPh3),	ADP	and	two	magnesium	
ions	 in	 each	 molecule,	 as	 well	 as	 a	 zinc	 ion	 coordinated	 by	 two	 cysteines	 and	 two	
histidines	in	the	C-lobe	of	the	protein	(Figure	3.9	-	B).	This	is	in	agreement	with	previously	
reported	data	(Baños-Sanz	et	al.,	2012;	González	et	al.,	2010).	 	
Chapter	3	–	Structural	studies	of	Arabidopsis	thaliana	inositol	1,3,4,5,6-pentakisphosphate	2-kinase	
(AtIPK1)	in	complex	with	novel	inositol	phosphate	surrogates	
88	
	
	 	
Figure	 3.9	 –	 AtIPK1-His	 BiPh(2,3’,4,5’,6)P5	 and	 ADP	 crystal	 structure	 represented	 as	 a	 cartoon	 and	 coloured	 by	
secondary	 structure	 elements.	 (A)	 The	 two	 molecules	 in	 the	 asymmetric	 unit.	 (B)	 A	 single	 molecule	 of	 the	
asymmetric	 unit	 -	 Chain	 F.	 The	 active	 site	 is	 indicated	 by	 the	 presence	 of	 BiPh(2,3’,4,5’,6)P5	 and	 ADP,	 and	 is	
represented	as	blue	sticks.	The	two	magnesium	ions	in	the	active	site	are	shown	as	green	spheres,	and	zinc	as	a	grey	
sphere.	A	tris	molecule	that	associates	with	the	protein	upon	crystallisation	is	shown	as	orange	sticks.	
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Both	AtIPK1-His	 structures	present	 cross	AU	 interactions	with	neighbouring	 symmetry	
related	 molecules	 in	 the	 lattice	 via	 what	 has	 been	 term	 as	 a	 ‘fireman’s	 grip’;	 the	
6xHistidine	tag	from	molecule	A	in	the	asymmetric	unit	(AU)	‘wraps	around’	a	6xHistidine	
tag	 from	molecule	 F	 in	 a	neighbouring	AU,	appearing	 to	 stabilise	 the	 lattice	 structure	
(Figure	3.10).	Again,	this	is	in	agreement	with	other	AtIPK1-His	structure	complexes	from	
the	group	(unpublished	data)	and	is	likely	to	be	a	reason	for	the	difference	in	space	group	
observed	when	compared	 to	 the	González	et	al.,	 (2010)	and	Baños-Sanz	et	al.,	 (2012)	
structures,	which	were	crystallised	without	a	histidine	tag.	
	
	 	
Figure	3.10	–	The	firemans	grip	interaction	formed	by	the	6xHis	tags	from	two	neighbouring	asymmetric	units	
between	molecule	F	(magenta)	and	molecule	A	(blue).	
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The	 two	molecules	 in	 the	AU	 for	 the	AtIPK1-His	BiPh1	structure	globally	align	 to	each	
other	with	a	RMSD	of	0.341,	and	the	active	site	residues	0.176.	The	near	equivalence	can	
be	seen	 for	 the	AtIPK1-His	BiPh3	structure	where	 the	respective	alignment	 results	are	
0.331,	 and	 0.155.	 This	 reveals	 that	 these	 complexes	 are	 likely	 to	 have	 a	 single	
conformation	within	the	AU,	with	reliable	models	built	for	both	chains	but	with	minor	
differences	which	were	also	revealed	in	previous	structures	from	the	lab	(unpublished)	
and	were	attributed	to	the	AU-AU	 interactions	between	the	6xHistidine	tags	acting	to	
stabilise	an	external	loop	in	molecule	A	when	compared	to	B	(results	not	shown).	In	the	
active	site	region	of	AtIPK1	BiPh1,	Arg45	is	in	a	different	position	in	each	molecule,	but	
this	is	not	supported	by	difference	electron	density	which	is	of	poor	quality	around	this	
residue,	preventing	clear	interpretation	of	the	position	of	this	residue.	Similarly,	this	also	
occurs	in	the	two	molecules	of	the	AtIPK1	BiPh3	complex.	It	is	also	noteworthy	that	the	
protein	is	in	complex	with	much	larger	ligands	when	compared	to	previous	structures.	As	
discussed	 later,	 it	 has	 undergone	 large	 conformational	 changes	 to	 accommodate	 the	
novel	ligands.	This	may	result	in	differences	between	the	two	molecules	in	the	AU	during	
model	 building	 and	 refinement,	 as	 parts	 of	 the	 polypeptide	 were	 manually	 built,	
particularly	in	flexible	regions.	
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Both	BiPh(2,3’,4,5’,6)P5	and	BiPh(3,3’,4,4’,5,5’)P6	were	found	to	be	bound	in	the	active	
site	of	AtIPK1-His;	between	the	N-	and	C-lobes,	where	density	maps	reveal	their	binding	
positions	(Figure	3.11).	The	molecules	were	in	the	same	binding	orientation	in	chains	A	
and	F	for	both	BiPh1	and	BiPh3,	this	together	with	the	low	RMSD	for	the	superimposition	
of	the	active	site	residues,	respectively	0.176	and	0.155,	suggest	that	both	ligands	possess	
a	single	energetically	stable	binding	position	within	the	active	site	of	AtIPK1.	However,	in	
respect	to	one	another,	the	ligands	are	bound	in	different	orientations.		
	 	
Figure	 3.11	 –	 Active	 sites	 of	 AtIPK1-His	 BiPh(2,3’,4,5’,6)P5	 and	 AtIPK1-His	 BiPh(3,3’,4,4’,5,5’)P6	 showing	 binding	
positions	and	simulated	annealing	omit	maps.	(A)	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(B)	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6.	
Ligands	are	shown	as	green	sticks,	ADP	as	red	sticks	and	magnesium	atoms	as	magenta	spheres.	The	density	maps	
are	represented	as	a	blue	mesh	and	are	at	a	contour	level	of	1.2	σ.			
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This	 is	 likely	 to	be	explained	by	 the	differing	numbers	of	phosphates	and	 their	 spatial	
positioning	on	the	phenyl	rings,	as	well	as	the	relative	planes	of	each	ring	in	the	molecule.	
The	rings	of	BiPh3	are	planar	with	respect	to	one	another,	and	slightly	rotated	in	BiPh1.	
This	 rotation	 around	 the	 C1-C1’	 bond	 allows	 the	 phosphate	 groups	 to	 optimise	 their	
interactions	within	the	binding	site.	Due	to	this	there	are	also	differences	in	the	residues	
that	co-ordinate	the	two	ligands	(Figure	3.12).		
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Figure	3.12	Ligplot	diagrams	of	the	contacts	formed	by	the	BiPh(2,3’,4,5’,6)P5	and	BiPh(3,3’,4,4’,5,5’)P6	ligand	in	the	
active	site	of	AtIPK1-His.	(A)	BiPh(2,3’,4,5’,6)P5	(B)	BiPh(3,3’,4,4’,5,5’)P6.	
A 
B 
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Analysis	 of	 hydrogen	 bonding	 and	 hydrophobic	 interactions	 was	 achieved	 using	 the	
LigPlot+	 program	 (Laskowski	 &	 Swindells,	 2011),	 which	 automatically	 generates	
schematic	diagrams	of	protein-ligand	interactions	based	on	the	distances	between	atoms	
in	a	given	PDB	file	(Figure	3.12).	This	revealed	that	both	compounds	are	coordinated	by	
K200,	 K170,	 N238	 &	 K168,	 suggesting	 that	 these	 residues	 are	 likely	 to	 be	 critical	 to	
coordinating	 and	 positioning	 substrates	 in	 the	 active	 site.	 These	mutual	 residues	 co-
ordinate	P5’	of	BiPh1,	and	P4’	of	BiPh3,	and	shed	light	on	the	relative	juxtaposed	binding	
orientations	of	the	two	ligands.	Interestingly,	with	a	physiological	substrate	(myo-IP5	or	-
IP6)	the	same	residues	interact	with	P6	(González	et	al.,	2010).	This	is	also	in	agreement	
with	structures	of	AtIPK1-His	with	benzene	polyphosphates	where	the	same	residues	also	
provide	coordination	to	a	particular	phosphate	(unpublished	data).		
	
Additionally,	 two	 of	 the	 four	 ‘P6-coordinating	 residues’,	 K168	 and	 N238,	 also	 form	
secondary	contacts	with	another	phosphate,	P2,	on	the	‘upper	ring’	of	BiPh1	and	P5	on	
the	lower	ring	of	BiPh3	(as	orientated	in	the	active	site	figures).	When	compared	to	myo-
IP5	/	-IP6	these	residues	form	similar	interactions	with	P1.	No	additional	interactions	with	
the	upper	rings	of	the	two	compounds	are	present	with	exception	of	R45	with	P4	of	BiPh3,	
but	as	discussed	previously	the	position	of	R45	is	not	supported	by	difference	electron	
density	therefore	its	role	must	be	considered	with	caution.	The	P3	of	BiPh1	is	coordinated	
by	 K411	 and	 R415,	 both	 of	 which	 form	 interactions	 with	 the	 P4	 phosphate	 on	 the	
canonical	inositol	phosphate	substrate.	It	seems	that	most	interactions	that	coordinate	
the	ligand	in	the	active	site	occur	on	the	“lower”	ring	of	the	biphenyl	compounds,	with	
the	 exception	 of	 P2	 of	 BiPh1.	 This	 is	 unsurprising	 when	 considering	 physiological	
substrates	are	single	ring	compounds.	
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Superposition	of	chain	F	of	the	AtIPK1-His	BiPh1	and	BiPh3	structures	reveals	that	the	
positioning	of	the	‘P6	coordinating	residues’	are	conserved	between	the	two	structures	
(Figure	3.13).	The	two	structures	globally	align	with	an	RMSD	of	0.186,	indicating	that	the	
difference	in	the	spatial	positioning	of	the	phosphates	between	the	two	ligands	does	not	
significantly	 alter	 the	 overall	 conformation	 of	 the	 AtIPK1.	 Additionally,	 there	 are	 no	
significant	domain	movements	and	the	active	site	features	such	as	the	G-loop,	L3	and	α6	
overlay	closely	(see	section	3.1).	There	is	a	small	difference	in	the	positioning	of	one	of	
the	magnesium	 ions.	 It	 should	 also	 be	 noted	 that	 there	 is	 no	 contact	 between	 these	
ligands	and	the	ADP	cofactor	via	the	magnesium	ions,	unlike	structures	with	traditional	
substrates.	
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Figure	3.13	-	Global	alignment	of	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(magenta)	and	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	(blue)	
complexes.	(A)	The	overlaid	active	sites	of	the	two	complexes.	(B)	Active	site	residues	that	co-ordinate	the	ligands.	
BiPh(2,3’,4,5’,6)P5	and	BiPh(3,3’,4,4’,5,5’)P6	can	been	seen	in	the	active	site	of	the	structures	in	both	images,	and	
are	represented	as	sticks.	The	magnesium	ions	are	shown	as	spheres	and	ADP	as	sticks,	coloured	according	to	the	
complex	to	which	they	belong.	Phosphate	positions	are	labeled	according	to	BiPh1.	
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As	mentioned	previously,	comparing	the	positions	of	the	ligands	in	the	active	site	shows	
they	are	bound	 in	very	different	orientations	despite	being	 structurally	 similar.	This	 is	
likely	achieved	by	the	differences	in	the	number	and	spatial	arrangement	of	phosphates,	
as	well	the	rotation	of	the	C1-C1’	bond.	The	two	ligands	bear	three	phosphate	positions	
that	are	superimposed,	and	are	labeled	in	according	to	the	numbering	of	BiPh1	(Figure	
3.13).	 Two	 of	 these	 have	 already	 been	 discussed	 above	 and	 occupy	 the	 P1	 and	 P6	
positions	 of	 a	 bound	myo-IP5	 or	 IP6.	 The	 additional	 alignment	 of	 phosphates	 occurs	
between	 P4	 of	 BiPh1	 and	 P3	 of	 BiPh3	 on	 the	 upper	 rings	 of	 both	 compounds.	 These	
phosphates	 appear	 to	 have	 no	 hydrogen	 bonding	 interactions	 with	 AtIPK1.However,	
nearby	hydrophobic	contacts	with	G19	and	G20	occur	with	both	ligands.	This	may	not	be	
an	 important	 artifact	 of	 anchoring	 a	 substrate	 in	 to	 the	 active	 site	 given	 the	 lack	 of	
hydrogen	 bonding	 between	 the	 protein	 and	 ligand	 in	 this	 region,	 but	 it	may	 provide	
further	 stabilisation	which	 in	 turn	 allows	 the	 protein	 to	 accommodate	 a	much	 larger	
ligand.	
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Global	alignment	of	both	AtIPK1-His	BiPh1	and	AtIPK1-His	BiPh3	to	AtIPK1-His	myo-IP6	
(unpublished	data),	 results	 in	RMSD	values	of	0.760	and	0.780,	 respectively.	Providing	
evidence	 that	 significant	 conformational	 changes	 are	 likely	 to	 have	 taken	 place	 to	
accommodate	the	novel	ligands.	These	changes	are	isolated	to	the	N-lobe	of	the	protein	
which	 appears	 to	have	been	effectively	 pushed	outward	 in	 a	 near	 rigid	 body	motion,	
doing	so	via	the	hinge	(Section	3.1).	These	conformational	changes	and	the	disorder	they	
cause	are	discussed	in	more	detail	in	section	3.2.4.	
	 	
Figure	3.14	–	Global	alignment	of	the	AtIPK1-His	myo-IP6	(green)	with	(1)	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(magenta)	
and	(2)	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	(blue);	(A)	The	overlaid	active	sites	of	the	two	complexes.	(B)	Active	site	
residues	that	 co-ordinate	the	 ligands.	Ligands	 are	represented	as	sticks,	magnesium	ions	 as	spheres	 and	ADP	as	
sticks,	coloured	according	to	the	complex	to	which	they	belong.	myo-IP6	numbering.	
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Upon	comparison	of	the	binding	orientation	of	myo-IP6	in	the	active	site	to	that	of	BiPh1	
and	 BiPh3	 (Figure	 3.14),	 it	 is	 apparent	 that	 fewer	 interactions	 anchor	 the	 biphenyl	
compounds	 in	 to	 the	 active	 site	 than	 do	myo-IP6.	 This	 likely	 arises	 from	 the	 differing	
spatial	arrangement	of	the	phosphates	within	the	compounds,	equatorial	to	the	puckered	
ring	of	inositol	or	in	the	plane	of	the	phenyl	rings.	This	could	provide	information	on	which	
interactions	could	be	more	prevalent	in	determining	how	and	why	a	compound	binds	in	
the	active	site	in	a	certain	manner.	The	majority	of	these	interactions	are	provided	by	the	
C-lobe	 in	both	 structures,	which	unlike	 the	N-lobe,	 has	not	undergone	any	 significant	
conformational	 changes	upon	binding	 the	biphenyl	 compounds.	Not	only	 are	 the	 two	
biphenyl	compounds	in	very	altered	orientations	when	compared	to	one	another;	they	
bind	 in	 an	 almost	 orthogonally	 to	myo-IP6,	 which	 provides	 explanation	 for	 the	 large	
movement	of	the	N-lobe	upon	biphenyl	binding.		
	
It	 can	be	clearly	 seen	 that	 the	position	occupied	by	P6	of	myo-IP6	 is	 satisfied	by	both	
ligands,	by	P5’	of	BiPh1	and	P4’	of	BiPh3.	Additionally,	the	‘P6-coordinating	residues’	that	
surround	the	phosphate	at	this	P6-equivalent	position	are	shared	in	all	three	structures	
and	are	in	equivalent	positions.	They	provide	a	pocket	in	which	this	phosphate	is	tightly	
bound	and	is	likely	to	be	imperative	in	anchoring	the	substrate	in	the	active	site	due	to	
these	 interactions	 being	 ubiquitous	 across	 all	 three	 structures.	 Although	 not	 entirely	
overlaid,	there	is	a	phosphate	in	the	equivalent	myo-IP6	P1	position	for	both	compounds,	
P2	of	BiPh1	and	P5’	of	BiPh3.	The	 interactions	are	provided	by	K168	and	N238,	which	
together	with	R130	also	coordinate	P1	of	myo-IP6.	The	R130	interaction	is	not	present	in	
the	structures	presented	here	and	may	explain	why	these	equivalent	phosphates	are	do	
not	align	fully	with	P1	of	myo-IP6.	However,	they	do	overlay	in	each	biphenyl	compound.	
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Interestingly,	there	is	no	phosphate	in	the	equivalent	position	of	the	axial	P2	of	myo-IP6	
for	 both	 BiPh1	 and	 BiPh3.	 This	 is	 perhaps	 not	 entirely	 unexpected	 due	 to	 the	 vast	
differences	 in	 structure	 between	 myo-IP6	 and	 the	 biphenyl	 compounds,	 making	 it	
impossible	 to	accommodate	a	phosphate	 in	 the	 ‘inositol’	 P2	binding	pocket.	 This	 also	
offers	explanation	for	the	lack	of	interactions	between	the	compound,	magnesium	ions	
and	 cofactor.	 This	 further	 supports	 that	 it	 is	 the	 ‘inositol’	 P6	binding	pocket,	 possibly	
together	with	the	‘inositol’	P1	binding	pocket,	that	provides	a	primary	anchoring	point	
for	substrates	in	the	active	site,	and	not	the	residues	coordinating	the	axial	P2-positioned	
hydroxyl	group.	The	structures	suggest	 that	 the	biphenyl	compounds	act	as	mimics	of	
inositol	substrates	but	are	unlikely	to	be	phosphorylated	due	to	the	 lack	of	a	hydroxyl	
group	occupying	the	‘inositol’	P2	position	or	more	specifically	an	axial	hydroxyl	group.	
The	presence	of	an	axial	hydroxyl	or	phosphate	is	not	required	for	AtIPK1-His	to	bind	a	
ligand,	 evidence	 of	 this	 can	 also	 be	 seen	 in	 structures	 with	 benzene	 phosphate	
compounds	(H.	Whitfield,	UEA,	unpublished)	which	are	discussed	in	due	course.	
	
The	 structures	 of	 the	 same	 recombinant	 AtIPK1-His	 protein	 in	 complex	 with	 three	
benzene	polyphosphate	substrate	mimics,	and	ADP,	have	previously	been	solved	by	a	
colleague	 (H.	 Whitfield,	 UEA,	 unpublished).	 These	 were	 benzene	 1,2,3,4-
tetrakisphosphate	(Bz1),	benzene	1,2,3,5-tetrakisphosphate	(Bz2),	and	benzene	1,2,4,5-
tetrakisphosphate	 (Bz3).	 The	 structure	 with	 Bz3	 represents	 the	 highest	 resolution	
structure	with	 these	compounds	 (1.90	Å),	of	which	 the	alignment	with	 the	AtIPK1-His	
BiPh1	and	AtIPK1-His	BiPh3	structures	can	be	seen	in	Figure	3.54.	As	these	mimics	closer	
represent	physiological	 ligands	due	to	their	single	ring	structure,	 it	 is	unsurprising	that	
the	 structures	 with	 the	 biphenyl	 substrate	 mimics	 also	 differ	 in	 conformation	 when	
compared	to	AtIPK1	Bz3	as	well	as	to	AtIPK1	myo-IP6.	
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Figure	3.15	-	Global	alignment	of	AtIPK1-His	Bz(1,2,4,5)P4	(cyan)	with	(1)	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(magenta),	
and	(2)	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	(blue);	(A)	The	overlaid	active	sites	of	the	two	complexes.	(B)	Active	site	
residues	that	 co-ordinate	the	 ligands.	Ligands	and	ADP	are	represented	as	sticks	&	magnesium	 ions	 as	spheres,	
coloured	according	to	the	complex	to	which	they	belong.	Phosphates	are	numbered	according	to	Bz3.	
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The	AtIPK1-His	Bz3	complex	aligns	to	the	AtIPK1-His	BiPh1	&	BiPh3	structures	with	an	
RMSD	of	0.699	and	0.687,	respectively,	indicating	that	the	protein	is	in	a	marginally	more	
similar	 conformation	 to	 AtIPK1-His	 Bz3	 than	 it	 is	 to	 the	 AtIPK1-His	myo-IP6	 structure.	
Having	said	this,	the	N-lobe	of	the	AtIPK1-His	Bz3	complex	is	not	as	far	displaced	as	it	is	
with	a	biphenyl	ligand	and	appears	to	be	more	ordered,	particularly	noticeable	at	α6.	It	
is	more	akin	to	the	AtIPK1-His	myo-IP6	structure	than	either	AtIPK1-His	BiPh1	or	AtIPK1-
His	BiPh3,	and	little	conformational	changes	take	place	when	in	comparison	with	those	
that	arise	from	the	binding	of	a	biphenyl	compound.	The	accommodation	of	a	biphenyl	
compound	not	only	displaces	and	disorders	the	N-lobe	significantly,	but	the	positions	of	
L3	and	the	G-loop	are	different	 to	those	 in	 the	AtIPK1-His	Bz3	and	AtIPK1-His	myo-IP6	
complexes.	 The	 origins	 of	 the	 conformational	 changes	 that	 accommodate	 a	 biphenyl	
polyphosphate	are	discussed	in	more	detail	in	section	3.2.4.	
	
Again,	 in	 the	 AtIPK1-His	 Bz3	 structure,	 the	 ‘inositol’	 P6	 and	 P1	 binding	 pockets	 are	
occupied	 just	 like	 all	 the	 previous	 structures	 discussed,	 but	 with	 P2	 and	 P1	 of	 Bz3,	
respectively.	 This	 further	 cements	 the	 notion	 that	 these	 binding	 pockets	 must	 be	
occupied	in	order	to	anchor	a	substrate,	and	that	any	novel	ligand	will	orient	itself	in	the	
active	site	to	satisfy	this.		
	
Neither	biphenyl	compound	forms	hydrogen	bonds	with	R130	or	G20,	unlike	Bz3	or	myo-
IP6.	As	the	residues	lie	within	the	N-lobe,	more	specifically	α6	and	the	G-loop,	the	lack	of	
hydrogen	bonding	of	BiPh1	or	BiPh3	by	R130	may	offer	explanation	to	the	de-stabilisation	
of	 α6,	 and	may	 be	why	 it	 appears	 disordered	 in	 both	 the	 structures	 presented	 here.	
Additionally,	the	G-loop	is	shifted	further	from	the	ligand.	
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Interestingly,	ADP	interacts	with	P5	of	Bz3	via	a	magnesium	ion	in	an	interaction	similar	
to	that	of	P2	of	myo-IP6,	whereas	no	such	interaction	exists	in	either	biphenyl	structure.	
However,	P5	of	Bz3	does	not	actually	reside	at	the	inositol	P2	binding	pocket,	nor	does	it	
overlay	 with	 P2	 of	myo-IP6	 when	 the	 two	 structures	 are	 aligned,	 yet	 this	 interaction	
between	Bz3,	a	magnesium	ion	and	the	cofactor	still	persists.	
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Figure	3.16	Overlay	of	the	binding	positions	of	ligands	in	complex	with	AtIPK1-His.	(A,B	&	C)	Views	of	ligand	binding	
from	different	perspectives;	myo-IP6	(green),	Bz3	(red),	BiPh(2,3’,4,5’,6)P5	(magenta)	&	BiPh(3,3’,4,4’,5,5’)P6	(blue).	
The	phosphates	(positions)	labeled	are	those	of	myo-IP6.	
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Overlaying	all	three	of	the	inositol	polyphosphate	mimics	mentioned	thus	far	to	myo-IP6	
in	the	active	site	of	AtIPK1-His	highlights	the	conserved	positioning	of	phosphates,	with	
the	most	striking	alignment	occurring	at	the	‘inositol’	P6	position	(Figure	3.16).	No	other	
position	shows	such	constricted	positioning	of	a	phosphate	across	all	ligands	therefore	
confirming	that	this	phosphate	is	tightly	bound	in	to	the	‘inositol’	P6	binding	pocket.	The	
‘inositol’	P1	position	is	also	clearly	occupied	by	all	ligands	but	is	not	as	tightly	conserved,	
especially	 when	 comparing	 the	 location	 of	 the	 Bz3	 phosphate	 at	 this	 position	 to	 the	
phosphate	 of	 the	 other	 three	 ligands.	 The	 ‘inositol’	 P5	 and	 ‘inositol’	 P3	 positions	 are	
unlikely	to	be	essential	in	substrate	binding,	but	the	‘inositol’	P4	position	may	have	some	
influence	as	Bz3	places	a	phosphate	at	this	position.	As	mentioned	earlier,	no	novel	ligand	
has	a	phosphate	occupying	the	‘inositol’	P2	catalytic	position,	confirming	that	this	is	not	
essential	 in	 orienting	 a	 substrate	 in	 the	 active	 site,	 therefore	 suggesting	 that	 none	of	
these	 inositol	polyphosphate	mimics	would	be	substrates	of	AtIPK1.	Nevertheless,	Bz3	
does	place	a	phosphate	between	the	‘inositol’	P2	and	P3	positions	that	interact	with	ADP	
via	magnesium,	just	like	the	P2	of	myo-IP6	would.	Additionally,	K168	forms	interactions	
with	all	the	ligands	but	would	normally	contact	the	axial	P2	of	myo-IP6;	suggesting	that	
K168	is	critical	for	ligand	binding	even	though	an	axial	hydroxyl	group	or	phosphate	at	
‘inositol’	P2	is	not.	BiPh1	and	BiPh3	also	share	positioning	of	a	phosphate	on	their	upper	
rings,	 P4	and	P3	 respectively.	 There	 is	 no	hydrogen	bonding	 to	 these	phosphates	but	
instead	 G19	 provides	 hydrophobic	 contacts	 nearby.	 G19	 also	 provides	 hydrophobic	
interactions	in	the	myo-IP6	and	Bz3	structures	despite	the	phosphates	around	the	single	
ring	molecules	being	in	different	positions	to	those	in	the	biphenyl	compounds.	Therefore	
the	hydrophobic	contacts	with	G19	may	also	have	to	be	satisfied	when	binding	a	ligand,	
and	may	confer	substrate	specificity	and	orientation.	
	
It	would	appear	the	four	residues	that	form	the	P6	binding	pocket,	which	have	retained	
positioning	across	all	the	structures	presented	here,	primarily	determine	the	orientation	
of	ligand	binding.	Furthermore,	binding	position	is	governed	by	the	‘inositol’	P1	position,	
which	is	prominently	demonstrated	by	the	juxtaposed	orientations	of	the	two	biphenyl	
phosphates	in	the	active	site.		
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3.3.5	Conformational	changes	of	AtIPK1	upon	ligand	binding	
	
Changes	in	intrinsic	tryptophan	fluorescence	of	AtIPK1	upon	ligand	and	cofactor	binding,	
together	with	 structures	 have	 revealed	 that	 it	 possesses	 three	 distinct	 conformations	
when	in	 its	apo-form,	and	inositide	and/or	nucleotide	bound	forms	(Baños-Sanz	et	al.,	
2012(Gosein	et	al.,	2012)).	As	mentioned	in	section	3.3.3,	residues	in	both	the	N-	and	C-
lobes	 coordinate	an	 inositide	 in	 to	 the	active	 site,	which	consequently	brings	 the	 two	
lobes	 together,	 this	has	been	 termed	 the	 “closed	 form”	of	 the	protein	 (Figure	3.17	&	
Figure	3.18	 (C)).	 The	 closed	 form	also	 features	 local	 changes	where	a	 clasp	 is	 formed	
between	residues	of	α6	and	L3,	effectively	closing	the	active	site.		
	
In	the	“open	form”,	represented	by	the	unbound	apo-protein	(W129A	mutant),	this	clasp	
is	unconnected	and	L3	can	be	considered	mobile.	Additionally,	α6	shows	disorder	in	this	
form	 therefore	 the	 conformation	 of	 α6	 and	 L3	 is	 dependent	 on	 the	 clasp	 formation.	
Furthermore,	the	N-	and	C-lobes	show	a	general	rigid-body	movement	and	are	further	
apart	(Baños-Sanz	et	al.,	2012).	Movement	occurs	via	three	hinges	that	are	highly	mobile	
and	therefore	disordered	in	both	the	closed	and	open	forms	of	the	protein.	This	disorder	
is	in	agreement	with	both	of	the	structures	presented	in	this	study.	
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α6"α5"
Figure	3.17	–	The	structure	of	the	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	active	site	superimposed	on	to	the	three	distinct	
binding	conformations	of	AtIPK1.	The	N-	and	C-lobes	of	AtIPK1-His	BiPh(2,3’,4,5’,6)P5	(red	&	black)	and	the	AtIPK1	
conformations	(pink	&	grey)	are	represented	as	a	cartoon,	and	BiPh(2,3’,4,5’,6)P5	(blue)	as	sticks.	(A)	The	apo-form	
of	a	W129A	AtIPK1	mutant,	which	denotes	the	“open”	conformation	of	the	enzyme	(PDB	4AXC).	(B)	The	AtIPK1	
AMPPNP	complex	in	the	“half-closed”	conformation.	AMPPNP	(orange)	and	ADP	(blue)	are	shown	as	sticks	(PDB	
4XAD).(C)	The	AtIPK1	myo-IP6	ADP	complex	that	describes	the	“closed”	conformation	of	the	protein	(PDB	2XAM).	
The	myo-IP6	and	ADP	molecule	associated	with	the	complex	are	shown	as	orange	sticks.	
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A	third	conformation	is	represented	by	the	nucleotide-bound	structure	of	the	protein	and	
is	termed	the	“half-closed	form”,	as	it	denotes	an	intermediate	state	between	the	apo-
form	and	the	closed-form	of	the	protein	(Baños-Sanz	et	al.,	2012).	In	this	conformation	
the	N-	and	C-lobes	are	closer	than	in	the	apo-form,	but	are	still	too	distant	to	fully	form	
the	 inositide	 binding	 site.	 Additionally,	 the	 clasp	 observed	 in	 the	 closed-form	 is	 not	
formed	and	L3	remains	flexible,	and	α6	disordered.	These	elements	are	only	fully	formed	
in	the	closed-form	where	L3	is	also	forming	a	“lid”	that	closes	over	the	active	site	pocket.	
When	superimposing	all	 three	of	 these	conformational	states	 to	AtIPK1-His	BiPh1	and	
AtIPK1-His	BiPh3,	it	becomes	apparent	that	both	structures	are	akin	to	this	half-closed	
form	(Figure	3.17	&	3.18).	They	align	with	an	RMSD	of	0.510	and	0.424,	respectively,	a	
result	 which	 is	 perhaps	 surprising	 given	 that	 they	 are	 ternary	 complexes	 with	 both	
nucleotide	 (ADP)	 and	 an	 inositide	 mimic	 bound.	 Possibly	 representative	 of	 a	
conformation	en-route	to	product	(ADP	&	myo-IP6)	release.	For	both	complexes,	L3	is	in	
nearly	the	exact	position	as	that	published	for	the	half-closed	structure,	and	α6	is	also	
disordered.	This	implies	that,	despite	a	ligand	being	bound	in	the	inositide	binding	pocket,	
the	inositide	binding	site	is	not	fully	formed	and	the	L3	lid	has	not	closed	over	the	ligand,	
nor	has	the	clasp	formed.	
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Figure	3.18	–	The	structure	of	the	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	active	site	superimposed	on	to	the	three	distinct	
binding	conformations	of	AtIPK1.	The	N-	and	C-lobes	of	AtIPK1-His	BiPh(3,3’,4,4’,5,5’)P6	(red	&	black)	and	the	AtIPK1	
conformations	(pink	&	grey)	are	represented	as	a	cartoon,	and	BiPh(3,3’,4,4’,5,5’)P6	(blue)	as	sticks.	(A)	The	apo-
form	of	a	W129A	AtIPK1	mutant,	which	denotes	the	“open”	conformation	of	the	enzyme	(PDB	4AXC).	(B)	The	AtIPK1	
AMPPNP	complex	in	the	“half-closed”	conformation.	AMPPNP	(orange)	and	ADP	(blue)	are	shown	as	sticks	(PDB	
4XAD).	(C)	The	AtIPK1	myo-IP6	ADP	complex	that	describes	the	“closed”	conformation	of	the	protein	(PDB	2XAM).	
The	myo-IP6	and	ADP	molecule	associated	with	the	complex	are	shown	as	orange	sticks.	
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Furthermore,	as	mentioned	in	section	3.3.3,	BiPh1	and	BiPh3	do	not	form	any	interactions	
with	residues	from	the	N-lobe	with	the	most	obvious	absence	being	the	coordination	of	
P1	by	R130	from	within	α6.	The	lack	of	interaction	from	the	N-lobe	not	only	explains	the	
failure	to	form	the	closed	conformation,	but	also	explains	how	α6	is	disordered,	lacking	
interaction	with	a	 ligand	and	 therefore	 L3.	 In	absence	of	 clasp	 formation,	 the	protein	
remains	in	the	half-closed	form	when	accommodating	a	biphenyl	polyphosphate	rather	
than	 transitioning	 to	 the	 closed	 form.	 The	 greater	 size	 (volume)	 of	 the	 biphenyl	
polyphosphates	 and	 the	 different,	 relative	 to	 inositol,	 spatial	 positions	 of	 their	
phosphates	are	likely	to	preclude	achievement	of	the	closed	form.	It	can	be	assumed	that	
the	conformation	of	a	ternary	complex	between	AtIPK1	and	a	biphenyl	polyphosphate	is	
mostly	determined	by	the	interaction	with	bound	ADP	rather	than	with	the	ligand,	as	the	
ligand	binding	site	 is	already	 fully	 formed	 following	nucleotide	binding	and	no	 further	
conformational	changes	take	place	post-biphenyl	polyphosphate	binding.	
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3.4	Conclusions	and	Future	work	
The	work	of	González	(Gonzalez	et	al.,	2010;	Banos-Sanz	et	al.,	2012)	identified	different	
conformational	 states	 representing	 different	 stages	 of	 the	 catalytic	 cycle	 of	AtIPK1.	A	
‘closed’	conformation	was	first	described	for	native	protein	with	inositide	and	cofactor	
bound	 (Gonzalez	 et	 al.,	 2010).	 Subsequent	 work	 with	 a	 W129A	 mutant	 allowed	
identification	of	the	apo-form	in	‘open’	conformation	and	‘half-closed’	nucleotide-bound	
conformation	 (Banos-Sanz	et	al.,	2012).	 In	 the	 ‘open’	state	 there	 is	 limited	 interaction	
between	the	N-lobe	and	the	C-IP	lobe.	In	the	presence	of	nucleotide	and/or	inositide	the	
protein	undergoes	rigid	body	motions	which	in	the	presence	of	inositide	that	culminate	
in	the	closing	of	a	clasp	formed	between	R130	of	the	α6	helix	of	the	N-lobe	and	G254	of	
the	L3	loop	of	the	C-IP	lobe	(Baños-Sanz	et	al.,	2012;	Gosein	and	Miller,	2013).	The	latter	
study	extended	understanding	of	the	contribution	of	the	phosphates	of	Ins(1,3,4,5,6)P5	
to	catalysis	suggesting	that	the	5-phosphate	and	the	6-phosphate	were	key	to	inositide	
binding,	while	the	1-phosphate	and	3-phosphate	contribute	most	importantly	to	enzyme	
activation.	 Of	 the	 protein	 residues	 involved	 in	 substrate	 recognition	 and	 enzyme	
activation,	 the	 authors	 concluded	 that	 R130,	 K170	 and	 K411	were	 critical	 to	 enzyme	
activity,	 and	 that	 the	only	N-lobe	 residue	 involved	 in	 substrate	binding	 is	R130	which	
coordinates	the	1-phosphate	(Gosein	and	Miller,	2013;	Gonzalez	et	al.,	2010;	Banos-Sanz	
et	al.,	2012).	The	outcome	of	this	is	that	binding	of	substrate	is	initiated	by	binding	of	the	
4-,	5-	and	6-phosphates	to	the	C-IP	lobe,	with	closing	of	the	clasp	and	enzyme	activation	
mediated	through	the	1-phosphate-mediated	interaction	of	the	N-lobe	with	the	C-IP	lobe.	
The	structures	with	 the	biphenyl	phosphates	present	an	argument	 for	a	non-essential	
role	of	clasp	formation	in	ligand	binding	and	perhaps	therefore	catalysis,	confirmed	by	
the	mutagenesis	studies	by	Banos-Sanz	et	al	2012,	where	shortening	of	L3	did	not	lower	
enzyme	activity	but	 instead	increased	enzyme	efficiently.	Rationalised	by	the	idea	of	a	
lowered	energetic	barrier	for	catalysis,	via	a	more	favourable	mechanism	for	the	release	
of	products	(Banos-Sanz	et	al,	2012).		
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Here	 crystal	 structures	 of	 AtIPK1	 were	 obtained	 in	 ternary	 complex	 with	
BiPh(2,3’,4,5’,6)P5	(BiPh1)	or	BiPh(3,3’,4,4’,5,5’)P6	(Biph3)	and	ADP.	The	data	clearly	show	
enzyme	 in	 ‘half-closed’	 conformation,	 a	 conformation	 previously	 obtained	 solely	with	
nucleotide	alone.	The	most	basic	explanation	is	that	the	addition	of	a	second	phenyl	ring	
prevents	formation	of	the	clasp	and	closure	of	N-	and	CIP	lobes.	The	binding	of	biphenyl	
phosphates	in	the	active	site	and	comparison	of	structures	obtained	with	these	and	with	
inositide	substrates	 (Gonzalez	et	al.,	2010;	Banos-Sanz	et	al.,	2012;	Gosein	and	Miller,	
2013)	 reveals	 the	major	 contribution	 of	 residues	 that	 coordinate	 the	 6-phosphate	 of	
inositide	 substrate,	 which	 ‘anchor’	 these	 ligands	 in	 the	 enzyme.	 By	 way	 of	 extensive	
mutagenesis,	enzyme	assay	and	isothermal	calorimetry	of	substrate	binding,	Gosein	and	
Miller	have	concluded	that	K170	which	coordinates	the	5-	and	6-phosphate	of	inositide	
substrate	are	critical	to	enzyme	activity,	an	observation	that	seems	to	be	supported	by	
the	data	in	this	chapter.	
	
Evidently,	 successful	 future	 crystallographic	 studies	 of	 AtIPK1	with	 the	 two	 additional	
biphenyl	compounds	presented	here,	BiPh2	&	BiPh4	(Table	1.2),	would	provide	further	
evidence	of	the	essential	features	in	ligand	binding	and	catalysis.	Following	this	up	with	
mutagenic	 studies,	 especially	 of	 those	 residues	 coordinating	 the	 P1	 position,	 could	
confirm	 if	 this	and	other	positions	 really	are	essential	 for	binding	of	 the	benzene	and	
biphenyl	phosphates.	Providing	these	mutations	do	not	compromise	crystallisation	of	the	
protein,	any	structural	information	of	mutants	that	encompass	the	binding	of	the	BiPh’s	
may	aid	in	the	empirical	validation	of	essential	binding	elements	and	residues.	Design	of	
binding	and	kinetic	assays	to	support	any	structural	information	would	be	desirable	in	the	
quest	for	elucidating	the	full	mechanism	of	catalysis	of	this	essential	enzyme	in	the	IP6	
synthesis	 pathway.	 It	 has	 not	 yet	 been	 confirmed	 that	 the	 benzene	 and	 biphenyl	
phosphates	are	not	substrates	for	AtIPK1.	As	it	currently	stands	it	is	unlikely	due	to	the	
lack	of	an	axial	2-OH	or	2-phosphate,	and	the	vacant	P2	binding	pocket.	
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Chapter	 4	 –	Novel	 fluorescent	 properties	 of	 the	 benzene-	 and	 biphenyl-	
polyphosphates,	and	the	use	of	 fluorescently	 tagged	 inositol	phosphates	
to	explore	ligand	binding	
4.1	–	Introduction	
4.1.1	–	Current	applications	of	the	benzene-	and	biphenyl-	polyphosphates	
As	previously	introduced	in	section	1.1.3,	the	benzene	polyphosphates	(BzPs)	were	first	
synthesised	as	a	simple	alternative	to	the	synthesis	of	inositol	phosphates	for	use	in	the	
study	 of	 the	 enzymes	 related	 to	 PI3K/Akt	 signalling,	 PtdIns(1,4,5)P3	 3-kinases	 and	
PtdIns(1,4,5)P3	 5-phosphatases.	 The	 utility	 and	 versatility	 of	 the	 BzPs	 prompted	 the	
synthesis	 of	 a	 second	 set	 of	 related	 derivatives	 that	 also	 act	 as	 inositol	 phosphate	
mimics,	 the	 biphenyl	 polyphosphates	 (BiPhs),	 also	 discussed	 in	 section	 1.1.3.	 Just	 like	
the	 benzene	 phosphates	 they	 have	 been	 shown	 to	 substitute	 for	 inositol	 phosphates	
and	phosphoinositides	in	many	of	the	same	incidences	since.	
	
As	discussed	previously	(section	1.1.3	&	2.1.4)	these	compounds	have	also	aided	in	the	
pursuit	of	crystal	structures.	Those	so	far	include,	for	the	BzPs;	Bz(1,2,3,4)P4	(Bz1)	with	
PKBα	 PH-domain,	 and	 type	 II	 inositol	 polyphosphate	 5-phosphatase	 (INPP5B)	 with	
Bz(1,2,4,5)P4	 (Bz3)	 (Mills	 et	 al.,	 2007,	Mills	 et	 al.,	 2016),	 and	 for	 the	 BiPhs;	 biphenyl-
(2,3’,4,5’,6)P5	(BiPh1)	with	the	catalytic	domain	of	SHIP2,	and	biphenyl	(3,3’,4,4’,5,5’)P6	
(BiPh1)	with	INPP5B	(Mills	et	al.,	2012,	Mills	et	al.,	2016).	
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Of	particular	interest	is	3-hydroxybenzene	1,2,4-trisphosphate	(Bz7)	because	it	has	been	
characterized	as	a	substrate	of	INPP5A,	where	the	2-phosphate	is	removed	to	yield	2,3-
dihydroxybenzene	 1,4-bisphosphate,	 and	 currently	 is	 the	 only	 compound	 out	 of	 the	
selection	used	in	this	study	to	have	been	reported	as	a	substrate,	the	rest	are	reported	
exclusively	as	inhibitors(Mills	et	al.,	2008).	
	
4.1.2	–	Current	applications	of	fluorescently	tagged	inositol	phosphates	
	
This	 chapter	 discusses	 the	use	of	 a	 set	 of	 fluorescently	 tagged	 inositol	 phosphates	 as	
probes	 for	 use	 in	 fluorescence	 polarisation	 binding	 assays	 to	 investigate	 the	 binding	
affinities	of	SHIP1cd,	SHIP2cd	and	AtIPK1	for	various	ligands	and	inhibitors	(see	table	4.1	
for	 structures).	 Like	 the	 benzene	 and	 biphenyl	 phosphates	 they	 were	 obtained	 from	
collaborators	at	the	University	of	Bath	(Potter,	B.V.L).	One	of	these	is	an	analogue	of	IP3	
with	a	fluorescein	5-isothiocyanate	(FITC)	at	the	2-position	of	the	inositol	ring	attached	
via	a	short	linker	(2-FITC-IP3),	and	was	used	in	similar	fluorescence	polarisation	assays	to	
those	in	this	study	to	investigate	the	IP3	binding	core	and	conformational	changes	in	the	
N-terminus	 of	 IP3	 receptors,	 which	 are	 intracellular	 Ca2+	 channels	 (Ding	 et	 al.,	 2010).	
Another	 study	 has	 used	 IP5	 conjugated	 at	 the	 2-position	 with	 5-carboxyfluorescein	
(FAM)	 to	yield	2-FAM-IP5,	 the	probe	utilised	most	 frequently	 in	 this	work	 (Riley	et	al.,	
2014).	It	was	used	to	visualise	the	internal	visualisation	of	inositol	phosphates	by	H1229	
tumour	 cells.	 Most	 recently,	 2-FAM-IP5	 has	 been	 used	 to	 investigate	 the	 binding	 of	
inositol	phosphates,	and	subsequent	activation,	 to	the	HDAC3:SMRT	complex	which	 is	
newly	understood	to	be	regulated	by	certain	inositol	phosphate	stereoisomers	(Watson	
et	al.,	2016).	
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4.1.3	–	Fluorescence	polarisation		
Fluorescence	polarisation	(FP)	provides	one	means	of	examining	ligand	binding.	When	a	
rigid	fluorophore	is	excited	by	plane-polarised	light,	and	it	remains	immobile	during	its	
fluorescence	 lifetime,	 60%	 of	 the	 emitted	 light	 will	 be	 detected	 in	 the	 plane	 of	 the	
exciting	 light,	 and	 the	 anisotropy	will	 be	 0.4.	 The	 relationship	 between	 anisotropy	 (r)	
and	the	angle	(q)	of	an	oriented	fluorophore	is	shown	by	equation	4.1.	
	
r	=	(3<cos2θ>	-	1	)	/	2	 	 	 	 											(Eq.	4.1)	
	
If	a	single	fluorophore	is	oriented	in	a	single	direction	θ	=	0	and	r	=	1.	However	it	is	not	
possible	to	obtain	a	perfectly	oriented	excited-state	population	so	r	is	always	less	than	
1.	 If	 the	 molecule	 rotates	 during	 its	 fluorescence	 lifetime,	 less	 emitted	 light	 will	 be	
aligned	with	the	excitation	plane,	and	r	will	be	<	0.4.	Anisotropy	measurements	reveal	
the	average	angular	displacement	of	 the	 fluorophore	 that	occurs	between	absorption	
and	emission	of	a	photon.	The	 rate	of	 tumbling	 is	 inversely	proportional	 to	molecular	
volume,	therefore	binding	of	a	small	fluorescent	probe	to	a	much	larger	protein	would	
increase	 anisotropy.	 FP	 measures	 this	 change	 in	 anisotropy	 as	 a	 fluorescent	 ligand	
binds.	 It	 thereby	allows	non-destructive	quantification	of	binding	without	 the	need	 to	
separate	bound	 from	 free	 ligand,	 and	 is	 calculated	using	 equation	4.2.	 It	 is	 useful	 for	
measurement	 of	 low-affinity	 interactions	 in	 which	 rapid	 ligand	 dissociation	 during	
separation	of	bound	and	free	ligand	compromises	analysis.	Additional	advantages	of	FP	
include	 the	 opportunity	 to	 make	 many	 measurements	 from	 the	 same	 sample	 under	
different	 conditions,	 cost-effectiveness,	 applicability	 to	 high-throughput	 analyses,	 and	
avoidance	of	radio	ligands	(Ding	et	al.,	2010).		
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4.1.4	Experimental	aims	
	
Upon	discovery	of	the	fluorescent	properties	of	the	benzene-	and	biphenyl-	phosphates,	
it	 was	 necessary	 to	 characterise	 them	 further	 and	 define	 their	 optimal	 absorption	
wavelengths,	and	excitation	and	emission	maxima	for	fluorescence	measurements.		
	
As	one	of	these	compounds	has	been	reported	as	a	substrate	of	5-phosphatases,	and	in	
light	of	the	structures	of	5-phosphatases	(section	1.1.3	&	2.1),	the	biphenyl	phosphates	
were	tested	as	substrates	in	both	end-point	and	real-time	kinetic	assays	by	utilisation	of	
changes	in	their	absorbance	and	novel	fluorescent	properties.		
	
Further	to	this,	attempts	were	made	to	characterise	the	binding	of	canonical	substrates,	
known	inhibitors	and	the	biphenyl	phosphates	to	SHIP1cd,	SHIP2cd	and	AtIPK1,	by	use	
of	a	fluorescence	polarisation	method	that	that	utilises	inositol	phosphates	conjugated	
to	fluorescent	moieties	as	novel	analogues.		
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4.2	Materials	&	methods	
	
4.2.1	UV	absorbance	wave	scans	
UV	 absorbance	 spectra	 between	 250	 –	 330	 nm	 of	 the	 benzene-	 and	 biphenyl-	
phosphates	were	performed	on	a	Hidex	Sense	multimodal	microplate	reader	using	a	96-
well	quartz	glass	plate	(Molecular	Devices).	Well	volume	was	40	µL,	and	each	compound	
at	100	µM	in	20	mM	HEPES	pH	7.3,	1	mM	MgCl2.		
	
4.2.2	Fluorescence	intensity		
Using	 a	 Hidex	 Sense	 multimodal	 microplate	 reader,	 and	 in	 a	 384	 well	 Corning	 low	
volume	black	flat	bottomed	polystyrene	plate,	finite	fluorescence	intensity	readings	of	
100	µM	benzene-	and	biphenyl-	phosphates	in	20	mM	HEPES	pH	7.3,	1	mM	MgCl2	were	
taken.	For	 the	excitation,	 filters	used	were;	265±25,	280±10,	and	289±10	nm.	And	 for	
emission,	340±80	nm.	Well	volume	was	20	µL.	
	
4.2.3	 Biphenyl	 phosphate	 anion	 exchange	 chromatography	 assays;	 SHIP1cd	 and	
SHIP2cd	
	
4.2.3a	Preliminary	assays	
Assays	of	1	µM	SHIP2cd	and	5	µM	biphenyl	phosphate	were	set	up	in	100	µL	reaction	
volumes	in	20	mM	HEPES	pH	7.3,	1	mM	MgCl2.	Samples	were	injected	on	to	the	column	
immediately	and	after	overnight	incubation	at	18	°C.	
	
Biphenyl	 phosphates	 and	 their	 reaction	 products	 from	 reaction	 with	 SHIP2cd	 were	
separated	 by	 anion	 exchange	 chromatography	 on	 a	 2mm	 x	 250	 mm	 IonPac	 AS11	
column,	with	2	mm	x	50	mm	AG11	guard	column,	eluted	with	NaOH.	The	column	was	
eluted	at	a	flow	rate	of	0.5	mL	/	min	according	to	the	following	gradient:	time	(min),	%	B	
(225	mM	NaOH);	 0,0;	 20,100;	 21,0;	 30,0.	 Samples	 (25	µL	 volume)	were	 injected	 by	 a	
Thermo	Separation	Products	AS3500	autosampler	and	peaks	were	monitored	either	by	
tandem	fluorescence	and	suppressed	ion	conductivity	detection,	or	by	tandem	UV	and	
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fluorescence	detection.	The	fluorescence	detector	(Jasco	FP-920)	was	set	at	270/10	nm	
excitation/band	 width;	 330/10	 nm	 emission/bandwidth	 and	 gain	 (photomultiplier	
voltage)	 setting	 of	 10.	 The	UV	 detector	 (Dionex	 AD20)	was	 set	 at	 270	 nm,	while	 the	
conductivity	detector	was	set	at	range	300	µS	with	100	mA	current	on	the	Dionex	4	mm	
ASRS-1	suppressor.	
	
4.2.3b	Complete	assays	
Assays	of	1	µM	SHIP2cd	and	5	µM	biphenyl	phosphate	were	set	up	in	200	µL	reaction	
volumes	in	20	mM	HEPES	pH	7.3,	1	mM	MgCl2.	Samples	were	injected	on	to	the	column	
immediately,	 then	 after	 incubation	 at	 37	 °C	 	 for;	 15,	 30,	 60	 and	 120	 min.	 Before	
injection,	 samples	 were	 diluted	 to	 0.2	 µM	 biphenyl	 phosphate	 with	 analytical	 grade	
water	and	boiled	for	1	min	to	terminate	the	reaction.	
	
Biphenyl	 phosphates	 and	 their	 reaction	 products	 from	 reaction	 with	 SHIP1	 or	 SHIP2	
were	separated	by	anion	exchange	chromatography	on	a	2	mm	x	250	mm	IonPac	AS11	
column,	with	2	mm	x	50	mm	AG11	guard	column,	eluted	with	NaOH.	The	column	was	
eluted	at	a	flow	rate	of	0.4	mL	/	min	according	to	the	following	gradient:	time	(min),	%	B	
(225	mM	NaOH);	 0,0;	 20,100;	 21,0;	 30,	 0.	 Samples	 (50	 µL	 volume)	 were	 injected	 by	
Jasco	 AS-950	 autosampler	 and	 peaks	 were	 monitored	 either	 at	 265/10	 nm	
excitation/band	 width;	 340/10	 nm	 emission/bandwidth;	 or	 285/10	 nm	
excitation/bandwidth,	340/10	nm	emission/bandwidth,	 in	a	 Jasco	FP-920	 fluorescence	
detector	at	a	gain	(photomultiplier	voltage)	setting	of	100.		
	
4.2.4	Kinetic	assays	with	the	biphenyl	polyphosphates	
A	 Corning	 96	 well	 half-area	 black	 polystyrene	 flat	 bottom	 plate	 was	 used	 with	 a	
Molecular	 devices	 SpectraMax	 M5	 plate	 reader.	 Reactions	 were	 followed	 at	 an	
excitation	wavelength	of	265	nm	and	emission	of	285	nm,	reading	every	5	seconds	for	
20	min.	Total	reaction	volume	was	100	µL,	and	were	started	by	addition	of	50	µL	of	the	
specified	concentration	of	biphenyl	phosphate	to	2	µM	SHIP2cd.	
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4.2.5	Fluorescence	polarisation;	dose-response	binding	and	inhibition	curves	
Polarisation	binding	assays	were	carried	out	 in	384	well	Corning	 low	volume	black	flat	
bottomed	polystyrene	plate	on	a	Clariostar	(BMG	LabTech,	Germany)	plate	reader	with	
excitation	at	485±5nm	and	emission	at	520±5nm.	For	saturation	curves,	2	nM	2-FAM-IP5	
in	 20	 mM	 HEPES	 pH	 7.3	 1mM	 MgCl2,	 was	 incubated	 with	 increasing	 protein	
concentrations	(up	to	2.5	µM).	Aliquots	(20	µL)	were	dispensed	 in	quadruplicate	wells	
and	 polarisation	 of	 the	 probe	 was	 measured	 at	 25°C.	 All	 data	 was	 averaged	 and	
analysed	by	a	4-parameter	fit	using	GraphPad	Prism	6	software	allowing	dose-response	
curves	to	be	constructed	and	EC50	values	to	be	obtained.	
Similarly,	 for	 inhibition	 assays,	 inhibitor	 (10	 nM-100	µM)	was	 titrated	 against	 AtIPK1,	
SHIP2cd	 or	 SHIP1cd	 protein	 at	 200	 nM	and	 2	 nM	2-FAM-IP5	with	 assay	 conditions	 as	
otherwise	described	above.	
	
	
	
	
	 	
Chapter	4	–	Novel	fluorescent	properties	of	the	benzene-	and	biphenyl-	polyphosphates,	and	the	use	of	
fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	
120	
	
	
4.3	Results	&	Discussion	
4.3.1	 UV	 absorbance	 and	 fluorescence	 properties	 of	 the	 biphenyl	 and	 benzene	
polyphosphates	
As	 discussed	 previously	 (section	 1.1.3	 &	 4.1.1),	 benzene	 1,2,4,5-tetrakisphosphate	
(Bz(1,2,4,5)P4	 /	 Bz3)	was	 designed,	 along	with	 six	 additional	 benzene	 polyphosphates	
and	four	biphenyl	polyphosphates,	as	a	simple	 inositol	phosphate	analogue	which	can	
been	exploited	as	novel	ligand	and	inhibitor	of	inositol	phosphate	metabolising	enzymes	
(Mills	et	al.,	2008).	 In	a	previous	assay	which	 followed	 the	conformational	 changes	of	
AtIPK1	by	monitoring	 its	 intrinsic	tryptophan	fluorescence	upon	ligand	binding	(results	
not	shown),	 it	became	apparent	 that	Bz3	exhibited	 its	own	fluorescence	properties	at	
similar	excitation	and	emission	wavelengths	to	tryptophan.	Before	further	exploring	the	
fluorescence	properties	of	 this	 inositol	phosphate	mimic,	 it	was	deemed	necessary	 to	
first	 investigate	 the	 UV	 absorbance	 properties	 of	 both	 the	 benzene	 and	 biphenyl	
phosphates	(Figure	4.1).	lmax	for	the	biphenyl	phosphates	are	summarised	in	table	4.1.	
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Figure	4.1	–	UV	absorbance	wave	scans	of	100	μM	biphenyl	phosphate	and	benzene	phosphate	in	a	96-well	quartz		
plate.	
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Table	4.1	–	UV	absorbance	lmax	of	100	μM	biphenyl	phosphate	
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Wavelength	scans	 in	a	96-well	quartz	plate	revealed	the	biphenyl	polyphosphates	had	
stronger	 UV	 absorption	 properties	 between	 250	 –	 330	 nm	 than	 the	 benzene	
polyphosphates	(Figure	4.1).	All	the	compounds	displayed	distinctive	profiles	with	clear	
differences	 in	 absorption	 maxima.	 Some	 compounds	 showed	 very	 weak	 absorption	
between	these	wavelengths,	with	biphenyl	2,3’,4,5’,6-pentakisphosphate	(BiPh1)	being	
the	weakest	 absorbing	 of	 the	 biphenyl	 phosphates,	 exhibiting	 no	 obvious	 peak	 in	 its	
absorbance	 spectra	 (Figure	 4.1	 -A).	However,	 it	 is	 evident	 that	 BiPh1	displays	 a	 small	
absorption	peak	around	250	nm.	Biphenyl	3,3’,4,4’,5,5’-hexakisphsphate	(BiPh3)	has	the	
highest	 absorbance	 between	 these	wavelengths	with	 a	 peak	maxima	 at	 266	 nm.	 For	
biphenyl	 2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2)	 and	 6,6’-difluorobiphenyl	 3,3’,4,4’-
tetrakisphosphate	 (BiPh4),	 absorption	 maxima	 occur	 at	 approximately	 285	 nm.	 The	
adjacent	positioning	of	the	phosphate	substituents	in	BiPh3	may	impact	on	the	rotation	
around	the	diaryl	bond	thus	effecting	electron	conjugation	between	the	two	equivalent	
aryl	rings,	and	could	offer	explanation	for	the	altered	and	more	prominent	absorption	
maxima	when	compared	to	the	other	biphenyl	compounds.		
	
Although	the	benzene	phosphates	are	generally	 less	absorbent,	 there	are	still	marked	
differences	 in	 their	 spectra;	 benzene	 1,2,4-trisphosphate	 (Bz(1,2,4)P3	 /	 Bz5)	 has	 the	
highest	absorbance	of	 the	benzene	phosphates	with	a	strong	absorbance	peak	at	275	
nm,	 whereas	 others	 such	 as	 Bz3	 are	 far	 less	 UV	 absorbent	 and	 have	 differing	
absorbance	maxima	(Figure	4.1	-B).	An	absorbance	peak	for	Bz3	occurs	at	279	nm.	Many	
have	higher	absorbance	at	260	nm,	but	this	is	common	to	the	absorbance	spectra	of	all	
the	 compounds.	 Visually,	 it	 is	 clear	 from	 looking	 at	 the	 spectra	 of	 the	 benzene	
polyphosphates	that	those	with	significant	absorbance	peaks,	have	maxima	occurring	at	
a	wavelength	longer	than	260	nm.		
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As	 the	 majority	 of	 the	 biphenyl	 polyphosphates	 displayed	 large	 peaks	 in	 their	 UV	
absorbance	 spectra,	 their	 fluorescence	 properties	 were	 subsequently	 investigated	
(Figure	4.2).		
	
Using	a	black	384-well	plate	and	a	plate	reader	with	fixed	fluorescence	filter	sets,	results	
agreeably	 showed	 that	 the	 BiPh’s	 did	 indeed	 possess	 fluorescent	 properties	 and	 the	
most	 appropriate	 emission	 wavelength	 to	 utilise	 this	 was	 340	 nm.	 After	 fixing	 the	
emission	wavelength,	 their	 fluorescence	 intensity	at	 three	excitation	wavelengths	was	
explored,	resulting	in	the	highest	 intensities	being	seen	at	an	excitation	wavelength	of	
265	nm	(Figure	4.2).	BiPh3	and	BiPh4	were	also	strongly	fluorescent	at	280	and	289	nm,	
and	overall	are	the	most	fluorescent	across	all	investigations.	Albeit	weak	in	comparison	
to	BiPh3	and	BiPh4,	BiPh1	and	BiPh2	both	display	fluorescent	properties	when	excited	
at	265	nm,	with	BiPh2	also	emitting	when	excited	at	280	nm.	Therefore	consideration	
must	be	given	to	selecting	the	most	appropriate	compound	when	wishing	to	exploit	the	
fluorescent	properties	of	these	inositol	phosphate	mimics	in	further	investigations.	
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Figure	4.2	–	Fluorescence	properties	of	100	μM	biphenyl	phosphates.	 Intensity	readings	at	emission	wavelength	
340	nm.	Values	are	corrected	against	the	background	signal	from	the	buffer.	
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In	 a	 different	 manner	 using	 a	 fluorimeter	 and	 quartz	 cuvette	 method,	 involving	
collecting	 excitation	 and	 emission	 spectra	 rather	 than	 single	 finite	 readings,	 the	
fluorescence	properties	of	the	benzene	polyphosphates	were	investigated	(Figure	4.3).	
Most	of	the	Bz’s	were	weakly	fluorescent	bar	Bz3	and	Bz5,	which	displayed	fluorescence	
maxima	at	an	excitation	wavelength	of	275	nm	(Figure	4.3	–A)	and	emission	wavelength	
of	310	nm	(Figure	4.3–	B).	Both	the	excitation	and	emission	peaks	for	Bz3	and	Bz5	are	
wide	 in	 nature	 and	 span	 a	 broad	 range	 of	 wavelengths,	 therefore	 expanding	 the	
wavelengths	at	which	 these	 compounds	 could	be	utilised	 in	 further	 studies	exploiting	
their	novel	spectral	properties	as	inositol	polyphosphate	surrogates.	
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Figure	 4.3	 –	 Fluorescence	 wave	 scans	 of	 100	 μM	 benzene	 polyphosphate	 (A)	 Excitation	 spectra	 at	 a	 fixed	 an	
emission	wavelength	 of	 310	 nm.	 (B)	 Emission	 spectra	 fixed	 at	 an	 excitation	wavelength	 of	 275	 nm.	 Spectra	 are	
corrected	for	against	buffer	background	signal.	
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Following	on	from	this,	the	same	methodology	used	to	investigate	the	fluorescence	of	
the	biphenyl	phosphates	was	applied	to	Bz3	and	Bz5	to	supplement	the	data	 in	figure	
4.3,	 and	 provides	 a	 more	 direct	 comparison	 to	 the	 BiPh’s	 (Figure	 4.4).	 Investigation	
under	 this	method	using	discreet	 filter	 sets	 at	 fixed	wavelengths	 revealed	 that	 unlike	
the	 BiPh’s,	 Bz3	 and	 Bz5	 exhibited	 low	 fluorescence	 intensities	 at	 an	 excitation	
wavelength	 of	 265	 nm	 and	 emission	 340	 nm.	 The	 most	 favourable	 excitation	
wavelength	was	280	nm	for	both	compounds.	Bz5	proved	to	be	the	most	fluorescent	at	
this	wavelength,	closely	followed	by	exciting	at	289	nm	whereas	Bz3	exhibited	a	much	
lower	emission	exciting	at	289	nm.	
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Figure	 4.4	 -	 Fluorescence	 properties	 of	 100	 μM	 benzene	 polyphosphates.	 Intensity	 readings	 at	 a	 fixed	 emission	
wavelength	of	340	nm.	Values	are	corrected	against	the	background	signal	from	the	buffer.	Only	benzene	1,2,4,5-
tetrakisphosphate	 (Bz3)	 &	 benzene	 1,2,4-trisphosphate	 (Bz5)	 are	 shown,	 since	 only	 they	 possess	 fluorescent	
properties	at	these	wavelengths.	
Chapter	4	–	Novel	fluorescent	properties	of	the	benzene-	and	biphenyl-	polyphosphates,	and	the	use	of	
fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	
127	
	
	
Currently,	 only	 empirical	 observations	 can	 be	 made	 when	 considering	 why	 these	
compounds	are	fluorescent.	As	has	been	seen,	some	are	more	fluorescent	than	others,	
which	 can	 likely	 be	 attributed	 to	 the	 different	 positioning	 of	 the	 phosphate	 groups	
around	the	benzene	rings.	Looking	forward,	efforts	are	focussing	on	collaboration	with	
physical	computational	chemists	to	elucidate	the	features	of	these	compounds	that	give	
them	 these	 unique	 spectral	 properties.	 Eventually,	 this	 may	 shed	 light	 on	 which	
hypothetical	 products	 of	 the	 turnover	 of	 these	 compounds	 would	 also	 have	 UV	 and	
fluorescent	properties	and	 in	 turn	would	hopefully	allow	them	to	be	 identified	during	
assays.	
	
Despite	 having	 been	 widely	 utilised	 as	 simple	 inositol	 polyphosphate	 surrogates	 in	
inhibition	and	structural	studies	(Mills	et	al.,	2008,	Mills	et	al.,	2012,	Mills	et	al.,	2016),	
formally	the	spectral	properties	of	these	compounds	have	been	left	undiscovered	until	
recently	 and	 these	 results	 are	 yet	 to	 be	 published.	 The	 unearthing	 of	 these	 novel	
properties	opens	up	new	opportunities	to	exploit	these	compounds	in	enzymatic	assays,	
where	 they	 would	 help	 interpret	 the	 catalytic	 scope	 and	 activity	 of	 inositol	
polyphosphate	metabolising	enzymes.	
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4.3.2	Biphenyl	polyphosphates	are	substrates	of	SHIP1	and	SHIP2	
As	 widely	 introduced	 previously,	 the	 biphenyl	 phosphates	 have	 been	 reported	 as	
inhibitors	of	the	inositol	polyphosphate	5-phosphatases,	including	SHIP2	for	which	there	
is	 also	 an	 available	 structure	 of	 the	 complex	 formed	 with	 biphenyl	 2,3’,4,5’,6-
tetrakisposphate	 (BiPh1)	 (Mills	 et	 al.,	 2012).	 Currently	 there	 has	 been	 no	 reports	 of	
BiPhs	as	substrates	against	the	proteins	that	have	been	demonstrated	to	accommodate	
them	 in	 their	 active	 sites.	 Characterisation	 solely	 as	 inhibitors	 of	 inositol	 phosphate	
phosphatases	has	been	described	with	no	reports	testing	for	catalytic	activity.	However,	
3-hydroxybenzene	 1,2,4-trisphosphate	 (Bz7)	 is	 an	 example	 of	 a	 simpler	 single	 ringed	
inositol	 phosphate	mimic	 (Table	1.1)	 that	has	been	 reported	as	 a	 substrate	 for	 type	 I	
Ins(1,4,5)P3	5-phosphatase	(INPP5A),	 in	which	 its	2-phosphate	 is	 removed	(Mills	et	al.,	
2006).	It	is	then	not	an	unreasonable	hypothesis	that	the	biphenyl	phosphates	may	also	
substitute	as	substrate	mimics	of	inositol	polyphosphate	5-phosphatases.	
	
As	 a	 preliminary	 assay	 to	 investigate	 if	 the	 biphenyl	 polyphosphates	 could	 indeed	 be	
substrates	 of	 SHIP1	 and	 SHIP2,	 SHIP2cd	 protein	 was	 incubated	 with	 biphenyl	
2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2)	 and	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	
(BiPh3)	overnight,	and	the	products	analysed	by	 ion	exchange	chromatography.	Three	
detection	 methods	 in	 series	 were	 used	 visualise	 the	 disappearance	 of	 BiPh2,	 and	 to	
monitor	 to	 the	 appearance	 of	 any	 products	 of	 the	 reaction	 which	 may	 or	 may	 not	
exhibit	 spectral	 properties	 like	 the	 parent	 compound.	 Despite	 using	UV,	 fluorescence	
and	 conductivity	 detectors,	 it	 cannot	 be	 guaranteed	 that	 new	 products	 would	 be	
detected,	as	the	detectors	were	set	to	fixed	wavelengths	and	new	products	are	likely	to	
have	different	spectral	properties,	 if	any	at	all,	due	to	the	removal	of	phosphate	from	
the	biphenyl	rings.	
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Reaction	products	were	separated	by	ion	exchange	chromatography	with	a	gradient	of	
225	mM	NaOH	 over	 20	min.	 Detection	 of	 BiPh2,	 in	 Figure	 4.5	 –	 A,	 was	 achieved	 by	
monitoring	 the	UV	absorbance	of	 the	column	eluent	at	270	nm.	 In	 the	overlay	of	 the	
reactions,	a	peak	of	UV	absorbing	material	can	be	seen	eluting	at	approximately	14	min,	
which	 has	 then	 disappeared	 after	 overnight	 incubation	 with	 SHIP2cd.	 This	 peak	 was	
confirmed	 as	 that	 of	 BiPh2	 by	 spiking	 the	 sample	 with	 a	 standard	 of	 BiPh2.	 The	
disappearance	of	BiPh2	 is	accompanied	by	 the	appearance	of	a	 series	of	peaks	of	UV	
absorbance	 eluting	 between	 5	 and	 12	 min,	 and	 an	 additional	 peak	 eluting	 after	 the	
parent	material.	 In	 the	absence	of	partially	dephosphorylated	BiPhs	as	 standards,	 it	 is	
not	possible	to	identify	the	products.	Nevertheless,	it	is	compelling	evidence	that	BiPh2	
is	a	substrate	of	SHIP2	and	that	several	UV	absorbing	turnover	products	are	generated.	
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Figure	 4.5	 –	 SHIP2cd	 vs.	 biphenyl	 2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2).	 Detection	 of	 reaction	 products	 by;	 (A)	
Absorbance	at	270	nm	(B)	Fluorescence	at	ex	270	nm,	em	330	nm	(C)	Suppressed	ion	conductivity,	left	to	right	the	
arrows	indicate	peaks	of	inorganic	phosphate	and	biphenyl(2,2’,4,4’,5,5’)P6,	respectively.	The	structure	of	BiPh2	is	
shown	in	the	top	right.	
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A	more	sensitive	method	of	detection	is	offered	by	monitoring	the	fluorescence	of	the	
column	 eluent	 at	 excitation	 of	 270	 nm	 and	 emission	 330	 nm,	 and	 produces	 a	much	
clearer	trace	(Figure	4.5	-	B).	A	fluorescence	peak	of	BiPh2	can	be	seen	at	approximately	
14	min,	 in	agreement	with	the	UV	trace,	and	again	 is	completely	diminished	after	 the	
overnight	 incubation.	 The	 appearance	 of	 new	 fluorescence	 peaks	 after	 incubation	 is	
observed	but	none	appear	to	elute	in	clear	agreement	with	the	UV	absorbing	peaks	in	
panel	 A.	 This	 suggests	 that	 some	 detectable	 products	 from	 the	 dephosphorylation	 of	
BiPh2	maintain	UV	properties,	but	lose	fluorescent	properties	at	these	wavelengths.	Or	
alternatively,	display	weak	UV	absorption	but	remain	detectable	by	fluorescence,	these	
properties	 are	 observed	 with	 with	 Bz3	 (Figure	 4.1	 &	 4.3).	 Again,	 in	 the	 absence	 of	
metabolites	of	BiPh2	by	SHIP2	 it	 is	unclear	what	 the	products	could	be	and	 therefore	
why	 they	 wouldn’t	 exhibit	 fluorescent	 properties.	 Investigations	 are	 hindered	 by	 the	
lack	of	information	about	which	and	how	many	phosphates	are	being	removed.	
	
Panel	 C	 of	 Figure	 4.5	 Shows	 the	 detection	 of	 reaction	 products	 monitored	 by	
suppressed	 ion	 conductivity.	 The	 steep	 gradient	 of	 the	 baseline	 is	 a	 result	 of	 the	
increased	conductivity	by	 the	gradient	of	 the	NaOH	solvent;	 therefore	 it	 is	not	wholly	
suppressed.	Again	a	peak	was	detected	at	approximately	14	min	and	had	disappeared	
after	 overnight	 incubation,	 supporting	 the	 turnover	 of	 BiPh2	 by	 SHIP2.	 A	 peak	 at	
approximately	6.5	min	 increased	 in	area	after	overnight	 incubation	with	SHIP2cd,	and	
corresponds	to	an	accumulation	of	inorganic	phosphate,	likely	liberated	from	BiPh2.		
	
Under	 the	 same	 conditions,	 the	 assay	 was	 carried	 out	 with	 an	 additional	 biphenyl	
polyphosphate;	BiPh3,	and	analysed	by	the	same	anion	exchange	method	(Figure	4.6).	
With	 all	 three	 detection	methods,	 the	 peak	 corresponding	 to	 BiPh3	 had	 disappeared	
after	the	overnight	incubation.	The	peaks	were	detected	at	the	same	retention	time	as	
BiPh2,	perhaps	not	surprising	as	they	possess	the	same	number	of	phosphates,	albeit	in	
different	 positions.	 No	 new	UV	 absorbing	metabolites	 of	 BiPh3	were	 visibly	 detected	
from	the	column	eluent,	unlike	for	BiPh2	(Figure	4.6	-	A).	 	
Chapter	4	–	Novel	fluorescent	properties	of	the	benzene-	and	biphenyl-	polyphosphates,	and	the	use	of	
fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	
132	
	
	
	 	
0 5 10 15 20
4.5×10⁴
5.0×10⁴
5.5×10⁴
6.0×10⁴
6.5×10⁴
Reten.on0.me0(min)
Ab
so
rb
an
ce
0 min
O/N
0 5 10 15 20
0
2000
4000
6000
8000
10000
12000
Reten.on0.me0(min)
Fl
uo
re
sc
en
ce
0(R
.F
.U
.)
0 min
O/N
0 5 10 15 20
1.0×10⁴
1.2×10⁴
1.4×10⁴
Reten.on0.me0(min)
Co
nd
uc
.v
ity
0 min
O/N
A
B
C
Figure	 4.6	 –	 SHIP2cd	 vs.	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	 (BiPh3).	 Detection	 of	 reaction	 products	 by;	 (A)	
Absorbance	at	270	nm	(B)	Fluorescence	at	ex	270	nm,	em	330	nm	(C)	Suppressed	ion	conductivity,	left	to	right	the	
arrows	indicate	peaks	of	inorganic	phosphate	and	biphenyl(3,3’,4,4’,5,5’)P6,	respectively.	
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Similarly,	 there	 also	 was	 no	 new	 fluorescent	 products	 of	 BiPh3	 dephosphorylation	
detected	(Figure	4.6-	B).	Fluorescence	is	a	very	sensitive	detection	method	for	BiPh3	as	
it	gives	a	stronger	detector	response	when	compared	to	BiPh2,	approximately	10000	to	
3200	R.F.U.,	respectively.	This	is	in	agreement	with	the	study	of	their	spectral	properties	
in	section	4.3.1,	where	BiPh3	was	found	to	be	far	more	fluorescent	than	BiPh2	at	those	
wavelengths	tested.	Nevertheless,	fluorescence	is	by	far	the	most	sensitive	method	for	
detecting	both	BiPh2	and	BiPh3	in	these	types	of	assays.	
	
Again,	the	peak	corresponding	to	the	accumulation	of	inorganic	phosphate	increased	in	
area	(Figure	4.6	 -	C).	Though	no	new	products	of	BiPh3	metabolism	were	detected	by	
these	methods,	 it	 can	 still	 be	assumed	 that	BiPh3	 is	 a	 substrate	 for	 SHIP2	due	 to	 the	
observed	loss	of	the	UV,	fluorescence	and	conductivity	peaks.	Additionally,	the	area	of	
the	 inorganic	 phosphate	 peak	 increased	 post	 incubation	 of	 BiPh3	 with	 SHIP2cd,	
suggesting	an	accumulation	of	phosphate	liberated	by	SHIP2cd	from	Biph3.	
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As	fluorescence	was	to	be	the	most	sensitive,	and	therefore	the	most	suitable	method	
for	monitoring	 the	biphenyl	polyphosphates,	 further	 investigations	 in	 to	 the	BiPh’s	 as	
substrates	 of	 both	 SHIP1cd	 and	 SHIP2cd	were	 performed	 based	 on	 this	 fluorescence	
method.	Assays	were	set	up	with	either	SHIP1cd	or	SHIP2cd,	and	with	each	of	the	four	
available	 biphenyl	 compounds.	 The	 reactions	were	 stopped	 at	 distinct	 time	points	 by	
diluting	and	boiling	the	sample	for	1	min,	before	injection	on	to	an	ion	exchange	column	
for	analysis.	The	two	assays	presented	in	Figure	4.7	&	4.8	represent	the	most	efficient	
turnover	 of	 a	 biphenyl	 polyphosphate	 by	 each	 of	 these	 enzymes,	 as	 summarised	 in	
figure	4.9	and	discussed	in	due	course.	
	
Figure	 4.7	 shows	 the	 disappearance	 of	 a	 fluorescence	 peak	 of	 BiPh2	 eluting	 at	
approximately	17	min	over	a	 time	course	of	120	minutes	 in	 the	presence	of	SHIP2cd.	
The	peak	of	biphenyl	2,2’,4,4’,5,5’-hexakisphosphate	(BiPh2)	decreases	 in	area	by	30.4	
%	in	the	initial	15	min	of	the	reaction.	After	120	min,	the	peak	area	had	decreased	by	a	
total	of	80.9	%,	confirming	that	BiPh2	is	a	substrate	for	SHIP2.	
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Figure	4.7	–	Turnover	of	biphenyl	2,2’,4,4’,5,5’-hexakisphosphate	(BiPh2)	by	SHIP2cd	analysed	by	anion	exchange	
chromatography.	Elution	of	BiPh2	from	the	column	was	detected	by	fluorescence	at	λex	=	285	nm	λem	=	330	nm.	
Inset	in	the	top	right	is	a	progress	of	reaction	curve	for	the	assay	and	the	structure	of	BiPh2	below.	
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The	 SHIP1cd	protein	was	 able	 to	hydrolyse	33.5	%	of	 the	 total	 biphenyl	 3,3’,4,4’,5,5’-
hexakisphosphate	(BiPh3)	in	the	first	15	minutes	of	the	reaction	(Figure	4.8).	By	the	end	
of	the	120	min	assay,	96.6	%	of	the	total	BiPh3	had	been	turnover	by	SHIP1cd,	therefore	
this	reaction	is	marginally	faster	than	the	one	between	SHIP2cd	and	BiPh2.	
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Figure	4.8	–	Turnover	of	biphenyl	3,3’,4,4’,5,5’-hexakisphosphate	(BiPh3)	by	SHIP1cd	analysed	by	anion	exchange	
chromatography.	Elution	of	BiPh3	from	the	column	was	detected	by	fluorescence	at	λex	=	285	nm	λem	=	330	nm.	
Inset	in	the	top	right	is	a	progress	of	reaction	curve	for	the	assay	and	the	structure	of	BiPh3	below.	
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The	two	assays	presented	in	Figure	4.7	&	4.8	represent	the	most	efficient	turnover	of	a	
biphenyl	polyphosphate	by	each	of	these	enzymes.	Comparing	the	progress	of	reaction	
profiles	for	all	the	biphenyl	compounds	as	substrates	corroborates	with	this,	and	reveals	
that	 the	 two	 isozymes	 may	 have	 differing	 substrate	 specificities	 (Figure	 4.9).	 Overall	
SHIP1cd	was	more	active	towards	these	substrate	mimics	than	SHIP2cd,	where	all	four	
compounds	were	hydrolysed	by	at	least	60	%	on	completion	of	the	assay.	In	the	case	of	
SHIP2cd,	 only	 the	 reaction	with	 BiPh2	 progressed	 to	 this	 extent.	 No	 enzyme	 kinetics	
parameters	 can	 be	 drawn	 from	 these	 investigations	 as	 only	 single	 concentrations	 of	
enzyme	and	biphenyl	polyphosphate	were	used	 in	 this	 instance.	However,	 the	 results	
show	an	exciting	new	substrate	flexibility	of	both	SHIP1	and	SHIP2.	 	
Figure	4.9	–	Progress	of	reaction	for	the	turnover	biphenyl	phosphates	by;	(A)	SHIP1cd	(B)	SHIP2cd.	Fractional	
change	in	peak	area	(%).	
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It	is	evident	that	the	biphenyl	polyphosphates	are	useful	in	studying	the	catalytic	activity	
of	 these	proteins	by	means	of	end-point	 reactions,	but	being	able	 to	 follow	turn-over	
and	subsequent	 loss	 in	 fluorescence	 in	real-time	assays	would	offer	 further	utility	and	
convenience	 to	 investigate	 these	 enzymes,	 and	 perhaps	 other	 inositol	 polyphosphate	
phosphatases	beyond	just	SHIP1	and	SHIP2.		
	
Assays	 of	 SHIP2cd	 and	 the	 BiPh’s	 were	 performed	 in	 96-well	 black	 plates,	 with	 the	
reaction	being	 instigated	by	 the	addition	of	a	 fixed	concentration	of	SHIP2cd.	Despite	
extensive	efforts	to	collect	full	sets	of	data,	by	fine-tuning	the	method	and	making	use	
of	 numerous	 plate	 readers,	 only	 preliminary	 data	 was	 obtained.	 This	 type	 of	
instrumentation	 is	 generally	 considered	 less	 sensitive	 when	 monitoring	 fluorescence	
than	detectors	that	are	employed	with	HPLC	and	IC	systems,	which	made	it	challenging	
to	 gain	 consistent	 results	 with	 this	 method.	 Other	 parameters	 such	 as	 temperature	
were	 also	 limiting	 factors.	 Nevertheless,	 Figure	 4.10	 shows	 the	 outcome	 of	 an	 assay	
between	 SHIP2cd	 and	 BiPh3.	Where	 BiPh3	was	 chosen	 specifically	 due	 to	 having	 the	
strongest	fluorescence	characteristics	of	the	BiPhs,	thus	minimising	the	problems	with	
sensitivity	 and	 detection	 of	 the	 loss	 in	 fluorescence	 of	 these	 compounds.	 Three	
concentrations	of	BiPh3	were	tested	and	it	is	evident	that	the	loss	of	fluorescence	which	
would	inevitably	be	occurring	at	the	lower	concentrations,	albeit	at	a	slower	rate,	is	not	
observable	under	this	method,	and	only	the	higher	concentration	(10	µM)	results	 in	a	
visible	 loss	 in	 fluorescence	 in	 real-time.	 This	 is	 considerably	more	 substrate	 than	was	
required	in	the	assay	in	Figures	4.7	&	4.8,	 in	which	the	method	was	able	to	detect	0.2	
µM	BiPh3	injection	on	to	a	column	(50	µL),	and	therefore	presents	another	limitation	to	
this	method.	
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Linear	regression	was	performed	on	the	kinetics	data	which	gave	gradients	equivalent	
to	the	rate	of	reaction	(∆F.I.	/	∆time	(s)).	As	 formerly	mentioned,	there	was	very	 little	
detectable	difference	 in	 the	reaction	rate	between	the	assay	conducted	at	0.1	µM,	to	
that	conducted	10-fold	higher	at	1	µM.	The	reaction	rates	were	essentially	undetectable	
or	too	slow	for	the	time	course	of	the	assay.	The	assay	performed	at	10	µM	resulted	in	a	
gradient	of	-0.52	±	0.006.	
	
Although	investigation	of	the	real-time	enzyme	kinetics	of	SHIP2cd	(and	SHIP1cd)	with	
the	BiPhs	is	desirable,	this	method	is	not	as	robust	and	reproducible	as	the	previous	ion	
chromatography	methods.	It	also	lacks	the	sensitivity	which	in	turn	leads	to	the	use	of	
much	too	high	concentrations	of	compound	and	inevitably	leads	to	wastage.	
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Figure	4.10	–	SHIP2	vs.	BiPh(3,3’,4,4’,5,5’)P6	preliminary	kinetics	data.	Loss	in	fluorescence	from	BiPh3	followed	at	
λex	=	265	nm	λem	=	330	nm.	SHIP2cd	fixed	at	1.5	μM.	
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4.3.3	 Using	 fluorescently	 tagged	 inositol	 phosphates	 to	 explore	 ligand	 binding	 by	
fluorescence	polarisation	
A	 selection	 of	 fluorescently	 tagged	 inositol	 polyphosphates	 were	 obtained	 from	
collaborators	 (Potter,	 B.V.L.;	 University	 of	 Bath,	 UK)	 and	 were	 utilised	 in	 creating	
binding	 curves	 with	 SHIP1cd,	 SHIP2cd	 and	 AtIPK1	 via	 a	 fluorescence	 polarisation	
method	 (section	 4.1	 &	 4.2.).	 The	 curves	 are	 constructed	 by	 titration	 of	 increasing	
concentrations	 of	 protein	 to	 a	 fixed	 concentration	 of	 fluorescent	 probe	 while	
monitoring	 the	 emissions	 in	 the	 perpendicular	 and	 parallel	 channels	 relative	 to	 the	
polarised	excitation	channel.	The	method	is	very	robust	and	reproducible,	and	offers	a	
high-through	put	means	 of	 conducting	 these	 types	 of	 investigations	 because	multiple	
data	sets	can	be	analysed	at	any	one	time	in	384-well	microtiter	plates.	
	
An	 EC50	 is	 related	 to	 but	 not	 equivalent	 to	 the	 disassociation	 constant	 (Kd),	 and	 is	
defined	 simply	 as	 the	 effective	 concentration	 of	 agonist	 that	 that	 provokes	 a	 half	
maximal	response;	the	concentration	required	to	bring	the	curve	to	a	half	way	point	(50	
%)	between	the	bottom	and	top	plateaus	of	the	dose-response	curve(0	and	100	%).	It	is	
regularly	 quoted	 in	 pharmacological	 studies	 when	 investigating	 the	 binding	
characteristics	of	drugs	to	proteins	and	measures	agonist	potency,	although	it	 is	not	a	
direct	measure	of	drug	affinity.	For	most	of	the	fluorescence	polarisation	dose-response	
curves	presented	in	this	study	the	bottom	baseline	was	set	to	35	mP	for	free	un-bound	
probe.	Additionally,	fluorescence	polarisation	methods	have	a	theoretical	maximum	of	
400	 mP.	 However	 these	 values	 are	 often	 not	 the	 experimental	 plateaus,	 this	 is	
recalculated	and	accounted	for	when	fitting	a	four	parameter	fit	to	the	dose-response	
curves,	which	actually	provides	what	is	referred	to	as	the	relative	EC50	but	the	adjective	
relative	 is	 usually	 omitted.	 The	 binding	 of	 SHIP2cd	 and	 AtIPK1	 to	 all	 the	 available	
fluorescent	 inositol	 phosphate	 probes	 was	 investigated,	 and	 a	 summary	 of	 the	 EC50	
values	are	shown	in	Table	4.2.	
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Table	4.2	–	Binding	of	fluorescently	tagged	inositol	phosphates	to	AtIPK1	and	SHIP2cd.		
AtIPK1 SHIP2cd
2-FAM-IP5
16.8	
±	1.11
57.2	
±	1.13
5-FAM-IP5
10.82	
±	1.06
26.51	
±	2.30	
2-FAM-IP3
302.30	
±	1.07
780.6	
±	1.06
1-FITC-IP3
68.06	
±	2.01
410.50	
±	1.12
2-FITC-IP3
67.86	
±	1.14
611.3	
±	1.04
scyllo-FITC-IP3
27.3	
±	1.12
1018	
±	2.31
EC50	(nM)
R	=	
R’	=	
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Binding	 curves	 and	 resulting	 EC50	 values	 for	 all	 three	proteins	with	 2-FAM-IP5,	which	
became	 the	most	widely	 used	 fluorescence	 polarisation	 probe	 due	 to	 being	 received	
prior	to	the	other	fluorescently	tagged	inositol	phosphates,	can	be	seen	in	Figure	4.11.	 	
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Figure	 4.11	 –	 Dose-response	 binding	 curves	 of;	 (A)	 AtIPK1,	 (B)	 SHIP1cd	 &	 (C)	 SHIP2cd	 to	 2-FAM-IP5.	 Binding	 is	
monitored	by	the	change	in	polarisation	of	2-FAM-IP5	upon	increased	concentration	of	protein,	λex	=	485,	λem	=	520.		
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AtIPK1	demonstrates	the	highest	affinity	for	2-FAM-IP5,	as	it	gave	the	lowest	EC50	value	
of	16.8	±	1.1	nM	(Figure	4.11	-	A),	when	compared	to	45.2	±	1.5	nM	and	57.2	±	1.1	nM	
for	SHIP1cd	and	SHIP2cd,	respectively.	Although	it	should	be	noted	that	these	values	are	
very	similar	with	very	low	errors	associated	with	them,	which	demonstrates	that	2-FAM-
IP5	binds	tightly	to	all	three	proteins.		
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Though	attempted,	no	structural	data	is	yet	available	for	AtIPK1,	SHIP1cd	or	SHIP2cd	in	
complex	 with	 the	 fluorescent	 tagged	 inositol	 phosphates	 therefore,	 though	 likely,	 it	
cannot	 be	 confirmed	 that	 they	 are	 binding	 in	 the	 active	 sites.	 Despite	 this,	 evidence	
from	 the	 displacement	 of	 these	 polarisation	 probes	 from	 SHIP1cd	 and	 SHIP2cd	 by	
traditional	substrates	suggests	that	they	do	indeed	bind	in	the	active	site	(Figure	4.12).	
Inhibition	 curves	 are	 produced	 using	 a	 similar	 polarisation	 method	 where	 both	 the	
probe	and	protein	concentrations	are	fixed,	 in	this	case	at	2	and	200	nM	respectively.	
The	IC50	is	calculated	in	the	same	way	as	the	EC50	by	a	four	parameter	fit	of	the	dose-
response	data,	and	is	defined	as	the	concentration	of	an	inhibitor	where	the	response	
(or	binding)	is	reduced	by	half.	IC50	curves	are	downwards	sloping	rather	than	positive	
slopes.	 Just	 like	 the	 EC50	 is	 related	 to	 Kd,	 the	 IC50	 is	 also	 indirectly	 related	 to	 the	
inhibition	 constant	 (Ki)	 and	 can	 be	 arrived	 at	 via	 use	 of	 the	 Cheng-Prusoff	 equation	
(Cheng	and	Prusoff,	1973).	
	
For	 both	 proteins,	 Ins(1,3,4,5,6)P5	 (IP5)	 displaced	 2-FAM-IP5	 more	 effectively	 than	
Ins(1,2,4,5)P4	 (IP4).	However,	displacement	by	 IP5	 in	SHIP1cd	was	more	potent	 than	 in	
SHIP2cd	with	IC50’s	of	101	±	1.3	and	4485	±	1.1	nM,	respectively.	For	SHIP1cd,	the	data	
remains	at	the	top	plateau	of	the	IP4	curve	up	to	a	higher	concentration	of	 ‘inhibitor’,	
than	with	IP5	(Figure	4.12	-	A),	also	observable	with	SHIP2cd	(Figure	4.12	-	B).			
The	graph	fitting	software	could	not	fit	a	complete	curve	to	the	IP4	/	SHIP2cd	data	and	
the	 resulting	 IC50	 is	 ambiguous	with	 a	 wide	 confidence	 interval.	 However,	 the	 value	
given	 along	 with	 a	 visual	 observation	 provides	 an	 insight	 in	 to	 the	 binding	 of	 IP4	 to	
SHIP2cd,	and	a	reference	for	comparison	to	other	substrates	or	inhibitors.	
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Figure	 4.12	 –	 Inhibition	 curves;	 Displacement	 of	 2-FAM-IP5	 by	 inositol	 1,3,4,5-tetrakisphosphate	 and	 inositol	
1,3,4,5,6-pentakisphosphate	from	(A)	SHIP1cd	&	(B)	SHIP2cd.	IC50	values	are	shown	in	black	for	displacement	with	
IP4	and	grey	for	IP5.	
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The	same	method	was	applied	using	the	biphenyl	polyphosphates,	previously	discussed	
in	detail	as	inositol	phosphate	mimics	that	act	as	ligand	analogues	and	as	substrates	of	
SHIP1cd	and	SHIP2cd	(sections	3.3.4	&	4.3.2);	backed	up	by	structural	evidence	(Mills	et	
al.,	2012).	All	four	BiPh	compounds	(Figure	1.13),	were	tested	for	their	ability	to	displace	
2-FAM-IP5	 from	 the	 active	 sites	 of	 AtIPK1,	 SHIP1cd	 and	 SHIP2cd,	 at	 fixed	 probe	 and	
protein	 concentrations	of	 2	 and	200	nM.	As	 an	example	of	 the	data	obtained,	 Figure	
4.13	 shows	 the	 results	 for	 all	 three	 proteins	 releasing	 2-FAM-IP5	 and	 simultaneously	
binding	to	biphenyl	(3,3’,4,4’5,5’)P6	(BiPh3).		
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Figure	4.13	–	Inhibition	curves;	displacement	of	2-FAM-IP5	by	biphenyl	(3,3’,4,4’,5,5’)P6	(BiPh3)	from	(A)	AtIPK1,	(B)	
SHIP1cd	&	(C)	SHIP2cd.	Protein	concentration	is	fixed	at	200	nM,	probe	at	2	nM.	
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The	probe,	2-FAM-IP5,	was	displaced	the	most	efficiently	with	BiPh3	from	SHIP1cd	with	
an	associated	IC50	of	18.4	±	2.8	nM	(Figure	4.13	-	B).	Fractionally	 lower	than	the	IC50	
values	for	AtIPK1	and	SHIP2cd	which	were	76.8	±	1.2	nM	and	30.5	±	1.1	nM.	
	
A	summary	of	the	IC50	values	for	the	displacement	from	AtIPK1,	SHIP1cd	and	SHIP2cd	
by	each	of	the	four	biphenyl	polyphosphates	can	be	seen	in	Table	4.3.	
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It	 is	 inherent	 in	 the	 interpretation	 of	 experiments	 performed	 in	 this	 and	 subsequent	
sections	 that	 2-FAM-IP5	 is	 an	 active	 site	 ligand	 of	 the	 proteins	 tested.	 For	 AtIPK1,	
chapter	3	provides	categorical	structural	data	showing	the	biphenyl	phosphates	ligands	
co-ordinate	 inositol	 phosphate-coordinating	 residues	 in	 the	 active	 site	 of	 AtIPK1.	
Furthermore,	 structures	 of	 SHIP2	 and	 an	 additional	 inositol	 5-phosphatase,	 INPP5B,	
show	 these	 surrogate	 ligands	 in	 the	 active	 site	 pocket	 coordinated	 by	 residues	 that	
interact	with	 P4	 of	 a	 canonical	 substrate	 (Mills	 et	 al.,	 2012,	Mills	 et	 al.,	 2016).	 Given	
displacement	occurs	in	all	three	proteins	it	 is	 likely	that	2-FAM-IP5	is	 indeed	binding	in	
the	 active	 site.	 Additionally,	 bona	 fide	 substrates	 were	 able	 to	 displace	 2-FAM-IP5	
(Figure	 4.12),	 inositol	 phosphates	 have	 not	 been	 shown	 to	 bind	 to	 these	 types	 of	
proteins	elsewhere	other	than	the	active	site.	
	
Despite	 high	 through	 put	 screening,	 SHIP2cd	 in	 complex	 with	 2-FAM-IP5	 failed	 to	
produce	 crystals,	 and	 due	 to	 time	 constraints	 SHIP1cd	 has	 not	 yet	 been	 subjected	 to	
crystallisation	screening.	Attempts	to	solve	crystal	structures	of	2-FAM-IP5	/	AtIPK1	did	
not	 resolve	 electron	 density	 that	 could	 be	 unambiguously	 assigned	 to	 2-FAM-IP5,	 but	
did	 suggest	 perturbations	 in	 the	 structure	 of	 N-lobe	 of	 AtIPK1,	 as	 seen	 upon	
accommodating	 larger	 ligands	 in	 chapter	 3,	 consequent	 on	 inclusion	 of	 2-FAM-IP5	
(personal	communication,	H.	Whitfield,	UEA).		
	 	
AtIPK1 SHIP1cd SHIP2cd
BiPh1 101.5 19.31 29.69
BiPh2 66.09 65.53 38.72
BiPh3 76.81 18.43 30.48
BiPh4 51.06 27.35 48.2
IC509(nM)
Table	4.3–	Binding	of	the	biphenyl	phosphates	to	AtIPK1,	SHIP1cd	&	SHIP2cd.		
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4.3.4	Known	inhibitors	of	SHIP1cd	&	SHIP2cd	–	validation	of	2-FAM-IP5-based	assays	
In	seeking	to	confirm	the	efficacy	of	2-FAM-IP5-based	fluorescence	polarisation	assays	it	
is	helpful	to	test	known	inhibitors	of	this	class	of	phosphatase	The	data	shown	in	Figure	
4.14	 test	 the	 effect	 of	 AS1949490,	 3-[(4-chlorobenzyl)oxy]-N-[(1S)-1-phenylethyl]-2-
thiophenecarboxamide.	This	compound	was	identified	as	a	potent	SHIP2	inhibitor	with	
an	IC50	of	0.62	µM,	measured	in	a	phosphate	release	assay	with	the	catalytic	domain	of	
this	protein	(Suwa	et	al.,	2009).	AS1949490	was	highly	specific	for	SHIP2	over	other	5-
phosphatases	 including	SHIP1.	The	compound	 increased	the	phosphorylation	of	Akt	 in	
L6	myotubes	 and	displayed	other	 in	 vivo	 effects	 indicative	of	 the	 activation	of	 insulin	
signalling	pathways.	
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Like	 the	 former	 study,	 the	 polarisation	 assay	 confirms	 the	 specificity	 of	 SHIP2cd	 over	
SHIP1cd.	The	IC50	value	of	0.99±1.1	μM,	though	remarkably	similar	to	that	of	Suwa	et	
al.	 (2009),	 cannot	 be	 meaningfully	 compared	 with	 results	 of	 assays	 performed	
differently	 in	 other	 studies	 as	 IC50	 does	 not	 account	 for	 differences	 in	 protein	 and	
ligand	 concentration.	 Nevertheless,	 the	 robust	 discrimination	 between	 SHIP	 isoforms	
provides	validation	of	polarisation-based	assays	as	tools	to	study	enzymes	of	this	class.	
AS1949490	was	shown	to	be	a	competitive	 inhibitor	of	SHIP2.	The	reduction	 in	probe	
polarisation	at	concentrations	approaching	1	μM	seen	here	may	therefore	be	explained	
Figure	 4.14	 –	 Displacement	 of	 2-FAM-IP5	 by	 AS	 1949490,	 a	 SHIP2	 inhibitor	 with	 a	 reported	 30-fold	 decreased	
affinity	for	SHIP1.	(A)	SHIP1cd.	(B)	SHIP2cd.	
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by	progressive	displacement	of	probe	 from	SHIP2,	providing	 indirect	evidence,	 that	2-
FAM-IP5	binds	in	the	active	site	of	5-phosphatases,	or	at	least	in	the	active	site	of	SHIP2.	
	
3-α-aminocholestane	 (3AC)	 was	 identified	 by	 high	 throughput	 screening	 to	 be	 a	
selective	inhibitor	of	SHIP1	(Brooks	et	al.,	2010).	The	assay	used	was	a	commercial	assay	
from	Echelon	Biosciences,	Utah,	USA.	While	the	mechanism	of	action	is	undefined	the	
similarity	of	 structure	with	pelorol,	 an	 allosteric	 activator	of	 SHIP1	 (Yang	et	 al.,	 2005)	
may	 suggest	 an	 allosteric	 role	 for	 3AC.	 Interestingly,	 pelorol,	 and	 its	 synthetic	
derivatives,	AQX-MN100	and	AQX-016	(Ong	et	al.,	2007),	have	been	reported	to	act	like	
PtdIns(3,4)P2	by	binding	to	the	C2	domain	of	SHIP1	to	allosterically	modulate	(enhance)	
SHIP1	activity	(Blunt	and	Ward,	2012).	
	
It	 is	 remarkable	 therefore	 that	 the	 experiment	 shown	 in	 Figure	 4.15,	 performed	 on	
SHIP1cd,	shows	that	3AC	interacts	with	SHIP1cd,	and	not	SHIP2cd,	and	does	so	with	an	
IC50	of	≈	2	μM,	and	increases	the	binding	of	2-FAM-IP5	to	SHIP1cd.		
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Irrespective	 of	 whether	 3AC	 can	 be	 considered	 an	 analog	 of	 pelorol	 or	 its	 synthetic	
derivatives,	these	remarkable	results	strongly	indicate	that	3AC	is	an	allosteric	regulator	
of	 SHIP1	 that	 acts	 on	 the	 catalytic	 domain	of	 the	protein.	While	 these	 results	 do	not	
directly	call	 into	question	the	reported	mode	of	action	of	pelorol	derivatives	that	have	
entered	Phase	2	clinical	trials	for	inflammatory	disorders	(Blunt	and	Ward,	2012),	they	
do	 highlight	 the	 efficacy	 of	 2-FAM-IP5-based	 assays	 in	 revealing	 allosteric	 as	 well	 as	
competitive	(active	site)	interactions	of	ligand	with	this	therapeutically	important	class	
of	phosphoinoisitide	5-phosphatase.	
	 	
Figure	4.15	–	Binding	of	3-α-aminocholestane	to	SHIP1cd		
*EC50	stated	was	calculated	in	MARS	data	analysis	software	(BMG)	not	 from	the	curve	above,	this	software	does	not	provide	a	
standard	error	but	 includes	3AC	concentrations	below	1	μM.	Concentrations	 are	plotted	on	 a	 log10	 scale	 rather	 than	requiring	
concentrations	 to	be	input	and	plotted	 in	log10	 (resulting	in	some	negative	x-coordinates).	Therefore,	in	this	instance	it	offers	a	
more	complete	and	accurate	binding	curve	and	EC50.	
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4.4	Conclusions	and	future	work	
The	 UV	 absorption	 and	 novel	 fluorescence	 properties	 of	 the	 benzene	 and	 biphenyl	
phosphates	have	been	unearthed	and	characterised.	Work	is	currently	continuing	with	
collaborators	as	to	what	attributes	give	these	compounds	fluorescent	properties	via	use	
of	 density	 functional	 theory.	 This	 may	 allow	 for	 design	 of	 additional	 fluorescent	
compounds	that	could	be	supplemented	with	certain	moieties	that	would	provide	new	
tools	for	exploring	specificities	and	functionalities	of	specific	enzymes	of	this	family	and	
perhaps	beyond.		
	
The	 biphenyl	 phosphates	 have	 been	 shown	 to	 be	 substrates	 of	 SHIP1	 and	 SHIP2	 as	
opposed	to	inhibitors,	and	have	provided	a	useful	tool	for	the	studying	the	enzymology	
of	 these	 5-phosphatases	 via	 their	 fluorescent	 properties.	 An	 ion	 exchange	
chromatography	method	provides	a	sensitive	means	of	detecting	the	metabolism	of	the	
biphenyl	 phosphates	 and	 in	 future	 can	 be	 extended	 and	 refined	 to	 extract	 kinetic	
parameters	 for	 SHIP1	 and	 SHIP2	with	 the	 fluorescent	 substrate	mimics.	 This	 has	 also	
revealed	 differing	 substrate	 specificities	 between	 SHIP1	 and	 SHIP2	 for	 the	 biphenyl	
phosphates.	 Both	 ion	 chromatography	 data	 and	 subsequent	 binding	 analysis	 reveal	 a	
preference	for	BiPh2	by	SHIP2,	and	BiPh3	by	SHIP1.	Although	no	formal	comparison	of	
the	substrate	specificities	and	affinities	of	SHIP1	and	SHIP2	have	been	carried	out	in	the	
same	study,	the	literature	does	suggest	that	they	possess	different	substrate	ranges	as	
well	 as	 affinities	 for	 the	 substrates	 that	 they	 have	 in	 common	 (Eramo	 and	Mitchell,	
2016).	As	described	in	chapter	2,	structural	data	would	greatly	aid	in	the	elucidation	of	
this.	
	 	
Chapter	4	–	Novel	fluorescent	properties	of	the	benzene-	and	biphenyl-	polyphosphates,	and	the	use	of	
fluorescently	tagged	inositol	phosphates	to	explore	ligand	binding	
157	
	
	
A	 robust	 high	 through	 put	 fluorescence	 polarisation	method	 has	 also	 been	 described	
which	 allowed	 the	 construction	 of	 dose-response	 curves	 giving	 descriptions	 of	 the	
binding	 of	 fluorescently	 tagged	 inositol	 phosphate	 analogs	 to	 AtIPK1,	 SHIP1cd,	 and	
SHIP2cd.As	mentioned	 earlier,	 attempts	 to	 obtain	 crystal	 structures	 of	 these	 proteins	
with	 2-FAM-IP5	 are	 on-going.	 It	 is	 reasonable	 to	 assume	 that	 these	 fluorescent	
polarisation	 probes	 are	 indeed	 binding	 in	 the	 active	 site	 of	 the	 proteins,	 due	 to	 the	
displacement	by	canonical	substrates,	defined	inhibitors	and	the	biphenyl	phosphates;	
of	which	there	are	structures	available	and	as	of	now,	are	substrates.	
	
Further	to	this,	the	fluorescence	polarisation	method	has	potential	in	screening	inositol	
phosphate-binding	 proteins	 for	 potential	 ligands	 or	 inhibitors	 via	 displacement	 of	 2-
FAM-IP5,	 or	 the	 most	 suitable	 probe,	 from	 the	 active	 site.	 The	 search	 for	 lead	
compounds	for	the	design	of	inhibitors	or	drugs	for	clinically	relevant	IP-kinases	and	IP-
phosphatases	is	desirable	due	to	the	wide	range	of	diseases	these	family	of	proteins	are	
implicated	in.	
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5.1	Introduction	
	
5.1.1	Screening	for	lead	compounds	in	drug	discovery	
During	drug	discovery,	the	“hit”	identification	and	lead	discovery	phase	follows	an	initial	
process	 of	 target	 identification	 and	 validation;	 a	 multifaceted	 process	 that	 can	 take	
many	years	to	settle	on	selecting	a	target	for	costly	drug	discovery	(Hughes	et	al.,	2011).	
As	 opposed	 to	 knowledge	 based	 screening	 for	 hit	 identification,	 high	 throughput	
screening	assumes	no	prior	knowledge	of	the	nature	of	the	chemotype	likely	to	have	an	
effect	on	the	target	protein,	and	involves	screening	an	entire	compound	library	directly	
against	the	target.	The	first	potent	small	molecule	 inhibitor	of	SHIP2,	AS1949490,	was	
discovered	through	such	a	method,	which	used	a	standard	malachite	green	assay	that	
measures	phosphate	release.	After	identification,	AS1949490	was	found	to	be	a	potent	
inhibitor	 (IC50	 =	 0.62	 µM)	 which	 increased	 Akt	 phosphorylation	 and	 reduced	 blood	
glucose	levels	in	mice	(Suwa	et	al.,	2009).	The	identification	of	the	SHIP1	inhibitor	3-α-
aminocholoestane	(3AC)	was	also	identified	via	a	high	throughput	screen	(Brooks	et	al.,	
2010).	 The	 screen	 used	 was	 the	 original	 version	 of	 the	 National	 Cancer	 Institute’s	
diversity	 set	 (see	 section	 5.3)	which	 is	 freely	 available,	 and	 a	 subsequent	 version	 has	
been	used	in	this	work.	3AC	was	identified	as	a	hit	by	use	of	a	fluorescence	polarisation	
method	 that	 detects	 the	 5-phosphatase	 activity	 of	 SHIP1,	 developed	 from	 an	 assay	
available	 from	 Echelon	 Biosciences	 (Drees	 et	 al.,	 2003).	 More	 recently,	 a	 study	 has	
developed	 an	 assay	 and	 screening	 strategy	 that	 is	 applicable	 to	 5-phosphatase	 and	
phosphoinositide-metabolising	enzymes,	and	from	this	a	specific	OCRL/INPP5B	inhibitor	
was	 identified	 (Pirruccello	 et	 al.,	 2014).	 Three	 assay	 formats	 were	 developed	 which	
allowed	for	the	exclusion	of	false-positives;	a	fluorescence	polarisation	assay	based	on	
the	same	principles	as	Brooks	et	al,	2010,	a	 less	sensitive	malachite	green	assay	and	a	
mobility	shift	assay	that	was	hindered	by	the	speed	of	detection.	
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5.1.2	The	Z-factor	
The	Z-factor	was	defined	to	as	a	simple	statistical	parameter	for	use	 in	the	evaluation	
and	 validation	 of	 high	 throughput	 screening	 assays,	 that	 ultimately	 can	 be	 used	 to	
compare	 the	 quality	 of	 assays	 and	 quantify	 how	 well	 the	 assay	 works	 (Zhang	 et	 al.,	
1999).	It	is	a	screening	window	coefficient	that	reflects	the	assay	signal	dynamic	range	
and	the	data	variation	associated	with	single	measurement,	and	has	become	standard	
for	this	type	of	assay.	It	defines	upper	and	lower	thresholds	calculated	from	the	mean	
of	the	background/negative	control	values	and	the	mean	of	the	positive	controls.	Any	
true	“hits”	will	be	three	standard	deviations	below	the	mean	of	the	positive	control,	and	
three	 standard	 deviations	 above	 the	 mean	 of	 the	 negative	 control.	 This	 creates	 a	
separation	band	which	is	defined	by	these	two	thresholds.	The	difference	between	the	
two	mean	values	is	called	the	dynamic	range,	and	dividing	the	separation	band	by	this	
computes	 the	Z-factor.	A	Z-factor	of	1.0	 is	 the	 ideal,	but	 is	unobtainable.	An	excellent	
assay	is	signified	by	a	Z-factor	between	0.5-1.0.	
	
5.1.4	Lipinski’s	rule	of	five	
Lipinski's	 rule	 of	 five	 (or	 Pfizer's	 rule	 of	 five)	 is	 a	 simple	 rule	 of	 thumb	 which	 is	
commonly	 cited	 as	 a	 means	 by	 which	 to	 compare	 the	 similarity	 of	 compounds	 with	
biological	 activities	 that	 might	 suit	 them	 as	 orally	 active	 drugs	 (Lipinski	 et	 al.,	 2001,	
Lipinski,	2004).The	rule	has	its	origins	in	the	observation	that	drugs	are	commonly	small	
hydrophobic	molecules	whose	physicochemical	properties	are	such	that	they	are	readily	
absorbed	(pass	across	membranes).	While	the	field	of	pharmacokinetics	addresses	the	
impact	 of	 a	 potential	 drug’s	 physicochemical	 properties	 on	 absorption,	 partition	 (or	
distribution),	metabolism	 and	 excretion,	 the	work	 described	 here	 does	 not	 extend	 to	
such	analysis.	
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Lipinski's	 rule	 rephrased	simply	 states	 that	an	orally	active	drug	should	have	no	more	
than	one	departure	from	the	following	criteria;	
•	 No	greater	than	5	hydrogen	bond	donors	(for	these	purposes,	hydrogen	bonds	
are	N-H	or	O-H	bonds)	
•	 No	 greater	 than	 10	 hydrogen	 bond	 acceptors	 (for	 these	 purposes,	 these	 are	
atoms	of	nitrogen	or	oxygen)	
•	 A	mass	of	no	more	than	500	daltons	
•	 A	partition	coefficient	between	octanol	and	water	log	P	not	greater	than	5	
	
5.1.5	Experimental	aims	
	
As	high	throughput	screens	are	freely	available,	and	a	robust	and	sensitive	fluorescence	
polarisation	 method	 has	 been	 developed	 for	 probing	 the	 active	 sites	 of	 inositol	
phosphate-binding	 proteins,	 the	 proteins	 in	 this	 study	 were	 subjected	 to	 two	 high	
throughput	 screens.	 Any	 inhibitor	 hits	 were	 followed	 up	 with	 binding	 curves	 to	
eliminate	false	positives	and	then	for	AtIPK1,	 taken	forward	for	binding	and	 inhibition	
kinetics	 assays.	 The	 screen	was	 approached	with	 proof	 of	 concept	 for	 the	method	 in	
mind	rather	than	from	a	strictly	pharmacological	point	of	view.	 	
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5.2	Materials	and	methods	
	
5.2.1	High	throughput	screening	of	compound	libraries	
For	 high	 throughput	 screening	 of	 drug	 discovery	 screens,	 assay	 conditions	 were	 as	
described	 in	 4.2.5,	 using	 5	 nM	 2-FAM-IP5,	 100	 nM	 protein	 and	 12.5	 µM	 screen	
compound.	The	assay	was	performed	in	a	96	well	plate	with	a	volume	of	100	µL	per	well	
(Corning	96	well	half-area	black	polystyrene	flat	bottom	plate).	Only	a	single	well	was	
each	compound	was	assayed.	
	
5.2.2	Changes	in	AtIPK1	intrinsic	tryptophan	fluorescence	upon	ligand	binding	
Changes	 in	 protein	 folding	 consequent	 on	 ligand	 binding	 or	 other	 treatments	 were	
reported	by	 the	 intrinsic	 fluorescence	of	2	µM	AtIPK1	protein	as	described	previously	
(Banos-Sanz	 et	 al.,	 2012).	 Additions	 were	 made	 of	 inositol	 substrate	 or	 inhibitor	
compound	 (0.25-2	 µM)	 and	 the	 fluorescence	 intensity	 measured	 at	 excitation	
wavelength	of	280	nm	and	emission	of	340	nm	using	a	Hidex	Sense	plate	reader.	
	
5.2.3	Coupled	enzyme	assay	
A	Molecular	Devices	 SpectraMax	M5	Plate	 Reader,	 using	 Corning	 flat	 bottom	96	well	
plates,	was	used	to	monitor	the	real	time	absorbance	at	340	nm	of	a	coupled	enzyme	
assay.	Enzyme	(500	ng)	was	mixed	with	20	mM	HEPES	pH	7.5;	1	mM	MgCl2;	20	mM	KCl;	
0.1	mM	ATP;	2	mM	PEP;	0.15	mM	NADH;	7.5	UmL-1	Lactate	dehydrogenase;	15	UmL-1	
Pyruvate	kinase	along	with	an	inositol	phosphate	substrate,	the	concentration	of	which	
is	specified	in	each	experiment	description.	The	reaction	was	monitored	for	15	minutes	
at	 25	 °C	 along	 with	 either	 a	 no	 enzyme	 or	 no	 substrate	 control.	 Each	 experiment	
consisted	 of	 3	 replicates	 of	 each	 condition.	 Initial	 linear	 rates	 were	 calculated	 using	
Molecular	 Devices	 Softmax	 Pro	 software	 for	 each	 reaction,	 normalised	 against	 the	
control	reaction	rates.		
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5.3.	Results	and	discussion		
	
5.3.1	Screening	compound	libraries	using	fluorescence	polarisation	
	
As	 introduced	 in	 section	 5.1.1	 large	 compound	 libraries	 are	 frequently	 used	 in	 the	
search	 for	 lead	 compounds	 for	 subsequent	 optimisation	 in	 inhibitor	 design	 and	
discovery	of	drugs	targeted	towards	proteins	whose	functions	are	implicated	in	human	
disease.	 Phosphoinositides	 and	 their	 soluble	 inositide	 counterparts,	 as	 discussed	
through-out	 this	 text,	 have	 been	 reported	 in	 multiple	 fundamental	 pathways	 of	 cell	
metabolism	and	 therefore	 the	proteins	 that	 govern	 the	 levels	 of	 these	molecules	 are	
naturally	desirable	drug	targets	for	therapeutic	intervention	of	many	diseases	including	
cancers	and	diabetes(Ooms	et	al.,	2009).	All	three	inositol	polyphosphate	metabolising	
enzymes	discussed	in	this	study	have	been	subjected	to	two	examples	of	these	screens	
using	 the	 fluorescence	 polarisation	 method	 developed	 in	 chapter	 4.	 The	 work	
demonstrates	the	versatility	of	this	type	of	assay	and	the	fluorescent	probes	at	its	core.	
	
Libraries	 were	 obtained	 from	 the	 National	 Cancer	 Institute	 (NCI)	 through	 the	 Drug	
Synthesis	 and	 Chemistry	 Branch	 (DSCB)	 of	 the	 Developmental	 Therapeutics	 Program	
(Maryland,	 USA),	 where	 they	 are	 freely	 available	 upon	 request.	 Two	 libraries	 were	
subsequently	 screened	 with	 both	 AtIPK1	 and	 SHIP2cd;	 Diversity	 set	 II	 (DivII)	 and	
Approved	 Oncology	 Drugs	 Set	 V	 (AODV),	 1872	 and	 114	 compounds	 respectively.	
SHIP1cd	was	also	screened	against	AODV.	
	
The	libraries	were	screened	with	2-FAMP-IP5	as	a	fluorescence	polarisation	probe	in	96-
well	plates,	using	the	method	introduced	in	chapter	4	(section	4.3.3).	Instead	of	titrating	
increasing	 increments	 of	 screen	 compound/potential	 inhibitor	 to	 fixed	 protein	 and	
probe	concentrations,	a	single	concentration	of	compound	was	used	(12.5	μM)	to	allow	
for	 a	 high-throughput	 screening	 method.	 Observed	 decreases	 in	 polarisation	 were	
compared	to	control	samples;	fluorescent	probe	bound	to	protein	and	free	un-bound		
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probe,	to	assess	if	any	change	in	polarisation	was	a	result	of	protein	binding	a	potential	
ligand.		
	
Convention	for	this	type	of	pharmacological	screen	is	that	any	given	polarisation	value	
below	 3	 standard	 deviations	 from	 the	 mean	 of	 the	 negative	 control	 is	 a	 “hit”	 and	
therefore	a	potential	 ligand/inhibitor	(see	section	5.1.2).	Due	to	the	robustness	of	the	
method	developed	in	this	study,	and	the	small	errors	generated	by	the	plate	reader,	a	
small	 standard	 deviation	 was	 achieved	 and	 thus	 resulted	 in	 an	 elevated	 number	 of	
potential	 hits.	 Upon	 closer	 inspection,	 many	 compounds	 were	 discounted	 due	 to	
concerns	 that	 they	possess	 their	own	spectroscopic	properties	 that	 interfere	with	 the	
working	wavelengths	of	this	assay	and	hence	provided	false	positive	results.		
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Eventually,	 potential	 hits	 were	 chosen	 rather	 more	 empirically	 by	 assessing	 which	
compounds	gave	a	larger	and	more	considerable	decrease	in	polarisation;	more	akin	to	
approximately	 12	 standard	 deviations	 from	 the	 mean	 of	 the	 negative	 control	 rather	
than	3.	The	Diversity	Set	II	screen	contained	1872	compounds	and	this	scrutiny	helped	
simplify	 the	 process	 of	 finding	 compounds	 to	 follow	 up	 and	 take	 forward	 for	 further	
investigation.	Unfortunately,	this	means	that	true	hits	may	have	been	by-passed.	
	
Across	 both	AtIPK1	 and	 SHIP2cd,	 nine	 potential	 inhibitors	 from	 the	DivII	 screen	were	
obtained	(Figure	5.1).	Four	of	these	were	hits	for	both	proteins,	an	additional	four	for	
AtIPK1	only	and	just	one	for	SHIP2cd	only.		
	
The	arrow	in	figure	5.1	indicates	a	compound	that	was	a	hit	for	both	proteins,	with	an	
observed	 decrease	 in	 polarisation	 of	 227.43	mP	 from	 the	mean	 negative	 control	 for	
AtIPK1.	
	 	
Figure	 5.1	 –	 Results	 of	 the	 Diversity	 Set	 II	 screen	 for	 AtIPK1,	 polarisation	 results	 for	 each	 compound	 are	
randomised	 for	 visual	 purposes	 and	 raw	 polarisation	 values	 plotted	 against	 the	 y-axis.	 Points	 shown	 in	 red	
indicate	 ‘hits’	 that	were	 chosen	for	 further	 investigation.	The	arrow	indicates	 a	hit	 that	 appeared	 in	results	 for	
both	AtIPK1	and	SHIP2cd.	
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The	AODV	 screen	only	 contained	 two	plates	 amounting	 to	 114	 compounds	 and	were	
analysed	in	the	same	way	as	the	Diversity	Set	II	screen	for	AtIPK1,	SHIP2cd	and	SHIP1cd	
(Figure	5.2).	For	these	‘displacement’	assays,	the	instrument	‘target’	gain,	a	parameter	
set	at	the	polarisation	value	of	maximally	bound	probe,	was	set	lower	than	for	Diversity	
Set	 II	 since	 discovering	 that	 some	 compounds/inhibitors	 caused	 an	 increase	 in	
polarisation	 of	 the	 probe	 (chapter	 4).	 The	 lower	 value	 of	 polarisation	 of	 maximally	
bound	 probe	 was	 achieved	 with	 a	 lower	 concentration	 of	 protein.	 Increases	 in	
polarisation	 imply	 an	 increased	 affinity	 between	 the	 protein	 and	 probe	 (2-FAM-IP5),	
while	 decreases	 imply	 displacement	 of	 2-FAM-IP5.The	 arrow	 in	 figure	 5.2	 indicates	 a	
compound	 that	 appeared	 to	 displace	 the	 probe	 from	 all	 three	 proteins	 tested.	
Polarisation	 dropped	 by	 33.5,	 19.7	 &	 24.9	 mP	 for	 AtIPK1,	 SHIP2cd	 &	 SHIP1cd	
respectively,	approximately	6	to	8	standard	deviations	from	the	mean	of	the	maximally	
bound	control.	One	other	compound	emerged	as	a	hit	for	all	three	proteins.	Further	to	
this,	AtIPK1	and	SHIP2cd	also	have	two	additional	hits	in	common	from	this	compound	
library.		
	
As	 demonstrated	 in	 chapter	 4,	 a	 reported	 SHIP1cd	 inhibitor	 (3-α-amino-cholestane,	
3AC)	 increased	 affinity	 of	 SHIP1cd	 for	 2-FAM-IP5.	 The	mechanism	 of	 action	 of	 3AC	 is	
unknown,	 but	 is	 intriguing,	 particularly	 when	 considering	 that	 the	 binding	 partner	
studied	 here	 is	 the	 catalytic	 domain	 not	 the	 full-length	 protein.	 Consideration	 of	
potential	mechanisms	 prompted	 re-inspection	 of	 the	 screen	 shown	 in	 Fig.	 5.2.	 Some	
hits	 that	produced	 increases	 in	polarisation	with	 SHIP1cd	were	 subsequently	 selected	
for	further	scrutiny	(Figure	5.2	-	C).	Overall,	screening	against	SHIP1cd	gave	6	additional	
hits	 that	 caused	 an	 increase	 in	 polarisation	 that	 did	 not	 emerge	 with	 the	 other	 two	
proteins.	
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Figure	 5.2	 –	 Results	 of	 the	 Approved	Oncology	 Drugs	 Set	 V	 screen	 for	 (A)	 AtIPK1,	 (B)	 SHIP2cd	 &	 (C)	 SHIP1cd.	
Polarisation	results	 for	each	 compound	are	randomised	for	visual	purposes	 and	raw	polarisation	values	plotted	
against	 the	 y-axis.	 Points	 shown	 in	 red	 indicate	 ‘hits’	 that	 were	 chosen	 for	 further	 investigation.	 The	 arrow	
indicates	a	hit	that	appeared	in	results	for	all	proteins.	
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As	 stated	 previously	 in	 chapter	 4,	 it	 is	 inherent	 in	 the	 interpretation	 of	 experiments	
performed	in	this	chapter	that	2-FAM-IP5	is	an	active	site	ligand	of	the	proteins	tested.	
For	 AtIPK1,	 chapter	 3	 provides	 categorical	 structural	 data	 showing	 the	 biphenyl	
phosphates	 ligands	 co-ordinate	 inositol	 phosphate-coordinating	 residues	 in	 the	 active	
site	of	AtIPK1.	The	displacement	data	presented	in	chapter	4	also	provides	compelling	
evidence	 that	 benzene	 and	 biphenyl	 phosphates	 are	 active	 site	 ligands	 of	 SHIP2	 and	
SHIP1,	 which	 was	 first	 described	 when	 biphenyl	 2,3’,4,5’,6	 -	 pentakisphosphate	 was	
resolved	 in	 the	 structure	 of	 SHIP2	 (Mills	 et	 al.,	 2012)	 That	 benzene	 phosphates	 and	
biphenyl	phosphates	displace	2-FAM-IP5	from	AtIPK1,	SHIP2cd	and	SHIP1cd	is	therefore	
itself	convincing	enough	evidence	that	2-FAM-IP5	is	an	active	site	probe	of	both	classes	
of	protein.	Additionally,	bona	 fide	 substrates	were	able	 to	displace	2-FAM-IP5	 (Figure	
4.12),	 inositol	 phosphates	 have	 not	 be	 shown	 to	 bind	 to	 these	 types	 of	 proteins	
elsewhere	other	than	the	active	site.	
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5.3.2	Dose-response	curves	of	the	binding	of	screen	hits	–	Diversity	set	II	
	
The	DIVII	 screen	and	 the	dose-response	curves	presented	 in	 this	 section	pre-date	 the	
purification	of	SHIP1cd,	therefore	only	results	for	AtIPK1	and	SHIP2cd	are	available	thus	
far.	Additionally,	all	hit	compounds	were	tested	on	both	proteins	regardless	of	providing	
a	positive	result	with	only	one	of	the	proteins	to	validate	that	the	screening	method	is	
effective.	
	
The	experiments	described	below	are	an	extension	of	the	unbiased	screen	shown	above	
(Figure	5.1).	They	were	designed	to	provide	proof	of	concept	that	2-FAM-IP5	is	a	useful	
probe	for	 identifying	potential	 therapeutic	agents	targeting	 inositol	phosphate	kinases	
and	inositol	polyphosphate	5-phosphatases.	
	
All	 compounds	 identified	 as	 ‘hits’	 and	 taken	 further	 for	 determination	 of	 dose-
responses	were	 re-inspected	 for	 optical	 properties,	 UV	 absorbance	 and	 fluorescence,	
that	might	give	rise	to	their	false	identification	as	‘hits’.	UV	spectra	were	run	in	a	96-well	
quartz	 glass	 plate	 on	 a	 Hidex	 Sense	 plate	 reader	 at	 100	 μM	 concentration,	 while	
fluorescence	 emission	 spectra	were	 run	 in	 384-well	 plates	 on	 a	 BMG	ClarioStar	 plate	
reader	with	excitation	band	width	16nm	centered	on	485nm	and	emission	centered	on	
515nm	 (same	 band	width).	 These	wavelengths	 represent	 the	 excitation	 and	 emission	
wavelengths	used	for	the	polarisation	measurements	described	here	and	in	chapter	4.		
The	compounds	tested	in	the	following	all	showed	absorbances	at	485nm	that	were	not	
considered	significant	(results	not	shown).	
	
For	 determination	 of	 dose-responses,	 probe	 (2-FAM-IP5)	 at	 2	 nM	 concentration	 was	
incubated	 with	 protein	 at	 200	 nM	 and	 ‘hit’	 compounds	 were	 titrated,	 according	 to	
compound,	 up	 to	 concentrations	 generating	 a	 4-parameter	 fit	 sigmoidal	 curve	
approaching	 ‘complete’	 displacement.	 The	 highest	 concentration	 tested	 for	 each	
compound	was	25	µM.		
	
	 	
Chapter	5	-	Application	of	fluorescently	tagged	inositol	polyphosphates	in	novel	inhibitor	and	lead	
compound	discovery	
169		
	
Alternatively,	for	some	compounds	the	plotted	curves	were	limited	to	concentration	of	
titrating	 ligand	 at	which	 the	 raw	 vertical	 and	 horizontal	 polarised	 emissions	 of	 probe	
were	 not	 ‘greatly’	 altered	 by	 ligand.	 Some	 of	 the	 curves	 do	 not	 therefore	 reach	 a	
minimum	asymptote.	
	
Where	 the	 data	 allowed,	 IC50	 values	 were	 determined.	 IC50s	 obtained	 from	 such	
experiments	 are	 not	 intrinsic	 inhibition	 constants;	 that	 is	 they	 reflect	 the	 local	
conditions	of	the	experiment	and	depend	on	the	concentration	of	displaced	probe	and	
concentration	 of	 protein.	 Nevertheless,	 in	 experiments	 in	 which	 different	 displacing	
ligands	are	 titrated	against	 a	 common	probe	and	common	protein	 concentration,	 the	
IC50	 values	 obtained	 do	 reflect	 in	 a	 meaningful	 way	 the	 affinities	 of	 the	 different	
titrated	 ligands	 for	 target	 protein.	 Such	 IC50	 experiments,	 polarisation-based	 or	
otherwise,	are	the	basis	of	many	pharmaceutical	screens	commonly	performed	at	 the	
initial	 stage	 of	 screening	 programs	 at	 a	 single	 concentration	 of	 ligand	 against	 fixed	
probe	and	protein	concentration	with	millions	of	 individual	compounds	from	chemical	
libraries	 far	 more	 complex	 than	 that	 tested	 here.	 Comparisons	 of	 common	 ligand	
titrated	against	different	proteins	offer	meaningful	comparisons	between	the	proteins	if	
the	probe	and	protein	concentrations	are	equivalent	to	all	titrations.	
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Figure	 5.3	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
purpurogallin,	an	aglycone	of	various	glycosides	obtained	from	oak	bark	which	has	been	
affiliated	 with	 antioxidant	 properties	 in	 cardiocytes	 (Wu	 et	 al,	 1996).	 Its	 structure	 is	
related	to	catechol,	1,2-dihydroxybenzene,	and	it	has	been	shown	to	inhibit	chatechol-
O-methyltransferase	 (Lambert	 et	 al.,	 2005)	 as	 well	 as	 innate	 immunity	 pathways	
consequent	 on	 activation	 of	 the	 Toll-like	 receptor	 2,	 in	 which	 downstream	 signaling	
from	TNF-α	and	IL-1β	is	repressed	(Cheng	et	al.,	2012).	
	
Titration	 of	 purpurogallin	 against	 IPK1	 and	 SHIP2cd	 revealed	 IC50s	 respectively	 of	
5.5±1.1	and	1.6±1.2	μM,	with	a	smaller	Hill	Slope	for	SHIP2cd	(Figure	5.3).	The	range	of	
the	assay	was	300	mP	and	250	mP	respectively,	the	difference	in	these	upper	plateaus	is	
likely	 determined	 by	 the	 differing	 proteins	 and	 their	 relative	 starting	 affinities	 for	 2-
FAM-IP5.	 They	 both	 reach	 the	 pre-determined,	 ‘target	 gain’	 set	 at	 35	 mP,	 a	 value	
representing	the	intrinsic	polarisation	of	un-bound,	free,	2-FAM-InsP5	probe	in	solution.	
 
Interestingly,	 purpurogallin	 has	 been	 identified	 as	 a	 ligand	 occupying	 the	 nucleotide	
binding	 site	 of	 cyclin-dependent	 kinase	 2	 (cdk2)	 by	 a	 screening	 assay,	 backed-up	 by	
structural	 data	 (Martin	 et	 al.,	 2012).	 CDK’s	 are	 serine/threonine	 kinases	 and	 their	
deregulation	 has	 been	 implicated	 in	 a	 range	 of	 diseases	 including;	 cancer,	
neurodegenerative	and	inflammatory	diseases	(Zhang	et	al.,	2009,	Bain	et	al.,	2007).	A	
second	structure	is	also	available	in	complex	with	human	thymidylate	synthase	(Lesa	et	
al.,	 2012	 –	 to	 be	 published).	 As	 IPK1	 is	 a	 reversible	 nucleotide	 to	 inositol	 phosphate	
phosphotransferase	 (Phillippy	et	al.,	 1994,	González	et	al.,	 2010),	 the	 identification	of	
purpurogallin	 as	 a	 ligand	 is	 perhaps	 explained	 by	 the	 dual	 substrate	 nature	 of	 this	
enzyme.	 Its	 identification	as	a	 ligand	of	SHIP2cd	 is	not	 so	 readily	explained.	However,	
recent	preliminary	attempts	by	colleagues	in	obtaining	the	crystal	structure	of	AtIPK1	in	
complex	with	purpurogallin	suggest	that	it	is	not	occupying	the	nucleotide	binding	site.	
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Inspection	of	the	structure	of	purpurogallin	(Figure	5.3),	taken	with	its	molecular	mass	
of	220.2	and	 logP	of	1.06	reveals	 that	purpurogallin	meets	Lipinski’s	 rule.	 (see	section	
5.1.4).		
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Figure	5.3		–	Purpurogallin	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd.	Errors	bars	(SE)	are	shown	or	
are	smaller	than	the	symbol	used.	
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Figure	 5.4	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
5,6,7,8,4’-pentahydroxyflavone,	also	known	as	nortangeretin.	The	same	compound	was	
identified	 in	 a	 screen	 of	 the	 same	 library	 for	 compounds	 that	 bind	 to	 the	 catalytic	
subunit	of	casein	kinase	2	(Rasmussen	et	al.,	2015)	.	
	
Here,	 titration	of	5,6,7,8,4’-pentahydroxyflavone	against	AtIPK1	and	SHIP2cd	 revealed	
IC50s	respectively	of	7.4±1.0	and	1.8±1.1	μM.	Similar	to	purpurogallin,	the	range	of	the	
assay	 was	 approximately	 300	 mP	 and	 250	 mP	 respectively,	 and	 both	 dose-response	
curves	reach	the	pre-determined	lower	limit	of	35	mP	which	represents	polarisation	of	
the	free	probe	in	solution.	
With	 a	mass	 of	 302	 Da,	 LogP	 of	 1.64,	 and	 seven	 H-bond	 acceptors	 and	 five	 donors,	
5,6,7,8,4’-pentahydroxyflavone	meets	the	criteria	of	Lipinski’s	rule	of	five. 
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Figure	5.4		–5,6,7,8,4’-pentahydroxyflavone	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd.	Errors	bars	
(SE)	are	shown	or	are	smaller	than	the	symbol	used.	
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Figure	 5.5	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
Galloflavin,	which	is	commercially	sold	as	a	lactate	dehydrogenase	(LDH)	inhibitor	that	
can	 uniquely	 exert	 its	 effect	 on	 both	 isoforms	 of	 the	 enzyme	 (Manerba	 et	 al.,	 2012).	
Galloflavin	 has	 recently	 been	 shown	 to	 reduce	 lactate	 levels	 in	 adenocarcinoma	 cells	
which	 subsequently	decreases	 their	migration	ability.	 This	was	 the	 result	of	 inhibiting	
isoform	A	of	 LDH	which	can	cause	enhanced	 levels	of	 lactate	 in	 tumour	 tissues	when	
upregulated	by	pro-inflammatory	cytokines	(Manerba	et	al.,	2016).	
	
Titration	of	galloflavin	against	AtIPK1	and	SHIP2cd	revealed	IC50s	respectively	of	1.5	and	
1.6±1.2	 μM.	 Like	 the	 previous	 dose-response	 curves,	 the	 range	 of	 the	 assay	 was	
approximately	 300	mP	 and	 250	mP	 respectively,	 and	 both	 curves	 approach	 the	 pre-
determined	 lower	 limit	of	35	mP	for	 free	probe.	The	curve	 fitting	software	could	only	
give	an	approximation	of	the	IC50	for	2-FAM-IP5	displacement	by	galloflavin	in	SHIP2cd	
as	it	claims	ambiguity	in	the	data,	likely	due	to	the	lack	of	data	points	on	the	Hill	slope.	
Nevertheless,	a	decrease	in	polarisation	down	to	35	mP	is	clearly	observed.	
	
With	 a	 mass	 of	 278	 Da,	 LogP	 of	 0.88,	 and	 eight	 H-bond	 acceptors	 and	 four	 donors,	
galloflavin	meets	the	criteria	of	Lipinski’s	rule	of	five. 
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Figure	5.5		–Galloflavin	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd.	Errors	bars	(SE)	are	shown	or	are	
smaller	than	the	symbol	used.	
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It	is	clear	from	the	foregoing	examples	(Figures	5.3	–	5.5)	that	with	such	small	standard	
deviations	as	achieved,	this	assay	with	2-FAM-InsP5	is	robust	and	shows	great	potential	
for	 discriminating	 between	 small	 structural	 changes	 in	 the	 displacing	 ligand.	 Such	
chemical	 modifications	 are	 commonly	 explored	 when	 ‘hits’	 are	 subjected	 to	 lead	
optimisation	 and	 subsequent	 selection	 of	 a	 candidate	 molecules	 for	 clinical	
development	(Hughes	et	al.,	2011).		
	
Even	 without	 detailed	 modeling	 of	 the	 interaction	 of	 these	 ‘hits’	 with	 the	 protein	
subjects,	it	is	clear	that	there	are	striking	similarities	in	the	structure	of	the	compounds	
above	 that	may	 rationalise	 their	 ability	 to	 yield	 these	 effective	 dose-response	 curves	
with	AtIPK1	and	SHIP2cd.	They	all	share	a	bicyclic	structure,	consisting	of	benzene	rings,	
bar	purpurogallin	which	bears	a	benzene	and	cycloheptane.	A	third	ring,	a	phenol	ring	
moiety,	is	present	in	5,6,7,8,4’-pentahydroxyflavone.	All	possess	at	least	three	adjacent	
hydroxyl	 groups	 on	 a	 single	 benzene	 ring,	 and	 exhibit	 a	 carbonyl	 group	 on	 a	 second	
distinct	 ring.	 Without	 structures	 of	 AtIPK1	 or	 SHIP2cd	 in	 complex	 with	 these	
compounds,	 it	 is	 difficult	 to	 reason	 exactly	 how	 purpurogallin,	 5,6,7,8,4’-
pentahydroxyflavone,	 or	 galloflavin	 would	 coordinate	 within	 the	 active	 site	 of	 these	
proteins,	 other	 than,	 as	mentioned	 above,	 it	 has	 been	 shown	 that	 purpurogallin	 is	 a	
nucleotide-binding	site	ligand	of	cdk2	(Martin	et	al.,	2012).		
	
As	 introduced	 previously,	 SHIP2cd	 has	 several	 commercially	 available	 inhibitors	
including	AS1938909	and	AS1949490	(Suwa	et	al.,	2009,	Suwa	et	al.,	2010).	Though	in	
themselves	 similar,	 there	 are	 no	 immediately	 apparent	 similarities	 between	 these	
inhibitors	and	the	compounds	tested	here,	nor	is	there	currently	any	mechanistic	insight	
in	 to	 how	 they	 exert	 their	 inhibitory	 action	 on	 SHIP2,	 therefore	 at	 this	 point	 no	
meaningful	 comparison	 can	 be	made	 between	 them.	 Nevertheless	 these	 papers	 and	
that	of	 Ichihara	and	coworkers	 (Ichihara	et	al.,	2013)	who	modified	a	4-substituted	2-
pyridin-2-ylamide	 scaffold	 derived	 rationally	 from	 a	 comparison	 of	 the	 structures	 of	
AS1949490	 and	 NGD-61338,	 a	 SHIP2	 inhibitor	 from	 NeoGenesis	 Pharmaceuticals	 Inc	
(Annis	 et	 al.,	 2009)	 indicate	 the	 kind	 of	 medicinal	 chemistry	 approach	 that	 can	 be	
undertaken	 to	 improve	 the	 affinity	 of	 ligand	 for	 target	 protein	 and	 to	 improve	
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bioavailability	 of	 lead	 compounds.	 In	 the	 case	 of	 Ichihara	 et	 al.	 (2013),	 the	 primary	
scaffold	 incorporated	 benzyl	 and	 (4-chlorobenzyl)oxy	 groups	 from	 AS1949490	 and	 a	
pyridine-2-amine	group	from	NGD-61338	(Figure	5.6).	
	
	 	
Figure	5.6	–	Taken	from	Ichihara	et	al.,	2013.	Example	of	the	incorporation	of	groups	to	increase	bioavailability	and	
improved	affinity	for	the	target	protein.	
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Among	the	various	compounds	tested,	dose-responsive	displacement	of	2-FAM-IP5	from	
AtIPK1,	but	not	SHIP2cd,	was	observed	with	two	additional	hits	from	the	Diversity	Set	II	
screen	(results	not	shown).	The	first	of	these	identified	compounds	was	cynarin	(Figure	
5.7	-	A),	a	hydroxycinnamic	acid	derivative	found	in	artichokes	formed	from	quinic	acid	
and	 caffeic	 acid,	 with	 postulated	 antioxidant	 abilities	 (Topal	 et	 al.,	 2016).	 Secondly,	
chaetochromin	(Figure	5.7	-	B),	a	natural	product	and	metabolite	of	Chaetomlum	graclle	
that	has	also	been	found	in	marine	sources	(Blunt	et	al.,	2015).	
	
As	for	the	AtIPK1	/	SHIP2cd	ligands	(potential	inhibitors)	discussed	above,	both	possess	
alcohol	and	carbonyl	moieties.	However,	they	are	much	larger	and	more	elaborate.	As	
demonstrated	in	chapter	3,	AtIPK1	accommodates	large	conformational	changes	made	
possible	by	a	global	shift	of	the	N-lobe,	which	may	offer	explanation	to	why	cynarin	and	
chaetochromin	are	able	to	bind	within	the	active	site	of	AtIPK1	and	not	SHIP2cd.	By	way	
of	 contrast,	 the	 inositide	 binding	 site	 is	 not	 located	 between	 two	moveable	 lobes	 in	
SHIP2cd	 and	 is	 consequently	 a	 smaller	 and	 more	 restricted	 binding	 pocket	 which	
appears	on	the	surface	of	the	protein	with	just	small	flexible	loop	that	closes	over	the	
active	site.	Other	structural	features	of	the	two	enzymes	may	account	for	discrimination	
of	cynarin	and	chaetochromin	ligands,	but	without	further	investigation	the	explanation	
offered	here	is	speculative	at	best.	
	 	
A	 B	
Figure	5.7	–	structures	of;	(A)	Cynarin,	(B)	Chaetochromin	
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5.3.3	Further	investigation	of	screen	hits	with	AtIPK1,	SHIP2cd	&	SHIP1cd	–	Approved	
Oncology	Drugs	Set	V	
	
Of	the	compounds	tested	for	effects	on	2-FAM-IP5	binding	are	a	number	of	compounds	
that	have	passed	all	regulatory	processes	of	the	Federal	Drug	Administration	(FDA)	and	
some	 of	 the	 EU	 European	 Medical	 Agency.	 These	 belong	 to	 the	 National	 Cancer	
Institute’s	Approved	Oncology	Drugs	Set	V	(AODV).		
	
As	 for	 the	 DivII	 screen,	 the	 experiments	 described	 below	 are	 an	 extension	 of	 the	
unbiased	 screen	 shown	 above	 (Figure	 5.2).	 They	 were	 designed	 to	 provide	 proof	 of	
concept	 that	 2-FAM-IP5	 is	 a	 useful	 probe	 for	 identifying	 potential	 therapeutic	 agents	
targeting	inositol	phosphate	kinases	and	inositol	polyphosphate	5-phosphatases.	
	
As	previously,	all	compounds	identified	as	‘hits’	and	taken	further	for	determination	of	
dose-responses	 were	 re-inspected	 for	 optical	 properties,	 UV	 absorbance	 and	
fluorescence,	 that	 might	 give	 rise	 to	 their	 false	 identification	 as	 ‘hits’	 (results	 not	
shown).	
	
For	 determination	 of	 dose-responses,	 probe	 (2-FAM-IP5)	 at	 2	 nM	 concentration	 was	
incubated	 with	 protein	 at	 200	 nM	 and	 ‘hit’	 compounds	 were	 titrated,	 according	 to	
compound,	 up	 to	 concentrations	 yielding	 on	 4-parameter	 fitting	 sigmoidal	 curves	
approaching	 ‘complete’	 displacement.	 The	 highest	 concentration	 tested	 for	 each	
compound	was	25	µM.		
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The	compound	estramustine	sodium	phosphate	was	a	hit	from	AODV	that	was	common	
to	AtIPK1,	SHIP2cd	and	SHIP1cd.	Dose-dependent	response	curves	up	to	100	µM	were	
constructed	 for	each	 in	which	 the	decrease	 in	polarsiation	 indicates	 that	2-FAM-IP5	 is	
being	displaced	from	all	three	proteins	(Figure	5.8).	For	all	three	proteins	the	curves	are	
not	complete	and	did	not	reach	the	lower	plateau	for	the	free	un-bound	probe,	and	in	
this	 case	 accurate	 IC50s	 could	 not	 be	 calculated	 by	 the	 graph	 fitting	 software.	
Nevertheless,	 a	 clear	 observation	 can	 still	 be	 made	 and	 the	 polarisation	 unarguably	
decreases.	 The	 range	 of	 the	 assay	 varies	 between	 each	 protein.	 Most	 notably	 for	
SHIP1cd	 (Figure	5.8-	C),	but	 this	 is	 a	 result	of	 the	polarisation	gain	 for	 the	 free	probe	
being	 adjusted	 to	 account	 for	 any	 increases	 in	 polarisation	 as	 observed	 by	 SHIP1cd	
previously	 (Figure	 4.15).	 The	 theoretical	 maximum	 for	 polarisation	 is	 400	 mP	 and	
without	adjustment,	any	increase	in	polarisation	would	likely	go	unresolved.	For	AtIPK1	
and	SHIP2cd,	 (Figure	5.8	 -	A	&	B)	 the	assay	was	 identical	but	 the	starting	polarisation	
still	differs,	 likely	due	to	the	differing	nature	of	the	proteins	and	their	relative	starting	
affinities	for	2-FAM-IP5.		
	
All	 compounds	 in	 the	 AODV	 screen	 are	 approved	 as	 oncology	 drugs,	 of	 which	
estramustine	sodium	phosphate	is	a	chemotherapeutic	agent	that	has	been	used	in	the	
treatment	 of	 prostate	 cancer	 across	 the	 world.	 It	 is	 a	 derivative	 of	 estradiol	 with	 a	
nitrogen	mustard-carbamate	ester	moiety	attached	and	goes	by	the	brand	name	Emcyt	
(Simpson	and	Wagstaff,	2003,	Perry	and	McTavish,	1995,	Fizazi	et	al.,	2007).	
	
An	immediate	observation	when	considering	a	rationale	for	the	binding	of	estramustine	
phosphate	to	these	enzymes	is	the	phosphorus	containing	head	group	at	one	end	of	the	
molecule.	 Similarly	 to	 the	 compounds	 previously	 discussed	 it	 mainly	 consists	 of	 an	
interconnected	multiple	ring	structure.	
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Figure	5.8		–Estramustine	sodium	phosphate	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd,	(C)	SHIP1cd.	
Errors	bars	(SE)	are	shown	or	are	smaller	than	the	symbol	used.	
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From	 the	 initial	 screening	 process	 valrubicin	 emerged	 as	 a	 positive	 hit	 for	 all	 three	
proteins	 tested.	 However,	 upon	 titration	 against	 the	 2-FAM-IP5	 bound	 proteins	 no	
decrease	 in	 polarisation	 was	 observed	 for	 SHIP1cd,	 only	 with	 AtIPK1	 and	 SHIP2cd	
(Figure	5.9).	As	with	estramustine	phosphate,	the	curves	are	not	complete	and	did	not	
reach	the	lower	plateau	for	the	free	un-bound	probe,	and	accurate	IC50s	could	not	be	
calculated	by	 the	graph	 fitting	 software.	Nevertheless,	a	 clear	observation	can	still	be	
made	 and	 the	 polarisation	 unarguably	 decreases.	 For	 SHIP2cd,	 the	 polarisation	 has	
decreased	 further	 indicating	 that	 at	 the	 highest	 concentration	 of	 valrubicin	 tested	 2-
FAM-IP5	 is	more	readily	displaced	 from	SHIP2cd	 than	AtIPK1.	The	starting	polarisation	
value	differs,	which	is	likely	due	to	the	differing	nature	of	the	proteins	and	their	relative	
starting	affinities	for	2-FAM-IP5,	and	this	appears	to	have	been	consistent	through-out	
the	construction	of	all	comparable	dose-response	curves	of	AtIPK1	and	SHIP2cd.		
	
Valrubicin	is	a	derivative	of	anthracycline	doxorubicin	and	is	a	cytotoxic	chemotherapy	
drug	 to	 treat	 bladder	 cancer	 (Onrust	 and	 Lamb,	 1999).	 Again,	 in	 common	 with	 the	
previous	compounds,	valrubicin	mainly	consists	of	an	interconnected	multiple	benzene	
ring	structure	with	hydroxyl	and	carbonyl	moieties.	
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Figure	5.9		–Valrubicin	as	a	2-FAM-IP5	displacing	ligand	(A)	AtIPK1,	(B)	SHIP2cd.	Errors	bars	(SE)	are	shown	or	are	
smaller	than	the	symbol	used.	
	
Chapter	5	-	Application	of	fluorescently	tagged	inositol	polyphosphates	in	novel	inhibitor	and	lead	
compound	discovery	
184		
	
Pomalidomide	from	the	AODV	screen	was	revealed	as	a	positive	hit	 for	AtIPK1	only,	a	
titration	 of	which	 against	 2-FAM-IP5	 bound	AtIPK1	 can	 be	 seen	 in	 Figure	 5.10.	Unlike	
with	other	dose-response	curves	presented	 in	 this	 section,	 it	 is	more	complete	and	 is	
approaching	the	lower	limit	of	35	mP	for	the	free	un-bound	probe.	An	IC50	of	97.4	±	1.3	
µM	was	calculated	even	though	the	lower	plateau	was	not	fully	reached.	
	
Thalidomide,	 the	 parent	 compound	 of	 pomalidomide,	 was	 originally	 discovered	 to	
inhibit	angiogenesis	and	then	followed	up	 in	clinical	trials	for	cancer	which	resulted	 in	
its	approval	by	the	FDA	for	use	multiple	myeloma	(D'Amato	et	al.,	1994).	Pomalidomide	
is	amino	substituted	and	has	improved	anti-tumor	activity	(D'Amato	et	al.,	2001).		
	
Again,	 it	 has	 an	 interconnected	 ring	 structure,	 consisting	 of	 a	 benzene	 and	 a	
cyclopentane	 ring	with	 carbonyl	 groups.	 However,	 it	 is	 considerably	 smaller	 than	 the	
other	compounds	that	appeared	as	hits	from	this	screen.	
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Figure	5.10	–Pomalidomide	displacing	2-FAM-IP5	from	AtIPK1.	
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There	 were	 two	 drugs	 from	 this	 screen	 that	 displayed	 striking	 effects	 when	 titrated	
against	SHIP1cd	(Figure	5.11)	but	not	IPK1	or	SHIP2	(data	not	shown).		
	
Bosutinib,	originally	synthesised	by	Wyeth	and	developed	by	Pfizer	is	a	tyrosine	kinase	
inhibitor	 (Vultur	 et	 al.,	 2008)	 that	 has	 found	 use	 in	 treatment	 of	 chronic	 myeloid	
leukemia	 (Cortes	et	al.,	 2011).	Crizotinib	 (Forde	and	Rudin,	2012)	 is	 an	aminopyridine	
that	is	a	competitive	inhibitor,	within	the	ATP-binding	pocket,	of	the	c-Met/Hepatocyte	
growth	factor	receptor	(HGFR)	tyrosine	kinase.	Both	these	compounds	when	tested	in	a	
2-FAM-IP5	displacement	assay	elicited	increases	in	the	affinity	of	2-FAM-IP5	binding,	just	
like	3AC	(Figure	4.15),	albeit	with	an	approximate	IC50,	as	the	curves	did	not	reach	an	
upper	 asymptote,	 that	 is	 10-fold	 higher	 than	 that	 of	 3AC.	 While	 the	 5-phosphatase	
family,	or	certainly	the	catalytic	domain	of	this	family,	 lack	obvious	nucleotide	binding	
sites,	 the	 similarity	of	 effect	of	 two	FDA	approved	drugs	when	compared	 to	a	 known	
allosteric	regulator	of	SHIP1,	shown	here	to	act	on	the	catalytic	domain	of	the	enzyme,	
is	a	notable	result	and	one	which	highlights	potential	therapeutic	opportunity	or	at	least	
the	identification	of	alternative	targets	for	known	and	approved	drugs.		
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Figure	5.11	–	SHIP1cd	exhibiting	increased	affinity	for	2-FAM-IP5	upon	titration	with	two	AODV	screen	compounds;	
(A)	Bosutinib	&	(B)	Crizotinib.			
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5.3.4	Utilising	the	intrinsic	tryptophan	fluorescence	of	AtIPK1	to	investigate	binding	of	
potential	inhibitors,	validation	of	polarisation	screens		
	
As	reported	 in	chapter	3,	AtIPK1	undergoes	 large	conformational	changes	upon	 ligand	
binding,	most	notably	in	the	N-lobe	of	the	protein.	The	use	of	the	intrinsic	tryptophan	
fluorescence	of	AtIPK1	to	monitor	protein	folding	consequent	on	ligand	binding	or	other	
treatments	 has	 previously	 been	 reported	 (Banos-Sanz	 et	 al.,	 2012).	 AtIPK1	 has	 four	
tryptophan	residues;	W13,	W69,	W129	and	W381.	As	a	 ligand	binds,	the	environment	
of	the	local	residues	can	change	and	this	in	turn	can	affect	the	fluorescence	properties	
of	 the	 aromatic	 amino	 acids.	 Conformational	 changes	 can	 affect	 these	 residues	
discretely,	or	quenching	of	fluorescence	can	occur	as	an	influence	of	other	residues.	
	
Previous	 to	 this	 study,	 probing	 of	 the	 structure	 of	 AtIPK1	 and	 the	 accessibility	 of	 its	
tryptophan	 residues	was	 achieved	by	 fluorescence	quenching	using	potassium	 iodide,	
and	concluded	that	the	quenching	mechanism	was	collisional	(temperature	dependent)	
(Baños-Sanz	et	al.,	2012).	Additionally,	two	tryptophan	residues	are	found	partially	in	a	
hydrophobic	pocket	(W13	&	W69)	and	the	other	two	are	fully	solvent	exposed	(W129	&	
W381),	where	W129	is	in	the	active	site.	This	work	was	followed	by	titration	of	inositol	
phosphates	 and	 a	 nucleotide	 substrate	 analogue	 (AMP-PNP)	 to	 assess	 the	 changes	 in	
tryptophan	 fluorescence	 in	 the	binary	and	 ternary	complexes	of	AtIPK1	and	a	W129A	
mutant	 (data	not	 shown).	 Changes	 in	 intrinsic	 fluorescence	upon	 ligand	binding	were	
attributed	to	changes	 in	the	 local	environment	of	W13	&	W69,	and	not	W129	or	 fully	
solvent	exposed	W381.		
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Figure	 5.12	 demonstrates	 the	 average	 fractional	 loss	 in	 intrinsic	 tryptophan	
fluorescence	 when	 increasing	 concentrations	 of	 IP5	 are	 titrated	 against	 a	 fixed	
concentration	of	AtIPK1.	In	this	instance,	a	one	site-binding	model	was	fitted	to	the	data	
and	 the	 dissociation	 constant	 (Kd)	 calculated	 2.8±0.8	 μM.	 In	 the	 previous	 work	
mentioned	above,	 the	Kd	 for	 IP5	binding	was	 calculated	as	0.35±0.12	μM.	Gosein	and	
Miller	obtained	a	value	for	In(1,3,4,5,6)P5	binding	of	0.6	μM	by	isothermal	calorimetry	
(Gosein	 and	Miller,	 2013).	 Although	 not	 far	 removed	 from	 these	 values,	 the	method	
used	 by	 the	 authors	 was	 different;	 it	 used	 a	 fluorimeter	 fitted	 with	 a	 1	 mL	 quartz	
cuvette	rather	than	a	384-well	black	plate	 in	a	BMG	ClarioStar	plate	reader	as	used	in	
the	results	presented	here.	
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Figure	 5.12	 –	 Fractional	 change	 in	 fluorescence	 intensity	 of	 AtIPK1	 upon	 binding	 inositol	 1,3,4,5,6	
pentakisphosphate	(IP5).	Error	bars	show	the	standard	errors	in	that	data.	
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The	same	fluorescence	titration	method	was	performed	on	AtIPK1	with	the	compounds	
that	manifested	as	hits	from	DivII	(section	5.3.1)	and	that	were	successful	in	subsequent	
dose-dependent	response	curves	(section	5.3.2),	as	supporting	evidence	of	the	efficacy	
of	this	high	through	put	screening	method	in	the	search	for	true	inhibitors	of	proteins	
that	act	upon	inositol	phosphates.	The	excitation	wavelength	was	limited	to	295	nm	to	
avoid	excitation	of	tyrosine	and	phenylalanine.	
	
The	average	fractional	change	in	the	decrease	in	fluorescence	intensity	was	plotted	and	
one	 site	 binding	model	 curves	 fitted	which	 generated	 dissociation	 constants	 for	 each	
compound.	 Figure	 5.13	 Shows	 the	 resulting	 curves	 and	 Kd	 for	 the	 three	 compounds	
from	 DivII	 that	 appeared	 as	 hits	 for	 both	 AtIPK1	 and	 SHIP2cd.	 Unfortunately	 this	
method	does	not	work	with	SHIP2cd,	due	to	a	surplus	of	tryptophan	residues	and	their	
associated	solvent	exposures.	
	
The	 curves	 revealed	 that	 AtIPK1	 has	 the	 highest	 affinity	 for	 5,6,7,8,4’-
pentahydroxyflavone	out	of	 the	 three	compounds	with	a	Kd	of	4.8±1.5	μM.	At	50	μM,	
the	upper	limit	of	this	assay,	the	fluorescence	intensity	had	decreased	by	50	%	(Figure	
5.13).	The	Kd	for	the	binding	of	purpurogallin	and	galloflavin	are	not	dissimilar,	8.0±1.7	
μM	 and	 7.7±1.9	 μM	 respectively.	 At	 the	 highest	 concentration	 of	 compound,	
purpurogallin	 appeared	 to	 almost	 completely	 diminish	 the	 intrinsic	 fluorescence	
intensity	of	AtIPK1,	whereas	galloflavin	reduced	fluorescence	by	approximately	60	%	at	
50	μM.	
	
As	 a	 rule	 of	 thumb,	 various	 authors	 suggest	 limiting	 the	 absorbance	 of	 extrinsic	
fluorophore	probes	to	values	<	0.05	to	minimise	inner	filter	effects,	or	the	use	of	short	
path	 length	 cuvettes	 to	 reduce	 the	 effect.	 Clearly,	 the	 low	 (single	 figure	 μM)	
concentration	of	AtIPK1	protein	 and	 the	 low	extinction	 coefficient	 of	 aromatic	 amino	
acids	 are	 unlikely	 contributors	 to	 inner	 filter	 effects	 in	 these	 experiments,	 but	 the	
extinction	 coefficient	 of	 purpurogallin	 ε420nm	 is	 2640	 M-1.cm-1	 in	 50	 mM	 pH	 7.0	
phosphate	 buffer	 (Wang	 et	 al.,	 2007),	 with	 an	 extinction	 coefficient	 approximately	
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double	 this	 value	 at	 290	 nm.	 The	 possibility	 remains	 that,	 at	 least	 for	 purpurogallin,	
some	of	the	effect	on	tryptophan	fluorescence	is	an	absorbance	effect.	
	
This	said,	the	considerably	reduced	absorbances	of	these	compounds	at	wavelengths	>	
420	 nm	 makes	 clear	 that	 the	 effects	 of	 these	 compounds	 observed	 in	 2-FAM-InsP5	
polarisation	experiments	are	minimal,	particularly	when	the	extremely	short	pathlength	
of	 the	 384	 well	 plate	 and	 485	 nm/515	 nm	 excitation	 and	 emission	 wavelengths	 are	
considered.	
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Figure	 5.13	 –	 Fractional	 change	 in	 the	 intrinsic	 fluorescence	 intensity	 of	 AtIPK1	 upon	 binding	 compounds	were	
positive	 hits	 as	 potential	 inhibitors	 from	 the	 diversity	 set	 II	 library.	 (A-C);	 Purpurogallin,	 5,6,7,8,4’-
pentahydroxyflavone	&	galloflavin.	Error	bars	show	the	standard	errors	in	that	data.	
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As	previously	described	in	section	5.3.2,	cynarin	and	chaetochromin	were	also	from	the	
DivII	 screen	but	only	emerged	as	hits	 for	AtIPK1.	The	 same	 fluorescence	 titration	and	
one	site	binding	model	analysis	was	carried	out	with	these	compounds	(Figure	5.14).		
	
Chaetochromin	 produced	 the	 lowest	 Kd,	 3.8±1.6	 μM,	 and	 therefore	 exhibited	 the	
tightest	 binding	 of	 all	 compounds	 tested	 using	 this	 method.	 At	 the	 higher	
concentrations	it	diminished	the	fluorescence	intensity	by	approximately	90	%,	whereas	
cynarin	only	elicited	around	a	50	%	response	with	a	larger	Kd	of	9.4±3.6	μM.	
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Figure	5.14	–	Fractional	change	in	the	intrinsic	fluorescence	intensity	of	AtIPK1	upon	binding	compounds	that	were	
positive	hits	as	potential	inhibitors	for	AtIPK1	only	from	the	diversity	set	II	library.	(A)	Cynarin	(B)	Chaetochromin.	
Error	bars	show	the	standard	errors	in	that	data.	
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5.4.5	Inhibiting	the	kinase	activity	of	AtIPK1	-	coupled	assay	
	
A	coupled	enzyme	assay	was	used	to	report	the	real	time	enzyme	activity	of	AtIPK1	in	
the	presence	of	purpurogallin.	The	coupled	assay	follows	the	loss	in	absorption	of	NADH	
at	340	nm	when	it	 is	converted	to	NAD+.	Upon	IP5	phosphorylation,	conversion	of	ATP	
to	 ADP	 occurs	 which	 is	 then	 used	 by	 pyruvate	 kinase	 (PK)	 to	 convert	
phosphoenolpyruvate	 (PEP)	 to	pyruvate.	The	pyruvate	 is	 then	converted	 to	 lactate	by	
lactate	 dehydrogenase	 (LDH)	 using	 a	 hydrogen	 atom	 from	 NADH.	 The	 conversion	 of	
NADH	to	NAD+	is	representative	of	the	turnover	rate	of	ATP	to	ADP	by	AtIPK1,	and	the	
rate	 of	 reaction	 can	 be	 determined	 from	 the	 gradient	 of	 the	 initial	 (linear)	 loss	 of	
absorption	(Δabs	/	Δtime	(s)).		
	
An	example	of	this	reaction	is	shown	in	Figure	5.15,	in	which	the	conversion	of	IP5	to	IP6	
is	inhibited	by	the	addition	of	100	µM	IP6.	The	traces	are	normalised	against	a	no	AtIPK1	
control.	The	gradient	between	20	and	120	seconds	for	the	non-inhibited	reaction	is	21.6	
s-1	with	 the	 reaction	 going	 to	 completion	by	 150	 seconds.	 In	 the	presence	of	 IP6,	 the	
gradient	is	11.2	s-1.	
	 	
Chapter	5	-	Application	of	fluorescently	tagged	inositol	polyphosphates	in	novel	inhibitor	and	lead	
compound	discovery	
196		
	
	
Figure	 5.16	 shows	 preliminary	 data	 for	 the	 inhibition	 of	 AtIPK1	 via	 this	 assay	 by	
increasing	 concentrations	 of	 purpurogallin.	 The	 calculated	 reaction	 rates	 were	
normalised	by	subtracting	the	inhibited	rate	from	the	rate	of	the	non-inhibited	reaction	
that	 was	 followed	 in	 tandem,	 and	 divided	 by	 the	 non-inhibited	 reaction	 to	 give	 a	
fractional	change	in	reaction	velocity.	Upon	increasing	concentrations	of	purpurogallin	
the	turnover	of	IP5	to	IP6	by	AtIPK1	is	clearly	inhibited,	with	the	reaction	being	slowed	
by	almost	60	%	in	the	presence	of	50	μM	purpurogallin.	Because	in	any	measurement	
the	 ‘inhibitor’	 concentration	 is	 constant,	 the	 slopes	 of	 the	 reaction	 curves	 are	
meaningful.	 Nevertheless,	 the	 extinction	 coefficient	 of	 purpurogallin	 at	 340nm	 is	
approximately	half	 that	at	420	nm.	These	preliminary	data	provide	 further	supporting	
evidence	for	purpurogallin	being	a	positive	inhibitor	hit	for	AtIPK1.	
	
	 	
0 50 100 150 200
0.22
0.24
0.26
0.28
Time-(s)
Ab
so
rb
an
ce
-(λ
₃₄
₀)
<-IP₆
+-IP₆
Figure	 5.15	 –	 Coupled	 enzyme	 assay;	 phosphorylation	 of	 inositol	 1,3,4,5,6	 pentakisphosphate	 by	 AtIPK1	 and	
inhibition	of	phosphorylation	by	100	µM	IP6.		
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Figure	 5.16	 –	 Fractional	 change	 in	 velocity	 of	 the	 phosphorylation	 of	 inositol	 1,3,4,5,6	 pentakisphosphate	 by	
AtIPK1	upon	increasing	concentrations	of	purpurogallin.	
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5.4	Conclusions	and	future	work	
	
The	experiments	described	 in	this	chapter	and	chapter	4	demonstrate	the	utility	of	2-
FAM-IP5	 as	 an	 active	 site	 ligand	 of	 inositol	 phosphate-converting	 enzymes	 which	 are	
either	 inositol	 phosphate	 –	 nucleotide	 phosphotransferases	 (AtIPK1)	 or	 inositol	
phosphate	5-phosphatases	 (SHIP1cd	and	SHIP2cd).	The	 latter	belong	 to	a	 family	of	10	
enzymes	in	humans	that	are	the	subject	of	considerable	pharmaceutical	interest	(Blunt	
and	Ward,	2012),	and	SHIP1	and	SHIP2	share	a	conserved	5-phosphatase	domain	with	
the	rest	of	the	family;	INPP5A,	INPP5B,	INPP5E,	INPP5J,	OCRL,	SKIP,	Synaptojanin	1	and	
Synaptojanin	 2	 (Ooms	 et	 al.,	 2009,	 McCrea	 and	 De	 Camilli,	 2009).	 While	 the	
physiological	substrates	of	these	enzymes	are	not	all	clearly	defined,	some	e.g.,	SHIP1	
and	SHIP2	which	act	physiologically	on	PtdIns(3,4,5)P3	have	become	therapeutic	targets,	
not	least	because	of	the	restricted	expression	of	SHIP1	in	blood	cell	lineages	(Hamilton	
et	 al.,	 2011).	 Because	 of	 the	 considerable	 therapeutic	 interest	 in	 phosphoinositide	
metabolising	 enzymes,	 there	 remains	 considerable	 interest	 in	 tools	 enabling	
identification	of	 small	molecules	 that	 influence	 the	activity	of	 specific	 enzymes	 (Blunt	
and	Ward,	2012).	These	small	molecules	may	represent	modulators	including	inhibitors	
or	activators,	and	may	represent	active	site	or	allosteric	modulators.	 Inhibitors	and/or	
activators	have	been	identified	for	SHIP1	and	SHIP2,	as	well	as	for	OCRL	and	the	related	
enzyme	INPP5B	(Yang	et	al.,	2005,	Suwa	et	al.,	2009,	Brooks	et	al.,	2010,	Pirruccello	et	
al.,	2014).	
	
The	efficacy	of	 inhibition	or	activation	of	 these	enzymes	 is	commonly	tested	 in	assays	
which	measure	the	ability	of	compounds	to	inhibit	or	activate	the	release	of	phosphate	
from	 a	 substrate	 in	 vitro.	 Phosphate	 is	 itself	 commonly	 measured	 using	 malachite	
green-	or	molybdate-based	assays	 (Pirruccello	et	al,	2014).	The	same	authors	used	an	
indirect	 polarisation	 based	 assay	 in	 which	 the	 action	 of	 5-phosphatases	 on	
PtdIns(3,4,5)P3	 yield	 a	 PtIns(3,4)P2	 product	 which	 competes	 with	 a	 fluorescent	
PtdIns(3,4)P2	for	a	post	–reaction	added	binding	protein.	While	such	assays	are	readily	
performed	 on	 plate	 readers,	 they	 are	 end	 point	 assays	 which	 require	 stopping	 of	
reactions	and	subsequent	additions	of	reagent	before	measurement.		
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In	consideration	of	the	search	for	allosteric	modulators	and	irrespective	of	the	mode	of	
inhibition	 or	 activation	 of	 inositide-	 or	 phosphoinositide-metabolising	 enzymes,	 the	
efficacy	 of	 inhibitors	 or	 activators	 reflects	 binding	 and	 subsequent	 effect	 on	 the	
catalytic	 processing	 of	 bound	 inositide/phosphoinositide	 substrate.	 There	 remains	
opportunity	and	need	for	the	development	of	assays	which	 interrogate	the	binding	of	
substrates,	 substrate	 analogs,	 inhibitors,	 and	 distal	 binding	 of	 allosteric	 regulators	 on	
enzymes.		
	
The	strategies	identified	here	for	high-throughput	screening	of	ligand	binding,	whether	
substrate,	substrate	analog,	inhibitor,	activator	or	modulator,	are	relevant	to	inositide-	
and	 phosphoinositide-binding	 enzymes.	 More	 generally,	 these	 enzymes	 include	
inositide-kinases,	 inositide	 phosphotransferases,	 inositide	 phosphatases,	
phosphoinositide	kinases	and	phosphoinositide	phosphatases.	The	strategy	revealed	is	
likely	 applicable	 to	 enzymes	which	 phosphorylate	 inositides	 and	 phosphoinositides	 at	
single	 or	 multiple	 positions	 and	 to	 enzymes	 which	 dephosphorylate	 inositides	 and	
phosphoinositides	at	single	or	multiple	positions.		
	
The	 identification	of	small	molecules,	approved	oncology	drugs,	such	as	Bosutinib	and	
Crozotinib,	 as	 ligands	 of	 SHIP1cd	 is	 intriguing.	What	 is	more	 remarkable	 is	 that	 both	
these	 compounds	 share	 with	 3-α-aminocholestane	 (chapter	 4),	 a	 known	 specific	
inhibitor	of	SHIP1cd,	but	not	active	on	SHIP2.	That	all	three	ligands	increase	the	affinity	
of	 SHIP1cd	 for	 2-FAM-InsP5,	 but	 not	 SHIP2	 or	 AtIPK1,	 implies	 a	 potential	 common	
mechanism	of	modulation	of	SHIP1.	That	they	increase	the	affinity	for	the	polarisation	
probe	 suggests	 that	 they	 are	 not	 active	 site	 competitors,	 rather	 that	 they	 have	 an	
allosteric	 role.	This	observation	 is	 remarkable,	particularly	 in	 light	of	 the	 identification	
for	 pelorol	 (a	 natural	 compound	 isolated	 from	 the	 marine	 sponge	 Dactylospongia	
elegans)	which	exerts	an	allosteric	 role	as	an	activator	of	SHIP1	catalytic	activity.	This	
allostery	 has	 been	 attributed	 to	 interaction	 with	 the	 C2	 domain,	 not	 the	 catalytic	
domain	(Yang	et	al.,	2005),	SHIP2	possesses	a	C2-domain	but	is	not	sensitive	(Blunt	and	
Ward,	 2012).	 Derivatives	 of	 pelorol,	 include	 AQX-016A,	 AQX-MN100	 and	 AQX-1125,	
which,	 produced	 by	 Aquinox	 Pharmaceuticals,	 have	 been	 taken	 forward	 to	 Phase	 II	
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clinical	trials	(Blunt	and	Ward,	2012).	Interest	in	pelorol	derivatives	is	current	with	other	
groups	undertaking	medicinal	chemistry	approaches.	The	identification	here	of	catalytic	
domain–limited	allostery	of	SHIP1,	but	not	SHIP2,	is	fascinating.	It	remains	to	be	tested	
whether	 Bosutinib	 and	 Crozotinib	 are	 inhibitors,	 like	 3-α-aminocholestane,	 or	 are	
activators,	like	pelorol	and	its	derivatives.	
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6.1	Cloning,	purification	and	structures	of	the	catalytic	domains	of	SHIP1	and	SHIP2	
The	human	SHIP	proteins	are	amongst	the	5-phosphatases	responsible	for	the	attention	
of	 signalling	 from	activated	Akt	 (PKB),	 and	 therefore	 they	 are	 implicated	 in	many	 cell	
regulatory	pathways	 that	 led	 to	diseases	such	as	cancers	and	diabetes	 (Kagawa	et	al.,	
2008,	Yu	et	al.,	2008).	SHIP1	and	SHIP2	are	isoenzymes	expressed	in	different	cell	types,	
and	exhibit	varying	affinities	and	specificities	(Ooms	et	al.,	2009).	
The	catalytic	mechanism	of	the	5-phosphatases	is	far	from	understood	and	only	recently,	
on	the	basis	of	new	structural	data,	there	have	been	encouraging	speculations	on	which	
conserved	residues	account	for	coordination	of	the	scisscile	bond	(Mills	et	al.,	2016)..	In	
light	of	a	structure	of	SHIP2cd	in	complex	with	biphenyl	2,3’,4,5’,6-	pentakisphosphate	
(BiPh1)	(Mills	et	al.,	2102),	attempts	were	made	here	at	obtaining	complexes	with	the	
rest	of	the	benzene	and	biphenyl	phosphates.	Due	to	time	constraints	and	the	need	for	a	
refined	purification	method,	SHIP1cd	has	not	yet	been	subjected	to	crystallisation	trials.	
Although,	 a	 successful	 ligation	 independent	 cloning	method	 has	 been	 used	 to	 obtain	
overexpression	of	soluble	recombinant	protein	for	in	vitro	assays.		
An	 apo-structure	 of	 SHIP2cd	was	 obtained	 that	was	 in	 agreement	with	 those	 already	
published	(Mills	et	al.,	2012,	Trésaugues	et	al.,	2014).	The	P4IM-containing	loop	that	has	
been	 postulated	 (by	 molecular	 dynamics)	 to	 close	 over	 the	 active	 site	 post	 inositide	
binding	was	constrained	 in	the	same	position	as	described	 in	the	published	structures	
confirming,	in	the	lack	of	the	ligand,	that	the	loop	is	not	essential	for	binding	of	BiPh1.	
SHIP1cd	was	subjected	to	structure	prediction	by	use	of	the	SWISS-MODEL	homology-
modelling	server,	which	suggested	the	use	of	apo	SHIP2	(PDB	3NR8)	as	a	template.	With	
this	guidance	in	mind,	modelling	was	undertaken	using	the	SHIP2cd	structure	from	the	
present	study	(chapter	2)	as	a	template	and	resulted	in	a	SHIP1cd	structure	similar	to	that	
of	SHIP2cd,	RMSD	of	0.141.	Small	changes	in	this	active	site	loop	can	be	seen	between	
the	 SHIP1cd	 model	 and	 the	 SHIP2cd	 structure,	 supporting	 the	 evidence	 for	 it	 being	
flexible	and	disordered.	The	homology	modelling	of	SHIP1cd	gives	a	 loop	of	 the	same	
length	(with	similar	numbers	of	residues)	as	in	the	SHIP2cd	structure,	as	can	be	seen	by	
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observing	the	secondary	structure	prediction	by	use	of	the	ENDscript	web	server.	There	
is,	however,	only	50%	sequence	 identity	 in	 these	secondary	structure	elements,	again	
supporting	the	hypothesis	that	the	P4IM-containing	loop	is	not	critical	in	ligand	binding	
and	can	likely	adjust	to	a	variety	of	ligands	interacting	with	the	binding	pocket.	Moreover,	
although	it	is	not	the	primary	structural	feature	that	anchors	a	ligand	in	to	the	active	site,	
it	is	not	unreasonable	to	hypothesise	that	the	differences	in	substrate	affinity	between	
SHIP1cd	and	SHIP2cd	could	be	accounted	for	by	variations	within	this	 loop.	Of	course,	
without	any	available	structures	of	SHIP1cd	and	considering	the	potential	bias	caused	by	
homology-modelling,	this	is	only	speculation,	therefore	future	efforts	should	concentrate	
on	obtaining	structures	of	SHIP1cd,	or	indeed	the	full	length	protein.	As	well	as	subjection	
of	 SHIP2cd	 to	 further	 crystallisation	 trails	 to	 explore	 conditions	 in	which	 crystals	with	
complexed	protein	can	be	obtained.	Future	efforts	will	be	focused	on	the	elucidation	of	
the	 substrate	 specificities	 and	 mechanism	 of	 SHIP1,	 SHIP2	 and	 the	 physiologically	
relevant	5-phosphatase	family.		
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6.2	 AtIPK1	 in	 complex	 with	 large	 inositol	 phosphate	 surrogates	 insights	 large	
conformational	changes		
Previous	to	this	study,	structures	have	been	obtained	of	AtIPK1	in	complex	with	the	single	
ringed	benzene	phosphates	(unpublished	data,	Hayley	Whitfield).	Additionally,	structures	
of	the	apo-protein	(W129A	mutant),	nucleotide-bound	(W129A	mutant),	and	the	ternary	
complex	 with	 nucleotide	 (ADP/ATP)	 and	 inositol	 polyphosphates	 (IP6/IP5),	 led	 to	 the	
characterisation	 of	 three	 conformational	 states;	 the	 open,	 half-closed	 and	 closed	
conformation,	 respectively	 (Banos-Sanz	 et	 al.,	 2012).	 The	 benzene	 and	 biphenyl	
phosphates	 have	 emerged	 as	 useful	 tools	 in	 both	 determining	 the	 specificity	 of	 an	
enzyme,	 since	 they	can	be	designed	 to	 test	various	phosphate	binding	positions	 in	an	
active	site	pocket,	and	in	prospective	design	of	inhibitors.	This	has	led	to	the	elucidation	
of	 the	 complexes	 with	 the	 biphenyl	 phosphates	 presented	 here.	 Complexes	 with	
BiPh(2,3’,4,5’,6)P5	(BiPh1)	and	BiPh(3,3’,4,4’,5,5’)P6	(BiPh3)	confirmed	the	importance	of	
the	 P6	 binding	 pocket	 that	 anchors	 all	 ligands	 into	 the	 active	 site.	 The	 ubiquitous	
occupation	of	this	pocket	across	all	structures	suggests	it	is	the	primary	determinant	of	
binding	orientation	and	forces	the	orientation	of	the	biphenyl	phosphate	ligands	to	an	
almost	 perpendicular	 (orthogonal)	 pose	 compared	 to	 the	 benzene	 phosphates	 and	
canonical	inositol	phosphate	substrates.	Additionally,	despite	having	a	similar	two	ringed	
structure	with	only	the	phosphate	substitutions	to	distinguish	between	them,	they	are	
bound	in	juxtaposed	orientations	because	of	the	need	for	the	P6	position	to	be	satisfied.		
The	almost	perpendicular	mode	of	binding	compared	to	previous	structures	has	caused	
knock	on	conformational	changes	within	AtIPK1.	Overlaying	the	BiPh	complexes	with	the	
defined	conformational	states	from	the	literature	revealed	that	the	BiPh	complexes	are	
akin	to	the	half-closed	structure	complexed	with	nucleotide	alone,	despite	being	ternary	
complexes.	There	are	large	conformational	global	changes	occurring	where	the	N-	and	C-
lobes	are	further	apart	to	accommodate	the	volume	of	the	ligand,	as	well	as	more	local	
changes.	The	distancing	of	the	N-lobe	(from	the	C-lobe)	has	the	consequence	that	the	
BiPh	is	mostly	coordinated	by	C-lobe	residues	with	a	key	interaction	missing	from	the	N-
lobe	that	is	usually	mediated	by	R130	in	the	closed	form	of	the	protein.	The	clasp	that	
forms	in	the	closed	conformation	of	the	protein	has	not	been	formed,	L3	has	not	folded	
over	the	active	site	and	α6	is	disordered	similar	to	the	reported	half-closed	structure.	In	
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absence	 of	 clasp	 formation,	 the	 protein	 remains	 in	 the	 half-closed	 form	 when	
accommodating	a	biphenyl	polyphosphate	rather	than	transitioning	to	the	closed	form.	
The	greater	size	(volume)	of	the	biphenyl	polyphosphates	and	the	different,	relative	to	
inositol,	spatial	positions	of	their	phosphates	are	likely	to	preclude	achievement	of	the	
closed	form.	Since,	crystallisation	screening	has	resulted	in	the	collection	of	successful	
high	quality	data	 sets	 for	complexes	between	AtIPK1	and	BiPh2	/	BiPh4,	although	 the	
presence	of	compound	in	the	inositide	binding	site	has	been	confirmed	the	structures	are	
not	 yet	 fully	 refined.	 Continued	 work	 is	 concentrating	 on	 elucidation	 of	 inhibitory	
characteristics	of	these	compounds	toward	AtIPK1	to	extract	inhibition	constants.	
	
6.3	Revealing	the	fluorescent	properties	of	the	benzene-	and	biphenyl-	phosphates,	-	
substrates	of	SHIP1	and	SHIP2.	
As	 discussed,	 the	 benzene	 and	 biphenyl	 phosphates	 have	 been	 utilised	 in	 both	
enzymology	 and	 structural	 studies	 with	 inositol	 phosphate-binding	 enzymes,	 and	 are	
mostly	reported	as	inhibitors	(Mills	et	al.,	2008,	Vandeput	et	al.,	2007,	Mills	et	al.,	2016,	
Swarbrick	 et	 al.,	 2015,	Ward	 et	 al.,	 1995,	Mills	 et	 al.,	 2007,	Mills	 et	 al.,	 2012).	 One,	
however,	 was	 reported	 as	 an	 unusual	 substrate	 of	 type	 I	 Ins(1,4,5)P3	 5-phosphatase	
(INPP5A)	(Mills	et	al.,	2006).	
Following	discovery	of	the	fluorescent	properties	of	the	biphenyl	phosphates	(chapter	4),	
assays	were	performed	against	SHIP1cd	and	SHIP2cd	as	alternative	members	of	the	5-
phosphatase	 family,	 for	 one	 of	 which	 there	 is	 a	 structure	 in	 complex	 with	 BiPh1,	 as	
discussed	 previously	 (Mills	 et	 al.,	 2012).	 The	 assays	 revealed	 firstly	 that	 biphenyl	
phosphate	 are	 substrates,	 and	 that	 the	 biphenyl	 phosphates	 provide	 a	 very	 sensitive	
method	 of	 detection	 via	 their	 fluorescent	 properties.	 Here,	 when	 resolved	 by	 anion	
exchange	chromatography.	Very	little	BiPh	was	required	to	gain	a	full	time	course	of	end-
point	reaction	results,	when	compared	to	attempts	at	less	sensitive	real-time,	enzyme-
coupled,	assays,	which	commonly	require	substrate	inositol	phosphate	in	the	high	tens	
of	micromolar	concentration.	The	use	of	these	fluorescent	BiPh	substrates	allowed	the	
construction	of	progress	of	reaction	curves.	Both	SHIP1	and	SHIP2	were	able	to	turn	over	
all	BiPh	as	visualised	by	a	decrease	in	fluorescence	of	an	hplc	peak	of	parent	compound.	
However,	differing	substrate	specificities	were	revealed	towards	the	BiPhs.	Additionally,	
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new	UV	absorbant	hplc	peaks	were	visualised	in	the	preliminary	O/N	only	experiments,	
revealing	 the	 appearance	 of	 products	 of	 BiPh	 dephosphorylation.	 In	 the	 absence	 of	
partially	dephosphorylated	BiPhs	as	standards,	it	is	not	possible	to	identify	the	products.	
Nevertheless,	these	data	provide	compelling	evidence	that	BiPhs	are	substrates	of	SHIP1	
and	SHIP2.	Work	in	due	course	would	likely	focus	on	extracting	enzymology	constants	of	
the	 turnover	 of	 these	 compounds	 by	 SHIP1cd	 and	 SHIP2cd,	 and	 subsequently	 data	
describing	the	inhibition	of	their	turnover	either	by	bone	fide	substrates	and	standard	or	
potential	 inhibitors.	 As	 mentioned	 above,	 efforts	 will	 focus	 on	 the	 attainment	 of	
structural	data	in	complex	with	these	substrates.	Additionally,	site-directed	mutagenesis	
of	postulated	key	residues	of	the	5-phosphatases	in	substrate	and	inhibitor	binding	prior	
to	subjection	of	this	assay	could	reveal	mechanisms	of	ligand	binding	and	catalysis.	The	
assays	should	also	be	tested	on	the	fluorescent	benzene	phosphate	compounds,	of	which	
there	are	two;	benzene	1,2,4,5-tetrakisphosphate	(Bz3)	&	benzene	1,2,4-trisphosphate	(Bz5).	
These	compounds	are	ever	increasing	in	utility	for	the	characterisation	and	structure	elucidation	
of	this	family	of	enzymes.	
	
6.4	 A	 robust	 fluorescence	 polarisation	 assay	 to	 explore	 ligand	 binding	 and	 its	
application	in	high	throughput	screening	for	lead	compounds		
Large	compound	 libraries	are	now	available,	often	 free	of	charge,	 to	both	private	and	
academic	 sectors	 for	 the	 use	 in	 screening	 methods	 against	 proteins	 that	 are	 usually	
targets	for	therapeutic	intervention.	High	throughput	screening	is	one	of	the	initial	stages	
of	lead	compound	discovery	and	is	commonly	used	over	partial	rational	design	methods.	
The	methods	in	which	these	screens	are	utilised	in	the	search	for	dose-responses	vary,	
but	 many	 consist	 of	 time	 consuming	 end-point	 assays,	 such	 as	 the	 malachite	 green	
phosphate	 release	assay	 (Suwa	et	al.,	 2009).	 Fluorescently	 tagged	 inositol	phosphates	
were	used	to	explore	the	binding	of	inhibitors	and	the	biphenyl	phosphates	to	AtIPK1,	
SHIP1cd	and	SHIP2cd	 in	fluorescence	polarisation	assays.	Dose-reponse	binding	curves	
were	constructed	 for	binding	of	2-FAM-IP5	 to	SHIP1cd	and	SHIP2cd,	and	subsequently	
IC50s	 for	 displacement	 by	 BiPh	 ligands	 were	 obtained,	 again	 revealing	 the	 substrate	
specificities	of	SHIP1cd	and	SHIP2cd	for	the	biphenyls	that	were	in	agreement	with	the	
anion	exchange	chromatography	assays.	The	fluorescence	polarisation	method	allowed	
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for	the	collection	of	large	data	sets,	in	384-well	plates	with	minimal	errors	associated.	As	
all	the	enzymes	in	this	study	present	various	physiologically	important	roles,	and	a	robust	
high	 throughput	 method	 was	 now	 available	 for	 probing	 the	 active	 sites	 of	 inositol	
phosphate-converting	enzymes,	they	were	subjected	to	two	screens	obtained	from	the	
NCI.	 Hits	 from	 the	 fluorescence	 polarisation	 screens	 that	 appeared	 in	 the	 separation	
band,	 were	 subjected	 to	 further	 investigation	 via	 completion	 of	 full	 dose-response	
inhibition	curves.	
Because	 of	 the	 availability	 of	 assays	 of	 AtIPK1	 function	 developed	 already	 in	 the	
laboratory,	 compounds	 identifed	 to	 have	 effects	 in	 fluorescence	 polarisation	 screens	
were	further	tested	on	AtIPK1	for	effect	on	intrinsic	tryptophan	fluorescence	which	has	
been	shown	to	accompany	conformational	changes	induced	on	substrate	binding	(Banos-
Sanz	et	al.,	2012).	Additionally,	hits	 identified	in	fluorescence	polarisation	screen	were	
tested	for	effect	on	catalytic	turnover	using	a	coupled	enzyme.	One	such	compound	that	
stood	out	from	these	assays	was	purpurogallin,	which	has	subsequently	been	entered	in	
to	crystallisation	trails	with	AtIPK1.	A	successful	high	resolution	data	set	for	co-crystallised	
purpurogallin	and	ADP	has	been	collected	since,	and	although	there	is	no	strong	electron	
density	for	purpurogallin	in	the	active	site,	structural	perturbations	suggest	the	presence	
of	 a	 ligand.	 In	 sumary,	 the	 fluorescence	 polarisation	 assay	 has	 produced	 a	 high	
throughput	 robust	method	 for	 the	discovery	of	novel	 inhibitors	of	 inositol	phosphate-
binding	 proteins,	 and	 provides	 a	 proof	 of	 concept	 for	 the	method	 rather	 than	 being	
approached	from	a	strictly	pharmacological	point	of	view.	 	
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Appendices	
Appendix	1	–	Supplier	addresses	
Company	 Location	
Bio-Rad	Laboratories	Ltd	 Hemel	Hempstead,	UK	
BMG	Labtech	 Aylesbury,	UK	
Clontech	 Saint-Germain-en-Laye,	France	
Corning	 Amsterdam,	The	Netherlands	
Dionex	 Sunnyvale,	USA	
DNASU	–	Plasmid	repository	 Arizona,	USA	
Echelon	 Utah,	USA	
Expedeon	 Harston,	UK	
GE	Healthcare	Life	Sciences	 Little	Chalfont,	UK	
Hidex	 Turku,	Finland	
Invitrogen	Ltd	 Paisley,	UK	
Life	technologies	(Novex)	 Paisley,	UK	
Melford	Laboratories	Ltd	 Ipswich,	UK	
Merck	Millipore	 Billerica,	USA	
Molecular	Devices	 California,	USA	
MWG	Eurofins	 Ebersberg,	Germany	
National	Cancer	Institute	 Maryland,	USA	
New	England	Biolabs	Ltd	(NEB)	 Hitchin,	UK	
Promega	 Southampton,	UK	
Qiagen	 Crawley,	UK	
Sigma-Aldrich	 Gillingham,	UK	
Source	BioScience	 Nottingham,	UK	
Thermo	Scientific	Ltd	 Loughborough,	UK	
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Appendix	2.1-	Bacterial	culture	(For	1	L)	
Luria-Bertani	(LB)	broth	 10	g	Tryptone	
5	g	Yeast	extract	
10	g	NaCl	
LB-Glucose	(LB-G)	 10	g	Tryptone	
5	g	Yeast	extract	
10	g	NaCl	
5	g	Glucose	
LB-Agar	 10	g	Tryptone	
5	g	Yeast	extract	
10	g	NaCl	
15	g	Agar	
TB	buffer	 10	mM	HEPES	pH6.7	
15	mM	CaCl2	
55	mM	MnCl2	
250	mM	KCl	
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Appendix	2.2	–Antibiotics	and	Additives	
Ampicillin	 100	µg	/	mL	
Kanamycin	 50	µg	/mL	
Isopropyl	β-D-1-thiogalactopyranoside	
(IPTG)	
0.2	-0.4	mM		
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Appendix	2.3	–	Buffers	for	protein	purification	
2.3.1	SHIP1	and	SHIP2	
Cell	Lysis	Buffer	 20	mM	HEPES	pH	7.5	
500	mM	NaCl	
10	mM	Imidazole	
10	%	Glycerol	
0.5	mM	TCEP	
0.5	%	Triton	
NiNTA	Buffer	A	 20	mM	HEPES	pH	7.5	
500	mM	NaCl	
25	mM	Imidazole	
10	%	Glycerol	
0.5	mM	TCEP	
NiNTA	Buffer	B	 20	mM	HEPES	pH	7.5	
500	mM	NaCl	
500	mM	Imidazole	
10	%	Glycerol	
0.5	mM	TCEP	
Sepharose	Buffer	(1)	 20	mM	Tris-HCl	pH7.5	
200	mM	NaCl	
2	mM	DTT	
10	%	Glycerol	
(Add	EDTA	for	tag	cleavage	buffer)	
Sepharose	(2)	
- For	crystallograpghy	
20	mM	HEPES	pH	7.5	
300	mM	NaCl	
10	%	Glycerol	
0.5	mM	TCEP	
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2.3.2	AtIPK1	(Also	tried	with	SHIP1	–	see	results)	
Cell	Lysis	Buffer	 50	mM	NaH2PO4	pH	7.5	
300	mM	NaCl	
20	mM	imidazole	
0.5	%	Triton	
NiNTA	Buffer	A	 50	mM	NaH2PO4	pH7.5	
300	mM	NaCl	
20	mM	imidazole	
NiNTA	Buffer	B	 50	mM	NaH2PO4	pH7.5	
300	mM	NaCl	
500	mM	imidazole	
Sepharose	Buffer	 20	mM	Tris-HCl	pH7.5	
200	mM	NaCl	
2	mM	DTT	
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